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ABSTRACT
The need for a new definition of infectious healthcare waste in the UK was identified 
through a review of current regulatory and management regimes and comparisons with 
International and European approaches. The philosophy of current infectious waste 
management has been examined and the underlying principles and concepts identified 
by reference to five assumptions:
1. People receiving healthcare in hospital produce infectious waste;
2. The majority of infectious healthcare waste is produced in hospitals;
3. People living in their own homes do not produce infectious waste;
4. The risks posed are directly proportionate to the hazard; and
5. Clinical waste (infectious waste) poses a greater risk of infection than 
Household Waste.
These five assumptions were examined in relation to healthcare waste characteristics 
and production trends by reference to published papers, published data and a 
questionnaire survey of community healthcare waste producers. The five assumptions 
were shown to be incorrect and two new assumptions were identified:
1. Infectious waste is produced both within and out-with healthcare premises; and
2. The infectious nature of the waste can be determined by a three step assessment 
methodology described as ‘TOP’ focusing on the type of waste, the likely 
outcome and the infection pathway.
Forthcoming regulatory changes were reviewed, focusing on the UK implementation of 
the Hazardous Waste Directive (91/689/EEC) and the European Agreement Concerning 
the International Carriage of Dangerous Goods by Road (ADR 2005).
The need to align the definitions used in forthcoming and current regulation concerned 
with health and safety, waste and transport has been identified.
A new approach to the management of infectious healthcare waste in the UK has been 
proposed, taking into consideration the regulatory requirements for both hazard and risk 
assessment, providing a practical classification for infectious waste for UK healthcare 
practitioners. In addition, a UK best practice colour coding system has been developed 
based on waste classification and the treatment/disposal requirements of components of 
the healthcare waste stream. Both the new approach to classification and the colour 
coding segregation system were subject to extensive peer review and the findings of this 
dissertation will be incorporated into a UK Joint Agency guidance document titled: ‘Safe 
Management of Healthcare Waste’, due to be published in 2006.
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1. INTRODUCTION
This dissertation is comprised of a number of integral pieces of research 
and investigation which review the definitionsrguidance and management 
practices associated with the management of infectious waste. The 
characteristics and sources of production are reviewed by assessment of 
published papers, data and a questionnaire survey of community based 
infectious waste producers in the Greater Edinburgh area. The implication 
of key health and safety, waste and transport regulations are reviewed 
both in the context of current and forthcoming regulation. A new 
management system for clinical waste is developed which aligns the 
approaches of the identified key regulations.
The key issues and ideas identified in this report have been developed 
from personal experiences. Valuable experience has been gained through 
work undertaken in association with NHSScotland, the Scottish 
Environment Protection Agency (SEPA), the Environment Agency (EA), the 
Chartered Institution of Wastes Management (CIW M) Healthcare Waste 
Special Interest Group, the Sanitary Medical Disposal Services 
Association (SMDSA) and the Infection Control Nurses Association (ICNA).
As the research was undertaken in Scotland, reference is made primarily 
to Scottish legislation and Scottish data. Although Scotland has a 
devolved Government and the authority to introduce environmental 
protection legislation, the influence of this on the management of clinical 
waste has not been discernable. Therefore the finding of this report may 
be equally valid in England and Wales.
1.1 Research Aim
To propose a new management system for the management of infectious 
healthcare waste aligning the different regulatory approaches of the UK 
Environmental Regulators, Health and Safety Executive and Department of 
Transport, and to provide a single classification system for infectious 
healthcare waste in the UK.
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1.2 Research Objectives
The ob jectives of th is research were to:
♦ identify  and sum m arise the current ph ilosophy and im plic it 
assum ptions which influence the current m anagem ent of 
in fectious healthcare m anagem ent as identified in de fin itions and 
guidance docum ents;
♦ to characterise  and quantify  in fectious healthcare waste 
production ;
♦ to review  philosophy and im p lic it assum ptions based on find ings; 
and
♦ to propose a new m anagem ent regim e based on revised 
assum ptions and forthcom ing regu la tory change.
1.3 Methodology
The research objectives and aim were identified by the author fo llow ing 
in itia l undergraduate research at the U n ivers ity  of G reenw ich. Follow ing 
the subm ission of the au thor’s undergraduate d isserta tion  and fu rther 
research in association with healthcare organ isa tions, the author identified 
that the lack of coherent and com plim entary regu la tory de fin itions and 
contro ls appeared to cause practica l problem s in the c lass ifica tion , 
segregation and managem ent of in fectious healthcare waste.
In itial literature Review
An in itia l lite ra ture  review was undertaken to identify existing research in 
the fie ld  of regulatory de fin itions and in fectious healthcare waste; lim ited 
inform ation was found. A re la tive ly sm all num ber of published papers 
were identified  which focused on the leg is la tive  contro ls in place for 
in fectious (c lin ica l) waste in the UK, including (C lark et al 1994), (M oritz 
1995), (Pocock, 1999) and (Taylor, 1988).
A number of the identified papers were published in the healthcare press 
and focused predom inate ly on waste m anagem ent de fin itions and 
c lassifica tions. The artic les were factua l in the inform ation provided 
reflecting regu la tory requirem ents but did not a ttem pt to assess the va lid ity
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of the regulatory approach by reference to published papers, waste 
analysis or surveys.
Limited references were found to academic research with respect to the 
regulatory controls applicable to infectious waste management. However, 
published papers and thesis were found relating to the composition of 
infectious waste and are referred to throughout this dissertation.
From this limited initial literature review the author identified a research 
methodology to review the principles on which healthcare waste is 
regulated and managed. The methodology chosen is similar to ontological 
research methods commonly used in both healthcare and information 
system research (Thompson et al, 2000), (Koch, 1995), (Myers, 1997), 
(Jarvinen, undated) and (Minger, 2001). The methodology focuses on the 
identification of assumptions (or analogous arguments) of a concept and 
the identification of what instantiates them. The methodology used in this 
dissertation identifies multiple assumptions and uses a variety of 
quantitative and qualitative information to review these assumptions; the 
methodology used can therefore be described as a plurist ontological 
approach.
The methodology included the following research methods:
a. Review of published papers in the academ ic, healthcare and  
legal press.
Review of academic, healthcare and legal publications to identify 
published research and findings in relation to the definitions and 
classifications of infectious healthcare waste, its characteristics 
and composition, and current management techniques.
b. Review of In ternational, European and UK regulatory contro ls;
Review of statutes and associated regulatory guidance with respect 
to the classification, storage, transport, treatment and disposal of 
infectious healthcare waste.
c. A survey of a producers
Survey of distinct producer group to ascertain current practices and 
awareness of regulatory controls.
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d. Peer review  of findings and identified way forw ard.
Peer review  of find ings and proposed c lass ifica tion  m ethodology.
1.4 Structure of the Report
This d isserta tion  has been structured to guide the reader through the key 
issues that in fluence the m anagem ent of in fectious healthcare waste to 
provide a deta iled understanding, cu lm inating in a new approach for the 
m anagem ent of in fectious healthcare waste described in section nine.
The d isserta tion  is structured as fo llow s:
♦ Section two and three review the current de fin itions, 
te rm ino logy and guidance com m only used in the 
m anagem ent of in fectious healthcare waste;
♦ In section four the author sum m arises the approach, 
underly ing princip les and im plic it assum ptions identified 
which influence current m anagem ent practices;
♦ Sections five and six review trends in the production of 
in fectious waste and the characte ris tics  of the waste using 
inform ation from published papers, research find ings and a 
producer survey;
♦ In section seven the underlying princip les and im plic it 
assum ptions identified by the author (in section four) are 
reviewed with respect to the au tho r’s find ings in earlie r 
sections;
♦ Section e ight reviews forthcom ing and recent regu la tory 
change which may influence fu ture m anagem ent practices;
♦ In section nine the author identifies and reviews the key 
drivers for a new approach in the m anagem ent of in fectious 
healthcare waste and proposes a new assessm ent and 
colour-coded segregation m ethodology. The peer review  of 
th is m ethodology and its use it a Departm ent of Health 
C onsultation is sum m arised;
13
♦ Conclusions and are made in section ten summarising the 
findings of the dissertation and the rationale of the proposed 
assessment methodology and colour-coded segregation 
system
♦ Recommendations for future research are made in section 
eleven. The recommendations identified have been grouped 
into five ‘work packages’ to aid further research and 
development.
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2. DEFINING INFECTIOUS HEALTHCARE WASTE
This section of the dissertation reviews current International, European 
and UK definitions of infectious healthcare waste. The definitions used in 
this section are used later in the dissertation and full definitions can be 
found in Appendix A.
2.1 Defining Waste
The term ‘waste’ is a descriptive term describing the status of materials or 
material flows in the economy; theoretically all material will be considered 
waste at some point in time. The UK’s current definition can be found in 
Environmental Protection Act 1990 and is based on the European definition 
of waste known as ‘directive waste’ which originates from the European 
Waste Framework Directive 75/442/EEC, amended by Directive 
91/156/EEC. In summary, an item is considered to be waste if the 
producer or the person in possession of it ‘discards’ or intends or is 
required to ‘discard’ it. The term 'discard' is the subject of much European 
case law (Zanetti, 1990), (Wallonie, 1997), (Tombesi, 1997) and (ARCO  
Chemie, 2000). In general, an item is thought to be discarded if it has 
"fallen from the commercial cycle or chain of utility" (Directive 
91/156/EEC); therefore objects capable of economic re-utilisation 
(including material or energy recovery) are included within the definition of 
waste.
2.2 Defining Healthcare Waste
The term healthcare waste is used to describe waste originating from 
healthcare premises or produced as a result of healthcare activities. The 
terminology used to describe healthcare waste and its constituent parts 
varies from country to country. In this section a number of current 
International, European and UK definitions are reviewed.
2.2.1 In ternational Defin itions of H ealthcare W aste  
World Health Organisation
The World Health Organisation (WHO) is the only organisation to define 
healthcare waste at an international level. The W HO definition can be 
found in Appendix A1. In summary the definition of healthcare waste 
includes “all the waste generated by healthcare establishments, research 
facilities, and laboratories" in addition it also includes “waste originating
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from m inor or scattered sources” which includes com m unity and home 
production (Prüss et al, 1998).
The W HO defin ition of healthcare waste is a broad and all encom passing 
term used to describe all w astes generated as a result of healthcare 
practices. Healthcare waste is fu rther c lassified  into groups according to 
its characte ris tics . Non-hazardous healthcare waste is described sim ply 
as ‘General Healthcare W aste ’ , w h ils t hazardous waste is c lass ified  into 
nine categories. Hazardous waste is categorised according to its physical, 
chem ical or b io log ica l characteris tics.
International Solid Waste Association
The In ternational Solid W aste Associa tion  (ISW A) has a working group 
that focuses on the m anagem ent of healthcare waste. ISW A defines 
healthcare waste as waste generated as a result of healthcare (Appendix 
A2). The ISWA defin ition of healthcare appears to be much broader than 
im plied by the W HO defin ition of healthcare waste as it encom passes 
wastes produced outside of the scope of healthcare practice, includ ing 
w astes produced as a result of product m anufacture and personal hygiene. 
The term  ‘Healthcare Risk W aste ’ is used by ISWA to identify  healthcare 
wastes w ith the greatest potentia l for harm; these include b io log ica l waste, 
in fectious waste and chem ical / toxic wastes (Rot, 1995).
United Nations
The Accord Européen Relatif Au Transport In ternational Des M erchandises 
Dangereuses Par Route, known as ADR, is an European agreem ent 
governing the carriage of dangerous goods by road. ADR is developed 
from the United Nations (UN) Model Regulations govern ing the 
in ternational movem ent of goods. ADR is transposed into leg is la tion  which 
is valid th roughout GB through the Carriage of Dangerous Goods (CDG) 
Regulations. The UN Model Regulations are amended b i-annua lly  and are 
drafted well in advance of the ir im plem entation date. For exam ple, UN 
Model Regulations due to be im plem ented in ADR 2007 w ill be re leased in 
2005.
The current GB transport regulations: Carriage of Dangerous Goods and 
Use of T ransportab le  Pressure Receptacles 2004 refer d irectly  to ADR and 
as such are due to be amended and updated in 2005 in line w ith the 
requirem ents of ADR. The 2004 CDG R egulations are cu rren tly
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inconsisten t w ith ADR; the current CDG Regulations refer to ADR 2003, 
but all fu ture CDG regulations w ill be released the same year as ADR. 
The next am endm ent to ADR is due to be released in 2005i, and then in 
2007, 2009, etc.
The UN Model Regulations do not have a specific  defin ition  for healthcare 
w aste; however certa in healthcare wastes fa ll w ith in the scope of 
dangerous goods regulations and are c lassified  as such. Dangerous 
goods (including waste m ateria ls) are assigned a fou r-d ig it code based on 
the ir prim ary hazard, known as the UN Number. Section 2.3.1 and 
Appendix A3 provides deta ils  on the de fin ition  of in fectious substances for 
transport and the use of the UN Numbers.
United States of America
In the United States of Am erica (USA) the term Hospita l W aste ’ is used to 
refer to all wastes generated from healthcare activ ities and the term 
‘Regulated Medical W aste ’ refers to m ateria ls generated as a result of 
patient d iagnosis, treatm ent, or im m unisation (ERA, 1989). A lthough it is 
genera lly  agreed that Regulated M edical W aste refers to that proportion of 
hospita l waste that has the potentia l to transm it in fectious disease, there is 
no un iversa lly  accepted de fin ition  (M cVeigh, 1992). The Environm enta l 
P rotection Agency (ERA) categorises Regulated M edical W aste into 7 
classes (Appendix A4) based on prim ary hazard. The ERA categories are 
sim ilar to the 9 hazard categories used by the WHO, though not as 
com prehensive as specific  waste m ateria ls, such as pressurised 
containers, are not listed.
2.2.2 European Defin itions of H ealthcare W aste  
Healthcare Waste Priority Waste Stream Project
The P riority W aste Stream Project in itia tive  was launched by the European 
Com m ission (EC) in 1991 to establish action plans for waste where it was 
fe lt additional data or in form ation was required (EC, 1993).
1 Since initial submission of this dissertation ADR 2005 has been published (applicable 
from 1st January 2005) and the GB CDG Regulations have been amended, the 
Dangerous Goods and Use of Transportable Pressure Equipment (Amendment) 
Regulations 2005 came into force on 22nd July 2005.
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In June 1992 the Healthcare Waste Priority Waste Stream Project was 
started with the UK as the lead country.
The project group found that differences in the definitions of clinical or 
healthcare waste used in European countries presented a fundamental 
problem and that a Europe-wide definition of healthcare waste was 
required (Watkinson, 1995). As a result of the Priority Waste Stream  
Project, Europe-wide definitions for healthcare waste were established. 
Today these definitions are widely used throughout mainland Europe but 
are not considered common terminology in the UK.
Healthcare and Healthcare Risk Waste
The European definition defines all wastes arising from healthcare 
activities as healthcare waste. Healthcare waste that is considered 
hazardous is further defined as healthcare risk waste (EC, 1993). 
European Member States are not legally obliged to use the European 
classification; however, most do. The use of the standardised definition is 
more pertinent to mainland Europe than in the UK, as waste may cross 
territorial borders for treatment or disposal. It is not common practice for 
waste generated out-with the UK to be transported to the UK for 
treatment/disposal. Historically healthcare waste was transported from the 
Republic of Ireland to the UK; however this practice ceased a number of 
years ago due to the availability of local treatment/disposal facilities.
Healthcare w aste is waste generated as a result of healthcare activities, 
where healthcare is defined as:
“Medical activities such as diagnosis, monitoring, treatment, prevention of 
disease or alleviation of handicap in humans or animals, including related  
research performed under the supervision of a medical practitioner or
veterinary surgeon”
(European Commission, 1993).
Healthcare risk w aste is healthcare waste that is considered hazardous. 
Healthcare waste is divided into five categories:
i. Biological (recognisable anatomical waste);
ii. Infectious*;
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iii. Chemical (toxic or pharmaceutical, including cyto-toxic 
materials);
iv. Sharps (e.g. needles, scalpels, etc.);
v. Radioactive.
‘ Infectious waste is any healthcare waste known or clinically assessed to be at risk of being 
contaminated with any of the biological agents mentioned in Article 2(d) groups 3 and 4 of 
the Council Directive 90/679/EEC of 26,h November 1990 on the protection of workers from 
risks related to exposure to biological agents of Article 16(1) of Directive 89/391/EEC or 
with other viable biological agents artificially cultivated to significantly elevated numbers 
(EC, 1993).
European Waste Catalogue
The European Waste Catalogue (EW C) is a list of wastes produced by the 
European Commission in accordance with the European Waste Framework 
Directive (75/442/EEC) to provide common terminology for describing 
waste throughout Europe. The EWC list is reviewed periodically and 
incorporates the European Hazardous Waste List pursuant to the 
Hazardous Waste Directive 91/689/EEC.
In the UK, the EWC is published in a colour-coded format to aid 
identification of hazardous waste. Absolute entries (shown in red) in the 
EWC are those deemed to be hazardous regardless of their composition or 
concentration. M irror entries (shown in blue) in the EWC are those which 
are recognised as having the potential to be hazardous and require an 
assessment of their composition and concentration. N on-hazardous  
w astes are shown in black (Environment Agency, 2003a).
A full copy of the EWC can be found in Appendix B
The EWC categorises waste into 20 chapters; each chapter is linked to a 
production sector. Table 1 on the following page lists the EWC chapter 
headings.
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Table 1 European Waste Catalogue chapters.
Chapter Number Production sector / Origin of Waste
Chapter 1 Wastes from exploration, mining and quarrying, 
physical and chemical treatment of minerals.
Chapter 2 Waste from agriculture, horticulture, aquaculture, 
forestry, hunting and fishing, food preparation and 
processing.
Chapter 3 Wastes from wood processing and the production of 
panels and furniture, pulp, paper and cardboard.
Chapter 4 Wastes from the leather, fur and textile industries.
Chapter 5 Wastes from petroleum refining, natural gas 
purification and pyrolytic treatment of coal
Chapter 6 Waste from inorganic chemical processes.
Chapter 7 Waste from organic chemical processes.
Chapter 8 Wastes from the manufacture, formulation, supply 
and use of coatings (paints, varnishes and vitreous 
enamels), adhesives, sealants and printing inks.
Chapter 9 Wastes from the photographic industry.
Chapter 10 Wastes from thermal processes.
Chapter 11 Wastes from chemical surface treatment and coating 
of metals and other materials, non-ferrous 
hydrometallurgy.
Chapter 12 Wastes from shaping and physical and mechanical 
surface treatment of metals and plastics.
Chapter 13 Oil wastes and wastes of liquid fuels.
Chapter 14 Waste organic solvents, refrigerants and 
propellants.
Chapter 15 Waste packaging, absorbents, wiping cloths, filter 
materials and protective clothing not otherwise 
specified.
Chapter 16 End of life vehicles from different means of transport 
and vehicle maintenance.
Chapter 17 Construction and demolition wastes.
Chapter 18 Waste from human or animal healthcare and/or 
related research.
Chapter 19 Wastes from waste management facilities, off-site 
waste water treatment plants and the preparation of 
water intended for human consumption and water for 
industrial use.
Chapter 20 Municipal waste (household waste and other similar 
commercial, industrial and institutional wastes 
(including separately collected fractions).
Source: (EA, 2003*)
Chapter 18 of the EWC relates to wastes produced as a result of 
healthcare activities. Within each chapter wastes are described using 6 
digit numerical codes; the first two digits of the code relate to the EWC
20
chapter, the second two digits relate to any sub-grouping within the 
chapter, and the final two digits are unique to the waste. Table 2 provides 
a list of all Chapter 18 EWC codes.
Table 2. Chapter 18 (healthcare waste) European Waste Catalogue codes.
EWC Code Description of Waste
18 01 XX Wastes from natal care, diagnosis, treatment or prevention of disease in
humans
18 01 01 Sharps
18 01 02 Body parts and organs including blood bags and blood preserves, except 18 
01 03*
18 01 03* Wastes whose collection and disposal is subject to special 
requirements in order to prevent infection
18 01 04 Wastes whose collection and disposal is not subject to special requirements 
in order to prevent infection, e.g. dressings, plaster casts, linen, disposable 
clothing.
18 01 06* Chemicals consisting of dangerous substances.
18 01 07 Chemicals other than those listed in 18 01 06*
18 01 08* Cytotoxic and cytostatic medicines
18 01 09 Medicines other than those mentioned in 18 01 08*
18 01 10* Amalgam waste from dental care.
18 02 XX Wastes from research, diagnosis, treatment or prevention of disease 
involving animals.
18 02 01 Sharps except (18 02 02)
18 02 02* Waste whose collection and disposal is subject to special requirements 
in order to prevent infection.
18 02 03 Waste whose collection and disposal is not subject to special requirements in 
order to prevent infection.
18 02 05* Chemicals consisting of dangerous substances
18 02 06 Chemicals other than those listed in 18 02 05*
18 02 07* Cytotoxic and cytostatic medicines
18 02 08 Medicines other than those mentioned in 18 02 07*
‘ Hazardous Waste List Entries
The terminology used in the EWC differs from European definitions of 
healthcare and healthcare risk waste.
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The statutory use of EWC codes on UK waste documentation, including 
duty of care transfer notes, was introduced recently through the Landfill 
(England and W ales) Regulations 2002, Landfill (Scotland) Regulations 
2003 and Landfill Regulations (Northern Ireland) 2003.
2.2.3 UK Defin ition of H ealthcare W aste
The Environmental Protection Act 1990 (ERA, 1990) is the primary 
legislative instrument for the classification of waste in the UK. The ERA 
1990 classifies waste into two broad categories: controlled and non­
controlled waste.
The Controlled Waste Regulations 1992
The Controlled Waste Regulations 1992 provide guidance on the 
categorisation of controlled wastes and were amended in 1994 to include 
the term 'Directive Waste' in accordance with the Directive on Waste 
(75/442/EEC). The Regulations categorise waste on the basis of who 
produced it and who is responsible for its collection and disposal. Figure 1 
illustrates the main classification groups for waste in the UK; the diagram  
has been simplified.
Figure 1. UK waste classification system.
WASTE
Controlled Waste (Directive Waste) Non-Controlled Wastes
i— — T — — I i
Radioactive
Household Commercial Industrial
(Clinical)
Non SpecialSpecial
Source: Adapted from (Croner, 1997)
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Unlike the International and European examples given, there is not a UK 
wide definition for waste generated as a result of healthcare.
Clinical Waste
The current legal definition of clinical waste in the UK is taken from the 
Controlled W aste Regulations 1992, issued under the Environmental 
Protection Act 1990 in England, Wales and Scotland and The Controlled 
Waste Regulations 2002 in Northern Ireland. It has remained virtually 
unchanged since it was first issued under the Collection and Disposal of 
Waste Regulations 1988, issued pursuant to the Control of Pollution Act 
1974.
Clinical waste is defined as:
(a )”Any waste which consists wholly or partly of human or animal tissue, 
blood or other bodily fluids, excretions, drugs or other pharmaceutical 
products, swabs or dressings, syringes, needles or other sharp 
instruments, being waste which unless rendered safe may prove 
hazardous to any person coming into contact with it; and
(b) any other waste arising from medical, nursing, dental, veterinary, 
pharmaceutical or similar practice, investigation, treatment, care, teaching 
or research, or the collection of blood for transfusion, being waste which 
may cause infection to any person coming into contact with it. ”
In practice the term clinical waste is used to define wastes from healthcare 
which pose or may pose a risk of infection or other hazardous 
characteristic.
Clinical waste produced in the home is defined as household waste 
(Schedule 2, Regulation 4, Controlled Waste Regulations 1992) whilst 
clinical waste produced within healthcare establishments is defined as 
Industrial Waste {Schedule 3, Regulation 5(1), Controlled Waste 
Regulations 1992).
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Non-clinical Healthcare Waste
Non-clin ica l waste produced as a result of healthcare activ ities includes a 
wide varie ty of waste m ateria ls:
♦ Household/Com m ercia l W aste (non hazardous) -  general ward 
waste, kitchen waste and o ffice waste e.g. paper, flowers, etc;
♦ Special W aste -  waste m ateria ls with hazardous properties, 
defined by the Special W aste Regulations 1996 e.g. x-ray fixe r and 
developer;
♦ Radioactive W aste2 -  as defined by the Radioactive Substances 
Act 1993.
W aste from residentia l homes, nursing homes or res identia l 
accom m odation w ith in hospita ls is defined as household waste (Schedule  
2, Regulation 4, Contro lled Waste Regulations 1992). All other wastes 
collected from healthcare prem ises should be c lassified as com m ercia l 
waste (Schedule 4, Regulation 6, Contro lled W aste Regulations 1992).
2.3 Defining Infectious Healthcare Waste
In fectious healthcare waste is the fraction  of healthcare waste which poses 
a risk of in fection.
2.3.1 International Defin itions of Infectious W aste
The W orld Health O rganisation (WHO) (Appendix A1) defines in fectious 
healthcare waste as: “ Waste Suspected to contain pathogens e.g. 
laboratory cultures, waste from isolation wards, tissues, (swabs), 
materials, or equipment that have been in contact with in fected pa t ien ts ” 
(WHO, 1999).
The International Solid W aste Associa tion  (ISWA) (Appendix A2) defines 
in fectious waste as ‘Healthcare Risk W aste ’. The ISWA defin ition  does not 
provide any exp lana tory inform ation to fu rther define ‘in fec tious ’ (ISW A, 
1999)
2 Radioactive Wastes are not controlled waste and are not subject to the requirements of 
the Controlled Waste Regulations 1992. The Radioactive Substances Act 1993 regulates 
the management of all radioactive waste.
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The United Nations (UN) c lass ifica tion  of Dangerous Goods includes 
in fectious substances. Infectious substances are defined as “ substances  
which are known or are reasonab ly expected to contain pathogens. 
Pathogens are defined as micro-organisms (including bacteria, viruses, 
r ickettsiae, parasites, fungi), p lasm ids and other agents such as prions, 
which can cause d isease in humans and animals" (UN, 2002a). In fectious 
substances are c lassified  in C lass 6.2 of ADR and are assigned an 
appropria te  UN Number. The assignm ent of a UN Num ber in re la tion to 
waste is based on the c lass ifica tion  of pathogens in the waste to one of 
three Risk Groups based on crite ria  developed by W HO in re la tionsh ip  to 
Laboratory B iosafety (WHO, 1993). Appendix A3 provides a lis t of UN 
Num bers used for in fectious waste and an explanation of the re la tionsh ip  
between UN Num bers and the W HO Risk Group c lass ifica tion  system . The 
WHO Risk Groups are characterised by the pathogen ic ity  of the organism , 
the mode and re la tive ease of transm ission, the degree of risk to both an 
ind iv idua l and the com m unity, and the revers ib ility  of the d isease through 
the ava ilab ility  of known and e ffective  preventative agents and treatm ent. 
The W HO Risk Groups are broadly s im ila r to the UK Hazard G roup system  
for categoris ing in fectious agents developed by the UK Advisory 
Com m ittee on Dangerous Pathogens (ACDP), shown in Appendix C.
W here the waste is reasonab ly expected to contain pathogens in Risk 
Groups 2,3 and 4 it is assigned to UN2814 or UN2900, in the UK this 
genera lly  relates to labora tory healthcare waste and waste from known 
h ighly in fectious d isease patients from isolation units only. General 
c lin ica l waste (derived from patient care) is considered to present a 
re la tive ly  low risk of in fection and is assigned to UN3291 (UN, 2002b). The 
UN Numbers used in re lation to in fectious waste are shown in Table 3.
Table 3. UN classification of infectious substances.
UN 2814 In fectious substance, a ffecting  humans. 
(where pathogen is known)
UN2900 In fectious substance, a ffecting  anim als, 
(where pathogen is known)
UN 3291 Clin ical waste unspecified  N.O.S* 
Regulated m edical waste N.O.S* 
(B io)m edica l waste N.O.S*
*N.O.S -  Not Otherwise Specified.
Source: (UN, 2002*)
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The UN c lass ifica tion  system d iffe ren tia tes between known human and 
animal pathogens and is assigned according to the host organism  (e.g. 
human or anim al) from which the waste was generated.
W hilst the UN c lass ifica tion  of healthcare waste is required for the 
transporta tion  of the waste, it has no form al links to waste regulation and 
the defin itions and term ino logy used do not easily  equate to common 
waste term ino logy. The d iffe rences in te rm ino logy lead to practica l 
d iffe rences w ith regard to waste segregation and transportations.
2.3.2 European Defin ition of Infectious H ealthcare W aste  
Healthcare Risk Waste
In fectious healthcare risk waste includes waste known or c lin ica lly  
assessed to be at risk of being contam inated with any of the b io log ica l 
agents m entioned in A rtic le  2(d) of G roups 3 and 4 of the Council D irective 
90/679/EEC on the protection of workers from risks related to exposure of 
b io log ica l agents of A rtic le l 6(1 ) of D irective 89/391/EEC or with o ther 
viable b io log ica l agents a rtific ia lly  cu ltiva ted to s ign ifican tly  e levated 
numbers. Exam ples of b io log ica l agents include Escherichia coli, 
Salmonella enteritid is  and Mycobacterium tuberculosis.
The Council D irective 90/679/EEC makes d irect reference to the WHO 
pathogen R isk Groups. A sum m ary of the W HO Risk G roups can be found 
in Appendix A3 in re lation to UN transport crite ria .
In the UK a s im plified  approach to the categorisa tion  of b io log ica l agents 
in line w ith D irectives 90/679/EEC and 89/391/EEC was undertaken by the 
UK Advisory Com m ission on Dangerous Pathogens (ACDP). The ACDP 
are appointed by the Health and Safety Com m ission as part of the ir form al 
advisory structure. The ACDP categorise b io log ica l agents (pathogens) 
into 4 ‘Hazard G roups’ on the ir ab ility  to cause human disease by in fection 
and the ava ilab ility  of prophylactic  treatm ent (ACDP, 1995a). The ACDP 
Hazard groups are based on the W HO Risk Groups but are lim ited to 
pathogens a ffecting humans only.
3 Since initial submission of this dissertation and following publication of the consultation 
document: Safe Management of Healthcare Waste (see section 9) , the Department for 
Transport (DPT) has issues guidance in anticipation of changes in ADR 2007 which align 
waste and transport definitions for infectious waste (Department for Transport, 2006).
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Further in form ation on ACDP categorisa tion  and exam ples of pathogens in 
each Hazard Group can be found in Appendix C.
In sum m ary, the European defin ition  of in fectious healthcare waste is 
lim ited to waste contam inated with b io log ica l agents listed in W HO Risk 
Groups 3 and 4. However, it should be noted that the UK in terpre ta tion  of 
the European de fin ition  refers to ACDP Hazard Groups 3 and 4. As the 
ACDP groups relate to human disease only, the UK in terpre ta tion  of the 
de fin ition  of in fectious healthcare waste does not include waste produced 
as a result of anim al healthcare, unlike its European counterpart.
EWC and ‘Special Requirements’
W ith regard to wastes m ateria ls listed in Chapter 18 of the EWC, in fectious 
wastes are those which are subject to ‘spec ia l requ irem ents ’ in order to 
prevent in fection.
The de fin ition  and in terpre ta tion  of ‘specia l requ irem ents ’ may vary 
between European Member States allow ing for harm onisation w ith existing 
defin itions.
2.3.3 UK Defin ition of Infectious H ealthcare W aste  
Special Waste
The Special W aste Regulations provide the regu la tory m echanism  for the 
m anagem ent of hazardous waste in the UK. The Special W aste 
Regulations are currently being am ended throughout the UK to re flect the 
requirem ents of the Hazardous W aste D irective 91/689/EC. In Scotland 
the Special W aste R egulations 1996 have recently been superseded by 
the Special W aste Am endm ent (Scotland) Regulations 2004 (see section 
8.5). S im ilar amendm ents are due in England and W ales; DEFRA has 
recently released a consulta tion docum ent for am endm ents to the Special 
W aste Regulations 1996. It is thought that the new regu la tions in England 
and W ales will be called the Hazardous W aste R egulations and are due to 
be released mid 20054.
4 Since initial submission of this dissertation The Hazardous Waste (England and Wales) 
Regulations 2005 have been published and came into force on 16th July 2005.
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Although the Northern Irish consultation to amend the Special Waste 
(Northern Ireland) Regulations 1998 has not been released, it is thought to 
be imminents. The UK is required to transpose the requirements of the 
Hazardous Waste Directive into relevant UK legislation by Ju ly 2005. 
Details of forthcoming changes in hazardous waste regulation can be 
found in section 8.5.
The interpretation of infectious waste in the new regulations has not been 
finalised and there is currently a project looking at this issue funded by the 
Department of Health (DH) which aims to revise the U K ’s primary guidance 
document: Safe Disposal of C linical Waste (see section 3.3.1). The 
research in this dissertation is used by DH in the revised guidance; 
Section 9 of this dissertation provides further details. The revised 
guidance is due to be released for consultation late 20056.
Until the f indings of the research project are released, in an agreement 
between NHSScotland and the Scottish Environment Protection Agency 
(SERA), the Special Waste Amendment (Scotland) Regulations 2004 are 
‘suspended’ with regard to infectious waste (NHSScotland, 2005). In the 
interim period reference is made to the Special Waste Regulations 1996. 
The requirements of the 1996 regulations in Scotland mirror the 
requirements of the Regulations in England and Wales and the 1998 
Regulations in Northern Ireland.
The Special Waste Regulations define infectious healthcare waste under 
section H9 in Schedule 2, part II. Waste materials defined under H9 are:
“Substances containing micro-organisms or their toxins which are known 
or reliably believed to cause disease in man or other living organisms”
Guidance on the interpretation of infectious special waste is given in SERA 
internal guidance: Special W aste Technical Assessm ent Guidance (STAG). 
S imilar guidance has been produced by the Environment Agency: Special 
Waste Explanatory Note (SWEN).
s Since initial submission of this dissertation The Hazardous Waste (Northern Ireland) 
Regulations 2005 have been published and came into force on 16th July 2005.
6 Since initial submission of this dissertation the consultation of the guidance ‘Safe 
Management of Healthcare Waste’ has taken place and ended February 2006.
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Both STAG and SWEN refer to World Health Organisation (WHO) 
pathogen Risk Groups and state that only waste known or suspected to be 
contaminated with Risk Group 4 pathogens should be regarded as 
infectious special waste.
As discussed in section 2.3.2 in relation to the UK interpretation of the 
European definition of infectious waste it is common practice in the UK to 
refer to the ACDP Hazard Groups as opposed to the WHO Risk Groups. 
Therefore, despite the reference to the WHO categorisation in UK 
guidance, practit ioners often refer to ACDP Hazard Group 4 as Special 
Waste.
Clinical Waste
Clinical Waste is defined by the Controlled Waste Regulations 1992 (see 
section 2.2.3) and includes waste “which may cause infection to any  
person coming into contact with i t ”. The term inology suggests that 
producers take a precautionary approach and evidence of the presence of 
an infectious agent is not required for the waste to be defined as clinical. 
In practice waste is deemed to be clinical if it is suspected to be 
contaminated with ACDP Hazard Group 2 and 3 pathogens.
The definition of clinical waste includes wastes from non-human 
healthcare activities.
2 .4  S u m m a ry  -  In fe c tio u s  H e a lth c a re  W a s te
The definition of healthcare waste varies between countries. International 
definitions of infectious healthcare waste are non-specific and, in general, 
have limited reliance on pathogen classif ication groups. The World Health 
Organisation (WHO) pathogen classification system is based on the 
severity of infection likely to be caused by the waste. The WHO pathogen 
classification system is used by the UN in relation to the classification of 
dangerous goods and is used to c lassify infectious waste, for the purpose 
of transport, from laboratories, healthcare centres and other sources of 
known and identified infections. International defin itions apply to 
infectious wastes generated as a result of both human and animal 
healthcare.
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The European definition of healthcare and healthcare risk waste is w idely 
used across mainland Europe. However, it is not com monly used in the 
UK. Historically, unlike other European Countries, the UK has not used 
term inology to describe all wastes from healthcare; instead defin itions 
relating to individual waste materia ls are used.
There are two defin it ions of infectious healthcare waste used in the UK: 
infectious waste as defined by the Special Waste Regulations and clinical 
waste as defined by the Controlled Waste Regulations. The defin it ion of 
infectious waste in the Special W aste Regulations refers to the most 
hazardous infectious waste materials and includes waste known or 
suspected to be contaminated with biological agents classif ied in 
WHO/ACDP Hazard Group 4. The definition of clinical waste takes a 
precautionary stance and does not require pathogen identif ication or 
classif ication; the defin ition is broad and non-specific and includes “ wastes  
which may cause in fec t ion ”. The defin ition of clinical waste was first used 
in the UK in 1988 and relates to both human and animal healthcare.
There is little or no correlation between the definitions used and although 
reference is made to pathogen groups or classif ications they are not used 
or interpreted in the same manner at International, European or UK level. 
This lack of correlation becomes apparent when reviewing the interaction 
of UN transport criteria in relation to UK waste defin itions. Producers of 
infectious waste are s ta tutorily  bound to comply with both sets of 
regulations; however they do not align; transport regulation requires a 
greater level of pathogen identification than waste regulation. This 
difference in approach leads to practical problems classifying and labelling 
waste.
This dissertation aims to explore the interpretation of both waste and 
transport defin itions, identify the diff icult ies experienced and propose a 
new approach to the management of infectious waste which will align 
regulatory approaches.
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3. CURRENT MANAGEMENT OF INFECTIOUS 
HEALTHCARE WASTE
The current management systems in place in the UK for infectious 
healthcare waste have developed over the past 15 years in response to 
changes in legislation and changes in the waste management industry. 
Today there are a wide variety of options available for the treatment and 
disposal of infectious healthcare waste. As waste management and 
treatment/d isposal systems have changed, guidance documents have 
been produced to help healthcare workers choose the most suitable 
disposal route. National guidance documents have been influential and 
are responsible for the ‘w ork ing ’ definition of clinical waste used in most 
healthcare settings today.
3.1 T h e  R o le  o f H is to ry
Over the past twenty years the management of clinical waste has 
undergone a series of significant changes which have influenced current 
management practices; undoubtedly the largest change was the loss of 
Crown Immunity.
3.1.1 The Loss of Crown Im m unity.
Historically the vast majority of healthcare (clinical and non-clinical) waste 
generated in the UK was incinerated in facil it ies owned and operated by 
the National Health Service (NHS). The incinerators were operated as a 
‘one-s top ’ disposal route for all waste generated on hospital sites.
As the incinerators were owned and operated by the NHS they were 
considered to be the property of the Crown (the nation) and as such were 
covered by Crown Immunity granting the NHS immunity from prosecution. 
As a result of Crown Immunity the NHS had no incentive to meet 
regulatory standards, resulting in the use of often ineffic ient and highly 
polluting facilit ies. The inadequacy of NHS facil it ies often made the 
headlines (BBC, 2003) and in 1991 the National Association for Clean Air 
published a list of twelve Crown Properties (the ‘dirty dozen ’) that it 
claimed polluted the atmosphere with dark smoke and foul emissions; the 
majority of these were hospital incinerators (Collins, 1993).
As a result of the European Union Directive on Combating Air Pollution 
from Industrial Plants 87/360/EEC, Crown Immunity was removed from 
hospital sites; the NHS and Community Care Act 1990 was the enabling
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legislative instrument. Crown Immunity was offic ia lly removed on 1st April 
1991, the year following the introduction of new and more stringent air 
emission standards in the UK via the Environmental Protection Act 1990. 
It was impossible for many hospitals to upgrade their incinerators to meet 
the standards as the financial burden of upgrade was substantia l. 
Estimates at the time suggested that it would cost between £0.25 mill ion 
and £0.75 mill ion per site to upgrade or to build new facil it ies (Willmore, 
1992). This would have meant that the NHS could have potentia lly faced a 
bill for over £300 mill ion (Newchurch, undated). The Government at the 
time acknowledged this and gave hospitals until October 1995 to meet the 
new standards during which time incinerators would be required to meet 
interim standards. The cost of upgrading existing facil it ies or building new 
plants was too high for most hospitals (Audit Commission, 1997) and 
within six years (by 1997) there were only fourteen NHS owned and 
operated incinerators in use (Fischer, 1997).
If hospitals were unable to upgrade their incineration facilit ies, they were 
left with no option but to contract the disposal of their waste to private 
sector waste contractors. The period between 1991 and 1995 brought 
immense change as NHS managers were required to assess, employ and 
manage suitable waste management contractors who were responsible for 
transporting the waste off-site for treatment and/or disposal. For the first 
time the NHS was required to comply with transport regulations in order to
move waste on the public highway. Although the vast majority of NHS
hospitals employed suitable and reliable contractors, the media portrayed 
a very different picture (Times, 1989). However, behind the sensational 
headlines there was real cause for concern, and the NHS waste 
management problem received serious attention in the specia list 
environmental press and journals (Griffiths, 1989a). The closure of
hospital incinerators signif icantly reduced the number of disposal facil it ies 
available and, as demand for facil it ies increased, the cost of d isposal went 
up; costs in excess of £300 per tonne were not uncommon and the NHS 
was not accustomed to paying commercial disposal rates (Pocock,1999), 
(Holliday et al, 2000). In order to reduce long-term costs, a number of 
hospitals negotiated favourable contracts with clinical waste contractors in 
return for allowing them to build facil it ies on their land; this was
encouraged by NHS Estates, an Executive Department of the Department 
of Health, who produced a guide on ‘Jo in t-Ventu res ’ for hospital managers.
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The building of new clinical waste treatment/d isposal plants on the site of 
old plant made planning applications simpler and more likely to succeed 
and often such arrangements brought added benefits to the hospital in the 
form of heat and steam, and in a few cases electricity. However, the 
number of hospital sites able to take advantage of these jo int-ventures 
was small and the pressure on disposal facil it ies remained, as did the 
increasing disposal costs.
In an effort to reduce costs the NHS had to review its waste management 
procedures. The easiest way to reduce disposal costs was to send less 
waste for disposal by incineration. As all hospital waste had historically 
been disposed of together, in the on-site incinerator, hospitals were not 
accustomed to segregating their waste.
The introduction of segregation protocols and clinical waste guidance was 
key to reducing d isposal costs. As new treatment and disposal 
technologies emerged and replaced the use of incineration, segregation 
protocols and guidance changed to meet the needs of these ‘non­
inc ineration ’ technologies.
Case Study One reviews the impact of the loss of Crown Immunity on the 
NHS in Scotland and can be found in the Case Study section following the 
reference section of this dissertation.
3 .2  C lin ic a l W a s te  T re a tm e n t & D is p o s a l
As incineration facil it ies were limited and the cost and time required for 
commission of new incinerators was often prohibitive, the NHS reviewed 
other options available for the safe and effective management of 
clin ical/infectious waste. There are currently a number of treatment and 
disposal options licensed or permitted for the management of clinical and 
other infectious wastes in the UK. However, not all treatment/d isposal 
processes are capable of taking all types of c lin ical/ in fectious waste; the 
types and quantities of waste that a treatment process can accept are 
specified in the waste management l icence/permit and are usually site 
specific.
NHS Estates (NHS England) produced a guidance document for NHS 
Trusts in order to help them assess the suitabil ity  of c lin ical/ in fectious 
waste treatment technologies.
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The guidance was titled: Health Technical Memorandum 2075 (HTM 2075) 
- ‘C linical W aste D isposal/Treatment Technolog ies (Alternatives to 
Inc ineration)’ , and was published in 1998. HTM 2075 is broadly sim ilar to 
a number of internal (unpublished) Environment Agency (EA) guidance 
documents (Environment Agency, 1997) (Environment Agency, 1998). The 
EA internal guidance documents were written to help waste management 
l icensing and enforcement officers assess the license criteria for non­
incineration c lin ical/ in fectious waste treatment technologies. A 
consultancy company called CL Associates provided technical support on 
both the NHS Estates and EA documents. Dr Wayne Turnberg, a 
consultant for CL Associates and author of one of the principal medical 
waste d isposal books in the USA (Turnberg, 1996), co-authored both UK 
guidance documents. The UK guidance documents adopt the US standard 
for m icrobial inactivation and classify  waste treatment technolog ies into 
two groups: ‘High Tem pera tu re ’ and ‘Medium Tem perature ’ technologies.
Guidance on the use of alternative, (non-incineration), technologies has 
not developed sign if icantly  from 1997 and the same standards and 
guidance have been reproduced in more recent guidance produced by 
NHSScotland (NHSScotland, 2002), Scottish Environment Protection 
Agency (unpublished) and Environment Agency (Environment Agency, 
2003b).
3.2.1 Rendered Safe
In order to be licensed/perm itted for operation in the UK all 
c lin ical/ in fectious waste treatment technologies, including incineration, 
must be able to demonstrate that they are capable of ‘ rendering sa fe ’ the 
waste (Holliday et al, 2000).
SERA have recently adopted the fo llow ing defin it ion of rendered safe:
“An accepted method or process had been applied which:
I. Reduced the apparent number or activity of pathogens so that no 
additional precautions are needed to protect workers or the public 
against infection by the waste;
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II. Destroys any human tissue, organ or body part so that it is ruined, 
torn apart, or muti la ted through processes such as thermal treatment, 
melting, shredding, grinding, tearing, or breaking such that it is no 
longer genera lly  recognisab le;
III. Renders any syringes, needles or equipment unusable and no longer  
in their orig inal shape or fo rm ”.
(Scottish Environment Protection Agency, undated3).
In the absence of international standards for the treatment of 
c lin ical/ in fectious waste, reference is made in the UK to the USA State and 
Territorial Association on A lternative Treatment Technolog ies (STAATT) 
standards. There are four STAATT recognised inactivation (disinfection) 
standards: Appendix D provides further information about all four 
standards and the development of the STAATT criteria.
Both the EA and SERA state that the minimum treatment (disinfection) 
standard for clin ical/ in fectious waste technologies in the UK must be 
STAATT III or equivalent. STAATT III is defined in relation to the microbial 
kill achieved by reference to a standard organism, and is defined as: 
‘‘Inactivation o f vegetative bacteria, fungi, l ipophil ic /hydrophilic  viruses, 
parasites and mycobacterium at a 6 lo g 10 reduction or g reater; and  
inactivation o f B .stearothermophilus or B.subtilis spores at a 4 lo g 10 
reduction or g rea te r ”. (Turnberg, 1996).
Once treated, the clinical / infectious waste is deemed to be non-infectious 
and may be disposed of in municipal waste disposal facil it ies such as 
incinerators or landfills.
3.2.2 High Tem perature Technologies
High temperature treatment technologies are generally defined as those 
that treat waste at a temperature in excess of 500-C. Examples of high 
temperature treatment systems include incineration, gasif ication and 
plasma technology (Schwager, 1998), (Chamberlain, 1997). High 
temperature technologies generally meet STAATT Level IV or greater and 
are often capable of treating a wide variety of clinical wastes, including 
radioactive and pharmaceutical wastes, and therefore less segregation 
prior to treatment is required by the producer (Brookes, 1997).
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The most commonly used high temperature technology is incineration. 
Incinerators capable of treating clinical waste are often expensive to build 
and maintain. Over recent years there has been a trend in a reduction in 
the amount of waste sent for incineration, with producers favouring lower 
temperature technologies which are often cheaper. However, high 
temperature technologies are the only treatment/d isposal route for certain 
types of clinical waste in the UK, including highly infectious waste.
3.2.3 Medium Tem perature Technologies
Medium temperature technologies are often referred to as ‘a lte rnative ’ 
technologies as they offer a viable alternative to incineration for a 
significant percentage of the clinical waste stream. The use of ‘a l te rnative ’ 
technologies is growing rapidly as they are often seen as easier to 
commission and they often attract less negative public opinion than 
experienced in the commissioning of incinerators. Generally medium 
temperature technologies operate under a waste management licence and 
operate to STAATT (disinfection) Level III. Some of the newer 
technologies recently introduced in the UK are capable of treating the 
waste to STAATT Level IV.
There are a number of medium temperature c l in ical/ in fectious waste 
treatment technologies currently in use in the UK. Of these there are three 
main types; dry heat disinfection, microwave dis infection and autoclaves 
(Galbraith et al, 1993), (Lamont, 1997). Other technologies, including 
chemical d isinfection are used elsewhere (Jette, 1992).
Treatment systems are available commercia lly based on one or more 
treatment types and a number of mobile sites have been licensed allowing 
producers to avoid costly transport. The most commonly used alternative 
technology in the UK is dry heat disinfection; however the use of other 
types of treatment is increasing.
Restrictions are often placed on the type and quantity of waste which can 
be accepted by alternative technologies, in line with their waste 
management licence. Generally alternative technologies are not l icensed 
to accept anatomical, pharmaceutical or radioactive waste (Unknown, 
1998), (Malloy, 1997a), (Malloy, 1997b) (Hoffman et al, 1994). Producers 
are therefore required to segregate their clinical waste at source and use 
suitable controls, including waste audits, to ensure that only waste
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specified in the treatment fac il i ty ’s licence is sent for disposal at such 
sites.
Producers have to demonstrate that an alternative, high temperature, 
facil ity is available to dispose of the anatomical, pharmaceutical and 
radioactive waste, which accounts for approximate ly 5% of the total clinical 
waste stream by weight.
Once treated, the residue (often called flock) may be landfilled or 
incinerated in a municipal solid waste (MSW) incineration facility. 
A lthough different treatment systems alter the volume of the waste, in 
general medium temperature technologies (e.g. autoclaves) reduce the 
volume of waste by approximate ly 20%, whereas high temperature 
technologies (e.g. incinerators) generally give a volume reduction in the 
region of 75%. Since the medium temperature technologies do not greatly 
reduce the volume of the waste treated they are considered to be a ‘p re ­
trea tm ent’ rather than a disposal option.
In the past there has been some confusion over the acceptance of sharps 
waste (primarily used needles) at medium temperature treatment facil it ies 
as this waste often contains residual amounts of pharmaceutical products. 
Both SERA and the EA have recently taken steps to clarify this s ituation 
and have stated that fu lly discharged sharps may be accepted at treatment 
facilit ies 7 (Environment Agency, 2003b) (Environment Agency, 2003°) 
(Environment Agency, 2003d) (Scottish Environment Protection Agency, 
undated). However the contractor has a duty to treat all residues from the 
treatment process as special wastes as medium temperature facil it ies do 
not signif icantly alter the chemical composition of the waste and the 
residual pharmaceuticals in the waste remain active.
7 Since initial submission of this dissertation the Environment Agency has released 
guidance for consultation (March 2006) in relation to permitting of clinical waste treatment 
facilities in line with the Pollution Prevention and Control (England and Wales) 
Regulations 2000 stating that medium temperature treatment facilities should not accept 
sharps waste. Ref: IPPC Alternative Treatment of Clinical Waste: Appendix 5 to Guidance 
for the Recovery and Disposal of Hazardous and Non-Hazardous Waste (IPPC S5.06)
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As the vast majority of pharmaceutical products used in healthcare are 
Prescription Only Medicines (ROMs), which are Special Waste in 
accordance with the Special Waste Regulations 1996, the treatment 
residue is considered Special Waste.
The disposal of large amounts of treatment residue as Special Waste 
poses a significant problem as the number of Special Waste landfill 
facil it ies is limited; current data suggests that there are less than fifteen 
suitable landfill facil it ies in England, one in Wales and none in Scotland 
and Northern Ireland (Environment Agency, 2005)
3 .3  C lin ic a l W a s te  G u id a n c e
As clinical waste management operations have changed, guidance 
documents have been used to help inform staff of changes in practice. 
Over the past fifteen years waste management in the NHS has undergone 
a period of immense change. When crown immunity was in place, there 
was little or no waste segregation and all waste was treated/d isposed of 
on-site. As the use of private contractors increased due to hospitals no 
longer being able to afford to operate their own disposal facil it ies fo llowing 
the removal of crown immunity, guidance was required to help staff 
segregate and package the waste for disposal off-site. It should be noted 
that changes in practice and guidance have focused on changing 
segregation practices in relation to disposal methods and little or no 
consideration has been given to requirements of transport regulation. The 
classification and defin itions used have primarily  originated from waste 
legislation.
By reviewing the most commonly referred to guidance documents 
produced in the past two decades, changes can be observed in the way 
clin ical/infectious waste has been classified and segregated. Full text of 
each of the classification systems, where applicable, can be found in 
Appendix E.
3.3.1 Change in Guidance  
British Standards Institution 1973/1987 (now withdrawn)
The earliest guidance document found that attempts to categorise 
c l in ical/infectious waste was published by the British Standards Institution 
(BSI) in 1973 as part of BS3316(4), the standard for incinerators
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destroying hospital waste. Re-published in 1987 (British Standards 
Institution, 1987) (Appendix E1) the Standard classifies all waste from 
hospital premises into four classes A to D. The classification system does 
not d ifferentiate between hazardous and non-hazardous waste and does 
not identify waste which poses a risk of infection. The classification 
system simply groups waste from the same origin, regardless of infection 
risk posed. The classification system reflects hospital and waste 
management practice of the time, as all waste would have been collected 
together and disposed of within the on-site incinerator facility.
The BSI definition pre-dates the first statutory definition of clinical waste 
found in the Controlled Waste Regulations 1988 and therefore at the time 
of its publication there was no statutory requirement to segregate waste on 
the premise of risk.
Health Services Advisory Committee 1982
The Health Service Advisory Committee (HSAC) 1982 guidance (Appendix 
E2), titled, ‘The Safe Disposal of Clinical W aste ’ was written for use in 
NHS Hospitals and, unlike the British Standards guidance and 
c lassification system, was written on the premise that “some waste  
generated in hospita ls and other healthcare establishments may be 
hazardous or o ffens ive ”.
Like the BSI classification system the HSAC 1982 guidance pre-dates the 
first statutory definition of clinical waste. Unlike the BSI classif ication 
system, the HSAC guidance is predominate ly written from a health and 
safety perspective and is based on the use of risk assessment. HSAC was 
appointed by the Health and Safety Commission (HSC) in 1980 to advise 
the HSC on health and safety in the work of the health services. The 
purpose of the HSAC 1982 guidance was to “provide employers with an 
indication o f the measures they shou ld  adopt to ensure compliance with 
their genera l legal duties under Sections 2 and 3 o f the Health and Safety  
at Work Act 1974”.
The HSAC 1982 guidance was the first comprehensive guidance docum ent 
on the management of clinical waste and the first to formally introduce the 
use of risk assessment in infectious waste management. The HSAC 1982 
guidance has been the template for v irtually all other guidance documents, 
including those used today, and the use of risk assessment in the
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identif ication and classification of clinical waste is a fundamental principle 
in the current management of clin ical/ infectious waste (Hart, 1982), 
(Storey et al, 1989), (Griff iths, 1983), (Griffiths, 1989b), (British Medical 
Association, 1994), (Gibbs, 1990), (Carlisle, 1996).
The HSAC 1982 guidance classifies waste into five groups, labelled A to 
E. The groups are based on the origin, or source, of the waste and the 
likely risk posed by the waste. In addition to the classif ication system 
HSAC also recommend a colour coding system for clinical waste 
containers based on the disposal route of the waste.
The HSAC 1982 guidance is based on the premise that all infectious 
waste, which it states should be placed in yellow bags, should be 
incinerated. This reflects the waste management arrangements of the 
NHS in the early 1980s when most hospitals operated their own 
incineration facilities.
London Waste Regulation Authority 1989
In 1986 the Greater London Council (GLC) established a group called the 
Clinical Waste Enquiry in London (CWEL), a working party set up to review 
clinical waste management. After the demise of the GLC, the group 
continued its work under the auspice of the London Waste Regulation 
Authority (LWRA) (Collins et al, 1993). In 1989 LWRA published 
‘Guidelines for the Segregation, Handling and Transport of Clinical W as te ’ 
(Appendix E3); this document was the first guidance document produced 
after the publication of the statutory definition of clinical waste in 1988.
Like the British Standards Institution and the HSAC, the LWRA proposed 
its own classification system for clinical waste. The LWRA classif ication 
system is very sim ilar to the HSAC classification system, as it is risk based 
and groups wastes which are likely to pose similar risk together. 
Legislative requirements relating to the transportation of the waste were 
limited and summary information was provided on registered carriers 
requirements. No reference was made to definitions used in transport 
regulation.
National Association of Waste Disposal Contractors 1991
The National Association of Waste Disposal Contractors (NAWDC) formed 
a Clinical Waste Working Party in 1990 at the request of the Assoc ia t ion ’s
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National Executive Council and was charged with the task of reviewing the 
various options available for the proper management of clinical waste. 
Unlike the BSI, HSAC and LWRA guidance, NAWDC guidance was written 
specif ica lly  for waste contractors, and had little or no relevance to 
healthcare providers and producers of clin ical waste.
The NAWDC guidance made a number of recommendations, including the 
segregation of infectious waste at source, the use of standardised 
packaging for transport, and the disposal of the waste by high temperature 
incineration (NAWDC, 1991).
These recommendations reflect the concerns of contractors embarking on 
waste disposal contracts with the NHS following the removal of crown 
immunity. The NAWDC guidance was the first to highlight packaging 
requirements in relation to transport regulations.
Health Services Advisory Committee 1992
In 1992 HSAC revised the document, ‘Safe Disposal of Clinical W as te ’ 
(Appendix E5). References to legislative instruments were up-dated and 
small changes were made to the classification system. Whilst the 
classification system of five groups labelled A to E remained, subtle text 
changes requiring further use of risk assessment were added. Phrases 
including “...where the assessment indicates a r is k ” and “. . .po tentia l ly  
infectious w aste” are present in the HSAC 1992 guidance that were not 
included in the earlier HSAC 1982 publication. It is likely that the ‘ r isk ’ 
phrases were added to align the HSAC classification with the 1988 
statutory definition of clin ical waste which states that clinical waste is 
waste “which may pose a risk o f in fec t ion ”.
Like the 1989 LWRA guidance the HSAC 1992 guidance does not contain 
any reference to transport regulations.
Department of the Environment 1993 (unpublished)
Waste Management Paper 25 (WMP25) was orig inally published by the UK 
Government in 1983; however there are very few copies of this publication 
in circulation. The last Waste Management Paper 25 to be issued was 
circulated as a consultation draft by the Department of the Environment 
(DOE) in June 1993. Amended to take into account changes in legislation, 
including the loss of crown immunity, WMP25 provided a com prehensive
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guide to the management of clinical waste from a wide range of sources, 
not only the NHS. Throughout WMP25, the DOE refers to the 1992 HSAC 
guidance and quotes the HSAC classification system, c lassifying waste 
into Groups labelled A to E.
The original WMP25 (1983) made no reference to transport regulations 
and it appears to assume that limited off site transportation would be 
required as "Hospita ls usually  endeavour to destroy their c l in ica l waste on­
site by incineration. If o ther incinerators within the hosp ita l group or an 
inc inerator at another private hospita l is to be used, the hospita l normally  
takes responsib il i ty  for the movements o f these w as tes”] (DOE, 1983). 
The 1993 consultation draft of the guidance reflected the current practice 
of the time and the change in waste management practices from on-site 
disposal to the transportation of the waste to off-site disposal facilit ies. 
The 1993 draft provides limited guidance regarding the transport of the 
waste and makes no reference to transport regulations. The draft focuses 
on the legal obligations of employers as related to the Control of 
Substances Hazardous to Health Regulations 1988 (COSHH) and makes 
direct reference to the NAWDC 1991 guidance with regard to packaging 
requirements.
WMP25 remained as a consultation document for 3 years before it was 
announced that it would not be published and that in its place a jo int 
Department of Environment Transport and Regions (DETR) and HSAC 
document would be published. The jo int guidance was published by HSAC 
and released in 1999.
London Waste Regulation Authority 1995
In 1995 LWRA revised their ‘Guidelines for the Segregation, Handling, 
Transport and Disposal of Clinical W aste ’ . Unlike the LWRA 1989 
publication, the 1995 document did not propose a classif ication system for 
clinical waste; instead the guidelines made direct reference to the HSAC 
1992 classification system.
The LWRA guidelines were com prehensive and provided guidance on the 
segregation, storage, handling, transport, treatment and disposal of a wide 
range of clinical wastes. Separate parts of the guidance document 
covered waste from non-NHS sources and the guidance even extended to 
clinical waste from non-human (animal) healthcare.
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Whilst the vast majority of information contained within the LWRA 
guidelines would be of use throughout the UK, not just London, the LWRA 
guidelines provided limited information on options for non-incineration 
treatment and disposal. By 1995 the NHS in other parts of the UK had 
a lready started to investigate non-incineration technologies for the 
treatment and disposal of clinical waste.
The LWRA guidelines provided information on the transport of clin ical 
waste and specified the requirements of transport regulation, notably: the 
Carriage of Dangerous Goods by Road and Rail (Classification, Packaging 
and Labelling) Regulations 1994, the Road Traffic (Carriage of Dangerous 
Substances in Packages, etc) Regulations 1992 and the Road Traffic 
(Training of Drivers of Vehicles Carrying Dangerous Goods) Regulations 
1992. The 1995 LWRA guidelines, provided information on the 
classification (definitions) of infectious waste for transport and the 
appropriate packaging and labelling of that waste. The guidelines dealt 
with transport as a separate issue and no attempt was made to compare 
the defin itions and classification used in waste regulation with those used 
in transport regulation.
NHS Estates 1995
In 1995 NHS Estates produced a Guidance Note tit led: ‘Safe Disposal of 
Clinical Waste: Whole Hospital Policy G uidance ’. The guidance was 
based on the premise of health and safety legislation and makes direct 
reference to the HSAC 1992 guidance and classification system.
Like the LWRA 1995 guidelines, the NHS Estates guidance does not 
provide comprehensive information on the disposal options for clinical 
waste. The NHS Estates guidance was produced to aid NHS Trusts in the 
procurement of waste contractors. It specif ica lly states that incineration is 
the only disposal route for the vast majority of clin ical waste. The release 
of the guidance was timely and coincided with the revocation of interim 
incineration standards that were put in place in 1990 following the loss of 
Crown Immunity, when many Trusts were faced with no option but to close 
their on-site incineration facil ity  and negotiate external contracts with 
waste management contractors. The 1995 guidance makes limited 
reference to transport regulations and reference is made in the context of 
procuring appropriate services, no information is provided on interpreting 
transport regulation and associated defin itions.
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Health Services Advisory Committee 19998
The most recent version of ‘The Safe Disposal of Clinical W as te ’ was 
published by HSAC in 1999 and written with the assistance of the 
Department of the Environment, Transport and Regions (DETR) (Appendix 
E5). Whilst the A to E classification system has remained virtually 
unchanged from the HSAC 1992 guidance, there have been a number of 
s ignificant changes in the guidance document. The 1999 guidance reflects 
current clinical waste management practice, where waste is segregated on 
the premise of generic risk assessments (based on assumptions about the 
health of the source population) and packaged and transported for off-site 
treatment and disposal. Unlike earlier HSAC publications the 1999 
guidance provides information about a range of treatment and disposal 
options for clinical waste and provides examples of non-incineration 
technologies.
The 1999 guidance is wider in scope and includes waste from a number of 
non-NHS sources. The guidance makes a number of broad assumptions 
about the health of those receiving healthcare and those in the general 
community and uses those assumptions as a basis for the guidance. The 
guidance assumes that those receiving healthcare cannot be assumed to 
be healthy or free from infection, whilst this assumption can be made of 
the ‘general popu la tion ’. By making these assumptions the HSAC 
guidance differentiates between two main producers: those in the ‘general 
com munity ’ and those receiving healthcare. Where healthcare waste is 
produced in the community (for example from community nursing or 
chiropody) the waste is only considered to be clinical fo llowing assessment 
by a qualif ied healthcare practit ioner.
The 1999 guidance, unlike earlier guidance, introduces the term ‘human- 
hygiene w astes ’ describ ing it as including items such as sanitary towels, 
nappies and incontinence pads. The guidance states that when such 
items are produced from the general community the waste may not be 
clinical as it may be assumed that the source population is healthy and 
free of infection. However, when human hygiene waste is produced from 
those receiving healthcare this assumption cannot be made.
8 Since initial submission of this dissertation HSAC 1999 guidance has been withdrawn.
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The 1999 guidance was the first guidance document to refer to the 
d ifferences in defin ition of infectious waste orig inating from transport and 
waste legislation, c learly stating that “the defin it ion o f c l in ica l waste for 
transport is d if ferent from the definition used in the Contro lled Waste  
Regulations” . The guidance attempted to direct the reader to the 
appropriate transport requirements by ‘s ign-posting ’ the relevant section of 
the transport regulations; however, no attempt was made to align the 
d ifferent regulatory approaches.
Institute of Wastes Management 2000
In the autumn of 1998, the Institute of Waste Management (IWM) held a 
workshop on clinical waste management. In response to delegate views 
expressed at the event the IWM decided to write a guidance document 
“drawing together the main developments in policy, operational practice  
and treatment techno logy”. In order to achieve this task the IWM formed a 
Healthcare Waste Special Interest Group, comprised of representatives 
from the NHS, Infection Control Nurses Association, Health and Safety 
Executive, International Solid Waste Association, Sanitary Medical 
Disposal Services Association, Association of British Healthcare 
Industries, technical consultants and academics.
The resulting guidance titled: ‘Healthcare Waste Management and 
M in im isation ’ was published in June 2000. Unlike earlier guidance 
documents the IWM document attempted to define existing best practice 
throughout the UK. The IWM guidance relates to both NHS and non-NHS 
practice and includes a number of case studies. Like many of the other 
guidance documents, the IWM guidance reiterates the HSAC 1999 
guidance classification (using risk groups labelled A to E) and considers 
the use of risk assessment with regard to NHS waste management as a 
“core ac t iv i ty ”. The IWM guidance provides a comprehensive summary of 
the main treatment and disposal options available for clinical waste and 
highlights the suitabil ity  of each technology by waste type. With regard to 
transport regulation the guidance refers to the existence of specific 
regulation (Carriage of Dangerous Goods (Classification, Packaging and 
Labelling) Regulations 1996), but provides no further detail.
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Scottish Hospital Technical Note 3, 2002
Scottish Hospital Technical Note 3 (SHTN3) was written by the 
NHSScotland Property and Environment Forum and was published in 
October 2002. Unlike the other guidance documents reviewed in this 
section, SHTN3 is issued free of charge to all NHSScotland premises. 
SHTN3 is the most comprehensive of all the guidance documents; 
however, it relates only to Scottish NHS waste management arrangements. 
Although in parts SHTN3 is relevant to other parts of the UK, the guidance 
is written predominantly from an NHSScotland perspective.
Although SHTN3 makes reference to the HSAC 1999 clinical waste 
c lassification, the HSAC classification system is not w idely used in 
Scotland. Instead, NHSScotland segregates and classifies waste on the 
basis of d isposal route (Appendix E6). In 1999, 39 Trusts (of the then 49 
Trusts in Scotland) signed a contract with the same non-incineration waste 
contractor to remove, treat and dispose of all clinical waste. As the non­
incineration technology, dry heat disinfection, was not licensed to accept 
all types of clinical waste, NHSScotland was required to segregate the 
waste at source. In order to aid the segregation process NHSScotland 
introduced a colour coding system for all waste containers. Waste suitable 
for heat treatment was placed in orange containers whilst waste requiring 
incineration (radioactive, pharmaceutical and anatomical waste) was 
placed in yellow containers. SHTN3 provides a detailed breakdown of the 
segregation process and suitabil ity  of various disposal routes for a wide 
range of clinical wastes. In order to reduce the amount of waste wrongly 
classified as clinical, SHTN3 devotes a whole chapter to the use of risk 
assessment.
SHTN3 provides guidance on transport regulation and its content is 
broadly s imilar to HSAC 1999 as it outlines the key transport requirements 
but makes no attempt to align waste and transport regulations defin it ions.
Department of Environment Food and Rural Affairs 2003
In April 2003 Department for Environment Food and Rural Affairs (DEFRA) 
published a brief guidance note on their web site 
(www.defra.gov.uk/env ironm ent/waste /top ics /c l in ica l.h tm ). The guidance 
note is not comprehensive and simply summarises the current legal
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definition and the minimum legal requirements, and refers the reader to 
the HSAC 1999 guidance for further information.
3 .4  S u m m a ry  -  M a n a g e m e n t o f In fe c tio u s  H e a lth c a re  W a s te
Prior to the loss of Crown Immunity the NHS did not specif ica lly  manage 
infectious waste separately from other healthcare wastes; all healthcare 
waste was disposed of in NHS incineration facilit ies. The loss of Crown 
Immunity resulted in the closure of the vast majority of NHS incinerators 
leaving the NHS with no option but to employ waste contractors to 
transport the waste off-site for disposal. The NHS faced signif icantly 
increased waste management costs as waste would often need to be 
transported s ignificant distances as disposal capacity was initially scarce.
Although incineration had been regarded as the only suitable option for 
healthcare waste disposal, new technologies capable of d isinfecting the 
waste emerged. These technologies required less infrastructure, were 
typically lower in cost and could be commissioned with relative ease as 
they did not require the same onerous planning consents as incinerators. 
However, non-incineration technologies were (and still are) limited in the 
type and volume of waste they can accept in accordance with their waste 
management l icence/permit. A lthough capable of treating over 90% of all 
clinical waste, non-incineration technologies are unable to process 
anatomical, pharmaceutical or radioactive waste as these wastes require 
high temperature treatment/d isposal, such as incineration.
In order to uti lise the new technologies the NHS was required to further 
segregate waste at source. Initially NHS segregation practices were used 
to separate clinical waste from other wastes in order to reduce the amount 
of waste requiring incineration. As new clinical waste treatment 
technologies developed the NHS adapted segregation techniques in order 
to produce waste streams suitable for non-incineration, medium 
temperature treatment.
Clinical waste c lassification systems and guidance have played a key-role 
in the development of segregation and management systems. By 
reviewing guidance documents produced over the past 20 years we can 
trace changes in waste management practice at ward level.
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In 1973 the British Standards Institution (BSI) produced guidance on the 
management of hospital waste in association with BS3316(4), the standard 
for hospital incinerators. The BSI guidance, which predates the 
introduction of the defin ition of clinical waste in 1988, did not differentiate 
between infectious waste and other hospital wastes as it assumed that all 
the waste would be treated in the same on-site incineration facility.
The first guidance document to identify and classify infectious healthcare 
waste was produced by the Health Service Advisory Committee (HSAC) in 
1982. A lthough the HSAC guidance also pre-dated the defin ition of clinical 
waste it viewed the management of clinical waste from a health and safety 
perspective rather than a waste management one and recommended that 
waste be segregated on the basis of generic risk assessment. The 
introduction of the definition of c linical waste in The Controlled Waste 
Regulations 1992 aligned the waste management regulatory approach with 
Health and Safety Regulation (COSHH) as the use of risk assessment, by 
identif ication of “ ...waste which m ay pose a r isk o f infection...", was 
included in the waste management definition.
Amended in 1992 and later in 1999 the HSAC guidance remains the 
primary guidance document used in clinical waste management in the UK. 
Whilst other classification systems have been published, the HSAC, 
c lassification of clin ical waste into 5 groups labelled A to E (on the basis of 
risk) remains in use and has been reproduced in many other guidance 
documents. The HASC classif ication is based on a risk assessment 
approach and, though the use of risk assessment is advocated in the 
guidance, it relies on generic risk assessments and assumptions about the 
waste and those who are producing it. The HSAC guidance, and other 
similar documents, refer to the use of risk assessment but provide no 
practical advice on how risk assessment should be undertaken and who 
the appropriate people are to carry out the assessments.
In general there has been an over-re liance on a selected number of 
guidance texts, with the majority of guidance documents cross-re ferencing 
each other. Guidance documents appear to have ‘evo lved ’ from each 
other, adapting as waste m anagement practices have changed. As the 
primary guidance texts, notably the HSAC and LWRA guidance, have been 
produced from a health and safety and waste regulation approach focusing 
on risk assessment (or ‘generic risk assessment approach ’) guidance has
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developed virtually ignoring the requirements of transport regulations. 
Initial guidance (BSI 1972; HSAC 1982; HSAC 1988) did not cover the 
implications of transport regulation despite the introduction of international 
transport regulation to Great Britain in 1968 (ADR, 2003). It appears that 
transport regulation has not been subject to the same evolution as waste 
guidance and is now considered an ‘add-on ’ to existing guidance 
documents. It is likely that this ‘add-on ’ approach has led to the current 
situation where transport considerations are given their own chapter in 
guidance and little or no effort is made to align the defin itions used in 
transport regulation with those used in Health and Safety and Waste 
Regulation.
The LWRA 1994 guidance (as amended in 1995) was the first to provide 
guidance on transport regulation. The key principles of transport 
regulation as detailed by LWRA later appeared in the HSAC 1999 
guidance, and were later transposed, albeit amended slightly, in the 
NHSScotland 2002 guidance. In each case transport considerations are 
included in a ‘transport chapter ’ and little or no reference is made to them 
in the main body of the guidance.
From the assessment of the guidance texts and the defin itions in section 
one it would appear that there are three separate regulatory drivers 
governing the management of infectious waste. These drivers can be 
viewed as ‘p i l la rs ’ supporting infectious waste management as shown in 
the figure 2
Figure 2. Three tier approach to the regulation of infectious waste in the UK.
Infectious Waste 
Management
Health & 
Safety 
Regulation
Transport
Regulation
Waste
Regulation
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The management of infectious waste is governed by waste, transport, and 
health and safety regulations. However, to date, guidance has relied on 
the use and interpretation of waste and health and safety regulation only. 
This d issertation will review current clinical waste practice, by examining 
the implicit assumptions in the guidance, assessing the infectious risk 
profile of the waste in comparisons to household waste and by identify ing 
sources of the infectious waste. This information will be used to generate 
a new approach to c lin ical/ in fectious waste management that will align 
waste, transport and health and safety legislation.
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4. THE PHILOSOPHY OF INFECTIOUS WASTE 
MANAGEMENT
The term philosophy is used to describe the study of basic principles and 
concepts of a discipline. By reviewing the principles and concepts of 
waste regulation and commonly used guidance documents, highlighted in 
sections two and three, the author has identif ied a number of implicit 
tenets and assumptions.
The assumptions stated below appear to have influenced infectious waste 
management practices and were identified by the author from the HSAC 
and LWRA guidance texts and the Environment A gency ’s Hazardous 
Waste Guidance: WM2. Other assumptions are made in guidance texts 
regarding specif ic  aspects of waste management practice; however those 
shown below represent the generally agreed guiding principles influencing 
practice.
4.1 Assumption One
People receiving healthcare in hospital produce in fectious w aste.
This assumption was identif ied from the HSAC 1999 guidance the 
definition of clinical waste in the Controlled Waste Regulations 1992 and is 
made up of two tenets:
♦ people receiving healthcare suffer with infectious d isease i.e. 
infectious people produce infectious waste;
♦ the infectious nature of the waste may be influenced by the 
origin of the waste, or point of production.
The basis of the assumption can be found in the defin ition of clin ical waste 
and the HSAC 1999 classification and guidance. The defin it ion of c linical 
waste states that waste produced as a result of healthcare (the defin ition 
lists various healthcare activit ies) “may cause infection". The HSAC 1999 
guidance makes a number of assumptions about the general health of 
people who produce healthcare waste; the HSAC clearly  d is tinguishes 
between the ‘source popula tion ’ in healthcare premises and in the ‘general 
com m unity ’ . The HSAC guidance states that healthcare premises cannot 
assume a healthy source population and that the infection risk posed by
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the waste is often greater than that from other sources of waste and should 
be treated as clinical.
4.2 Assumption Two
The m ajority  of in fectious healthcare w aste is produced in hospitals.
This assumption is based on the abundance of clinical waste guidance 
written for use in large NHS hospitals. Limited information or guidance is 
available to help the producers of waste from other sources.
4.3 Assumption Three
People living in the ir own homes do not produce in fectious w aste.
This assumption, like assumption one in section 4.1, is based on both the 
defin ition of clinical waste and the HSAC 1999 guidance. These 
specif ica lly exclude waste from households (household waste), unless 
produced as a result of medical intervention (care by a qualif ied 
practit ioner). Therefore, waste produced by individuals in their homes is 
not considered to be infectious waste.
The HSAC guidance makes general assumptions about the health of the 
source population and specif ica lly  states that the source population of the 
‘general com m unity ’ (including householders) can be considered to be 
healthy and free of infection.
4.4 Assumption Four
The risk posed is d irectly  proportional to the hazard.
The terms ‘r isk ’ and ‘hazard’ are often used in relation to the management 
of infectious healthcare waste. The European defin it ion of infectious 
healthcare waste makes the assumption that if waste is contaminated with 
a biological hazard an infectious risk is posed, and that the greater the 
hazard the greater the risk posed.
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4.5 Assumption Five
Clin ical w aste (in fectious w aste) poses a greater risk of infection than  
Household W aste.
This assumption is based on the HSAC 1999 guidance which uses 
domestic waste as a comparator to c linical waste.
Through the review of scientif ic  literature and empirical data these 
assumptions are reviewed in section 5 and 6 and the findings summarised 
in section 7.1. This information along with a review of forthcoming 
regulatory changes, (in section 8), is used as the basis of a proposed new 
definition of infectious waste, which addresses the requirements of waste, 
health and safety and transport regulation.
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5. CHARACTERISTICS OF INFECTIOUS HEALTHCARE 
WASTE
This section of the d issertation explores the characteristics of infectious 
waste by reviewing its composition and assessing the microbial content of 
the waste. The findings of this section are used to explore the 
assumptions made in section 4.
Section 5.1 provides an overview of the composition of infectious waste, 
providing the reader with a greater understanding of the type of waste 
products which are generated by healthcare activities and which may be 
considered infectious.
The microbial characteristics of infectious waste are reviewed section 5.2 
and a comparison with municipal waste is made in section 5.2.2, providing 
information to review assumptions 3 and 5 shown in section 4.3 and 4.5.
Section 5.2.3 reviews the infections of most concern, blood borne viruses, 
exploring their increase and chronic nature which influences where 
infectious waste is generated. The information from section 5.2.3 will be 
used to review assumptions 1 and 2 shown in sections 4.1 and 4.2.
The conditions for an infection to occur are explored in section 5.2.4 and 
the generic risks posed by waste in each of the HSAC classification groups 
(Labelled A to E) are shown in section 5.2.5. A risk framework, initia lly 
developed by the Health and Safety Executive (HSE) is used in section 
5.2.6 to compare and quantify the infection risk posed by Infectious 
(clinical) and municipal waste, providing information to review assumption 
4 shown in section 4.4.
5.1 Average Composition
The composition of infectious waste varies widely depending on the source 
or origin of the waste. For example, infectious waste from hospital 
operating theatres is likely to be comprised of d ifferent waste materia ls 
than infectious wastes generated at ward level. The composit ion of 
infectious waste will vary in relation to the healthcare practice. This 
section of the dissertation is based on data found in l iterature and relates 
to ‘average ’ waste samples taken from large hospitals. It is assumed that 
the samples are representative of waste produced in all areas of the 
healthcare sector for the purpose of comparison.
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A study carried out in Scotland and published by NHS Estates in 1997 
identified four healthcare waste streams, as shown in Table 4. Domestic 
waste and clinical special waste, (shown in the grey and red columns of 
Table 4), are not considered to be infectious waste.
Table 4 shows two infectious waste streams, segregated on the basis of 
treatment/d isposal technologies. Waste segregated into orange 
containers, (shown in the orange column of Table 4), is clinical ( infectious) 
waste suitable for non-incineration treatment/d isposal. C linical (infectious) 
waste segregated into yellow containers, (shown in the yellow column of 
Table 4), requires disposal by incineration.
Data from the NHSScotland Environment Report 2001-2002 (NHSScotland 
Property and Environment Forum 2003a) indicates that the incineration 
only clinical wastes (shown in the yellow and red columns) constituted 4% 
of the total clinical waste produced in Scottish Hospitals, the remaining 
96% of clinical waste was classified in the orange clinical waste stream.
Table 4. Colour-coded segregation of clinical waste used by NHSScotland.
Domestic Waste Clinical Waste 
(Orange container)
Clinical Waste 
(Yellow container)
Clinical Special 
Waste
• Paper • Dressings, • All Human Tissue, • Pharmaceuticals,
Towels, • Incontinence • Recognisable  Body • Chemicals,
• General Pads, Parts, • Drugs.
Clean Waste, • D ia lysis Waste, • Waste from Highly
• Boxes and • Blood and Liquid Infectious Disease
Conta iners, Waste, Cases,
• Cans and • S teri l ised High • Infected Blood,
Bott les, Risk Laboratory • Contam inated
• Flowers, Waste, Large Metal
• Broken Glass, • C ontam inated Objects,
• Newspapers. Sharps, • Foetal T issue and
• Uncontam inated Placentae.
Drug Vials.
Source: adapted from (NHSScotland, 2002).
The information in Table 4 describes the types of waste items segregated 
e.g. dressings, contaminated sharps, etc. However, it does not provide 
information about the composition of those waste materials.
55
A study in southern Italy in 1992, published by Liberti in 1994, assessed 
the average composition and characterisation of source segregated 
(potentia lly infectious) hospital waste, which is equivalent to waste shown 
in the orange and yellow waste streams in Table 4. Hospital waste from 
several Italian general hospitals was used by Liberti and the f indings are 
based on daily infectious waste production of 4.0 litres or 0.44kg per bed 
per day. Liberti ’s findings are shown in Tables 5 and 6 and identify the 
composition of waste in relation to heating value, chemical content and 
material constituents e.g. paper, plastic, glass, etc.
Table 5. Average composition of hospital waste (Italy) 1992.
Material Mass (%) (wet-weight basis)
Paper 34
Plastics 46
Glass 7.5
Metals 0.4
Anatomical waste 0.1
Liquids 12
Others 0.1
Source: (Liberti, 1994)
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Table 6. Hazardous healthcare waste characterisation (Italy) 1992.
Density 0.1 kg/Litre
Heating Value:
high: dry waste 5400 kcal/kg (22.6 MJ/kg)
wet waste 3900 kcal/kg (16.3 MJ/kg)
low: wet waste 3500 kcal/kg (14.7 MJ/kg)
C hlorine Content 0.4%
M ercury Content 2.5 mg/kg
Cadm ium  Content 1.5 mg/kg
Lead Content 28 mg/kg
Source: (Liberti, 1994)
Liberti ’s findings differ from analysis published in the USA and China in 
1990’s, shown in Table 7, 8 and 9.
Table 7. Heat value of infectious (Regulated M edical) waste (USA) 1990’s.
Calorific value 2000-40,000 kJ/kg (ca. 500-10,000 kJ/kg)
Density ca. 80 kg/m3
Source: Adapted from (Wagner, 1998), (U.S Congress, 1990).
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Table 8. Average composition of infectious (Regulated Medical) waste (USA) 1990’s.
Material Mass (%)
Paper, ca rdboard , p las tic  com pounds 25
G lass 9
M etal (not inc lud ing  separa te ly  co llec ted  frac tions  fo r recyc ling  and 
recovery)
1
P lastics 10
O rgan ics (inc. b lood, anim al w aste, etc) 29
D om estic  and industria l garbage 18
Bandages, etc 8
Source: Adapted from (Wagner, 1998), (U.S Congress, 1990).
Table 9. Composition of waste from the National Taiwan University Hospital (China) 
1993.
Mass (%)
Paper 16.17
T extiles 9 .77
C ardboard , wood and leaves 1.12
Food w aste 21.51
P lastics 50.45
metal 0.4
g lass 0.57
Source: (Li et al, 1993)
The variation in results is due to a number of factors including d ifferences 
in definition, source or origin of the infectious waste, variation in 
healthcare practices and the medical devices and equipment used.
Infectious waste typically contains a large percentage of waste materials 
made from paper, plastics or composite packaging materials. The density
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of the waste analysed in the Italian and American surveys differed; the 
Italian study recorded an average density of 0.1 kg/litre; equivalent to 
110kg/m3, whilst the American study recorded a density of 80kg/m 3. The 
Italian waste contained the highest percentage of paper, the Chinese 
waste contained the highest percentage of plastic and American waste 
contained the highest percentage of glass, reflecting the predominant 
types of packaging used in each country.
The calorif ic value of the waste in both the Italian and American studies 
was higher than the calorif ic value of domestic waste (municipal solid 
waste) as reported by the UK Department of Trade and Industry (DTI), 
reflecting the greater concentration of combustib le materials, primarily 
paper and plastic in the healthcare waste stream. The DTI study assumed 
an average calorif ic value of 13MJ/kg (PriceWaterHouseCoopers, 2002) 
compared to the values identif ied in the Italian study of 14.7-22.6MJ/kg 
and values from the American study of 20-40MJ.kg. The calorif ic value of 
the Chinese waste is not known, however it is likely to be as high as the 
American waste due to its high plastic content. The calorif ic  value of 
segregated Infectious waste is s imilar to that of wood (approximately 
20MJ/kg) and may even be as high as coal (approximately 30MJ/kg) 
(Electric ity Association Services, undated), (World Energy Council, 2003).
The Italian study indicated that 80% of the source segregated ( infectious 
waste) was combustib le; studies in Wales looking at municipal solid waste 
(MSW) indicate that the combustib le fraction of MSW is much less, 
approximate ly 44% (AEA Technology, 2000). Further details of the Welsh 
study can be found in Appendix F.
The combustib le nature of infectious waste and its high calorif ic value 
make it ideally suited to disposal by incineration with energy recovery. 
However, as outlined in section three, the use of incineration as a disposal 
option has been reduced as a result of financial and legislative pressures.
5.2 Microbial Characteristics of Infectious Healthcare Waste
Appendix G contains a brief introduction to the three most common groups 
of pathogens: bacteria, viruses and fungi. These pathogen groups are 
referred to in this section and the information in Appendix G is provided as 
a basic introduction to aid in the understanding of the fo llowing text.
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Infectious waste, like all waste streams, including MSW, has the potentia l 
to contain hazards in the form of bacteria, viruses and fungi. This section 
looks at the microbial content of infectious waste streams at international, 
European and UK level from published data.
5.2.1 M icrobial Assessm ent of Infectious W aste
There have been a number of investigations, (predominate ly carried out by 
American scientists in the early 1970s), il lustrating that freshly d iscarded 
infectious waste contains a broad range of m icro-organisms (Smith, 1970), 
(Wallace et al, 1972), (Trigg, 1971), (Burchinal et al, 1973). However, 
most of the micro-organisms isolated and identif ied, including those from 
known infectious patients, were considered to be commensals or symbiotic 
and are part of the ‘normal’ f lora of the human body. The human body 
‘hosts’ large numbers of micro-organisms and those isolated from 
infectious waste are commonly found on the skin and in the intestinal and 
upper respiratory tracts (Meers et al, 1980), (Lynch et a,I 1986). In 1988 
Hendrick concluded in his paper ‘ Infectious Waste Management: Will 
Science Prevail? ’ that the presence of common micro-organisms such as 
Pseudomonas  and Klebsiella  spp. in infectious healthcare waste was not 
surprising as the organisms often found in waste are readily found in the 
environment and that their presence did not necessarily make the waste 
infectious. In 1989 Daschner assessed the microbial content of infectious 
waste from a sample of hospitals in the USA and concluded that the vast 
majority of segregated infectious waste did not pose a risk of infection and 
that the infectious content was approximate ly 3.5% of the microbial mass.
Whilst the American research findings are broadly accepted, the World 
Health Organisation (WHO) does not understate the potentia l infection risk 
posed from infectious healthcare waste and has published examples of 
human infections which may be initiated by exposure to infectious 
healthcare waste, shown in Appendix H. A number of the infections 
identified by WHO are not commonly found in the UK (for example, Lassa 
and Ebola viruses) and it should be noted that the spread of infection 
associated with many of the m icro-organisms listed (for example 
Salmonella, Streptococcus  and Staphylococcus  spp.) will be due to poor 
hygiene rather than waste management practices.
Research carried out in the UK (Birm ingham) in the 1990’s indicated that 
the link between infectious disease and infectious waste was questionable
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as fewer m icro-organisms were found in waste from patients in isolation 
wards, (used for infectious disease cases), than in other hospital wards 
(Ayliffe, 1994). However, there is evidence to suggest that some 
infectious healthcare waste can pose a significant risk as the frequency of 
pathogenic viruses, such as hepatitis, can be high (Environment Agency, 
2003a).
A more recent study carried out by Mühlich et a l looking at waste from 
European Hospitals published in 2003, concluded that although hospital 
waste represented a suitable medium; for the reproduction of bacteria, 
studies indicate that it is not a very good culture medium, therefore 
pathogens within the waste are unlikely to remain viable.
5.2.2 Com parison w ith  M unicipal W astes
Municpal waste is often used as a comparator to infectious healthcare 
waste, and a number of research studies have been undertaken comparing 
the microbial content of these waste streams. The terms household waste, 
domestic  waste and domestic  refuse are used to describe fractions of the 
MSW stream.
Municipal waste, whether from medical institutions or homes, may contain 
human pathogens. These may enter the waste stream from food products, 
human excreta, (from disposable diapers), animal excrement, blood, 
exudates, or secretions from dressings, feminine hygiene products, facial 
t issue, condoms or bandages (Turnberg, 1996).
Table 10 compares the total viable count of m icro-organisms per gram in 
untreated infectious healthcare waste, domestic refuse and common 
foodstuffs. The table clearly shows that infectious healthcare waste often 
contains fewer numbers of v iable m icro-organisms per gram than either 
domestic refuse or common foodstuffs.
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Table 10. Total viable count of m icro-organism s in untreated infectious healthcare  
waste, dom estic refuse and common food stuffs.
Total V iable Count of 
O rganism s per Gram
Average result taken from 69 samples of untreated 
infectious healthcare waste.
105
Shredded lettuce 104-106
Raw hamburger 104-105
Cooked chicken 104-106
Domestic refuse 106-108
Source: Data adapted from (NHS, 1995); (Peterson, 1971), (Galbraith et 
al, 1993)
An investigation in Germany in the 1980’s compared 263 waste samples 
from infectious healthcare waste generated in hospitals with municipal 
solid waste (MSW) samples collected from 21 rubbish dumps. It was 
found that hospital waste contained fewer pathogens than MSW and that 
some of the samples of infectious waste contained no micro-organisms. 
Of the 21 pathogenic bacteria and fungi identified in the infectious waste, 
12 were also identif ied in the MSW and the tests for viruses gave negative 
results for both waste streams (Althaus et  a/,1983). Other sim ilar surveys 
comparing MSW with infectious healthcare waste from intensive therapy 
units, nurseries, dental practit ioners and veterinary surgeries have 
concluded that the infection risk posed by infectious healthcare waste is 
not signif icantly greater than the infection risk posed by MSW (Kalnoski et 
al, 1983), (Trost et al, 1985), (Mose et al, 1985), (Rutala et al, 1992).
In 1983 Kalnowski et al. found that MSW often contained greater amounts 
of intestinal bacteria (coliforms) than infectious waste; the bacteria l load of 
infectious healthcare waste found to be 10 to 100,000 times less than 
MSW. Similar findings were published by Mose et al. in 1985 stating that 
although infectious healthcare waste was found to contain a wider range of 
bacteria, larger numbers, especially of faecal bacteria, were present in 
MSW.
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An important finding made in 1990 by Jager et al. identified that fewer 
m icro-organisms and, more s ignificantly, fewer nosocomial agents 9 were 
found in infectious healthcare waste than in household refuse.
It has been stated that the infection risk posed by infectious healthcare 
waste is s imilar to a ‘domestic dish c lo th ’ (Taylor, 1988), or sewage 
(Cimino et al, 1987) and that the public health risks are nominal (AORN, 
1993).
The microbial load of infectious healthcare waste and MSW differ due to 
the types of microbes present. Some of the microbes present in infectious 
healthcare waste are likely to have orig inated from the human body and 
are only capable of surviving within narrow environmental parameters or 
conditions (temperature, pH, etc) and therefore do not survive outside the 
body. Many of the microbes present in MSW do not require a specialised 
environment and are opportunistic (such as intestinal bacteria), and are 
capable of surviving changes in their environment and do not require a 
specific host to initiate an infection.
A recent report on the ‘risk assessment for clinical waste handling and 
d isposa l’ produced by Det Norske Veritas (DNV) for the Environment 
Agency analysed the types of m icro-organisms present in clinical waste 
compared to MSW (Det Norske Veritas, 2000). The DNV report identified 
that clinical waste contained a greater d iversity of m icro-organisms, 
however the microbial loading (the number of micro-organisms) was much 
larger in MSW. Whilst MSW typically contained a higher number of m icro­
organisms capable of causing respiratory and gastro-intestinal infections 
(for example Escherichia co li  and Salmonella enteritid is) the frequency of 
pathogenic blood borne viruses such as Hepatitis B and HIV was higher in 
clinical waste.
5.2.3 Blood Borne Viruses.
Blood borne viruses, in particular hepatitis are often a cause for concern in 
both MSW and infectious healthcare waste (Advisory Committee on 
Dangerous Pathogens, 1995b). W hils t studies undertaken in Germany in 
the 1980s identified that the microbial load of infectious waste was often 
lower than MSW, an important observation was that 2% of all blood-
g Nosocomial agents are those that are spread through contact in close environmental
proximity, typically referred to in relation to hospital acquired infections.
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stained wastes tested were positive for hepatitis viruses (Mose et al. 
1985).
The risk of exposure to blood borne viruses such as Hepatitis B (HBV), 
Hepatitis C (HCV) and the Human Immunodefic iency Virus (HIV) are 
recognised as health hazards facing workers (Croner’s, 1995). HBV, HCV 
and HIV are all chronic diseases with sufferers often remaining infected for 
their life-time. Those infected are often asymptomatic and do not 
demonstrate symptoms for periods in excess of 20 years. The 
asymptomatic period is often referred to as the ‘la tent’ period (Madigan, 
1999). Blood borne viruses in waste pose a specific hazard, and their 
prevalence in waste is increasing as the number of people infected 
increases. Appendix I shows the increase in HBV, HCV and HIV infections 
in the UK. Over the past 21 years the number of notified cased of HIV has 
increased by 251%. A similar trend has been observed in HBV 
notifications during the past 13 years with an increase of 247% being 
recorded. The most s ignif icant increase in notified cases has been 
recorded for the HCV as over the past 11 years the number of notif ied 
cases has increased by 2,455% (equivalent to a 25 fold increase).
5.2.4 Conditions for In fection to Occur
In order for an infection to occur fo llowing contact with infectious waste a
number of conditions must be satisfied:
a) the presence of a pathogen of suffic ient viru lence and in a 
suffic ient number to cause an infection;
b) a portal of entry must be available for the pathogen to enter the
body of a new host; and
c) the host must be susceptible.
There are few situations where these requirements are likely to be met 
(Ayliffe, 1994). A chain of sequential events is required for an infection to 
occur and any break in the chain reduces the likelihood of infection. For a 
risk to be realised to health and/or the environment:
♦ pathogens must be present;
♦ they must be released from the waste mass (from the conta iner or
process);
♦ they must survive and be mobile after release;
♦ they must be present in suff ic ient numbers;
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♦ there must be a pathway to a host;
♦ host must intake the pathogen;
♦ host must be susceptib le to the pathogen; and
♦ the host must not take prophylaxis.
Adapted from: (Environment Agency, 2003b)
This chain of events has been mapped out as a flow diagram shown below:
Figure 3. Flow diagram of conditions for infection to occur.
Contact with
No
No
Infectious Agent Present ? No
Yes
Viable dose ? 
(Time and Quantity)
I Yes
Prophylaxis taken and 
effective ?
No
Injury, but no infection
Injury/Infection does not 
occur
, Yes
No
Infection Occurs
Has previous infection 
occurred?
(If not then seroconversion 
is not relevant)
Yes
Seroconversion occurs and 
is effective.
(If it is effective then 
infection will not occur 
irrespective of the viable 
dose or effectiveness of 
prophylaxis).
Adapted from: (Det Norske Veritas, 2000)
In order to assess the risk of infection posed by infectious waste, one 
would need to assess the likelihood of each of the series of events shown 
in Figure 3. The number of organisms required to initiate infection, the 
viability of organisms in the environment and the infection pathway 
required to enter the host are pathogen specific. As the host’s
susceptib il ity  to a pathogen (or series of pathogens) is specific to the 
individual, it is impossible to accurately assess the likelihood of infection
occurring. In order to undertake a risk assessment a number of
assumptions are required; these assumptions are often based on generic
empirical data.
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Appendix J provides a summary of the infection pathways and viable 
doses for a number of common hospital acquired infections by primary 
pathway e.g. inhalation, ingestion, skin contact and blood-borne. A 
summary of the information is shown in Table 11.
Table 11. Summary table of infection pathways for selected hospital acquired  
infections.
Pathogen Summary Infection Pathway Total viable 
count of 
Organisms per 
gram to initiate 
infection.
Significant risk in 
infectious waste 
?
Aspergillus
spp
Ubiquitous fungus, 
sporeforming.
Airborne (inhalation); 
also contact 
transmission.
2 x 103 NO
(Common 
contaminant -  
reservoirs 
aspergillus 
fumigates 
naturally occurring 
in the 
environment)
Clostridium
difficile
Spore forming bacillus 
responsible for the 
development of 
antibiotic-associated 
diarrhoea and colitis. 
C.difficile forms heat- 
resistant spores that 
can persist in the 
environment for 
several months to 
years.
Ingestion 
(Faecal -O ra l route)
NO
Available in 
natural 
environment. 
Infection requires 
disruption of the 
normal bacteria 
flora of the colon.
Klebsiella
spp.
Gram-negative 
bacillus. 
Ubiquitous colonise 
skin, pharynx, or 
gastrointestinal tract. 
Klebsiella may be 
regarded as normal 
flora in many parts of 
the colon and intestinal 
tract.
Contact and 
contaminated 
invasive devices and 
respiratory support 
equipment.
Greater than 100 NO
Available in 
natural 
environment and 
are considered 
normal flora of the 
body.
Strict attention to 
personal and 
environmental 
hygiene will 
prevent infection.
Hepatitis B 
Virus 
(HBV)
HBV is a Hepadna 
virus. HBV is resistant 
to extreme 
temperatures and 
humidity. It can survive 
for 6 months at room 
temperature and 7 
days at 44-C.
Blood, infectious 
bodily fluids.
Data per gram not 
available. 
Less than 0.04 pL 
(10'8) of infected 
blood required to 
initiate infection 
following needle- 
stick injury.
YES
Risk posed by 
liquid blood and 
infectious bodily 
fluids.
Most significant 
risk presented by 
sharps.
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Table 11 Sources of information: (Johnson, 2000), (Horton et al, 2002), 
(Albright, 2001), (Centre for Disease Control, 1999), (Sprenger, 1997), 
(Ballard et al, 1999), (Public Health Laboratory Service, 2000), (WHO, 
2000a), (WHO, 2000b)
Table 11 and the information in Appendix J indicate that the most 
significant risk of infection is posed by blood-borne viruses, and that the 
risk is at its greatest in relation to needle-stick and other ‘sha rps ’ injuries. 
Many hospital acquired infections are caused by ubiquitous m icro­
organisms. Good personal and environmental hygiene will reduce the risk 
and may prevent infection. Many hospital acquired infections are
opportun istic and occur as a result of increased immunodefic iency or 
changes in the normal flora of the body following drug therapy, such as 
antibiotics (Dial et al, 2004).
5.2.5 C haracteris tics and Risk posed by HSAC C lassification  Group
The Health Services Advisory Committee (HSAC) classifies clinical waste 
into 5 groups on the basis of generalised risk assessment where wastes 
posing s imilar infection risks are grouped together. (See section 3.3.1 for 
further information on the HSAC classification system).
Group A
Group A waste typically includes both liquid and dried blood, infectious 
bodily f luids and waste from infectious disease cases. Group A waste will 
therefore be considered hazardous as it will contain a variety of m icro­
organisms and pathogens. The risk posed by the waste will be dependent 
on a number of environmental factors and will u ltimately be determ ined by 
the viabil ity  of the pathogen, susceptib il ity  of the host and the availabil ity  
of an infection pathway.
Basic environmental and human hygiene will prevent the spread of the 
vast majority of infections and will therefore minimise the infection risk 
posed. The waste is likely to pose the most signif icant risk when 
‘uncontro lled ’ contact is made with the waste through splashing and/or 
contact with unprotected skin or open wounds.
Blood borne viruses, such as HBV and HCV have been identif ied as posing 
a signif icant risk of infection (Appendix J) as they have the ability to 
survive and remain viable in the environment. All waste materia ls
67
contaminated with blood, or other infectious bodily fluids, should be 
considered potentia lly infectious waste.
As the prevalence of blood borne viruses increases in the general 
population (see Appendix I) there is a greater probability  of coming into 
contact with the infectious agent, which in turn will increase the risk posed.
Group B
Group B waste is often defined as ‘sharps ’ waste and includes needles, 
sharp edged instruments and broken glassware (NHS Estates, 2000). 
Sharps pose a signif icant risk of infection as they provide a pathway for 
pathogens to enter the body. Injuries caused by needles are called 
needlestick injuries and despite efforts by healthcare staff to reduce the 
occurrence of needlestick injuries, accidents still occur (British Medical 
Association, 1994), (Griffiths, 1989a), (Rutala et al, 1992), (Gwyther, 
1990).
Syringe needles and other sharp instruments are known to have 
transmitted infection to hospital staff (Ayliffe, 1994), (Kuhls et al, 1997), 
(Public Health Laboratory Service, 1998), (Inagaki et al, 1994),(Malion, 
1992). Collins and Kennedy (1987) reported that at least 22 microbial 
infections have been acquired through needlesticks with the risk of 
becoming infected with HBV, HCV and HIV usually causing the greatest 
concern (Hopper et al, 1991), (Ava et al, 1989), (DiVito et al, 1991). 
Although the risk of HIV transmission through needlestick injuries is 
considered low, a number of cases have been reported (Belani et al, 
1984), (Anon, 1984), (Fitch et al, 1995), (Oksehendeer et al, 1986), 
(Neisson-Vernant et al, 1986). The HIV virus ceases to be infective very 
soon after it leaves the human body (Slade et al, 1989) and in general the 
amount of infected blood required to initiate an infection is greater than 
that contained within the shaft of a needle. An extremely small amount of 
blood, 0.1 pL or less, is injected into the victim of a needlestick injury. It is 
known that 0.04pL is enough to transmit HBV (Napoli, 1987), whilst at 
least 10OpL is required to initiate HIV infection (British Medical 
Association, 1994).
As relatively small amounts of blood are capable of causing infection, 
sharps must be regarded as potentia lly infectious (Collins et al, 1993). In 
addition to the risk of infection, sharps often have other hazardous
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characteristics as they may have been used to administer medicinal 
products.
In addition to the risk posed in the healthcare environment, sharps often 
pose a signif icant risk of infection when discarded as waste out-with 
healthcare activit ies. Collins and Kennedy (1993) reported that almost 11 
million needles and syringes are disposed of as household waste in the UK 
and that in New York (USA) waste collectors and sanitation workers suffer 
from 50-100 needlestick injuries annually (Cimino, 1975).
Group C
Group C waste is comprised of m icrobiological cultures and potentia lly 
infectious waste from pathology departments. The number of pathogens 
present in microbiological cultures is likely to be elevated, and the risk 
posed is likely to be significant as the number of pathogens may be high 
enough to produce a viable dose. However, an infection will not occur 
unless an infection pathway exists.
Group C waste is usually treated in autoclaves to reduce the number of 
pathogens prior to removal from laboratories, therefore Group C does not 
normally pose a s ignificant risk of infection. If Group C waste is not 
treated, an infection risk will be posed and measures will be required to 
ensure that pathogens do not ‘escape ’. Control measures include storage 
in rigid, airtight containers for transportation to specialist incineration 
facilities. If the pathogens present pose a significant risk to human health 
a police escort may be required.
Group D
Group D waste is comprised of drugs and pharmaceutical products. 
A lthough these wastes may be hazardous, with the exception of live 
vaccines they are unlikely to present a risk of infection. Live vaccines are 
usually treated as a Group C waste for waste management purposes.
Group E
Group E waste is comprised of items used to dispose of urine, faeces and 
other bodily secretions or excretions that do not fall within Group A. 
Group E waste will contain a s ignif icant number of pathogens, for example 
Escherichia  spp. and Salmonella  spp; however the risk of infection posed 
may be relatively small. As a large number of pathogens associated with
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incontinence waste are common flora of the body, it is unlikely that they 
will pose a risk of infection unless the host’s immune system is operating 
at a reduced level for example, when the host is taking antib iotic drugs 
(Dial et al, 2004). Antib iotics lower the host’s immune response by 
altering the natural flora of the body resulting in them being more 
susceptib le to opportun istic infections.
The spread of pathogens through skin contact and ingestion (faecal-oral 
route) does pose a risk of infection; however the risk can be s ignif icantly 
reduced by good environmental and human hygiene.
In general, Group E wastes pose a relatively low risk of infection to those 
handling them, although they are often offensive in nature.
Human Hygiene Wastes
The HSAC 1999 guidance (see Section 3.3.1) introduced the term ‘human- 
hygiene wastes ’ describ ing it as including items such as sanitary towels, 
nappies and incontinence pads. The guidance states that when such 
items are produced from the general community the waste may not be 
clinical as it may be assumed that the source population is healthy and 
free of infection, such wastes are often referred to as sanpro waste.
Human hygiene waste is comprised of incontinence products and sanitary 
products and as such will contain a broad range of pathogens. Appendix K 
contains data on the total v iable count of m icro-organisms per gram from a 
selection of human hygiene products. The data shows that large numbers 
of bacteria were present in all the samples examined ranging from 
8.4 x 104 to >3.0 x 1010per gram (Wimpey, 1995). The bacteria l loads 
found in the human hygiene waste were equivalent to, and in some cases 
greater than, those found in infectious waste from healthcare sources; 
therefore human hygiene waste has similar hazard characteris tics to 
infectious healthcare waste. W im pey Environmental Limited, who carried 
out the research, concluded that there were large numbers of v iable 
bacteria, capable of causing a range of infections. However, the risk of 
infection to the waste operatives who manually empty the bins was low as 
air and surface contamination was low.
The Wimpey analysis did not test the waste for the presence of blood- 
borne viruses. However, research carried out in 1992 indicated that the 
incidence of blood-borne viral infections in the community  was probably
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about the same as in hospital patients (Collins et al, 1992) and therefore 
the risk of infection would be broadly similar.
5.2.6 HSE Risk Assessm ent Matrix
The Health and Safety Executive have produced a generic ‘Risk 
Assessment Matrix ’ , which compares the magnitude of the hazard to the 
likelihood of occurrence to calculate risk.
The HSE guidance HSG65 interprets the magnitude of hazard as follows: 
High: Where it is certain, or near certain that harm will occur;
Medium : Where harm will often occur;
Low: Where harm will seldom occur.
If this framework is used to assess the infection risk posed by infectious 
healthcare waste, we would generally find the magnitude of the hazard 
would be ‘ low ’ as harm ‘se ldom ’ occurs from the waste, and the likelihood 
of occurrence would be ‘unlikely ’ as a number of conditions would need to 
be met for an infection to occur. The framework in Figure 4 has been 
adapted to show the risks posed by infectious, human hygiene and 
municipal waste; the adapted framework is shown in Figure 5.
Figure 4. Health and Safety Executive risk assessm ent matrix.
Likelihood of occurrence
M agnitude of 
hazard
Unlikely Likely Very Likely
Low Low risk Low risk Medium risk
Medium Low risk Medium risk High risk
High High risk High risk High risk
Source (Health and Safety Executive, 1997)
Liquid blood and ‘sharps ’ may pose a signif icant risk due to the ability of 
blood-borne viruses to survive in the waste stream and remain viable. The 
magnitude of the hazard may be considered ‘m edium ’, as harm ‘o ften ’ 
occurs as a result of needlesticks, and the likelihood of occurrence would 
be ‘l ike ly ’ as needlestick injuries are relatively commonplace in a
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healthcare setting. Based on the information in section 5.2, infectious 
waste with the exception of heavily blood soiled waste and sharps waste, 
poses a low risk of infection. The magnitude of the hazard from infectious 
waste is generally low and harm seldom occurs. The risk posed by human 
hygiene waste and municipal solid waste are likely to be comparable and 
equivalent to blood-soiled infectious waste and sharps as they pose a 
medium risk. Human Hygiene waste is often contaminated with blood; as 
b lood-borne viruses are known to remain viable in waste the magnitude of 
the hazard is considered to be medium. As human hygiene waste is 
commonly produced both within and out-with the healthcare setting, people 
are likely to come into contact with it. Municipal solid waste hosts a wide 
variety of pathogens; however the magnitude of the hazards is low as they 
generally do not result in serious infection. However, as people are likely 
to come into contact with the waste on a daily basis, the likelihood of 
occurrence is high.
Figure 5 Risks posed by infectious healthcare waste, sanpro waste and m unicipal 
solid waste using HSE risk assessment matrix.
Infectious
Healthcare
Waste
Low Risk
(HSAC Group A and G roup E) 
M agnitude of hazard = Low 
L ike lihood of occurrence = U n like ly
Medium Risk
(L iqu id  blood and heavily  b lood 
so iled  HSAC Group A and 
Group B)
M agnitude of hazard = M edium
Like lihood  of occurrence = L ike ly
Human
Hygiene
Waste
Medium Risk
(B lood so iled  san ita ry  p roducts  and incon tinence  products)
M agnitude of hazard = Medium 
L ike lihood  of occurrence  = L ike ly
Municipal
Solid
Waste
Medium Risk
M agnitude of hazard = Low 
L ike lihood  of occurrence  = Very L ike ly
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Figures 4 and 5 simplify and summarise the flow diagram shown in Figure 
3 that outlines the conditions for infection to occur. Figure 3 considers 
each step required for infection to occur whilst f igures 4 and 5 consider the 
likelihood of occurrence and the magnitude of hazard (severity of disease) 
only. Figures 4 and 5 implicitly assume that an exposure pathway is 
available; the infectious agent present as a viable dose and prophylaxis 
has not been taken.
5.3 Summary -  Characteristics of Infectious Healthcare Waste
Over the past 30 years there has been a significant amount of research 
into the microbial content of infectious healthcare waste, much of it carried 
out in the United States and Germany. Although both the US and 
European defin itions for infectious healthcare waste differ from the UK 
definition of clinical waste, they are suffic iently s imilar to allow composition 
and pathogen comparisons to be made.
A signif icant number of pathogens isolated from infectious waste are 
considered to be part of the normal flora of the body and are commonly 
found on the skin and in the intestinal and upper respiratory tract. These 
micro-organisms are considered to be commensals or symbiotic and do not 
routinely cause infection. For an infection to occur the normal balance of 
flora within the body would need to be altered and the m icro-organism 
opportunistic. Many hospital acquired infections are caused by 
opportun istic pathogens that are ubiquitous in institutional environments 
and, in general, the risk of infection from these can be reduced by good 
environmental and human hygiene. The presence of such pathogens in 
waste does not signif icantly add to the environmental load.
In the 1980 ’s several studies were carried out in Germany comparing the 
microbial load of infectious waste and municipal solid waste (MSW) 
(Kalnowski et al, 1983), (Althaus et al, 1983). Whilst there was variation in 
the s tudy ’s f indings, in general it can be concluded that infectious waste 
often contains a broader range of pathogens whilst MSW contains a 
greater number of pathogens. When the total viable count of m icro­
organisms in infectious waste is compared to MSW, we find that MSW 
waste has the highest microbial load and infectious waste has the least.
73
In order for an infection to occur from waste, a number of conditions must 
be satisfied:
• a pathogen must be present of suffic ient viru lence and in suffic ient 
numbers to cause an infection;
• the pathogen must enter the body;
• the host must be susceptible.
In practice assumptions are made about the conditions required as it is 
often impractical and time consuming to assess the likelihood of an 
infection occurring at each stage. Assumptions are often based on local 
knowledge and generic empirical data.
By viewing a number of common hospital acquired infections (Appendix J) 
it becomes apparent that in general blood-borne viruses pose the most 
significant risk of infection. Despite media concerns and heightened 
public ity of healthcare acquired infections such as MRSA (Times, 2004), 
blood borne infection pose the most significant risk of infection. Healthy 
people with normal immune systems are not, in general, susceptib le to 
healthcare acquired infections, which generally occur in surgical wards 
where the microbes are introduced into the human body by instruments or 
where patients are vulnerable and their immune system is not working 
properly (Williams, 2003).
Blood-borne viruses pose a particular problem in all types of waste as they 
are able to survive and remain viable for relatively long periods of time. 
Hepatitis B (HBV), Hepatitis C (HCV) and Human Immunodefic iency Virus 
(HIV) are recognised as signif icant health hazards facing healthcare 
workers, as over the past 20 years the prevalence of these viruses has 
increased dramatically. Sharps pose the most signif icant risk of infection 
of all types of infectious waste, as they are often contaminated with blood 
or infectious bodily fluids and they create a pathway for pathogens to enter 
the body through puncture wounds.
Human hygiene waste is comprised of sanitary and incontinence products 
and, in line with HSAC guidance published in 1999 (see section 3.3.1), 
when it is produced from the ‘general com m unity ’ it is not considered to be 
infectious waste. However, analysis of the microbial content of the waste
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reveals that it contains a far greater microbial load than infectious 
healthcare waste.
In summary, using a risk criteria fram ework developed by the HSE, it can 
be concluded that infectious healthcare waste poses a low/medium risk of 
infection, and that human hygiene waste and municipal solid waste often 
pose a greater risk of infection and should be c lassified as a medium risk.
With regard to the assumptions listed in section 4 the findings from this 
section indicate that waste posing a risk of infection is produced both in 
healthcare premises and the wider community. Healthcare waste has 
different hazard characteristics to household waste but does not pose a 
greater risk of infection. The risk posed is not directly proportionate to the 
hazard, as for the risk to be realised a pathway must exist.
In order to fu lly  examine the assumptions in section 4, one must look at 
where infectious waste is produced. Section 6 of this d issertation reviews 
the production of infectious waste.
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6. PRODUCTION OF IN FEC TIO U S H EALTHCARE W ASTE
This section of the d issertation explores the production of infectious waste 
by reviewing International, European and UK data, and by looking 
specif ically  at the production of waste within and out-with the acute 
(hospital) healthcare environment.
The findings of this section are used to explore the assumptions made in 
Section 4.
Section 6.1 briefly reviews the way data on waste is compared and the use 
of key performance indicators (KPIs) as comparators. Section 6.2 looks at 
International data, focusing on the USA, and Section 6.3 reviews European 
data and compares the production of infectious waste (healthcare risk 
waste) in 12 European Countries. The use of in ternational and European 
comparisons is important as it allows benchmarking between countries and 
indicates differences in practice and management regimes. Section 6.4 
reviews recent UK data, which is further explored in relation to the NHS in 
Section 6.5 and 6.6, and community sources in 6.7. Information relating to 
the source or point of production of the waste provides the necessary 
information to assess the valid ity of assumption 2 and 3 made in Sections
4.2 and 4.3.
6.1 Data Collection
It can be difficult to compare data on waste arising from different 
countries, as different defin itions and reporting systems are often used.
Key performance indicators (KPIs) are often used as comparators for the 
production of healthcare waste. The accuracy of a KPI is dependent on the 
quality of collection and monitoring systems in place. Different KPIs are 
used by different healthcare establishments and there is no International 
or National standard KPI for infectious waste. Commonly used KPIs 
include tonnes/kg per annum (tpa, kg pa), tonnes/kg per bed per annum 
(t/bed pa, kg/bed pa) or tonnes/kg per capita per annum (t/capita pa, 
kg/capita pa). Throughout Section 6 of this d issertation a number of 
d ifferent KPIs have been used, as it has not been possible to collate all 
the necessary information in such a way to present it using a common KPI.
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6.2 International Comparisons
6.2.1 Production of In fectious W aste in the U.S.A
In the USA, infectious healthcare waste is described as Regulated Medical 
Waste (see Section 2.2.1 and Appendix A4). The Environmental 
Protection Agency (ERA) collates national data on the production of 
Regulated Medical Waste across the USA. Table 12 provides an overview 
of the sources of production of Regulated Medical Waste collated by the
ERA in 1990.
Table 12. USA production of Regulated Medical Waste (1990).
Source Quantity (tons/year)
H osp ita ls 359,000
N ursing Homes 29,600
P hys ic ians ’ p rem ises 26,400
C lin ics 16,700
Labora to ries 15,400
D ental S urgeries 7,600
V e te rina ry  P ractices 4,600
Funeral Homes 3,900
Blood Banks 2,400
Total Infectious Waste 465,600
Source: (US Department of Health and Human Services, 1990)
From the data in Table 12, it appears that approximately 77% of infectious 
waste is generated in a hospital environment. Appendix A4 conta ins the 
definition of Regulated Medical Waste. The definition is clearly aimed at 
hospital and clinic premises as it refers to culture and stocks, body parts 
removed during surgery or autopsy and items saturated with human blood. 
Based on an estimated population of the USA of 293 million, the 
information shown in Table 12 indicates that approximate ly 1.6kg of 
infectious waste are produced per capita per year in the USA.
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6.3 European Comparisons
Comparisons between European countries are of particular interest with 
regard to the assumptions listed in Section 4 and in the broader context. 
The UK is currently transposing the Hazardous Waste Directive (see 
Section 8) into municipal legislation. Ultimately this should lead to a 
greater consistency in the definition of, and management of, infectious 
waste across Europe. Table 13 provides an overview of practice in 12 
European Countries; it c learly shows differences in the amount of waste 
produced, reflecting different waste management policies and definitions.
Table 13. Comparison of Healthcare Risk Waste production in Europe.
European 
Member State
Healthcare 
Risk Waste 
(tpa)
Date of 
Survey
Population
(millions)
Healthcare Risk 
Waste 
(kg/capita/annum )
Belgium 13,700 1992 9.86 1.4
Denmark 10,000 1989 5.11 1.95
France 105,000 1990 56.61 1.9
Germany 33,000 1990 79.75 0.4
Greece 14,600 1987 9.97 1.4
Ireland 9,000 1992 3.44 2.6
Italy 50-60,000 1991 57.13 1.0
Luxembourg unknown unknown 0.37 unknown
Netherlands 8,500 1992 14.45 0.6
Portugal 15,000 unknown 10.13 1.5
Spain 23,000 unknown 38.82 0.6
UK 308,000 1991 55.78 5.5
Source: (European Commission Environment, 1993)
The data in Table 13 was collected as part of the European Commission 
Priority Waste Stream project in 1991 and attempts to compare the 
production of healthcare risk waste (see definition in section 2.2.2.) using 
the amount of healthcare risk waste produced per person per year in each 
country as a KPI. The term healthcare risk waste was comm only used 
across mainland Europe in the 1990s but was not used in the UK or the 
Republic of Ireland (see Section 2.2.2). Therefore it is important to
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understand that a number of assumptions have been made in the collation 
of data shown in Table 13, it is likely that the data for UK and Republic of 
Ireland relates to clinical waste (see definition in section 2.2.3) whilst data 
for Mainland European Countries relates to the definition of healthcare risk 
waste.
Table 13 clearly shows that there is a large variation in the amount of 
healthcare risk waste produced per person per year across Europe. From 
the Table it can be seen that Germany produced the least amount of 
healthcare risk waste per person per year, whilst the UK and Ireland 
produced the most. If the UK and Ireland are removed from the table, on 
the assumption that the data relates to a d ifferent and broader waste 
stream, the average for the remaining European countries is 1.2 kg per 
person per year, s lightly less than but comparable the corresponding 
estimate with the USA (1.6kg per person per year) shown in section 6.2.1.
6.4 UK Comparisons
In 2000 the Department of Environment, Transport and Regions (DETR) 
published an estimate of the amount of clinical waste produced in the UK 
in Chapter 8 of Waste Strategy 2000. DETR stated that the best available 
estimate indicated that 193,000 tonnes of clinical waste were produced by 
the NHS per annum and although no similar estimates were made of 
clinical waste production from ‘other sources ’, “surveys ind icated that it 
might be in the range o f 100,000 to 200,000 tonnes pe r  y e a r ”.
The DETR estimate highlights the lack of good quality and reliable data 
relating to infectious (clinical) waste in the UK. Data collection relating to 
the production and management of clinical waste is predominate ly  
undertaken by the NHS and the UK Regulatory Agencies; Environment and 
Heritage Service (EHS) in Northern Ireland, the Environment Agency (EA) 
in England and Wales, and the Scottish Environment Protection Agency 
(SERA) in Scotland.
6.4.1 Data Collection by Regulatory Agencies
In theory, the Regulatory Agencies could collect clinical waste data from 
the information provided on Duty of Care Transfer Notes that accompany 
all waste movements; however, to date, this has not been achieved.
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A study undertaken by a consultancy company as part of the ‘Data Bridge’ 
Project 10 on behalf of SERA for the Scottish National W aste Strategy found 
that the information on transfer notes was often incomplete and ‘a lluded ’ to 
the amount of waste being transferred in terms of bins and bags, but did 
not provide quantitative amounts (Ferguson, 2001).
The UK Regulatory Agencies do not currently have data on the production 
of clinical waste, they currently rely on the production of data and statistics 
by the NHS. The need for com prehensive and accurate data has been 
highlighted in each UK region.
SEPA and EHS Healthcare Waste Priority Waste Stream Project
In response to the Data Bridge Project findings, SEPA identified a number 
of Priority Waste Streams (PWS) based on the availabil ity  of data and the 
hazards posed by the waste. SEPA identified clinical waste as a PWS in 
the National Waste Strategy: Scotland (NWSS) docum ent published in 
1999. In fu lf i lment of its obligations outlined in NWSS, SEPA have 
recently commissioned a PWS project to review the production and 
management of clinical and sanpro waste. This project is being carried 
out jo in tly  with the Environment and Heritage Service (EHS) in Northern 
Ireland through the Scottish and Northern Ireland Forum For 
Environmental Research (SNIFFER). Data will be collected for both 
Scotland and Northern Ireland. Results from the project are expected in 
2006.
Environment Agency Data Collection
The Environment Agency (EA) (England & Wales) is also trying to improve 
waste data in relation to clinical waste. It is hoped that the use of 
European Waste Catalogue (EWC) codes on Transfer Notes (a recent 
regulatory requirement brought in by the Landfill Regulations) will increase 
the data available at the point of d isposal.
io Data Bridge Project was undertaken to establish a national picture of waste 
management in Scotland and to identify any data gaps.
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In addition to regulating the disposal of waste, the EA has recently 
proposed producer registration for all hazardous waste producers in 
England and Wales. This will shift the focus of data collection from the 
point of disposal to the point of production. Producer registration will be 
unique to England and Wales and is not currently being proposed for 
Scotland and Northern Ireland. The impact this will have on the reporting 
of cross-border movements of waste has not been fully assessed. The EA 
has stated that there will be ‘mutual recogn it ion ’ of the systems in different 
geographic regions; however there is concern within the waste industry 
that regulatory difference will lead to regulatory inequalities.
Forthcoming regulatory change (see Section 8) is likely to lead to an 
increased amount of clinical waste falling within the definition of hazardous 
waste, which in turn will lead to the requirement for clinical waste 
producers to register with the Environment Agency. This in turn will lead 
to a large number of ‘com m unity ’ producers requiring registration in 
addition to large hospital sites.
6.4.2 Defining NHS and ‘C om m unity ’ Producers
In the UK the National Health Service (NHS) is considered to be the 
largest single producer of clin ical/ in fectious waste. However, the NHS is 
managed regionally, with Northern Ireland, Scotland, England and Wales 
operating autonomously. In addition to the NHS, there are a myriad of 
producers who act as contractors to the NHS providing healthcare 
services. In order to simplify the assessment of non-NHS and NHS 
producers this dissertation will divide healthcare services into those that 
operate as full-t ime NHS services directly managed and funded by the 
NHS, and other non-NHS ‘community  sources ’ . Community sources 
produce significant amounts of infectious waste and include independent 
(non-NHS) hospitals and nursing homes.
6.5 National Health Service Data
Data relating to the production and management of clinical waste from 
NHS premises is not collected or collated at UK level.
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Table 14, is taken from Waste Management Paper 25 (WMP25) published 
by the Department of the Environment. A lthough the data contained within 
the table is over 10 years old, it is still the most recently published 
comparison between the UK NHS regions.
Table 14. C linical waste production in the National Health Service(NHS) by region.
Region Tonnes per annum Percentage of total NHS 
waste.
England 120,000 77
W ales 7,500 5
Scotland 24,000 15
Northern Ireland 4,000 3
Total 155,500 100
Source: (Department of the Environment, 1993)
Since the publication of the data in Table 14, waste management practices 
have changed dramatically within the NHS and regional variations in 
practice have emerged. Therefore the data in Table 14 is unlike ly to 
reflect current trends in NHS waste generation.
In a report titled ‘Getting Sorted ’ , published in 1997, the Audit Commission 
summarised clinical waste practices in Hospitals in England and Wales. 
The report did not provide accurate information on the amount of clinical 
waste produced but did highlight the variation in waste reporting methods. 
The Audit Commission report compared the amount of clinical waste 
produced per bed and identif ied that clinical waste production varied from 
0.3 to 1.2 tonnes per bed per annum (Audit Scotland, 2001). Similar 
studies using the amount of waste produced per bed as a KPI have been 
undertaken by NHSScotland (see Section 6.6). The Scottish data clearly 
identifies trends in waste production associated with the primary type of 
clinical practice undertaken. The Scottish data c learly shows that 
teaching, acute and maternity facil it ies produce the greatest amount of 
waste. NHSScotland is the only part of the UK NHS to collect, collate and 
annually publish data on waste arisings. Whilst other regions and groups
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(usually waste contract consortia groups) within the NHS may collect 
waste data, it is often collected sporadica lly  and not recorded at a central 
point. In order to remedy this situation, and in light of forthcoming 
regulatory change, a number of the NHS regions, including NHS Estates 
(England) and Welsh Health Estates, have recently (2004) commissioned 
consultancy companies to review waste arisings.
6.6 The National Health Service in Scotland.
The NHSScotland Property and Environment Forum Executive (NHSScot 
PEFEX) collect and collate waste management data from all of the 32 
Scottish NHS Trusts; this data is published annually in the NHSScotland 
Environment Report.
6.6.1 NHSScotland C lin ical W aste Production
Figure 6, taken from the NHSScotland Environment Report 2001-2002 
shows the trend in c lin ical waste production from NHSScotland premises 
over a 6 year period. The graph shows a general downward trend 
indicating a reduction in clinical waste production, however a slight 
increase in production is noted between 2001-2002. The 2001-2002 
NHSScotland Environment Report states that the increase in clinical waste 
production in 2001 was due to a change in reporting methods and is not 
believed to be an actual increase in production rate (NHSScotland 
Property and Environment Forum, 2003a)
Figure 6. Trends in clinical waste production, NHSScotland 1995/6-2001/2
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NHSScotland Clinical Special Waste
Assessm ent of the waste management data used to produce the 
NHSScotland Environment Report 2001-2002, shows that approximate ly 
4% of the clin ical waste produced (605 tonnes) was classif ied as 
‘ incineration on ly ’ waste and was comprised of anatomical, pharmaceutical 
and radioactive waste.
Therefore, the majority of the waste (96%) was classif ied as ‘genera l’ 
infectious (clinical waste). In accordance with the NHSScotland colour 
coding system (See Appendix E6) this waste would have been placed in 
orange colour-coded clinical waste containers.
NHSScotland Key Performance Indicators
NHSScot PEFEX compares clinical waste production from NHSScotland 
using two key performance indicators (KPI); tonnes of waste per bed per 
year, and tonnes of waste per unit of heated volume per year (m3). The 
first KPI, tonnes per bed per year, provides a comparative measure in 
relation to ward based environments, whilst the second KPI, heated 
volume per year, provides a comparative tool for measuring patient 
throughput or activity in clinics and outpatient departments. The first KPI 
is commonly used throughout the NHS in the UK, whilst the second KPI 
relating to heated volume appears to be unique to NHSScotland. The use 
of heated volume in the calculation of KPIs should be treated with caution 
as they can often provide misleading results as they do not reflect patient 
activity; older hospital build ings tend to have a larger heated vo lume per 
unit f loor area than more modern build ings due to high ceil ings and other 
architectural features found in older properties.
NHSScotland Care Groups
In order to compare the performance of sim ilar NHS facil it ies, NHSScot 
PEFEX divides NHSScotland premises into 8 Care Groups on the basis of 
their primary function. A summary of the Care Groups is shown below:
Teaching: Large hospitals, usually with university medical school
attached. Healthcare practice carried out is broadly 
sim ilar to Major Acute premises.
M aternity: Maternity hospitals and pre- and post-natal care fac il it ies.
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M ajor Acute: Large ‘District Hospita ls ’ providing both specia lis t and
general surgery and other specia lis t disciplines. Major 
Acute premises will normally house the major Accident & 
Emergency (A&E) department fo r  a region.
Cottage: Smaller, often rural or remote, hospital premises providing
routine medical services and minor surgery. It should be 
noted that in rural locations in Scotland, Cottage Hospitals 
may undertake procedures often associated with Small 
Acute Hospitals.
Elderly: Elderly care facil it ies, both residentia l and day care.
Sm all Acute: Smaller acute facil it ies often providing general medical,
surgical and Accident and Emergency facilit ies.
Psychiatric: Facilities providing psychiatric care.
Other: Facilities that cannot be categorised into one of the above 
groups.
Appendix L provides further detailed information of clinical waste 
production by NHSScotland fac il ity  and by Care Group. Data provided on 
the total weight of waste produced in each fac il ity  and waste production is 
compared using the KPIs: tonnes of waste per bed per year, and tonnes of 
waste per unit heated volume per year. Appendix L also contains bar 
graphs comparing the amount of clinical waste produced per bed per year 
in each fac il ity  by Care Group.
Figure 7, summarises the information in Appendix L and graphica lly  shows 
the average amount of waste produced per bed per year in each Care 
Group. Facilities in the same Care Group should theore tica lly  produce the 
same type of waste (assuming that they carry out sim ilar clinical 
practices). Figure 7 clearly shows that Teaching, Maternity and Major 
Acute facil it ies produce the greatest amount of waste per bed per year. 
This is due to the large number of inpatient episodes (including surgical 
procedures), which result in the generation of potentia lly  infectious waste. 
Facilities not associated with major surgery or pro-longed inpatient stays, 
such as Small Acute and Psychiatric facilit ies, produce the least amount of 
waste.
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Figure 7. Average amount of Clinical W aste Produced per Bed per Year by Care 
Group in NHSScotland facilities 2000-01.
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Elderly Care Facilities, although not associated with surgical practice or 
post-surgical care, produce significant quantities of clinical waste, much of 
this is thought to be through mis-classif ication, where sanpro waste has 
been mis-classified as clinical waste (see Section 5.2.5 for defin it ion of 
sanpro waste).
In January 2001 Audit Scotland produced a Performance Audit Report 
t it led ‘Waste Management in Scottish Hospitals '. The report made a 
number of recommendations based on best practice and potentia l cost 
savings. Audit Scotland estimated that NHSScotland could make potentia l 
savings of between £1.3 million and £2.4 million by reviewing waste 
segregation practices. Audit Scotland stated that Trusts were not 
adequately segregating sanpro waste (defined in section 5.2.5) from the 
clinical waste stream and estimated that approximate ly 40-50% of Clinical 
Waste from Acute Trusts and 80-90% of clinical waste from Primary Care 
Trusts could be classified as Sanpro Waste (Audit Scotland, 2001).
The characteristics of waste production, both type and quantity, by Care 
Group provide a national ‘p ic ture ’ of waste production and allow estimates 
to be made about future waste management needs based on current waste 
trends.
8 6
Joint Futures Initiative
Over the past decade there has been a reduction in the number of Acute 
Hospital beds and an increase in the amount of clinical practice 
undertaken in the community in NHSScotland. As healthcare practices 
progress and change, hospital in-patient stays have shortened, and an 
increasing amount of care is provided by community based clinics and 
community nursing staff.
In 2000, the Scottish Executive set up the Joint Futures Unit to better 
integrate community care services and develop jo int working arrangements 
between Local Authorit ies and NHSScotland (Scottish Executive Health 
Department, 2000). Often community care involves a mix of ‘persona l’ and 
‘medica l’ care and Joint Futures is designed to better integrate these with 
respect to Care Homes, Learning Disability and Mental Health facilities.
The Joint Futures and other similar initiatives will result in a shift of 
healthcare practice and healthcare waste from NHS hospital sites to the 
community. The shift in waste production will bring with it a number of 
complications and will u lt imately require a change in waste management 
infrastructure. Future waste management defin itions and classification 
systems will need to be suited to meet changing healthcare delivery. The 
assumptions which underpin current infectious waste management practice 
in the UK (as detailed in Section 4) are not robust enough to cope with the 
change in healthcare practice brought about by Joint Futures and other 
similar initiatives as they are fundamenta lly  based on the delivery of 
healthcare in a hospital setting.
6 .7  T h e  ‘C o m m u n ity ’ S e c to r
There are a large number of producers of community infectious (clinical) 
waste. The term ‘com m unity ’ is not often defined although often referred 
to. For the purpose of this document, ‘com m unity ’ producers are those not 
forming part of NHS hospital premises although staff operating these 
facilit ies may be directly contracted by the NHS.
The voluntary (not-for-profit) sector also plays a signif icant role in the 
provision of community based healthcare, especially  in residential care for 
the elderly and infirm.
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The provision of free personal care to people aged over 65 residing in 
Scotland was announced by the Scottish Minister for Health and 
Community Care, Susan Deacon, in January 2001. This initiative has 
fuelled a growing healthcare market in Scotland and has led to an increase 
in both voluntary and private sector investment. It is uncertain whether 
this initiative will be replicated in England, Wales and Northern Ireland. If 
it is, the provision of community-based healthcare is likely to expand 
rapidly throughout the UK.
Although the residential and nursing home sector is growing in the UK, 
there are other significant sources of community infectious/c lin ical waste, 
including:
♦ General Practit ioners; ♦ Home Care;
Veterinary Practices ♦ Nursing Homes;
Animal Hospitals; ♦ Residentia l Homes
Farm & Equine Centre; ♦ Health Centres;
Research Institutes; ♦ Cosmetic Piercers;
Clinics; ♦ Opticians;
Pharmacies; ♦ Tattooists;
Acupuncturists; ♦ Funeral Directors;
Chiropodists; ♦ Embalmers;
Beauticians; ♦ Mortuaries;
Hospices; ♦ Blood Transfusion
Centres;
♦ Independent (Non NHS)
Hospitals.
In 2000, the DETR in Waste Strategy 2000, estimated that the amount of 
clinical waste generated outside NHS Trusts was in the range 100,000-
200,000 tonnes per year. This is in the same range as an estimate made 
by the Department of the Environment in 1993 in Waste Management 
Paper 25 (WMP25). The estimates made in WMP25 are shown in Table 
15.
Data on the production of clinical waste from community  sources is limited 
as there is no central register or registration authority. Limited data can
be gathered when waste is collected under a Local Authority or NHS 
contract. However, community  producers often employ private sector 
waste contractors to manage their waste; these contractors are often small 
and work in localised geographic areas.
There is no central register of waste collected by the private sector and 
information provided on waste transfer notes is often limited.
Table 15. Clinical waste from sources other than Health Authority and Trust 
premises.
Source Tonnes per annum
Independent Hospitals 4,900
GPs & Dentists 20,000
Nursing Homes 11,400
Private Residentia l Homes 33,300
Blood Transfusion Centres 400
Home Treatment 24,500
Funeral Directors 150
Embalmers, Mortuaries 900
Other M iscellaneous Sources 12,500
Veterinary Practices 19,500
Research Centres 23,000
Farm/Equine Centres 2,500
DUMPn Campaigns 250
TOTAL 153,300
Source: (Department of the Environment, 1993)
11 DUMP campaign -  encouraging householders to return unused and unwanted 
medicines
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The lack of information on the type and quantity of clinical waste produced 
by the community sector causes a problem as it does not enable Local 
Authority planners and those involved in waste strategy to plan waste 
treatment and disposal requirements in each geographic area.
6.7.1 C lassification  of Com m unity C lin ical W aste
Section 3.3 of this d issertation reviewed commonly referred to infectious 
(clinical) waste guidance documents. These documents were, in general, 
produced for use by ‘ large sca le ’ or hospital producers of clinical waste 
and provide limited information for smaller ‘com munity ’ producers.
The most commonly referred to guidance document, Safe Disposal of 
Clinical W as te ’ produced by the Health Service Advisory Committee 
(HSAC) in 1999, (see Section 3.3.1 and Appendix E5 for further 
information), provides some, albeit limited, guidance on the identif ication 
and classification of clinical waste in the community.
The HSAC guidance states that many items of waste s imilar to clinical 
waste generated by hospitals may be generated in the community; 
however this waste is not necessarily clinical waste. The assessment of 
clinical waste relies on the use of risk assessments, which should be 
carried out by a suitably qualif ied healthcare practit ioner, assessing the 
health of the source population. Where the source population is known to 
be healthy and free of infection there is no requirement to classify the 
waste produced as clinical. Whilst this may seem a stra ightforward 
posit ion, it does not allow for uncertainty, and practit ioners often take a 
precautionary approach, that leads to all healthcare waste generated in 
the community being classified as clinical waste.
Without suitable guidance documents, community producers are unable to 
identify and segregate clinical waste leading to the mis-classif ication and 
m is-management of the waste.
6.7.2 Survey of Com m unity Producers in Edinburgh
A review of clinical waste production by ‘com m unity ’ producers in the 
Edinburgh area was undertaken in 1999 by the author.
Survey Aim
The aim of the study was to evaluate the amount and type of c linical and 
sanpro (incontinence) waste produced by community producers in a
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specific area and to compare it to the waste arisings from a large NHS 
hospital site in the same area. For the purpose of the research, 
‘com m unity ’ producers included all producers of clinical waste not located 
on, or within, NHS Trust Acute Hospital Sites. The Greater Edinburgh 
Area, (designated by postcodes starting with EH), was chosen as the 
geographical study area. The Greater Edinburgh Area was considered to 
be representative of other large urban areas although no comparisons 
were made with other cities.
Survey Methodology
The survey was carried out by anonymous questionnaire. Approximately 
600 questionnaires were posted to 12 different types of ‘com m unity ’ 
organisations and establishments likely to produce clinical and sanpro 
waste. A prepaid reply envelope was enclosed for the return of the 
questionnaires. The identif ied organisations and establishment (the 
‘survey popu la tion ’) were identified from data provided by the NHS and 
regulatory bodies (including NHS and Social Services Inspectorates), 
including:
♦ Lothian Health Board;
♦ Edinburgh City Council;
♦ East Lothian Council;
♦ West Lothian Council;
♦ Midlothian Council;
♦ British Veterinary Association; and
♦ Yellow Pages.
The survey population identified was not verified as being representative 
of all possible community  producers. Ideally, verification should have 
been made using Standard Industry Classification (SIC) code data, 
however this was unavailable. SIC code data is only available at request 
from a Government agency.
In order to make the questionnaires relevant to those completing them, 
five types of questionnaire were designed. Examples of the 
questionnaires used can be found in Appendix M. The questions in each
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questionnaire type were broadly s imilar however, they were designed to be 
applicable to the type of organisation and therefore not all organisations 
were asked about all waste types, for example Children Hom e’s were not 
asked to provided information about m icrobiological cultures or pathology 
wastes as it was unlikely they would produce such waste. In total eight 
waste types were identif ied as shown in Table 16.
Table 16. W aste types used in questionnaire.
W aste type 1.
Blood, soiled dressings, swabs and other sim ilar soiled waste.
W aste type 2.
Items used for the collection of human excreta / secreta e.g. incontinence pads, 
sanitary towels etc.
W aste type 3.
Microbio logical cultures and pathology wastes.
W aste type 4.
Separate ly collected special wastes, including highly infectious waste and dental 
amalgam, but excluding pharmaceutical products.
W aste type 5.
Human /Animal Tissue.
W aste type 6.
Prescription only medicines.
W aste type 7.
Cyto-toxic drugs.
W aste type 8.
Sharps waste (needles, etc).
Respondents were asked to provide the following information for each 
waste:
♦ The type and colour of the container used to store the waste;
♦ The size of the container;
♦ The number of containers used per month;
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♦ The approximate massi2 of an ‘average ’ container.
♦ The final treatment / d isposal destination of the waste and method 
of transportation, if known;
♦ The length and value of their current waste disposal contract.
The questions were designed to provide information on the total amount of 
waste produced (mass) and the current management and contractual 
arrangements in place.
Initial research undertaken, looking at completed waste transfer notes, 
identified that producers frequently  did not know the mass or volume of the 
waste they produced and the information on transfer notes was often 
incomplete. In order to gain the required information, the questionnaires 
were worded in a non-technical format and the information requested 
allowed the researcher to estimate the total mass of waste produced per 
annum by multiplying the number of containers used per month with the 
average mass of an ‘average ’ container.
Survey Results
Table 17 shows the number of questionnaires sent to each type of 
organisation and the response rate. The response rate by organisation is 
also shown graphically in Figure 8.
Table 17. Questionnaires posted and returned by type of organisation.
Organisation type Total number of 
questionnaire sent
Percentage of completed 
questionnaires returned.
Nursing Homes 139 21%
Veterinary Surgeons 54 19%
Residential Homes * Approx 45%
Children’s Homes * Approx 45
Tattooists 11 9%
Chiropodists 54 20%
Acupuncturists 11 27%
Dental Surgeons 91 30%
1 2  The term ‘weight’ was used on the questionnaire as it was felt respondents would be 
more familiar with this term, although respondent were required to complete in units of 
mass (kg).
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Funeral Directors 40 10%
Blood Service 4 0%
Adult Day Care Centres * Approx 45%
Total Approximately 600 Average response 23%
‘ Combined estimate. Questionnaires distributed by Local Authority (approximately 200) for 
reasons of confidentiality.
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Data provided from the respondents was collated and an estimate made of 
the total amount of waste produced by type. Not all respondents who 
stated that they produced a waste type provided mass (weight) related 
data. Table 18 shows the numbers of respondents who provided mass 
(weight) related data.
Table 18. Number of respondents providing weight related data
Waste Type Total Number 
of
Respondents 
Per Specified 
Waste Type
Total 
Number of 
Respondents 
providing 
Mass 
(Weight) 
Related 
Information
Percentage of 
Respondents 
Providing 
Mass 
(Weight) 
Information
1. Blood, soiled dressings, swabs, etc. 101 52 51%
2. Incontinence waste. 62 19 31%
3. Cultures & pathology waste. 2 2 100%
4. Highly infectious waste & dental 
amalgam.
13 9 69%
5. Human / animal tissue waste. 9 6 67%
6. Prescription only medicines. 51 4 8%
7. Cyto-toxic wastes. 6 3 50%
8. Sharps 96 42 44%
The average response rate to the questionnaire survey was 23%. Of that, 
approximate ly 50% provided data on the mass of waste produced; 
therefore mass related data were supplied by only 12% of the survey 
population.
Table 19 and Figure 11 summarise the amount of waste produced per 
annum by waste types calculated from respondent information.
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Table 19. Calculated annual waste arisings of 12% of survey population by waste 
type.
Waste Type Calculated arising 
per annum 
(kg)*
Calculated arising 
per annum 
(Tonnes)*
1. Blood, soiled dressings, swabs, etc. 33,134.0 33.1
2. Incontinence waste. 142,772.0 142.8
3. Cultures & pathology waste. 288.8 0.3
4. Highly infectious waste & dental amalgam. 35.7 0.04
5. Human / animal tissue waste. 20,700.0 20.7
6. Prescription only medicines. 108.0 0.1
7. Cyto toxic wastes. 106.0 0.1
8. Sharps 1,712.5 1.7
Total
198,857.0 198.9
* Data rounded to one decimal point
The table has been colour-coded; wastes considered to be ‘ in fectious ’ are 
shown in red text, sanpro waste is shown in blue text and pharmaceutical 
wastes are shown in green text. It has been assumed that data relating to 
waste type 4 (highly infectious waste and dental amalgam) related to 
dental amalgam rather than highly infectious waste as the majority of 
respondents producing this waste were dental surgeons.
From the data collated, it is estimated that approximate ly 12% of the 
survey population produced just under 200 tonnes of clinical and sanpro 
(incontinence) waste per year, of this approximate ly 56 tonnes (28%) was 
infectious waste, 143 tonnes (72%) was sanpro waste and 0.2 tonnes 
(0.1%) was pharmaceutical waste.
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If it is assumed that the survey data represent com munity  clinical and 
sanpro waste producers in the Greater Edinburgh area and the weight 
related data provided by 12% of the survey population reflects clinical and 
sanpro waste production of the whole survey population, an estimate of 
annual total comm unity  aris ings can be made. Table 20 shows the 
estimated annual total com m unity  arisings.
Table 20. Estimated arisings of clinical and sanpro waste from producers in the 
Greater Edinburgh area
Waste Type Calculated arising from 
survey population 
(representing 12 % of 
total producers) 
(Tonnes)*
Estimated total 
arisings in the 
Greater Edinburgh 
area (based on 
survey data) 
(Tonnes)*
1. Blood, soiled dressings, swabs, etc. 33.1 276.1
2. Incontinence waste. 142.8 1189.8
3. Cultures & pathology waste. 0.3 2.4
4. Highly infectious waste & dental 
amalgam.
0.04 0.3
5. Human / animal tissue waste. 20.7 172.5
6. Prescription only medicines. 0.1 0.9
7. Cyto toxic wastes. 0.1 0.9
8. Sharps 1.7 14.3
Total 198.9
1,657.1
* Data rounded to one decimal point
The estimated total annual aris ings from community producers of c linical 
and sanpro waste in the Greater Edinburgh area is 1,657.1 tonnes. From 
the data collated, it is estimated that approximate ly 465 tonnes (28%) was
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infectious waste, 1,190 tonnes (72%) was sanpro waste and 2 tonnes 
(0.1%) was pharmaceutical waste.
Data provided by Lothian Universities Hospital Trust for the year 
2000/2001, published in the NHSScotland Environment Report (shown in 
Appendix L) shows that the largest hospital (by bed numbers) in the 
Greater Edinburgh area, Edinburgh Royal Infirmary, produces 801.32 
tonnes of waste per annum. Therefore the estimated annual arisings for 
community producers of clinical and sanpro waste in the Greater 
Edinburgh area is approximate ly twice that of the largest hospital in the 
area.
However to compare arising of infectious waste, we need to compare, like- 
with-like and identify the infectious fraction of the clinical waste produced 
by Edinburgh Royal Infirmary. Based on Audit Scotland estimates of 
sanpro waste aris ings in NHSScotland Hospitals, published in 2001 (see 
section 6.6.1), 50% of clinical waste from Acute Hospitals is likely to be 
sanpro waste. Therefore half of the clinical waste produced by Edinburgh 
Royal Infirmary (400 tonnes) is estimated to be sanpro waste with the rest 
of the clinical waste comprised of infectious, pharmaceutical and 
radioactive wastes.
Whilst the amount of pharmaceutical and radioactive waste produced by 
Edinburgh Royal Infirmary is unknown for 2001-2002, it can be estimated 
to be less that 4% (32 tonnes) of the total clinical waste stream. Analysis 
of the waste data used in the NHSScotland Environment Report 2001-2001 
(see section 6.6.1) shows that 4% of clinical waste produced by 
NHSScotland requires disposal by incineration, this waste include 
anatomical radioactive and pharmaceutical waste. For ease of 
comparison, this waste is excluded from the calculation of infectious waste 
arisings for Edinburgh Royal Infirmary for 2001-2002 (as shown below):
800 tonnes (total clinical waste arisings)
-400 tonnes (sanpro waste, based on Audit Scotland estimates)
-32 tonnes ( incineration only waste -  includes pharmaceutical 
wastes)
= 368 tonnes ( infectious clinical waste).
1 02
It is estimated that Edinburgh Royal Infirmary produced 368 tonnes of 
infectious waste in 2001-2002, this is signif icantly less (approximately 
21%) than the estimated arsing for community producers in the Greater 
Edinburgh Area (465 tonnes).
Insufficient information was provided in relation to waste contract duration 
and value. Information gathered about the treatment/d isposal routes of 
the waste indicated a lack of knowledge on the part of the producers. 
Figure 12, shows the number of responses received indicating the use of a 
particular disposal route.
Figure 12. Disposal routes used by respondents.
Pet Crematorium 
Amalgam Recovery
G.P Surgery 3 3  
Returned to  Pharmacy 
Other 
Unknown 
Microwave 
Gasification 
MSW Incineration 
C.W Incineration 
Landfill 
Autoclave 
Heat treatment
0 20 40 100 120 140 160
Number of Responses
Figure 13, provides a further breakdown of the information and shows the 
number of responses received indicating the use of a particular disposal route 
per waste type. The information received identifies clinical waste incineration 
facilit ies as the most frequently used disposal route (137 responses) with a large 
number of respondents (85 responses) unaware of the disposal route used. 
Only 1 response indicated that autoclave disposal was used with no respondents 
indicating that either microwave or heat treatment was used.
103
Fi
gu
re
 
13
. 
D
is
po
sa
l 
ro
ut
e 
by 
w
as
te
 
ty
pe
.
3
o  O
d) 
m 
0
tc
O)
CC
E<
Üc
CO 0  0 O
IS =0 0
i l
a 
c 0 00 w
□ □
£ > 0
I I !  
0 0 0 0
E
co
c Q
§) 0
o !q 0  o oo 0
|||
c l o  œ 
□ □ □
%
v \
<yÔ
X
Vx
X
x )
%  x
\
%
sasuodsay ;o jaqiunN
D
is
po
sa
l 
R
ou
te
The responses received do not reflect the treatment and disposal options 
available at the time. Case Study One (located after the reference section of 
this d issertation), looks at the impact of the loss of Crown Immunity on NHS 
clinical waste disposal in Scotland. The Case Study identifies the clinical waste 
disposal routes available in 1999/2000. Figure 14 is taken from the Case Study 
and shows the location and type of clinical waste disposal facil it ies available in 
1999/2000
M ATERIAL REDACTED AT REQUEST OF UNIVERSITY
Given the limited clinical waste incineration capacity available at the time, 
it is unlikely that much of the clinical waste produced by the survey 
respondents was incinerated. The majority of clinical waste produced by 
the NHS in Scotland in 1999/2000 was treated at autoclave, m icrowave or 
dry heat treatment facil it ies to render it safe prior to being landfilled. As
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disposal by incineration was historically the only method for disposing of 
clinical waste (see section 3.2) it is likely that the questionnaire 
respondents assumed this was how their waste was being managed.
In line with the requirements of Section 34 of the Environmental Protection 
Act 1990 and the Environmental Protection (Duty of Care) Regulations 
1991 (as amended) waste producers are responsible for ensuring that the 
waste they produce is treated and disposed of appropriately. Therefore 
waste producers should be aware of the disposal route of their waste. The 
survey results indicate that the vast majority of community producers are 
not aware of the true disposal route of their waste. In fact, some of 
responses indicated that waste was being treated inappropriately; for 
example 7 respondents indicated that blood soiled waste and 2 
respondents indicated that sharps wastes were being disposed of in 
landfill facilit ies.
Survey Conclusions
The response to the questionnaire survey was good with all but one 
organisation type responding and responses were received from 
organisations across the Greater Edinburgh Area. Almost one quarter of 
those surveyed responded (23%) providing information about the type of 
clinical and sanpro waste they produce. Of these approximate ly half 
provided information about the mass (weight) of waste produced.
Mass related information was provided by approximately 12% of the survey 
population, from the data it was estimated that they produced 
approximate ly 200 tonnes of clinical and sanpro waste. It is estimated that 
approximate ly 56 tonnes (28%) was infectious waste, 143 tonnes (72%) 
was sanpro waste and 0.2 tonnes (0.1%) was pharmaceutical waste.
Based on the mass related dated provided by 12% of the survey 
population an estimate of total amount of clinical and sanpro waste 
produced in the Greater Edinburgh area has been made and is 1,657.1 
tonnes per annum. It is estimated that approximate ly 465 tonnes (28%) 
was infectious waste, 1,190 tonnes (72%) was sanpro waste and 2 tonnes 
(0.1%) was pharmaceutical waste. This estimate is based on the fo llowing 
assumptions:
i. the survey population represents all community clinical and sanpro 
waste producers in the Greater Edinburgh area; and
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ii. the mass related data provided by 12% of the survey population 
reflects clinical and sanpro waste production of the whole survey 
population.
Comparisons with the largest hospital (by bed numbers) in the survey 
area, Edinburgh Royal Infirmary, shows that the total amount of clinical 
and sanpro waste produced in the Community (approximately 1,657 
tonnes) is equivalent to twice the amount of clinical waste produced by the 
hospital (approximately 801 tonnes). However, when a comparison is 
made looking at estimated infectious waste arising only the d ifference is 
not so large. Community  clinical waste producers in the Greater 
Edinburgh area produced approximate ly 465 tonnes of infectious waste 
compared to approximate ly 368 tonnes of waste produced by Edinburgh 
Royal Infirmary.
The estimate of total amount of clinical and sanpro waste produced should 
be treated with caution and given a low confidence rating as it is unlikely 
that the survey population represented all community producers in the 
Greater Edinburgh area. Mass related data provided by 12% of the 
population survey is unlikely to be representative of all community  clinical 
and sanpro waste producers.
Based on the information and data from the questionnaire survey it can be 
estimated that the total amount of clin ical and sanpro waste produced in 
the Greater Edinburgh area, by community sources, is greater than 200 
tonnes per annum (identified from the survey respondents who provided 
mass related information). However, without further information about the 
total number and type of producers in the survey area a complete estimate 
showing an upper and lower range cannot be calculated.
Information from the survey relating to the disposal routes used for clinical 
and sanpro waste indicates that a large number of community producers 
are unaware of the disposal route of their waste.
6.8 Summary -  Production of Infectious Healthcare Waste
Section 6 of this dissertation reviews the production of infectious waste in 
the USA and in 12 European Countries. Data from the USA shows that the 
majority of infectious waste, approximate ly 80%, is produced from 
hospitals and clinics. Based on an estimated population of the USA of 293
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million, the data in Table 11 indicates that approximate ly 1.6kg of waste 
per capita per annum is produced.
In Section 6.3 the production of healthcare risk waste (see Section 2.2.2) 
was compared between 12 European Countries using data collected in the 
early 1990s and collated by the Institute of Waste Management (IWM). 
The data showed a wide variation in the amount of waste produced in each 
country and used the key performance indicator (KPI) k ilograms of waste 
per capita per annum to compare waste production. The data showed that 
the average amount of healthcare risk waste produced in mainland Europe 
was 1.2kg compared to 5.5kg in the UK. Based on data from the USA and 
Europe it can be seen that that the UK produces three times more waste 
than its International and European neighbours.
The difference in production rate is likely to be twofold; the use of a 
different definition in the UK to mainland Europe (see Section 2.2.2) and 
the clinical waste management changes brought about by the loss of 
Crown Immunity in 1990 (see Section 3.1.1).
In general, data on the production of infectious waste is extremely poor. 
There is no overall dataset relating to the UK leading to an incomplete 
picture of infectious waste management. Data relating to the production of 
infectious waste from NHS sources is available at UK level but is in excess 
of 10 years old (Department of the Environment, 1993) and is unlikely to 
represent current production trends. As data representing production are 
not available, recent government publications (Department of Environment, 
Transport, and Regions, 2000) have used estimates of the amount of 
waste produced. The UK regulatory agencies have acknowledged the 
need to collect data on infectious waste arisings and have established 
future waste collection strategies, including a priority waste stream project 
in Scotland and Northern Ireland and the collection of hazardous waste 
related information from producer registration in England and Wales.
In general, the NHS collects and collates the greatest amount of data on 
infectious waste aris ings. However, this information is not collected at a 
UK level. The NHS is managed regionally with each region acting 
autonomously and data collection varies between each region (England, 
Scotland, Wales and Northern Ireland) and is often collected at individual 
NHS Trust/Board level. NHSScotland is one of the few parts of the UK to 
collect NHS data at a regional level; data is collected and collated for
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inclusion in the annual NHSScotland Environment Report. NHSScotland 
data is collated on the basis of Care Groups (see section 6.6.1 and 
Appendix L) where NHS premises are grouped together on the basis of the 
primary type of care provided. The data shows that those premises 
classified as ‘teach ing ’ , ‘m atern ity ’ and ‘acute ’ produce the greatest 
amount of waste per bed per annum, approximate ly 0.7-0.8 tonnes.
The variation in production of infectious waste in NHSScotland premises is 
in line with the f indings of a study carried out by the Audit Commission 
looking at hospitals in England and Wales; the study found that the 
production of clinical waste varied from 0.3 to 1.2 tonnes per bed per 
annum between sites.
Figure 6, shows the trend in clinical waste production in Scotland over an 
eight-year period. The graph shows an overall reduction in the amount of 
waste produced, which has been realised through contractual changes in 
waste management practices (see Case Study One), changes in the 
provision of healthcare and changes in guidance (see Section 3.3).
Over the past decade there has been a reduction in the number of beds in 
acute (large hospital) NHS facil it ies and a greater amount of healthcare 
practice carried out in the community. This trend has been recognised by 
projects such as the ‘Joint Futures ’ initiative. The community healthcare 
providers include many non-NHS organisations and agencies which, in 
terms of waste management, have historically been seen as a separate 
and distinct group of infectious waste producers.
The term ‘community producers ’ generally refers to producers of infectious 
waste that do not form part of NHS hospital premises, although they may 
be contractually connected to the NHS. Examples of community  producers 
include General Medical Practit ioners (GPs), General Dental Practit ioners, 
Care Homes, Veterinary Surgeons and Cosmetic Outlets e.g. Tattooists, 
Beauticians and Body Modification Artists. Data relating to the production 
of infectious waste from these sources is scarce and often relies on 
estimates; for example, a recent estimate by the Department of 
Environment, Transport, and Regions (2000) stated that the amount of 
waste generated was in the range 100-200,000 tonnes per annum in 
England and Wales, which is comparable to the amount of waste produced 
from NHS sources in the same area.
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In order to gain a better picture of community infectious waste production, 
a questionnaire survey of ‘com m unity ’ clin ical waste producers was 
undertaken (see section 6.7.2). The aim of the study was to evaluate the 
amount and type of clinical and sanpro ( incontinence) waste produced by 
community producers in a specific area (Greater Edinburgh Area) and to 
compare it to the waste arisings from a large NHS hospital site in the same 
area.
The survey was carried out by anonymous questionnaire, with 600 
questionnaires distributed to ‘com m unity ’ organisations and 
establishments likely to produce clinical and sanpro waste. The identified 
organisations and establishment (the survey popula t ion ’) were identified 
from data provided by the NHS and regulatory bodies. The response rate 
to the questionnaire survey was 23%, with completed questionnaires 
received from producers throughout the Greater Edinburgh Area. Of the 
responses received, approximate ly 50% (12% of the survey population) 
provided data on the mass (weight) of waste produced.
From the data collated, it is estimated that approximate ly 12% of the 
survey population produced just less than 200 tonnes of clinical and 
sanpro (incontinence) waste per year, of this approximate ly 56 tonnes 
(28%) was infectious waste, 143 tonnes (72%) was sanpro waste and 0.2 
tonnes (0.1%) was pharmaceutical waste.
Using the data provided by 12% of the survey population an estimate of 
total amount of clinical and sanpro waste produced in the Greater 
Edinburgh area has been made and is 1,657 tonnes per annum. From the 
data collated, it is estimated that approximate ly 465 tonnes (28%) was 
infectious waste, 1,190 tonnes (72%) was sanpro waste and 2 tonnes 
(0.1%) was pharmaceutical waste.
Comparisons with the largest hospital (by bed numbers) in the survey 
area, Edinburgh Royal Infirmary, shows that the total amount of clinical 
and sanpro waste produced in the Community (approximately 1,657 
tonnes) is equivalent to twice the amount of clin ical waste produced by the 
hospital (approximately 801 tonnes). However, when a comparison is 
made looking at estimated infectious waste arisings only, the d ifference is 
not so large. Community clinical waste producers in the Greater 
Edinburgh area produced approximate ly 465 tonnes of infectious waste
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compared to an estimated 368 tonnes produced by Edinburgh Royal 
Infirmary
The estimate of total amount of clinical and sanpro waste produced should 
be treated with caution as it is unlikely that the survey population 
represented all community  producers in the Greater Edinburgh area and 
the data received from the respondents was representative. Based on the 
information and data from the questionnaire survey it can be estimated 
that the total amount of clinical and sanpro waste produced in the Greater 
Edinburgh area, by community  sources, is greater than 200 tonnes per 
annum.
Information from the survey relating to the disposal routes used for clinical 
and sanpro waste indicates that a large number of community producers 
are unaware of the disposal route of their waste.
The information in Section 6 of this dissertation highlights the inadequacy 
of a number of the assumptions identif ied in Section 4. The valid ity  of the 
assumptions is explored in greater detail in Section 7.1. However the 
information provided demonstrates that signif icant amounts of infectious 
waste are produced outside hospital premises (assumption 2) and that 
people in the community, including private households, produce infectious 
waste (assumption 3).
I l l
7. REVIEW OF CURRENT PHILOSOPHY & ASSUMPTIONS
Section 4 of this d issertation identified a number of implicit assumptions 
which underpin the principles and concepts in waste regulation and the 
guidance documents detailed in section 2 and 3. This section primarily  
uses the information in sections 4 and 5 to review the valid ity  of those 
assumptions.
7.1.1 Assum ption One
People receiving healthcare in hospital produce in fectious waste.
This assumption is made up of two tenets:
♦ people receiving healthcare suffer with infectious disease i.e. 
infectious people produce infectious waste;
♦ the infectious nature of the waste may be influenced by the 
origin of the waste, or point of production.
Conditions fo r Infection to Occur
The infectious nature of waste is determined by a number of factors. In 
order for an infection to occur, a number of conditions must be satisfied: 
viru lent pathogens in suffic ient numbers must enter a susceptib le host (as 
identified in section 5.2.4). In order for the waste to pose a risk of infection 
it must contain pathogens in a viable state. Section 5.2.1 of this 
dissertation summarised literature reviewing the microbial load of 
infectious waste. Evidence from research undertaken in America in the 
1990 ’s illustrated that the pathogens found in infectious waste were 
predominate ly classed as commensals and were ubiquitous in the 
environment, so that their presence did not necessarily  make the waste 
infectious. Recent studies undertaken in Germany in 2002 stated that the 
infectious waste environment was not a good culture medium and any 
pathogens in the waste were unlikely to remain viable (MOhlich, 2003).
A wide variety of potential pathogens are present in the environment and 
people suffering from a broad range of diseases (including infectious 
diseases) can be found in both healthcare establishments and the wider 
community. Section 5.2.5 reviews the hazard characteristics of waste by 
HSAC classification group and reviews the infection pathways for selected 
infectious diseases (see also Appendix J) and the prevalence of blood-
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borne pathogens. The review of infection pathways clearly  demonstrates 
that the greatest risk is presented by blood-borne pathogens as they may 
remain viable for prolonged periods and a relatively small dose is required 
to initiate an infection. Those infected with blood-borne viruses are not 
necessarily in healthcare establishments. Due to the chronic nature of 
diseases caused by blood-borne pathogens, those infected resume normal 
activities following diagnosis and remain living and working in the wider 
community.
Prevalence of Infection
Appendix I c learly shows the prevalence of three blood-borne infections 
(HBV, HCV and HIV) in the UK population. Over a 10 year period (1993- 
2002) the number of notified blood-borne infections has increased 
significantly: notif ications of both Hepatitis B (HBV) and Human
Immunodefic iency Virus (HIV) have doubled, whilst notif ications of 
Hepatitis C (HCV) have increased virtually twenty five fold.
Hospital Episode Statistics
Appendix N contains data relating to primary diagnosis in Hospitals in NHS 
England in 2000-2001. The data show that the number of admissions due 
to infectious or parasitic disease is less than 2% suggesting that the vast 
majority of those in hospital are free of infection. The vast majority of 
procedures undertaken in hospitals are elective, which are planned, non­
emergency procedures, undertaken for a medical reason to improve quality 
of life (e.g. knee surgery) and are not associated with the immediate care 
of infectious disease.
In Conclusion
Assumption one is not valid. Whilst it is acknowledged that a small 
percentage, approximately 2%, of people in a hospital environment are 
there to receive healthcare associated with an infectious disease the vast 
majority of patients in hospital have the same ‘infectious s ta tus ’ as those in 
the general community. Therefore people receiving healthcare in hospital 
are as likely to produce infectious waste associated with an infectious 
disease as those in the general community.
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In order for an infection to occur a viable pathogen, infection pathway and 
a susceptib le host are required. By reviewing infection pathways it can be 
seen that the greatest risk is presented by b lood-borne pathogens. The 
nature of clinical waste produced in a hospital environment (often from 
invasive procedures) means that it is likely to be contaminated with blood 
or other infectious bodily fluids. However evidence undertake from 
research Germany in 2002 suggest that the infectious waste environment 
is not a good culture medium and any pathogens in the waste were unlikely 
to remain viable. Therefore, the infectious nature of waste is not 
influenced by the origin of the waste or point of production.
7.1.2 Assum ption Two
The m ajority of infectious healthcare w aste is produced in hospitals. 
Prevalence of Infection
As discussed in section 7.1.1 less than 2% of hospital in-patient episodes 
relate to infectious or parasitic disease. However, the prevalence of some 
infectious diseases is increasing, e.g. Hepatitis (see section 5.2.3 and 
Appendix I). Many of these infectious diseases are chronic and those 
infected often live and work in the general community.
Data Estim ates and Case Study Results
Section 6.7 of this d issertation reviews community  clinical waste 
producers. Data relating to this group of producers is poor, estimates 
published by DETR in 2000 suggest that community producers generate 
between 100,000-200,000 tonnes of infectious waste per annum, which is 
approximate ly equivalent to the amount of infectious waste produced by 
the NHS (based on a study conducted by the DOE 1993).
Findings from the community producer survey carried out in the Greater 
Edinburgh Area (see section 6.7.2) estimate that the amount of infectious 
waste produced in the community is slightly higher (approximately 21%) 
than the amount of infectious waste produced by the largest hospital (by 
bed numbers) in the area.
Both the estimates, from DETR and the community survey, indicate that 
similar amounts of infectious waste (same of order of magnitude) are 
produced by NHS sources (hospital sites) and ‘com m unity ’ producers.
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Shift in Healthcare Practice
The valid ity of assumption two is very important with respect to the shift in 
healthcare practice from NHS premises to the community. As community 
healthcare practices increase through jo int working initiatives such as the 
‘Joint Futures’ programme in Scotland (see section 6.6.1), a greater 
amount of infectious waste will be produced out-with NHS facilit ies.
In Conclusion
Assumption two is not valid and does not reflect the prevalence of chronic 
disease in the community or current practice as shown by Government 
data estimates and estimates based on results of the community producer 
survey in the Greater Edinburgh Area.
Joint working initiatives between the NHS and other bodies will lead to an 
increase in the provision of healthcare in the community and the continued 
used of assumption two will lead to inappropriate waste m anagement 
practices in the future.
7.1.3 Assum ption Three
People living in the ir own homes do not produce infectious w aste. 
Infectious Household W aste
Householders produce a wide variety of waste that may be considered 
infectious. Section 5.2.2 of this dissertation and the review of assumption 
five (section 7.1.5) compare infectious healthcare waste with municipal 
solid waste in detail. Both infectious healthcare waste and municipal solid 
waste contain pathogens capable of causing infection (section 5.3).
Household Healthcare W aste
The HSAC guidance published in 1999 (see section 3.3.1 and Appendix 
E5) d ifferentiates between healthcare waste produced as a result of 
qualified medical intervention and waste produced from self-care or 
equivalent. The HSAC guidance states that in order for waste to be 
considered infectious in a household environment, a qualif ied healthcare 
practit ioner must assess the waste. The healthcare practit ioner will use 
clinical judgement based on the patien t’s symptoms and known medical 
history to determine if any waste produced is infectious (clinical). Where
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patients are undiagnosed and are asymptomatic, which is common with 
blood borne viruses (see section 5.2.3), the waste will not be identif ied as 
infectious by the practit ioner. Additionally, waste produced from self-care 
and feminine hygiene not associated with healthcare contaminated with 
infectious bodily f luids will be produced from households and may contain 
infectious agents including b lood-borne viruses.
In Conclusion
A wide range of wastes including municipal solid waste produced within 
private households can be considered infectious. Waste contaminated 
with infectious agents, including blood-borne viruses, will be produced as 
a result of healthcare intervention and self-care. Therefore assumption 
three is not valid.
7.1.4 Assum ption Four
The risk posed is d irectly  proportionate  to the hazard
A hazard is the abil ity of something, in this case a pathogen, to cause 
harm. Risk is the likelihood that the hazard will cause harm; therefore risk 
and hazard should be considered independently. While the risk posed will 
u lt imately relate to the hazard that is present, the re lationship is not 
always proportionate.
C onditions Required to In itia te  an Infection
Section 5.2.4 of this d issertation outlines the conditions required to initiate 
an infection which have been summarised below:
a) the presence of a pathogen of suffic ient viru lence and in a
suffic ient number to cause an infection;
b) a portal of entry must be available for the pathogen to enter the
body of a new host; and
c) the host must be susceptible.
The conditions can be viewed as steps identifying a risk pathway. If a step 
is missing the risk pathway is incomplete and risk is not realised; e.g. an 
infection does not occur. Table 11 (section 5.2.4) and Appendix J identify 
infection pathways for selected hospital acquired infections and indicate
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that the most signif icant risk of infection is posed by blood borne viruses 
and that the risk is at its greatest in relation to needle-stick and other 
‘sharps ’ injuries. Other pathogens are identified in the tables and are 
considered a hazard, including a number of healthcare acquired infections 
(such as MRSA). However, they are generally not considered to pose a 
significant risk of infection as the risk pathways require a number of 
conditions to be met and it is unlikely that these will be met under ‘normal’ 
c ircumstances. Hospital acquired infections are generally associated with 
patients with a compromised immune system.
HSE Risk C riteria  M atrix
Whilst reliance on the presence of a hazard and assessment of a risk 
pathway is used to evaluate the risk posed, it does not provide information 
about the magnitude of risk posed. Section 5.2.6 of this dissertation 
reviews the HSE risk assessment criteria matrix which uses the magnitude 
of the hazard and the likelihood of occurrence to evaluate the risk. The 
magnitude of the hazard requires an assessment of the effects once the 
risk is realised. In relation to infection this involves an assessment of the 
severity of the resulting disease. For example, the result of an infection 
with a rhinovirus may result in the common cold, whilst an infection with 
Pseudomonas aeruginosa  may result in septicaemia or sim ilar life 
threatening disease. The HSE framework is used in Figure 5 to evaluate 
and compare the risk of infection posed by infectious healthcare waste, 
human hygiene waste and municipal solid waste based on the information 
in sections five and six. Figure 5 shows that the risk posed by some 
healthcare waste was considered to be low compared to a medium risk 
posed by blood-stained infectious wastes, human hygiene waste and 
municipal solid waste. The evaluation of a ‘m edium ’ risk of infection for 
blood-stained infectious waste and human hygiene waste is due to the 
severity of the resulting diseases, notably septicaemia, hepatitis and HIV, 
whilst the evaluation of ‘medium ’ risk for municipal solid waste is based on 
the high probability  of contact with the infectious agents resulting in a 
minor infection, for example Salmonella  spp. It should be noted that the 
risk framework used is based on the most common UK infections and does 
not take account of human infections associated with foreign travel, such 
as Avian Flu caused by the Influenza Virus.
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In Conclusion
By reviewing risk pathways and the HSE risk framework criteria it can be 
seen that the risk posed by waste is not proportional to the hazard, 
therefore assumption four is not valid. Waste containing pathogens which 
are classed as hazardous do not pose a risk of infection unless a pathway 
exists for the risk to be realised. In calculating the magnitude of risk 
posed, information is required relating to the likelihood of occurrence, the 
infection pathway and the resulting disease.
The magnitude of risk is influenced by the presence of a hazard (the 
pathogen) but is not d irectly proportionate as other factors need to be 
taken into account.
7.1.5 Assum ption Five
Clin ical waste (in fectious w aste) poses a greater risk of infection than  
Household W aste. 
Com parisons w ith Municipal Solid W aste
Section 5.2.2 of this dissertation compares the microbial load of clinical 
waste with municipal solid waste and common food stuffs. Municipal solid 
waste is similar in composition to household waste and was chosen for 
comparison as a broad range of reference papers were available for this 
waste stream. Municipal solid waste includes household waste and other 
non-industria l wastes such as waste from offices, schools and institutions. 
A review of papers published in the 1980s from predominantly German 
studies identified that infectious waste often contains a broader range of 
pathogens than municipal solid waste, whilst municipal solid waste 
contains a greater number of pathogens, and that in general, the risk 
posed by infectious waste was not signif icantly greater. The papers 
reviewed the types of pathogens present and concluded that municipal 
solid waste tended to contain a higher number of m icro-organisms capable 
of causing respiratory and gastro-intestinal infections, (for example 
Escherichia coli), whilst infectious healthcare waste contained a greater 
frequency of pathogenic blood-borne viruses (for example HBV, HCV and 
HIV) (Kalnoski et al, 1983), (Trost et al, 1985), (Mose et al, 1985), (Rutala 
et al, 1992), (Bet Norske Veritas, 2000). Whilst there is no evidence to 
suggest that the prevalence of b lood-borne viruses is greater in hospita ls
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than anywhere else, it is likely that some healthcare practices (e.g. 
operations) will result in a greater amount of b lood-contaminated waste 
being produced in healthcare premises.
In conclusion
Assumption five is not valid. There is little evidence to suggest that 
infectious waste poses a greater risk of infection that household waste, 
however, the magnitude of the risk posed by the waste may differ. 
Infections caused by contact with household, or similar, waste may result 
in short-lived, non life-threatening disease, whilst contact with blood-borne 
viruses in infectious waste may lead to chronic life threatening disease.
7.2 Identification of new assumptions
It can be seen from the review of each of the five assumptions that they 
are not valid and do not apply to current healthcare practice or knowledge 
regarding the prevalence of infectious disease. As the assumptions 
identified originate from waste legislation and guidance documents (as 
identified in sections 2 and 3), new guidance is required based on revised 
assumptions about healthcare practice.
From the review of published papers, community producer survey and data 
provided by NHS and other producers, the author has established a set of 
new simplif ied assumptions.
7.2.1 Assum ption One
Infectious healthcare waste is produced both within and out-with 
healthcare premises.
7.2.2 Assum ption Two
The infectious nature of the waste is determined by a number of factors. 
The risk of infection posed can be evaluated using a three step simple 
assessment methodology, simply described as a ‘TO P ’ :
T y p e  -  type of infectious waste; e.g. b lood-stained materials, sharps, etc.
O u tcom e  -  the magnitude and type of disease resulting from an infection.
P a thw ay -  pathway required for an infection to occur; e.g. inhalation, 
ingestion, etc
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The T O P ’ assessment methodology simplif ies the risk assessment 
process and attempts to quantify the risk and assess its magnitude. 
Assessing the type of infectious waste and the pathway allows the user to 
quantify the risk, e.g. identify high, medium and low risk of an infection 
occurring. By assessing the possible outcomes the user can assess the 
magnitude of the risk if realised, e.g. common ‘m ild ’ d iseases such as the 
common cold, compared to life threatening disease such as septicaemia.
These assumptions are used as a foundation for a new waste classif ication 
and segregation system proposed in section 9. However, before this can 
be developed fully, a review of forthcoming regulatory change is required 
to ensure that future classif ication and segregation is compatib le with both 
current and future regulatory requirements.
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8. FORTHCOMING/RECENT REGULATORY CHANGE
There are a number of forthcoming regulatory changes on the horizon 
which will affect the management of healthcare waste. The following 
section summarises the key changes, where applicable, with respect to the 
current Landfil l Regulations 2002/2003, Waste Incineration Regulations 
2002/2003, and forthcoming changes with respect to Waste Electrical and 
Electronic Equipment (WEEE) and Hazardous Waste Regulations.
Each of the key legislative drivers will impact on healthcare waste 
management practice. However the combined effect of the proposed 
regulations will lead to signif icant changes in waste segregation, treatment 
and disposal.
8.1 Landfill Regulations 2002/2003
The Landfill (England & Wales) Regulations 2002, Landfill Regulations 
(Northern Ireland) 2003 and the Landfill (Scotland) Regulations 2003 
implement the requirements of the Landfill Directive (1999/31/EC).
The aim of the legislation is to reduce the environmental impacts relating 
to landfill sites, including a reduction in methane emissions. In particular, 
the Regulations prevent hazardous, non-hazardous and inert wastes from 
being disposed of in the same landfill, prohibit the landfill ing of certain 
wastes including tyres, liquid waste and infectious waste and requires pre- 
trea tmenti3 of all waste prior to landfill ing from October 2007 (Department 
of Environment Food and Rural Affairs, 2003b). The defin ition of infectious 
waste is taken from the European Waste Catalogue. Details about how 
this relates to the current definition of clinical and special waste can be 
found in section 2 .2 .2 .
It is not current practice to landfill infectious waste in the UK; waste 
management l icences and permits already prohibit the practice. 
Therefore, the prohibition of landfill ing infectious waste will not have a 
s ignificant affect.
13 Since initial submission of this dissertation, DEFRA has released guidance, (November 
2005), titled: ‘Government Interpretation of the Landfill (England and Wales) Regulations 
2002 (As Amended)’; the guidance outlines waste pre-treatment requirements.
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However, the effect of increased regulation will result an increase in 
healthcare waste disposal costs as an increased levy will be placed on 
waste destined for landfill, including the residues of treated infectious 
healthcare wastes.
8.1.1 European W aste Catalogue Codes
In addition to specifying the type of waste permitted in UK Landfills, the 
Regulations 2002/2003 place a statutory responsib il ity  on producers of 
waste to adequately describe the waste they produce using EWC six digit 
codes (see section 2.2.2 and Appendix B). In the UK, the codes should be 
used on ‘Duty of Care ’ Transfer and Consignment Notes that accompany 
all movements of waste from point of production to final disposal.
8.2 Forthcoming WEEE & RoHS Regulations
The forthcoming Waste Electrical and Electronic Equipment (WEEE) 
Regulations will implement the European WEEE Directive (2002/96/EC). 
The WEEE Directive aims primarily to reduce the amount of waste 
e lectrical and electronic equipment generated for disposal (mainly to 
landfill), through increasing the re-use, recycling and recovery of waste.
The forthcoming Restriction of Hazardous Substances (RoHS) 
Regulations^ will implement the European RoHS Directive (2002/95/EC), 
which accompanies the WEEE Directive. The RoHS Directive is aimed in 
part at EU market harmonisation, restricting (effectively banning) the use 
of heavy metals and brominated fire retardants in the manufacture of 
electrical and electronic equipment from 1st July 2006. The RoHS 
Directive also sets Maximum Concentration Values (MCVs) for lead, 
mercury, cadmium, hexavalent chromium, polybrominated biphenyls (PBB) 
and polybrominated diphenyl ethers (PBDE).
In order for the UK to meet its requirements under the WEEE and RoHS 
Directives, collection, treatment and financing systems for W EEE are 
required to be in place by August 2005 and the first collection and 
treatment targets must be reached by December 2006.
1 4 Since initial submission of this dissertation the Restriction of the Use of Certain 
Hazardous Substances (RoHS) in Electrical and Electronic Equipment Regulations 2005 
have been published and come into force on the 1st July 2006.
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To date the UK has failed to produce specific W EEE regulations and 
therefore it is antic ipated that the UK will fail to implement UK legislation 
within the prescribed time limitis.
The WEEE Regulations, once implemented in the UK, will have a 
significant impact on the healthcare sector. However the effect in relation 
to infectious waste will be limited as infectious implanted medical devices 
are excluded from the Directive.
Infectious implanted devices include pacemakers and neuro-stimulators, 
many of which require specialist disposal, due to the composition of the 
device and it’s power source (battery). Anecdotal evidence suggests that 
such devices are being stored for indefinite periods of time due as 
disposal options are not readily available.
8.3 Waste Incineration Regulations 2002/03
The Waste Incineration (England and Wales) Regulations 2002, The Waste 
Incineration (Scotland) Regulations 2003 and The Waste Incineration 
Regulations (Northern Ireland) 2003, transpose the requirements of the 
Waste Incineration Directive 2000/76/EC. The Directive was adopted in 
December 2000 and in time will replace existing hazardous and non- 
hazardous incineration Directives (1994/67/EC, 89/429/EEC and
1989/369/EEC).
The requirements of the Regulations came into force in 2002/03; however 
existing incineration plants were given a deadline for compliance of 
December 2005. In order to meet the deadline, existing plants must apply 
for permit modifications by the end of March 2005.
The Regulations introduce more stringent regulatory standards for 
incineration plant and require continuous monitoring of emissions. The 
requirements are onerous and both investment and changes in practice 
will be required to upgrade existing plants to meet the new standards. For 
example, the Regulations require that ash quality be limited to 3% total 
organic carbon content; in order to meet this some current c lin ical waste
is Since initial submission of this dissertation, the Department of Trade and Industry and 
have stated that the WEEE Regulations will not be implemented until late 2006.
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incinerators will have to reduce their organic carbon content by as much 
as 90% (Department for Environment Food and Rural Affairs, 2004a).
In addition to upgrading plants, incinerator operators may choose to alter 
the throughput and types of waste processed; by reducing throughput and 
prescrib ing the mixture of waste to be incinerated, plant operators can 
achieve improvements in ash quality.
The Regulations will have a signif icant impact on the disposal of infectious 
waste as many smaller incineration plants (less than 1 tonne per hour), 
that currently operate under less str ingent regulatory controls, will be 
unable to meet the new standard without significant investment and may 
close. The closure of sites may lead to increases in disposal costs and 
waste being transported greater distances for disposal. Larger 
incineration facilit ies designed to take hazardous waste will require little 
upgrade and therefore should continue to operate. However, these sites 
are limited in number and are not found in all parts of the UK. Scotland 
and Northern Ireland currently have no incineration facil it ies capable of 
taking hazardous infectious waste, whilst there are two facil it ies in Wales 
and approximate ly ten in England.
8.4 Changes in Transport Regulations.
Section 2.2.1 of this dissertation outlines the relationship between 
International, European and UK transport regulation. The current CDGTPE 
Regulations are due to be superseded in 2005 when the requirements of 
ADR 2005 are transposed into UK transport regu la tion^. ADR 2005 is 
based on the 13th Edition of the UN Recommendations on the Transport of 
Dangerous Goods. ADR 2005 will introduce a new classification system 
for infectious substances into the UK (the current c lassification system is 
outlined in section 2.3.1). The new classification system will replace 
reference to WHO/ACDP pathogen groups and introduce a new two group 
c lassification system: Category A and Category B.
Pathogens included on the Category A list have been assessed as posing 
the greatest risk of infection by a team of UN experts and have been
, 6 Since initial submission of this dissertation the Carriage of Dangerous Goods and Use 
of Transportable Pressure Equipment (Amendment) Regulations 2005 have been 
published and came into force July 2005.
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defined as highly infectious with both the ability to spread to the community 
and also cause life threatening disease or permanent disability. In putting 
together the list of Category A pathogens the United Nations have used the 
expertise of a number of national and international expert bodies including 
the Basel Convention Healthcare Waste Group. (Townend, undated). 
Waste classified as Category A due to contamination by pathogens on the 
Category A list relies on knowledge of a patient’s medical history and/or 
assessment of symptoms. The indicative list of Category A pathogens 
published by the UN is shown in Appendix O.
Infectious waste not listed in Category A which is identif ied as posing a 
risk of infection falls into Category B. Waste contaminated with Category B 
pathogens is given the UN transport number: UN3291, which is assigned to 
wastes which are reasonably believed to have a low probability  of 
containing infectious substances. The identif ication of Category B 
pathogens and infectious waste relies on municipal legislation. In the UK, 
the definition of clinical waste (see section 2.2.3 and 2.3.3) is used.
With regard to the management of infectious waste in the UK, the removal 
of references to WHO pathogens groups will cause a potentia l problem as 
other, non-transport regulations refer to the WHO groups. The lack of a 
Europe-wide definition of Category B pathogens will lead to inequalit ies in 
the management of waste between countries as defin itions of infectious 
waste differ.
8.5 Forthcoming Hazardous Waste Regulations
The Special Waste Amendment (Scotland) Regulations 2004, The Special 
Waste Regulations (Northern Ireland) 1998 and The Special Waste 
Amendment Regulations 2001 (England and Wales only) currently define 
and control the management of the most hazardous wastes in the UK.
Throughout the UK the Special Waste Regulations are currently being 
amended to incorporate the requirements of the Hazardous Waste 
Directive (91/689/EEC)17.
1 7 Since initial submission of this dissertation the Hazardous Waste (England and Wales) 
Regulations 2005, the Hazardous Waste (Wales) Regulations 2005 and the Hazardous 
Waste Regulations (Northern Ireland) 2005 have been published and came into force on 
16th July 2005.
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The Scottish Executive is responsible for the drafting of the Scottish 
Regulations, the Department of Environment Food and Rural Affairs 
(DEFRA) and the Welsh Assembly Government (WAG) are responsible for 
drafting the Regulations in England and Wales respectively, and the 
Department of the Environment (DOE) are responsible for drafting the 
Regulations in Northern Ireland.
Hazardous W aste in Scotland
Scotland was the first part of the UK to put in place waste regulation 
complying with the requirements of the Flazardous Waste Directive 
(91/689/EEC). The new regulations are called the Special Waste 
Amendment (Scotland) Regulations 2004 and came into force on the 1st 
July 2004, replacing the Special Waste Regulations 1996.
W aste in England and W ales
It is anticipated that the new Regulations for England and Wales will be 
called the ‘Hazardous Waste Regulations’ and will be s ignif icantly different 
from the current Special Waste Regulations. The DE FRA/WAG 
consultation on the proposed regulations has recently fin ished and the 
results of the consultation process are expected in 2005. The consultation 
outlined the proposed approach which included altering the system for 
multiple collections, consignment and required producer registration.
Hazardous W aste in Northern Ireland
The Department of Environment (DOE) Northern Ireland (Nl) has not 
indicated a release date for their forthcoming hazardous waste regulation 
consultation. However, it is likely that the Nl Regulations will be broadly 
similar to the forthcoming regulations for England and Wales.
Neither DEFRA, nor DOE Nl have indicated when the final Hazardous 
Waste Regulations will be released. However, it is likely that July 2005 
will be chosen, to coincide with the Landfill Regulation deadline for the 
implementation of the ‘Waste Acceptance Crite r ia ’ (Regulation 10 and Part 
3 of Schedule 1 of the Landfill Regulations), due 16th July 2005.
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8.5.1 Hazardous W aste Technical Guidance (W M2)
The ‘Joint Agenc ies ’ (Scottish Environment Protection Agency (SEPA), 
Environment Agency (EA) and the Environment and Heritage Service 
(EHS)) have produced technical guidance on the ‘ Interpretation, Definit ion 
and Classification of Hazardous W aste ’ . The Joint Agencies guidance is 
titled ‘W M 2 ’ i8. Like its predecessor ‘W M T  technical guidance on ‘The 
Definition and Classif ication of Special W aste ’ pursuant to the Special 
Waste Regulations 1996, WM2 provides guidance on the basis of 
European Waste Catalogue (EWC) Codes (section 2 .2 . 2  and Appendix B 
provide further information on EWC codes).
WM2 and the Classification of Infectious Waste
Appendix C9 of WM2 provides guidance on the assessment of infectious 
waste and relies on clinical assessment to determine if the waste has been 
generated from a human/animal with an infectious disease and whether 
the waste is likely to contain an infectious agent or toxin (Environment 
Agency, 2003a). A decision tree is provided in WM2 to aid the 
identif ication of infectious waste, a simplif ied version of the tree is shown 
as Figure 15.
The new assessment procedure introduces a number of practical 
challenges as the producer of the waste (healthcare practit ioner) is not 
always aware of the disease causing pathogen or its v iabil ity  in the waste 
stream. Whilst practit ioners may be able to assess the presence of 
pathogens based on experience and clinical knowledge, the assessment of 
viabil ity  is more complex.
In order to assess if a disease causing pathogen is viable in a waste mass, 
the waste would need to undergo laboratory analysis. If practit ioners are 
unable to segregate waste containing viable pathogens, WIVI2 states (page 
C45) that all waste should be considered subject to special requirements 
in order to prevent infection. In practice this would lead to all c linical 
waste being classified as hazardous infectious waste.
1 8  Since initial submission of this dissertation the Environment Agency has released 
(November 2005) a revised second edition of the WM2 guidance. The guidance provides 
further guidance on the classification of infectious and pharmaceutical healthcare wastes.
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Figure 15. S im plified decision tree for infectious hazardous waste, adapted from  
WM2.
Is the waste listed in chapter 18 of the EWC ? 
Yes
Does the waste arise from (or is contaminated with) material from a human / animal 
clinically assessed to have a disease caused by a micro-organism or its toxin ?
Yes
Does the waste contain 
the viable causal 
pathogen or toxin ? Yes
Yes
Special Requirements Apply 
Hazardous by H9
No
Is the waste a culture, or enrichment of a 
micro-organism or toxin known or reliably 
believed to cause disease in man or other 
living animal.
OR
A sample for an animal or animal known or 
clinically assessed to have a disease caused 
by a micro-organism or its toxin.
No
Special Requirements DO NOT Apply 
NOT Hazardous by H9
Source: (Environment Agency, 2003a)
Unlike the current c lassification system (see section 2.3.3), the WM2 
assessment does not d ifferentiate between disease groups or the severity 
or effect of diseases. Currently, waste posing a signif icant risk of infection 
and a potential public health hazard is identified as clinical special waste 
using WHO Risk Group assessment. Waste contaminated with WHO Risk 
Group 4 pathogens is considered clin ical special waste; examples of WHO 
Group 4 pathogens include Ebola Virus and Lassa Fever. All other 
infectious waste is classified as clin ical waste.
1 2 8
The assessment procedure in W M2 uses a single classif ication infectious 
waste where ‘m ild ’ disease, such as Salmonella  spp., is c lassified 
alongside pathogens which cause life threatening disease such as the 
Ebola and Margburg virus (WHO Risk Group 4 pathogens).
WM2 states that ‘t r iv ia l ’ , ‘background ’ and pathogens present at ‘natural 
leve ls ’ need not be considered as hazardous infectious waste; the common 
cold is given as an example of a ‘tr iv ia l ’ infection.
As the new assessment m ethodology d iffers s ignif icantly from the current 
risk based system and it is likely that in the short-term healthcare 
practit ioners may choose to classify all clinical waste as hazardous 
infectious waste. This will have a s ignif icant impact as it wil l require 
consignment of waste, and modifications to existing waste m anagement 
licences and permits.
Consignment of Hazardous Waste
It is likely that hazardous waste will be subject to consignment. The 
current cost of consignment is £15.95 (England, Wales and Scotland). 
W hilst no amendments to the charging regime were introduced in the new 
Scottish Regulations (Special Waste Regulations (Scotland) 2004), the 
recent DEFRA/WAG consultation on the proposed Hazardous Waste 
Regulations introduced a new charging system ig . The consultation 
document proposed that producer should register with the Environment 
Agency prior to having waste collected. Registration would be charged at 
between £18-£28 and once made registration would be valid for a period of 
12 months. Additional charges will also be due for each consignm ent of 
hazardous waste, the consignment charge will vary from £5-£15 per 
collection depending on the type of collection (Department for Environment 
Food and Rural Affairs (2004b).
The costs of consignment are likely to be significant. If c linical waste is 
c lassified as infectious hazardous waste (as per WM2 assessment) the 
costs associated with consignment of this waste for a large dis tr ic t 
hospital, which requires a daily collection of waste, could be in excess of 
£ 1 0 , 0 0 0  per annum.
ig Since initial submission of this dissertation the Environment Agency has introduced a 
system of hazardous waste producer notification (registration).
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If we consider that the average NHS Trust/Health Board is comprised of a 
large number of premises, the costs begin to escalate. At a recent 
NHSScotland waste management meeting an estimate was made that the 
consignment costs for NHS Greater G lasgow could be in excess of 
£ 1 million per annum.
Waste Management Licences and Permits
Facilities that currently treat or dispose of clinical waste may not have the 
necessary licences and permits to accept hazardous infectious waste and 
amendments have both f inancial and time implications. If p lanning 
consent is also required (in areas w ithout planning permission for 
hazardous waste) it may take an extended period of time for the consent to 
be given and this may involve public consultation.
If a fac il ity  is likely to treat in excess of 10 tonnes of hazardous waste per 
day (which is a plausible scenario if all c linical waste is classif ied as 
hazardous waste) the fac il ity  will require a Pollution Prevention and 
Control (PPG) Permit. There are signif icant financia l and time constraints 
in the application process for PPG permits. No guidance is given in W M 2  
or the recent DEFRA/WAG consultation on the type of treatm ent and 
disposal plants that will be authorised to accept hazardous infectious 
waste and it is therefore assumed that both medium and high temperature 
treatment systems (see section 3.2) will be able to accept hazardous 
waste.
The change in c lassification to hazardous waste may also effect the on­
site treatment of waste, for example the use of bench-top autoclaves in 
hospital pathology departments. Under current W aste Management 
Licensing Regulations, the autoclaves do not require a licence as long as 
they are not treating special waste as they are covered by an exemption 
(exemption 39).
As there are currently no exemptions for the treatment of hazardous 
waste, in future hospital and other autoclaves used to steril ise infectious 
hazardous (clinical) waste prior to disposal may require a waste 
management licence.
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Other Healthcare Waste Covered by WM2
In addition to introducing a new system for the c lassification of infectious 
waste, W M 2  introduces a new system for the c lassification of medicinal 
products, it is antic ipated that this system will also be referenced in the 
forthcoming Hazardous Waste Regulations.
The Special Waste Regulations 1996 made direct reference to Prescription 
Only Medicines (ROMs). The term POM does not exist in the EWC and is 
therefore not referenced in W M 2 ; instead WM2 has two entries for 
medicinal products:
18 01 08* Cytotoxic and cytostatic medicines;
18 01 09 Medicines other than those mentioned in 18 01 08*.
* Hazardous waste
Cytotoxic and cytostatic medicines are the only classification of medicinal 
products to be considered as hazardous waste. Cytotoxic wastes are 
those used in cancer care and are listed in chapter 8  of the British 
National Formulary (BMA, 2004). The term cytostatic is not used in the UK 
and there is currently no UK defin ition. At the current time the regulatory 
agencies are discussing the defin ition of cytostatic with the NHS and Royal 
Pharmaceutical Society. The debate focuses on whether the term 
‘cytosta tic ’ is an alternative term for cytotoxic or whether it refers to a 
different type of medicinal product capable of altering normal cell function. 
If the latter definition is chosen, this may lead to a s ignif icant amount of 
medicinal products being classif ied as hazardous waste 2o.
The classification of medicinal products affects the treatment and d isposal 
of sharps waste. Sharps are considered to be an infectious waste; 
however, if they may also be contaminated with medicinal products and as 
such may have other hazardous properties.
2o Since initial submission of this dissertation the Environment Agency has produced 
guidance on the classification of cyto-toxic and cyto-static medicines and defines them as 
medicinal products which are toxic (H6 ), carcinogenic (H7), toxic for reproduction (H10) or 
mutagenic (H11).
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Practical In terpretation  of W M2 Hazardous W aste G uidance
Whilst WM2 is a current guidance document, its use in relation to 
hazardous waste regulation is only applicable in Scotland. The rest of the 
UK (England, Wales and Northern Ireland) will not be required to interpret 
the new guidance at a practical level until July 2005 when revised 
Hazardous Waste Regulations are introduced.
The current s ituation in Scotland in relation to healthcare waste has 
resulted in no change in practice as the NHS has negotiated an interim 
position with both SEPA and the Scottish Executive. The interim position 
is valid until July 2005 when the revised regulations will apply to the rest 
of the UK. The interim position has been granted as it is acknowledged 
that Scottish healthcare waste is treated and disposed of in England and 
Wales.
8.6 S u m m a ry  - Forthcoming Regulatory Change
Recent and forthcoming changes in regulation will affect the management 
of infectious waste.
The Landfill Regulations 2002/2003 will require producers to identify waste 
using EWC codes. This will alter landfill practices which may increase 
landfill d isposal costs.
Forthcoming WEEE and RoHS Regulations will have an impact on the 
management of healthcare waste, although it is unlikely to impact on the 
management and disposal of infectious waste, as infectious and implanted 
devices are likely to be excluded from requirements of the Regulations.
The Waste Incineration Regulations will introduce new and more str ingent 
regulatory standards for incinerators, which may lead to the closure of 
smaller sites and will inevitably lead to an increase in the cost of d isposal 
as facilit ies are upgraded. The Regulations are likely to lead to a 
consolidation in the specialist healthcare waste incineration market as 
smaller operators may find it d iff icult to operate under such condit ions.
The adoption of ADR 2005 into UK Transport Regulations will introduce a 
new classification system for infectious waste replacing the previous 
system which relied on the use of the WHO Risk Groups. The new system
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will c lassify waste into two categories, Category A and Category B. 
Category A waste is waste contaminated with pathogens included on the 
Category A Indicative Pathogen list, whilst Category B waste is all other 
waste identif ied as infectious. The use of the Category A and B 
classification is unique to Transport Regulation.
The revision of the Special Waste Regulations to incorporate the 
requirements of the Hazardous Waste Directive (91/689/EEC) will lead to 
significant changes in the c lassification and management of infectious 
healthcare waste. Scotland is the only part of the UK to have amended 
regulations in place (Special Waste Amendment (Scotland) Regulations 
2004). However, DEFRA and WAG are expected to issue hazardous waste 
regulations in early 2005 following the recent consultation process. The 
DOE Nl has not issued amended regulations for consultation; however, it 
is antic ipated that the content of the Nl regulations will be broadly sim ilar 
to those being produced by DEFRA and WAG. In order to help producers 
c lassify and segregate hazardous waste, the UK’s environmental 
regulatory agencies (EA, SEPA and EHS) have produced a jo int hazardous 
waste interpretation guidance document, tit led WM2. By reviewing the 
guidance in W M 2  it can be seen that there are a number of changes 
effecting infectious waste, including a change in definition.
In WM2, infectious hazardous waste is defined as being “subject to special 
requirements in order to prevent in fection” and its assessment relies on 
clinical knowledge and judgement of the presence of viable pathogens 
from identified sources of infection. Reference to W HO pathogen Risk 
Groups has been removed and there is no d ifferentiation between the 
severity of infectious diseases. If waste is not segregated on the basis of 
the new assessment, WM2 states that clin icians must treat all c linical 
waste as infectious hazardous waste. If all clinical waste is classif ied as 
infectious hazardous waste, it will lead to increased costs of consignm ent 
and amendments to waste management l icenses and permits.
The differing approaches taken in forthcoming waste and transport 
regulation waste with regard to the classification of infectious waste may 
lead to confusion and inconsistent waste m anagement practices. The 
healthcare industry has expressed concern about the d ifferences in the 
approach which has lead to the revision of the UK’s primary clinical waste 
guidance document, The Safe Disposal of Clinical Waste. The revision of 
this guidance in relation to infectious waste is discussed in section 9.
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9. THE NEED FOR A NEW APPROACH
The information used in this dissertation was collated with the help of 
many private organisations, public bodies and individual experts in the 
field. In discussing the key issues relating to the management of 
infectious waste, the key barrier to change identified was the use of 
inappropriate defin itions and classification systems. In this section, a ‘new 
approach ’ is discussed which was developed by the author from research, 
notably the survey of community based producers in the Edinburgh area 
and review of published papers, as outlined in earlier sections of this 
dissertation. The concepts for the new approach have been developed 
over the past four years and have been subject to much influence and 
debate. Following discussion of the approach earlier this year with NHS 
Estates and the Health and Safety Executive, the opportun ity  to project 
manage the re-write of the UK’s primary guidance document: T h e  Safe 
Disposal of Clinical W aste ’ arose. The role of project manager was 
accepted by the author in the capacity of an Environmental Consultant 
employed by Enviros Consulting Ltd. This section of the dissertation 
reviews the development of the ‘new approach ’ and how it has been 
influenced by the experts involved in the re-write of the guidance ‘The 
Safe Disposal of Clinical W as te ’. It should be noted that, whilst the 
research outlined in this dissertation has influenced the production of the 
guidance, and the opinions of the experts involved in the guidance have 
influenced the later stages of the research, the ‘new approach ’ outlined in 
this dissertation is based on research undertaken by the author and may 
differ from the final guidance document.
9.1 Re-write of the Safe Disposal of Clinical Waste
The original Safe Disposal of Clinical Waste document was produced in 
1982 by the Health Services Advisory Committee (HSAC) and was 
published by the Health and Safety Executive (HSE). It has been revised 
twice: 1992 and 1999. The current re-write will go further than past 
amendments and will result in a guidance document reflecting the needs of 
the changing healthcare sector, placing equal importance on community  
producers and hospital sites, and will summarise the UK regulatory 
requirements with respect to waste, health and safety and transport 
regulation.
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The new guidance document is due to be released for consultation in 
December 2004 and following a 6  week consultation period the final 
guidance will be produced in February 2005 and released in Spring 20052i. 
The timing is important, as the guidance needs to be released prior to the 
forthcoming Hazardous Waste Regulations coming into force but not 
before the final content of the Regulations has been agreed.
The cost of the re-write is being borne by NHS Estates 22 (England). 
However, representatives from the NHS throughout the UK and the UK 
Regulatory Agencies (EA, SEPA, EHS and the HSE) have all agreed to 
support the final guidance document and will adopt its content as agreed 
guidance. The support of the UK Regulatory Agencies is of particular 
importance, as the new guidance is viewed as a ‘b r idg ing ’ document that 
will provide a practical interpretation and ‘put flesh on the bones’ of the 
existing hazardous waste guidance document, WM2, with respect to the 
definition of “ in fectious” . The Environmental Regulatory Agencies have 
stated that following the production of the new guidance, they would 
consider minor amendments to W M 2  to align the two guidance 
docum ents 23 .
9.1.1 Safe Disposal of C lin ical W aste Steering Group
The new guidance is being produced on behalf of NHS Estates (England). 
However the content and the layout of the guidance is being managed by a 
steering group comprised of representatives of the following 
organisations/bodies:
• NHS Estates;
• NHS RASA;
• Health & Safety Executive;
• Environment Agency;
• Environment & Heritage Service;
21 Since initial submission of this dissertation the consultation of the revised guidance 
titles Safe Management of Healthcare Waste’ has taken place and finished February 
2006. It is anticipated that the guidance will be published late 2006.
22 NHS Estates ceased to exists in 2005 and the work of the Agency transferred to the 
Department of Health, who took over management of the guidance project.
23 WM2 was amended in November 2005 prior to the release of ‘Safe Management of 
Healthcare’ Consultation in December 2005.
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• Department of Environment, Food and Rural Affairs;
• NHSScotland Property & Environment Forum Executive;
• Welsh Health Estates;
• Health Protection Agency;
• Health & Personal Social Services, Northern Ireland.
Members of the steering group were chosen by NHS Estates on the basis 
that they were considered key public stakeholders with expertise and 
knowledge of both current practice and regulation. Non-public 
stakeholders were not invited to join the steering group, as both 
Department of Environment, Food and Rural Affairs and the Environment 
Agency expressed concern about private sector involvement in the drafting 
of an influential document that will provide guidance on hazardous waste 
regulation prior to the release of the Hazardous Waste Regulations. NHS 
Estates acknowledged their concern and the private sector involvement in 
the drafting of the guidance was limited to participation in the expert 
working groups.
9.1.2 Safe Disposal of C lin ical W aste - W orking Groups
It was important that the content of the guidance provided best practice 
and regulatory advice applicable to a wide range of sectors. In order to 
take into account the view of and wealth of knowledge held by a large 
number of stakeholders, three expert working groups were set up to 
provide expert opinion and advice.
Members of the working groups were nominated by members of the 
steering group and represented a number of industries and public bodies. 
Appendix P contains a list of those that attended the steering and working 
groups. There were a number of influential individuals in the working 
groups, notably: Bill Townend, Chair of the International Solid Waste 
Association (ISWA) Healthcare Waste Working Group; Sue Berry, C linical 
Waste Lead for the Infection Control Nurses Association (ICNA); and John 
Newbold, Senior Specialist Inspector Biological Agents for the HSE and 
member of the UK Advisory Committee on Dangerous Pathogens (ACDP).
Members of the steering and working groups have essentia lly  peer 
reviewed the new approach to the classification outlined in this 
dissertation, produced by the author. Whilst the final version of the
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guidance document may differ slightly, the underlying concepts and 
philosophy have been reviewed and agreed.
The three working groups were designed to look at key issues at each 
stage of the waste management process:
♦ working group one focused on classification and segregation of 
waste;
♦ working group two looked at packaging, on-site storage and 
transport; and
♦ working group three considered the implications with regard to 
treatment and disposal.
Working Group Meetings
The working group meetings were hosted by the Department of Health, 
Health & Safety Executive and DEFRA in London and Birm ingham. The 
meeting groups were chaired and facilitated by the author as Enviros 
Consulting Ltd project manager. Each working group met twice with a 
three week interval between the first and second meeting, allowing 
partic ipants enough time to discuss the ideas and principles with 
colleagues before returning for the next meeting. Each meeting followed 
an agenda focusing on presentation of ideas and discussions, either as a 
single group, or in ‘b reak-out’ groups. The principles and assumptions 
discussed in the working groups were based on the research in this 
dissertation. Minutes of the meetings were taken but have not been 
included in the d issertation due to their confidential nature^.
Following the round of meetings for each working group, a final working 
group meeting was held with representatives from all working groups 
present. The aim of the final meeting was to link the d iscussions and to 
ensure that there was agreement regarding the content of the guidance.
9.2 New Approach
The fundamental principle behind the new approach is the a lignment of 
waste, transport and health and safety regulation. The basis of the new
24 Copies of minutes have been presented to the examiners and supervisors; however 
they have been removed prior to publication.
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approach is a single classification system suffic iently robust to meet the 
needs of all three regulatory approaches, underpinned by the new 
assumptions identified in section 7.2 and shown below:
Assum ption One - Infectious healthcare waste is produced both within 
and out-with healthcare premises.
Assum ption Two - The infectious nature of the waste is determ ined by a 
number of factors. The risk of infection posed can be evaluated using a 
three step simple assessment methodology, simply described as a ‘T O P ’ :
T y p e  -  type of infectious waste; e.g. b lood-stained materials, sharps, etc.
O u tc o m e  -  the magnitude and type of disease resulting from an infection.
P a thw ay -  pathway required for an infection to occur; e.g. inhalation, 
ingestion, etc
The defin itions of infectious waste in both waste and transport regulation 
are taken from international and European agreements, leaving no 
immediate opportunity to change them. Therefore, the classification 
system in the new approach must support existing defin itions and build on 
them, providing a single infectious waste management fram ework in the 
UK.
The new classification system is based on an assessment methodology to 
identify infectious waste and a colour-coded segregation scheme that 
segregates waste on the basis of type of waste and treatment/d isposal 
options. The colour-coded scheme will ensure easy identif ication of 
waste, aiding regulatory compliance, and simplify ing the labelling of waste 
with both EWC codes and UN numbers. In producing the new classification 
system the needs of the community (non-hospital based) producers was 
considered, drawing on the findings of the community  producer survey 
undertaken in Edinburgh by the author (see Section 6.7.2).
9.2.1 A ligning Defin itions and C lassification
Practit ioners require one system that complies with all regulatory 
approaches. In developing this approach some f lexib il ity  is required in the 
interpretation of the current legal definitions.
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9.2.2 Repeal of the Defin ition of C linical W aste
During discussions at the first steering group meeting for the rewrite of 
Safe Disposal of Clinical Waste, Department of Environment, Food and 
Rural Affairs were approached regarding repealing the definition of clinical 
waste (see section 2.2.3 and 2.3.3) in The Controlled Waste Regulations 
as shown below:
(a )“..any waste which consists wholly or part ly  o f human or animal tissue, 
blood or other bodily fluids, excretions, drugs or o ther pharm aceutica l  
products, swabs or dressings, syringes, needles or o ther sharp  
instruments, being waste which unless rendered safe may prove  
hazardous to any person coming into contact with it; and
(b) any other waste aris ing from m edical , nursing, dental, veterinary, 
pharm aceutica l or s im ilar practice, investigation, treatment, care, teaching  
or research, or the collection o f b lood for transfusion, being waste which 
may cause infection to any person coming into contact with i t . ”
The definition is over 15 years old and conflicts with both current 
European and International regulations. Reference to ‘excretions’ and 
‘swabs or dressings’ as ‘be ing waste which unless rendered safe may  
prove hazardous’ in part (a) implies that these items have intr insic 
hazardous characteristics. This approach conflicts with hazardous waste 
and transport regulations which are based on the assessment of the 
pathogens in the waste stream and do not refer to waste items specifically. 
The inclusion of waste items within the definition of clinical waste which 
may not be an infectious hazard leads to confusion and results in a 
s ignificant amount of waste being classified as clinical that does not pose 
a risk of infection. The use of the definition of clinical waste has lead to 
waste segregation practices on the basis of precaution with waste being 
segregated regardless of the risk posed and treated as infectious. This 
has resulted in a situation where practit ioners c lassify waste as clinical on 
the basis of point of production rather than hazard or risk. Results from 
the survey of community based producers in the Edinburgh area (see 
Section 6.7.2) show that the vast majority of infectious waste produced 
was actually sanpro waste and posed little or no risk of infection. The use 
of the definition of clinical waste has resulted in the UK producing more 
waste that is classified as infectious than any other European nation (see 
sections 6.2 and 6.3).
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Part (b) of the definition refers to types of healthcare practice and uses the 
term ‘waste which may cause in fec t ion ’. Whilst the list of healthcare 
practices is by no means comprehensive, it does not conflict with other 
regulations. However, the reliance on risk assessment (identif ication of 
waste which may cause infection) rather than hazard identif ication 
(identif ication of pathogens in the waste) does not fu lly comply with 
forthcoming Hazardous Waste Regulations.
It may be argued that hazard identif ication is required in order to carry out 
risk assessment however, the assessment practices differ with respect to 
the c lassification of infectious hazard. For example: pathogens present in 
the waste may be identified as a hazard, thus making the waste 
‘hazardous w as te ’ . However, the presentation of the waste (e.g. 
packaging, such as a sharps box) may mean that the waste poses a low 
risk of infection as the infection pathway has been removed The use of 
hazard and risk assessment is discussed in relation to defin itions in more 
detail later.
Whilst it may be beneficia l to keep the risk assessment element in the 
classification of infectious waste, the use of two regulatory definitions, one 
primarily based on risk (clinical waste) and the other based on hazard 
(hazardous waste), leads to unnecessary confusion for both healthcare 
practit ioners and regulators. The need to have two defin itions in UK 
statute for one waste stream may be questioned. Removal of the 
definition of clinical waste by repealing it would simplify the UK position.
At a steering group meeting for the guidance ‘Safe Disposal of Clinical 
W aste ’ , DEFRA concluded they would consider repealing the definition of 
clinical waste but as this would require an amendment to The Controlled 
Waste Regulations it was unlikely to happen in the near future. It was 
suggested that the new guidance document should be written in such a 
way as to guide the reader away from reliance on the definition of clinical 
waste. Whilst the DEFRA suggestion provides an interim solution, in the 
longer term it does not clarify the s ituation, and ideally removal of the 
definition of clinical waste should be considered.
This dissertation has only considered the use of defin itions in relation to 
infectious waste; however, before repealing definitions, the implications for 
other healthcare waste streams such as medicinal and pharmaceutical 
wastes should be fully reviewed and considered.
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9.2.3 A lignm ent of Hazardous W aste and Transport Regulation
It is assumed that for the purposes of waste regulation, the definition of 
infectious waste in the forthcoming Hazardous Waste Regulations is the 
primary definition as it is used by both UK and European agencies. 
Therefore it is this definition that should be aligned with forthcoming 
transport regulation.
In order to align the defin itions of ‘ in fectious’ in both waste and transport 
regulations, the individual definitions, their interpretation, and 
classification must be reviewed.
The definition of infectious waste in the forthcoming Hazardous Waste 
Regulations is taken from the Hazardous Waste Directive and is:
“substances conta in ing viable m icro-organisms or their toxins which are 
known or re liably be lieved to cause disease in man or o ther liv ing
organisms” .
Transport regulation in the UK refers directly to European Transport 
Regulation -  ADR for defin itions and classification. ADR is based on the 
assessment of dangerous substances and although it can be applied to 
waste, it is not specif ica lly  a waste definition. ADR 2005 states that:
“ Infectious substances are those substances known or reasonab ly  
expected to contain pathogens, which are defined as m icro-organisms  
( including bacteria, viruses, rickettsia, parasites, fungi) or recom binant  
micro-organisms (hybrid or mutant), that are reasonably expected to cause  
disease in animals or humans” .
The definition of infectious hazardous waste and an infectious substance 
appear compatib le as they both rely on the assessment of the presence of 
m icro-organisms or pathogens that can be reasonably expected or 
believed to cause disease in both humans and animals. The only notable 
difference is the reference in the hazardous waste defin ition to the 
presence of toxins produced by micro-organisms. Examples of these 
toxins are microcystins and cylindrospermopsin which are caused by 
cyanobacteria from algal b looms (GDC, 2004). Such toxins are covered by 
transport Regulation but are considered separate ly from infectious 
pathogens. Toxins are defined and classified as toxic in Class 6.1 of ADR 
2005.
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Within waste regulation, infectious substances are classified as “waste 
whose collection and disposal is subject to special requirements in order 
to prevent infection”.
This classif ication is used in the EWC under chapter 18 where the 
following EWC codes are used:
18 01 03* Wastes whose collection and disposal is subject to
special requirements in order to prevent infection
18 01 04 Wastes whose collection and disposal is not subject to
special requirements in order to prevent infection, e.g. 
dressings, p laster casts, linen, d isposable c lothing.
* Hazardous waste
In forthcoming transport regulations, two classif ications groups are used 
for infectious substances ( including waste) based on the type of pathogen 
the material is contaminated with; Category A or Category B pathogens. 
Section 8.4 provides further details and Appendix O contains an indicative 
list of Category A pathogens. The concept of the categories is based on 
risk principles and risk assessment (WHO, 2004). Category A pathogens 
are those assessed as posing the greatest risk of infection due to their 
ability to spread to the w ider com m unity  and cause life-threatening disease 
or permanent disability. Infectious waste not contaminated with pathogens 
listed in Category A, is classed a Category B infectious waste.
The following UN numbers are used to identify these waste containing 
infectious substances (waste) in transit:
Category A
UN2814 
(Pathogens affecting humans)
UN2900 
(Pathogens affecting animals)
Category B UN3291
If the definition of infectious in forthcoming Hazardous Waste Regulations 
is aligned with the definition of an infectious substance in Transport
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Regulations, hazardous infectious waste would include both Category A 
and Category B pathogens. Table 21 shows the relationship between EWC 
codes and UN numbers if transport and waste regulation are aligned:
Table 21. Relationship between EWC codes and UN Numbers when definitions of 
infectious in waste and transport regulation are aligned.
W aste C lassification Transport C lassification
(EW C) Transport C ategory UN Num ber & 
Description
UN2814
18 01 03
C ategory A (Pathogens affecting  
hum ans)
UN2900
(Pathogens affecting  
anim als)
C ategory B UN3291
9.2.4 A New Assessm ent M ethodology
If the defin ition of clinical waste and hazardous infectious waste are 
aligned, it would mean that all waste currently classified as clin ical would 
be considered hazardous waste. The alignment of these defin it ions was 
discussed at a number of the working group meetings for the gu idance 
‘Safe Disposal of Clinical W as te ’, to which there was unanimous 
d isagreement with this position. Much of the concern was in relation to the 
knock-on effects that would be caused by the change in c lassif ication. 
Hazardous waste is subject to more onerous licensing and permitt ing 
consents and the f inancial implication of these and the additional costs of 
consignment would be signif icant (section 8.5 provides further deta ils on 
this).
Whilst the knock-on issues are relevant, they should not alter the need to 
have a single approach and defin it ion that works. There was general 
agreement that Category A pathogens should be aligned with hazardous 
infectious waste as these present the most signif icant risk and the
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consignment of these wastes would be consistent with the need for greater 
control over wastes that pose the greatest environmental harm. Category 
A pathogens are generally associated with serious infectious disease, 
which in general relate to those contracted outside the UK (e.g. Ebola) and 
certain laboratory cultures. The d isagreement in relation to aligning the 
two waste defin itions focused on the need to include Category B 
pathogens within the hazardous waste framework outlined by the 
hazardous waste guidance, WM2. Despite the concerns raised the 
proposed approach aligns the defin itions of infectious waste and infectious 
substances in hazardous waste and transport regulation as these are legal 
requirements.
A new classification system is required to identify infectious waste which is 
able to d ifferentiate between Category A and Category B pathogens. The 
new classification system proposed in this dissertation provides an 
assessment framework in which Category A and B pathogens can be 
d istinguished. Waste currently classified as clinical waste not included 
within either category would not be considered infectious waste and would 
not be subject to hazardous waste controls in order to prevent infection. 
The waste may however still be hazardous waste due its characteris tics 
and properties, for example clinical pharmaceutical wastes.
The assessment methodology identif ied relies on clinical judgem ent to 
identify Category A pathogens and uses a simple risk assessment
approach to identify Category B pathogens.
Risk Assessment
Whilst the use of risk assessment is not a fundamental part of hazardous 
waste regulation, there is a requirement within UK Health and Safety 
Regulation for it to be used. Schedule 3 of the Control of Substances 
Hazardous to Health Regulations 2002 (COSHH) requires those dealing 
with potentia lly infectious materials (including waste) to assess the risk to 
both the public and staff who may come into contact with them. COSHH
specif ica lly  requires consideration of the biological agents that may be
present. The risk assessment proposed for identifying Category B
pathogens is based on standard precautions and the assessment of 
infection pathways which is summarised by the ‘TO P ’ assessment. 
Standard precautions are designed to reduce the risk of transm ission of 
m icro-organisms from both recognised and unrecognised sources of
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infection. Standard precautions involve healthcare practit ioners taking 
precautions to protect themselves and others from the infection risk posed 
by coming into contact with certain wastes (WHO, 2004). The wastes 
identified by W HO include sharps waste and waste contaminated with 
bodily fluids, namely blood, or other body fluids containing v iable blood, 
semen and vaginal secretions and cerebrospinal, synovial, pleural, 
peritoneal, pericardial, and amniotic fluids (WHO, 2001). Standard 
precautions are often summarised by reference to infectious bodily fluids 
and sharps. Infectious bodily flu ids in the context of standard precautions 
does not include faeces, nasal secretions, sputum, tears, urine, and 
vomitus unless they contain visible blood or there is clinical knowledge of 
a infection pathway, for example sputum may be considered infectious 
from certain Tuberculosis cases.
The TOP assessment summarises where precautions in addition to 
standard precautions are required. The TOP assessment involves 
assessment of:
Type -  this involves an assessment by healthcare practit ioner of the type 
of waste and the type of contamination; e.g. soiled with sputum, vomit, etc.
Outcome -  This involves an assessment by the healthcare practit ioner of 
type and magnitude that would result from an infection.
Pathway -  This involves an assessment by the healthcare practit ioner of 
the infection pathway.
By using this assessment procedure in addition to standard precautions, 
healthcare practit ioners can identify waste posing a risk of infection. 
Based on the f indings of the survey of community producers in Edinburgh 
(see Section 6.7.2) this will prove especia lly  useful to community  (non­
hospital-based producer who produce signif icant qualit ies of sanpro 
(hygiene) wastes. For example, an incontinence pad contaminated with 
faeces would not be considered to pose a risk of infection unless it was 
generated by a patient with a known enteric infection such as E.co//; where 
the infectious agent was known to be present in the type of waste, the 
outcome would be an E .co li infection and the pathway would be faecal- 
oral.
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Figure 16 (overleaf), shows the assessment methodology designed to aid 
the healthcare professional to segregate waste on the basis of hazardous 
and risk, in line with waste, health and safety and waste regulation.
Figure 16. Proposed assessm ent methodology for Category A and Category B infectious 
waste.
YesNo
No
Yes
Yes
YesYes
No
No
YesN o
Yes
N o
Not infectious
DomesticOffensive
Is the waste 
sharp?
Is the waste a 
laboratory culture?
Infectious Waste 
Category B
Does the waste arise from 
direct patient care?
Infectious Waste 
Category A
Is the culture on 
the Category A 
list?
Is the disease 
causing pathogen 
on the Category A 
list
Is the waste from 
known/ assessed 
communicable disease 
that may have 
originated outside the 
UK?
Is the waste contaminated with an 
infectious bodily fluid?
Is the waste infectious by ‘TOP 
assessment?
The assessment methodology makes the following assumptions:
♦ laboratory staff will be familiar with pathogen groups and will be 
able to work using the Category A list of pathogens;
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♦ infection control teams within hospitals will be able to identify 
diseases caused by pathogens on the Category A list; and
♦ all sharps will have had contact with an infectious bodily fluid.
It is assumed that laboratory staff wil l be familiar with pathogen groups and 
will be able to work using the Category A list of pathogens. Laboratory 
staff in the UK are trained in the management of infectious pathogens and 
cultures; protocols already exist to segregate this waste (HSAC, 2003). It 
is common practice for all laboratory cultures to be autoclaved prior to 
disposal, therefore, in practice they are not transported as a Category A 
infectious substances.
The assessment methodology presumes that infection control teams within 
hospitals will be able to identify d iseases caused by pathogens on the 
Category A list. The assessment of whether the communicable d isease 
has orig inated outside the UK has been added as a fi lter, as none of the 
pathogens on the Category A list are indigenous to the UK and it is likely 
that infection will have occurred abroad. As the vast majority of people 
receiving healthcare treatm ent in the UK will be based in the UK, th is fi lter 
will aid staff in segregating out potentia lly contaminated Category A waste 
in the first instance.
In the past, where such diseases have been identif ied in the UK, the 
patients have been quickly moved to appropriate containment fac il i t ies and 
all waste, bedding, and if necessary furniture, is d is infected to
remove/attenuate the causal pathogen before being sent for high
temperature incineration.
The assessment methodology presumes that all sharps (needles, etc) will 
have had contact with an infectious bodily fluid (generally blood from 
injections) and therefore the waste is considered infectious.
The methodology assesses other potentia lly infectious waste on the 
presence of an infectious bodily fluid in line with standard precautions. All 
waste contaminated with infectious bodily flu ids is considered infectious 
waste. If the waste is not contaminated with an infectious bodily fluid, a 
‘TO P ’ assessment is required to see if an infection risk is posed, if so it is
considered infectious waste. Infectious waste, other than that from
disease caused by Category A pathogens and Category A laboratory
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cultures, should be transported as a Category B infectious substance in 
accordance with ADR 2005.
In practice, the vast majority of infectious waste produced and transported 
to disposal facil it ies will fall under the classification of an Infectious Waste 
Category B.
The assessment criteria were reviewed by both the steering and working 
groups of the safe disposal of clinical waste. In general, they met with 
approval. However, concern was expressed about the practica lity  of 
practit ioners being able to use the TOP assessment. There was concern 
that practit ioners would err on the side of caution and may choose to treat 
all waste as infectious. This was debated, and it was concluded that the 
classification of all waste as infectious was a risk, but the assessment 
criteria were of value as they comply with all regulatory approaches and 
would be of equal use in both community and hospitals sites. If all waste 
was treated as infectious, on the basis of a precautionary approach, this 
would not be in breach of regulations. It was also noted that whils t in the 
first instance practit ioners may adopt a precautionary approach, the 
financial burdens of Hazardous Waste Regulation would lead to 
improvements in segregation practice. It would become cost effective to 
train staff and provide them with guidance on the segregation of infectious 
waste, as the cost of hazardous waste treatment is s ign if icant 
(approximately 10-15 times the cost of domestic waste disposal).
At the second meeting of the classification and segregation working group, 
a representative from the Environment Agency commented that based on 
the new assessment model, approximate ly one third of what is currently  
considered clinical waste would be deemed infectious and that th is would 
bring UK production of infectious waste in line with other European nations 
(see section 6.3). In the original assessment model, non-infectious waste 
was considered to be domestic waste, however fo llowing a debate about 
the need for a greater range of waste disposal options, the c lassif ication of 
offensive waste was added. It was acknowledged that a s ign if icant number 
of waste items are produced in the clinical setting that do not pose a risk of 
infection but are often classif ied as infectious due to their offensive nature. 
Examples of offensive wastes include sanpro waste (such as incontinence 
pads and nappies, as defined in section 5.2.5), p laster casts, 
uncontaminated aprons and d isposable bedding. It was agreed at the 
working group meeting that whilst these items did not require infectious
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waste treatment, they should be segregated at source and handled in a 
manner to protect people from coming into contact with them. It was 
agreed that these items posed no greater risk of infection than domestic 
waste and could be landfilled, however measures should be put in place to 
avoid compaction.
Although not common in a hospital setting, offensive waste segregation 
already exists in the community where incontinence waste is placed in 
yellow and black (tiger striped bags) and sent to landfill.
It was estimated, that when the classification of offensive waste is 
introduced, a bag of what is currently called clinical waste could be divided 
into three waste classif ications as Figure 17 shows.
Figure 17. C lassification of typical clinical waste bag using new assessment 
methodology.
Approximately % of the waste could 
be classified as domestic and would 
consist of packaging materials, 
wrappers, etc.
Approximately 1/ 3 of the waste could 
be classified as offensive and would 
consist of plaster casts, incontinence 
wastes, etc
Approximately % of the waste could 
be classified as infectious waste and 
would be subject to hazardous waste 
controls.
If the proposed assessment system was put in place, reducing the amount 
of infectious waste to a third of what is currently classified as clinical 
waste, this would be financially advantageous to the health service whilst 
providing a mechanism to comply with waste, transport and health and 
safety legislation.
9.2.5 Segregation of Infectious W aste on Basis of D isposal Route.
Once infectious waste (Category B) has been identified, a segregation 
system is required to ensure that all waste is treated and disposed of
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appropriately. In order to identify the wide range of waste items produced 
in healthcare, members of the working groups were asked to complete a 
table listing example waste items and their c lassification with regard to 
hazardous waste and transport regulations. Reference is made in the 
table to special waste (current Special Waste Regulations) and hazardous 
waste (in relation to forthcoming Hazardous Waste Regulations) to assess 
if the c lassification of waste items would change with the change in 
regulation. WM2 guidance (see section 8.5.1 and 8.5.2) was used to 
assess which waste items would be affected by forthcoming regulation. 
The only notable change in classif ication is that of infectious waste and 
dental amalgam which, under the forthcoming hazardous waste regime, will 
be hazardous waste. The information from this waste table was used to 
produce a colour-coded segregation system for infectious waste. The 
principles behind the segregation are based on treatment disposal options 
and approved packaging requirements as specified by ADR 2005. Figure 
18 shows the final segregation methodology. Figure 18 makes reference 
to the management of medicinal wastes as these were discussed at the 
Safe Disposal of Clinical Waste working groups. However, they are not 
discussed in this dissertation.
Section 3.2 of this dissertation reviews the current treatment and disposal 
options used for infectious waste and clearly differentiates between high 
temperature technologies such as incineration and medium temperature 
(non incineration) technologies. The colour-coded segregation system 
differentiates between these technologies by using yellow and orange 
colour-coded containers. The colour coding denotes the minimum 
standard of treatment permitted. Yellow containers require high 
temperature treatment such as incineration while orange conta iners 
require, at minimum, treatment using a d isinfection technology capable of 
rendering the waste safe (see section 3.2.1). The use of both yellow and 
orange containers for clinical waste is developed from the NHSScotland 
segregation model that can be found in Appendix E6. Table 22 
summarises the colour coding system used in Figure 18 and the packaging 
requirements for waste in each colour code are summarised in Table 23.
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Table 22 Summary of the proposed colour coding system
Colour-coded
Container
Waste Description / Contents Minimum Treatment / 
Disposal
Yellow ♦ Recognisab le  human / animal tissue
♦ Implanted devices, e.g. pacemakers
High Tempera ture  
Treatm ent (In icneration)
Orange including  
orange lid sharps 
containers.
♦ Risk assessed swabs, dressings and 
bandages.
♦ Laboratory cultures (not Category A)
♦ Au toc laved/d is in fec ted  Category A 
wastes.
♦ Blood and other potent ia l ly  infectious 
liquid wastes
♦ Used sharps
Medium Tem pera ture  
T reatm ent
(Non-Inc inera t ion  
D is in fect ion Technology)
Yellow and Purple ♦ Waste, including in fectious waste 
contam inated with cy to-tox ic  drugs
High Tem pera ture  
T reatm ent author ised to 
accept hazardous 
pharm aceu t ica ls  
(In icneration)
Yellow and Black 
Stripes (Tiger 
Striped)
♦ Offensive wastes including plaster 
casts and used incontinence products
Landfi ll
Table 23 Packaging requirem ents for infectious waste under ADR 2005 by colour- 
coded container.
Colour-coded Container Packaging Requirement
Yellow Packaging Instruction 621 or
LP621 Combined Package (wheelie bins and sacks)
Orange including orange lid sharps 
containers.
Packaging Instruction 621 or
LP621 Combined Package (wheelie bins and sacks)
Yellow and Purple Packaging Instruction 621 or
LP621 Combined Package (wheelie bins and sacks)
Yellow and Black Stripes (Tiger 
Striped)
Offensive waste is not cons idered in fect ious and is not 
subject to the requ irements of ADR 2005.
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The use of the assessment and segregation system to identify and classify 
infectious waste will lead to an improvement in the management of this 
waste. The use of the assessment criteria will be of use in both community 
and acute hospital settings allowing the practit ioner to identify Category A 
infectious substances and other infectious wastes (Category B infectious 
substances) using a generic risk based methodology based on standard 
precautions. Once assessed, infectious waste (Category B infectious 
substances) can be segregated on basis of packaging and disposal 
requirements using the colour-coded segregation system shown in Figure 
18.
9.3 Adoption of New Approach in Safe Disposal of Clinical 
Waste
The assessment and segregation methodologies identif ied in this 
dissertation have been used in the re-write of the guidance Safe Disposal 
of Clinical Waste. The methodologies will appear in the consultation 
document. The methodologies will be amended subject to consultation 
comments. However, it is likely that the underlying principles of aligning 
the defin itions and classification systems used in both waste and transport 
regulation will remain. Whilst the use of standard precautions for 
assessing infection risk is common in the healthcare environment, the use 
of the TOP assessment proposed by the author may be altered fo llowing 
review by a wider clinical audience. The use of the colour-coded 
segregation system will be published in the final guidance document. 
Whilst there is little argument regarding the use of orange and yellow 
colour coding, the use of purple for cyto-toxic contaminated waste may 
change. The packaging industry may wish for this to be changed as only 
one packaging manufacturer in the UK currently uses the purple system. 
The colour purple was chosen as it is used internationally to denote the 
presence of cyto-toxic substances.
In summary, the approach proposed uses current systems which c l in ic ians 
are familiar with, modifies them in line with changing healthcare and 
regulatory requirements and simplif ies a number of regulatory approached 
into one singe approach applicable to all healthcare environments.
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10. CONCLUSIONS
The objectives of the research were to:
• identify and summarise the current philosophy and implicit 
assumptions which influence the current management of infectious 
healthcare management as identified in defin itions and guidance 
documents;
• to characterise and quantify infectious healthcare waste 
production. To review philosophy and implicit assumptions based 
on findings; and
• to propose a new management regime based on revised 
assumptions and forthcoming regulatory change.
The defin itions of infectious waste are reviewed in Section 2 of this 
dissertation. The review identified that there is little or no correlation 
between the defin itions used and although reference is made to pathogen 
groups or classif ications they are not used or interpreted in the same 
manner at International, European or UK level. The lack of corre lation 
becomes even more apparent when the defin itions of infectious waste are 
compared to the definition of an infectious substance in transport 
regulation.
The UK has two defin itions of infectious healthcare waste; clinical waste, 
as defined by the Controlled Waste Regulations 1992 and clinical special 
waste, as defined by the Special Waste Regulations 1996 (As Amended) . 
The vast majority of infectious healthcare waste produced in the UK is 
defined as clinical waste with the later definition being used only for the 
most dangerous (infectious) fraction of the clinical waste stream.
Section 3 of this dissertation reviewed the current management of 
infectious healthcare waste focusing on historic drivers, current treatment 
and disposal options, and the evolution of UK guidance texts. The loss of 
the Crown Immunity in the 1990 ’s was discussed and was identif ied as a 
significant driver, leading to changes in infectious waste management 
practice. The loss of Crown Immunity resulted in the closure of the vast 
majority of on-site hospital NHS incinerators, leaving the NHS with no 
option but to employ waste contractors to transport the waste off-site for 
disposal. Off-site disposal capacity was initially limited and relied on the
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use of specia lis t incineration facil it ies. New technologies capable of 
d is infecting the waste were introduced into the market, which were, in 
general cheaper (with respect to both capital and recurring costs), and did 
not require the same level of p lanning consent as incinerators, leading to 
less delays in commissioning. However, non-incineration technologies 
were (and stil l are) limited in the type and volume of waste they can 
accept. Although capable of treating over 90% of all c linical waste, non­
incineration technologies are unable to process anatomical, 
pharmaceutical or radioactive waste therefore the NHS was required to 
segregate these wastes at source.
Guidance documents used by healthcare professionals over the past 20 
years were identified and reviewed. The guidance documents reflect the 
changes in segregation practice required by changes in infectious waste 
treatment and disposal practices. It was found that the majority of texts 
were aimed at NHS healthcare professionals and focused on the 
management of healthcare waste in a hospital environment. There would 
appear to have been an over-re liance on a selected number of guidance 
documents, with the majority of documents cross-referencing and 
‘evo lv ing ’ from each other. The ‘Safe Disposal of Clinical W aste ’ produced 
by the Health Service Advisory Committee (HSAC) and published by the 
Health and Safety Executive was identif ied as a key guidance document. 
The HSAC publication was first published in 1982 and pre-dates the UK 
regulatory definition of clinical waste, the guidance was later revised in 
1992 and 1999. The HSAC guidance is based on the use of generic risk 
assessment and identifies five categories of clinical waste.
From the assessment of the guidance texts and the defin it ions in Section 1 
it would appear that there are three separate regulatory drivers governing 
the management of infectious waste, namely waste management 
regulation, health and safety regulation, and transport regulation. The 
HSAC guidance and the majority of guidance documents reviewed 
appeared to have been developed from a health and safety and waste 
regulation approach focusing on risk assessment (or ‘generic risk 
assessment approach’) and did not take account of the regulatory 
requirements associated with the transport of the materia ls on the public 
highway.
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From the initial review of definitions, classif ications and management 
practice a number of assumptions were identified. These assumptions, 
(shown below), were identified from the HSAC guidance and other 
guidance documents and appear to have influenced infectious waste 
management practice:
i. people receiving healthcare in hospital produce infectious waste;
ii. the majority of infectious healthcare waste is produced in hospitals;
iii. people living in their own homes do not produce infectious waste;
iv. the risk posed is directly proportional to the hazard; and
v. clinical waste ( infectious waste) poses a greater risk of infection 
than household waste.
Through the review of scientif ic li terature and empirical data these 
assumptions have been reviewed.
The characteristics and composition of infectious waste were reviewed in 
Section 5 of this dissertation. Using data from research undertaken in 
Italy and the USA in the 1990 ’s it was identified that infectious waste is 
comprised of signif icant percentages (by mass) of paper and plastic which 
result in the waste having a high calorif ic value, equivalent to that of wood.
Over the past 30 years there has been a significant amount of research 
into the microbial content of infectious healthcare waste, much of it carried 
out in the USA and Germany. The research shows that a large number of 
pathogens isolated from infectious waste originate from the human body 
and do not routinely cause infection.
Comparisons between infectious waste and municipal solid waste (MSW) 
undertaken in the 1980 ’s show that infectious waste often contains a 
broader range of pathogens than MSW, but that MSW contains a greater 
number of pathogens. When the total viable count of m icro-organisms in 
infectious waste is compared to domestic waste, domestic waste has the 
higher microbial load and infectious waste has the least.
The microbial load of waste is only one factor of many, which must be 
taken into consideration when determining the infectious potentia l of 
waste.
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For an infection to occur a number of conditions are required; pathogens 
must be present in the waste of suffic ient virulence and in sufficient 
numbers, the pathogen must enter the body and the host must be 
susceptible. By viewing a number of common hospital acquired infections 
it was identif ied that despite media concerns and heightened public ity of 
healthcare acquired infections such as MRSA, blood borne viruses pose 
the most significant risk of infection. Infectious sharps waste was identif ied 
as a particular problem as sharps are often contaminated with blood or 
infectious bodily f luids and they create a pathway for pathogens to enter 
the body through puncture wounds.
Using a risk criteria framework based on a model developed by the UK 
Health and Safety Executive, it was concluded that infectious healthcare 
waste poses a low/medium risk of infection, and that human hygiene waste 
(nappies and feminine hygiene waste) and MSW often pose a greater risk 
of infection.
The production of infectious waste was reviewed in Section 5 of this 
d issertation. Data from the USA and 12 European countries was 
compared. The data showed that the average amount of waste produced in 
the UK, 5.5 kg of waste per capita per annum is much greater than the 
amount of waste produced per capita per annum in Europe and the USA. 
There are two reasons for the d ifferences; the use of different defin it ions 
and historic segregation practices in relation to Crown Immunity.
In general, data on the production of infectious waste is extremely poor. 
Data sets available are incomplete and do not provide an overv iew of 
management practices across the UK. Data is available from NHS sources, 
but is limited to specific geographical regions of the UK. Data from 
‘comm unity ’ sources (producers of infectious waste that do not form part of 
NHS hospital premises) is not collated on an annual basis. Examples of 
community producers include General Medical Practit ioners (GPs), 
General Dental Practit ioners, care homes, veterinary surgeons and 
cosmetic outlets e.g. tattooists, beauticians and body modification artists.
In order to gain a better picture of community infectious waste production, 
a questionnaire survey of ‘com m unity ’ clinical waste producers was 
undertaken. The aim of the study was to evaluate the amount and type of 
clinical and sanpro ( incontinence) waste produced by comm unity  
producers in a specific area (Greater Edinburgh Area) and to compare it to
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the waste arisings from a large NHS hospital site in the same area. The 
response rate to the questionnaire survey was 23%, with completed 
questionnaires received from producers throughout the Greater Edinburgh 
Area. Of the responses received, approximate ly 50% (12% of the survey 
population) provided data on the mass of waste produced. Using the data 
provided an estimate of total amount of clinical and sanpro waste 
produced in the Greater Edinburgh area by community producers has been 
made and is 1,657 tonnes per annum, of this approximate ly 465 tonnes 
(28%) was infectious waste. Comparisons with the largest hospital (by 
bed numbers) in the survey area, Edinburgh Royal Infirmary, shows that 
the total amount of clinical and sanpro waste produced in the Comm unity  
is equivalent to tw ice the amount of clinical waste produced by the hospital 
(approximately 801 tonnes) and of that, the total amount of infectious 
waste produced by the hospital (approximately 368 tonnes) is less than 
that produced in the Community. The information gained from the survey 
provided an insight into the management of infectious waste from non-NHS 
sources but as the survey population was not verified as being 
representative of producers in the survey area the data should not be 
considered as such.
Section 7 of this dissertation used the information presented in Sections 5 
and 6 to review the assumptions identif ied from the review of guidance 
documents and waste management practice. All five assumptions were 
identif ied as invalid for the fo llowing reasons:
♦ the vast majority of patients in hospital have the same ‘infectious s ta tus ’ 
as those in the general community;
♦ pathogens within infectious waste were unlikely to remain viable, and 
even if they do, an infection pathway and a susceptib le host are required 
before an infection can be realised;
♦ they do not reflect the prevalence of chronic disease in the community;
♦ they do not reflect current practice based on findings from the community  
producer survey which identif ies that a s ignif icant amount of infectious 
waste is produced out-with hospital sites;
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♦ they do not acknowledge that a wide range of wastes including municipal 
solid waste produced within private households can be considered 
infectious;
♦ the magnitude of risk is influenced by the presence of a hazard (the 
pathogen) but is not directly proportionate as other factors need to be 
taken into account;
♦ there is little evidence to suggest that infectious waste poses a greater 
risk of infection that household waste; however, the magnitude of the risk 
posed by infectious waste may be higher.
From the review of published papers, community producer survey and data 
provided by NHS and other producers, the author established a set of 
simplif ied assumptions:
i. Infectious healthcare waste is produced both within and out-with 
healthcare premises; and
ii. The infectious nature of the waste is determined by a number of 
factors. The risk of infection posed can be evaluated using a three 
step simple assessment methodology, simply described as a T O P ’ :
Type -  type of infectious waste; e.g. b lood-stained materials, 
sharps, etc;
Outcome -  the magnitude and type of disease resulting from 
an infection;
Pathway -  pathway required for an infection to occur; e.g. 
inhalation, ingestion, etc.
The T O P ’ assessment methodology simplif ies the risk assessment 
process and attempts to quantify the risk and assess its magnitude.
Before proposing a revised approach to the management of infectious 
waste based on the simplif ied assumptions identified, Section 8 of the 
dissertation reviews recent and forthcoming changes in regulation. The 
most significant of the changes identified are introduced by amendments 
to transport regulation by the Carriage of Dangerous Goods and Use of 
Transportable Pressure Equipment (CDG) Regulations 2004 (As Amended) 
and the revision of the Special Waste Regulations to incorporate the
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requirements of the Hazardous Waste Directive (91/689/EEC). These 
regulatory changes introduce revised classif ications for infectious waste 
which require a degree of interpretation to be used at the same time.
Changes in the CDG (transport) Regulations introduce a new classification 
system for infectious substances, based on pathogen classification. 
Waste contaminated with pathogens listed on the Category A Indicative 
Pathogen is classified as a Category A infectious substance. All other 
infectious waste (including the majority of clinical waste) is classified as a 
Category B infectious substance. The new classif ication system replaces 
a system based on four pathogen ‘Risk G roups ’ published by the World 
Health Organisation.
The UK Environmental Regulatory Agencies (EA, SERA and EHS) have 
produced guidance, titled WM2, on the classification of hazardous waste in 
line with the Hazardous Waste Directive (91/689/EEC). WM2 was 
released prior to the introduction of Hazardous Waste Regulations in 
England, Wales and Northern Ireland. In 2004, Scotland incorporated the 
requirements of the Directive in the Special Waste Amendment (Scotland) 
Regulations 2004. The classification of infectious waste in WM2 relies on 
clinical knowledge and judgement of the presence of viable pathogens 
from identified sources of infection. Similar to the changes in the CDG 
Regulations, the WM2 classification does not require the use of pathogen 
Risk Groups.
The aim of this dissertation was to explore the interpretation of both waste 
and transport definitions, identify the difficulties experienced and propose 
a new approach to the management of infectious waste which will align 
regulatory approaches. Sections 2 to 8 of this d issertation explore the 
definitions and management practices used for infectious healthcare waste 
and through the evaluation and review of assumptions have identified 
inadequacies in the current system. Section 9 of the d issertation outlines 
the author’s proposed new approach which aligns regulatory requirements.
The proposed approach was developed from the research undertaken and 
is fundamenta lly  based on the simplif ied assumptions identified. The 
approach has been peer reviewed as part of the production process for the 
guidance ‘Safe Management of Healthcare W aste ’ which is being produced 
by the Department of Health, with the assistance of a number of 
government departments and bodies including the Health & Safety
160
Executive, Environment Agency, Health Protection Agency and the 
Department of Transport. In addition, representatives of the producer 
sector (NHS and non-NHS) and the waste industry were involved in the 
process as part of expert working groups.
The basis of the proposed approach is a single classification system 
suffic iently robust to meet the needs of waste, transport and health and 
safety regulatory requirements. It is based on an assessment 
methodology to identify infectious waste and a colour-coded segregation 
scheme that segregates waste on the basis of type of waste and 
treatment/d isposal options. The colour-coded scheme will ensure easy 
identification of waste, aiding regulatory compliance, and simplifying the 
labelling of waste with both EWC (waste) codes and UN (transport) 
numbers.
To simplify the process it is suggested that a single definition of infectious 
healthcare waste is adopted in the UK and that the definition should be the 
one cited in the Hazardous Waste Directive. The definition of clinical 
waste should be repealed, it is over 15 years old and does not represent 
current practice and conflicts with European and International Regulation.
The proposed approach uses the definition of infectious healthcare waste 
in the Hazardous Waste Directive and aligns this with the definition and 
classifications of infectious substances in transport regulation. As both 
definitions and classif ications rely on pathogen identification they are 
compatible, however interpretation is required to align them. The 
proposed approach d ifferentiates between the two categories of infectious 
substances (Category A and Category B) as defined in transport regulation 
to aid waste producers package and label infectious waste for transit.
In order to ensure that the regulatory approach used is proportionate to 
the risk posed, the new approach is based on the use of generic risk 
assessments. Figure 16, initially shown on page 145 of this d issertation 
and reproduced overleaf, d iagrammatica lly  shows the assessment 
methodology of the new approach.
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Figure 16. Proposed Assessment methodology for infectious waste.
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The assessment methodology proposed is based on a number of 
assumptions:
♦ laboratory staff will be familiar with pathogen groups and will be 
able to work using the Category A list of pathogens;
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♦ high risk infections caused by Category A pathogens are not 
indigenous to the UK and infection control teams within hospitals 
will be able to identify these; and
♦ all sharps will have had contact with an infectious bodily fluid.
The risk assessment proposed for identifying Category B pathogens is 
based on the presence of an infectious bodily fluid, as defined by the 
World Health Organisation (WHO, 2001), or an infection risk identif ied 
using the T O P ’ (Type, Outcome and Pathway) assessment produced by 
the author as part of the s implif ied assumptions. Using the T O P ’ 
assessment, c lin ic ians can identify if the conditions for an infection to 
occur are present and if they are, classify the waste as infectious 
(Category B) waste. For example, sputum is not considered to be an 
infectious bodily flu id by the WHO, however sputum from patients 
diagnosed with pu lmonary tuberculosis (TB) is considered infectious using 
the T O P ’ assessment as the M ycobaterium  tubercu los is  is able to cause 
infection via an airborne pathway.
If the conditions for infection to occur are not present the waste is 
c lassified as either offensive or domestic. Examples of offensive wastes 
include sanpro waste (such as incontinence pads and nappies), p laster 
casts, uncontaminated aprons and disposable bedding, these items do not 
require infectious waste treatment but should be segregated at source and 
handled in a manner to protect people from coming into contact with them.
In practice, the vast majority of infectious waste produced and transported 
to disposal facil it ies in the UK will be c lassified as Infectious W aste 
Category B.
A colour-coded segregation system is proposed based on minimum 
acceptable treatment/d isposal route of the waste. The proposed system 
has been based on existing successful system used by NHSScotland. 
Table 22, reproduced overleaf, summarises the colour coding system 
proposed.
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Table 22 Summary of the proposed colour coding system
Colour-coded
Container
Waste Description / Contents Minimum Treatment / 
Disposal
Yellow ♦ Recognisab le  human / animal t issue
♦ Implanted devices, e.g. pacemakers
High Tem pera ture  
T rea tm ent (In icneration)
Orange including 
orange lid sharps 
containers.
♦ Risk assessed swabs, d ressings and 
bandages.
♦ Laboratory cultures (not Category A)
♦ A u toc laved/d is in fected  Category A 
wastes.
♦ Blood and other potentia l ly  in fectious 
liquid wastes
♦ Used sharps
Medium Tem pera ture  
T rea tm ent
(N on-Inc inera t ion  
D is in fect ion  Technology)
Yellow and 
Purple
♦ Waste, including in fectious waste 
contam inated with cy to-tox ic  drugs
High Tem pera tu re  
T rea tm ent au thor ised to 
accep t hazardous 
pharm aceu t ica ls  
( In icnera tion)
Yellow and Black 
Stripes (Tiger 
Striped)
♦ Offensive wastes including p laster 
casts and used incontinence products
Landfi l l
The use of the proposed assessment and segregation system (the ‘new 
approach ’) to identify and classify infectious waste will lead to an 
improvement in the management of this waste.
In summary, the approach proposed, unlike other methodolog ies to date, 
uses current systems which c linicians are familiar with, m odifies them in 
line with changing healthcare and regulatory requirements and aligns the 
requirements of waste, health and safety and transport regulation in a 
simple practical system applicable to all environments where healthcare is 
provided.
The proposed approach has undergone signif icant peer rev iew as part of 
the production process for the forthcoming guidance ‘Safe M anagem ent of 
Healthcare W as te ’ . However, the approach used in the final, published, 
version of the guidance may differ from that proposed in this d isserta tion.
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11. RECOMMENDATIONS
This section outlines recommendations for future work based on the 
findings of this dissertation. Five groups of recommendations have been 
identified:
♦ Development of proposed approach;
♦ Research into viabil ity  of pathogens in waste;
♦ Research in treatment and disposal;
♦ Research into the psychology of infectious waste management; and
♦ Development of a m ult i-d iscip linary expert group.
The recommendations in each group are detailed below.
Development of Proposed Approach
The proposed approach outlined in this dissertation could be developed 
further by undertaking the following:
♦ a review of the effect of the repeal of the defin ition of clinical 
waste, (as defined in the Controlled Waste Regulations 1992) with
respect to non-infectious clinical waste such as medicinal and
radioactive wastes;
♦ additional community producer surveys using verified 
representative survey populations across the UK;
♦ a case study review of the use of the proposed ‘TO P ’ assessment 
methodology in practice and development of guidance in relation to 
its use with respect to common infectious d iseases likely to be 
encountered in the UK;
♦ a case study review of the proposed colour-coded segregation 
system, its effectiveness and impact on the UK healthcare sector;
♦ production of guidance using the proposed methodology; ideally 
this should be sector specific, providing advice to producers of 
infectious waste both in large hospital sites and in the community.
165
This dissertation only reviewed the classifications and defin itions 
associated with infectious healthcare waste and did not consider other 
healthcare wastes such medicinal and radioactive waste. The proposed 
repeal of the definition of clinical waste and the proposed colour-coded 
segregation system may effect the management of these waste streams.
Data available on the production of infectious healthcare waste was limited 
and further information is required by the UK Government Agencies 
(including regulators) to ensure adequate resources are developed for this 
producer sector. The community producer survey undertaken in the 
Greater Edinburgh Area provided useful information but was not verified as 
being representative of producers in that area. Information from further 
similar studies, using verified representative data, from across the UK 
would be provide valuable information which could be used to influence 
management decisions. A verified and representative survey could be 
undertaken using producer information by reference to Standard Industry 
Classification (SIC) codes.
Case studies reviewing the use of the proposed ‘TO P ’ assessment 
methodology and colour-coded segregation system in both hospital and 
community settings would be of use. The results of the survey could be 
used to adapt the methodologies to meet waste producers needs. In 
particular, a ‘users gu ide ’ to the TO P ’ assessment system, providing 
guidance in relation to common infectious diseases not associated with 
infectious bodily f luids may be helpful. Common pathogens and infectious 
likely to be subject to the TO P ’ assessment include: H elicobate r p y lo ri 
associated with certain gastric ulcers, M ycobaterium  tubercu los is  
associated with pulmonary tuberculosis, Escherich ia  co li associated with 
food poisoning and S taphylococcus aureus  associated with common skin 
infections.
The production of sector specific guidance would be of benefit to infectious 
waste producers. Much of the current guidance available is aimed at 
producers in a hospital environment. Guidance, providing practical advice, 
based on the proposed approach to community producers, is required.
Research into Viability of Pathogens in Waste
This dissertation used information and data from studies undertaken in 
Germany and the USA (Section 5.2) to evaluate the viabil ity  of pathogens 
in infectious waste. It is recommended that research into the v iabil ity  of
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pathogens in the waste stream be undertaken in the UK and that waste 
from hospital and community  producers is considered. In particular, 
research is required in relation to the v iabil ity  of blood borne virus, as 
limited evidence was available from studies in this area. Information from 
this research could be used to influence future defin it ions, segregation 
practices and treatment and disposal systems.
Research in Treatment and Disposal
This d issertation used research predominantly from Italy and the USA to 
review the composition of infectious healthcare waste. It is recommended 
that research into the composition of this waste stream be undertaken in 
the UK and that waste from hospital and community producers is 
considered. Information from the research could be used to evaluate 
recycling and recovery treatment systems for infectious healthcare waste.
Research into the Psychology of Infectious Waste Management
Historically, assumptions on the ‘ in fectiousness’ of waste have been based 
around the delivery of healthcare in a hospital environment and have 
assumed that people in hospital have an infectious disease. By reviewing 
hospital episode statistics and the prevalence of chronic blood borne 
viruses this d issertation suggests that very few patients in hospital are 
there due to an infectious d isease (<2%) and that the diseases of most 
concern (caused by blood borne viruses) are chronic in nature, with those 
infected living in the community.
Research into the psychology of infectious waste management practices 
and the assumptions made would provide useful information and could be 
used to produce future c lassification systems and guidance documents.
Development of Multi-Disciplinary Expert Group
The aim of this dissertation was to explore the interpretation of health and safety, 
waste and transport definitions and propose a new approach to the management of 
infectious waste which will align regulatory approaches. The proposed 
approach in this dissertation aligned waste, health and safety and 
transport regulatory requirements, no other sim ilar approach was found. It 
is recommended that in order for future approaches to take into 
consideration the often differing regulatory requirements of regulation 
effecting infectious healthcare waste management that a mult i-d isc ip l inary
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expert group is set up at UK level. The group should be comprised of 
recognised experts in the field and should meet on a periodic basis.
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CASE STUDY
CASE STUDY ONE - THE IMPACT OF THE LOSS OF CROWN 
IMMUNITY ON NHSSCOTLAND CLINICAL WASTE DISPOSAL.
This brief case study outlines the key stages and decis ions taken 
regarding c linical waste management and disposal by NHSScotland at 
both a national and regional level fo llowing the removal of crown immunity.
Information used within the case study was collected and collated from 
members of the NHSScotland Waste Management Steering Group. In 
particular Ken W alker from NHS Grampian Primary Care Trust provided 
data and information on the orig inal Northern Consortium contract.
Crown Im m unity
National Health Services (NHS) Hospitals and facil it ies owned and 
operated by the Government were subject to crown immunity, granting 
them immunity from prosecution. Crown immunity was removed from NHS 
sites in 1991 by the NHS and Community Care Act 1990. The loss of 
crown immunity had a signif icant impact on the NHS as it required 
compliance with all relevant regulatory standards, including environmental 
standards. The requirement to comply with environmental s tandards 
posed a particular problem as the NHS had relied for many years on the 
use of on-site incinerators to dispose of all waste. Through years of 
under-investment the vast majority of NHS incineration fac il it ies were 
operating below the required environmental standards. This problem was 
compounded by the introduction of new and more str ingent environmenta l 
regulation via the Environmental Protection Act 1990. Interim, less 
stringent, environmental regulatory standards were introduced and were 
valid until 1995. Post-1995 all hospital and healthcare waste treatm ent
and disposal facil it ies were required to fu lly meet current environmenta l 
standards.
1989 Scottish O ffice Survey
In 1989 the Scottish Office commissioned a survey of existing hospita l 
incinerators and a review of the various options to deal with 
N HSScotland’s clinical waste. Of the 304 hospitals, located in 15 Scottish 
Health Boards, approximate ly half (154), had on-site incineration capacity  
for the disposal of clinical waste (McCullough, Undated). Genera lly  these
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incinerators were old and inefficient, functioning well below the 
) environmental standards of the time. However, these sites were free from
prosecution as they were covered by Crown Immunity.
In order to ascertain the disposal capacity  required post crown immunity, 
the 1989 survey collated clinical waste data provided by each of the 15 
Scottish Health Boards. The data collected are shown in Table 24. It 
would appear that the data has been calculated on the basis of number of 
bags of clinical waste produced and it has been assumed that each bag 
weighed 2.5 kg.
)
Table 24. NHSScotland Clinical W aste Data (approxim ately 1998/9)
Health Board Bags/Day Kg/Day Tonnes/Day Annual Total 
(Tonnes)
Argyll & Clyde 1513 3780 3.78 1380
Ayrshire & Arran 1192 2980 2.98 1088
Borders 226 565 0.57 208
Dumfries & Galloway 603 1508 1.51 551
Fife 674 1685 1.69 617
Forth Valley 774 1935 1.94 708
Grampian 2352 5880 5.88 2146
Greater Glasgow 9600 24000 24 8760
Highland 847 2118 2.12 774
Lanarkshire 3164 7910 7.91 2887
Lothian 3818 9545 9.55 3486
Orkney 109 273 0.27 99
Shetland 36 90 0.09 33
Tayside 1343 3358 3.36 1226
Western Isles 82 205 0.21 77
Total 26333 65832 65.86 24040
Source (Wassermann, 1998)
Based on the clinical waste data collected, the Scottish Office survey 
produced a short-l ist of options for the future disposal of NHSScotland 
clinical waste. These included:
• Replace all existing incinerators;
• Install one new incinerator per Health Board;
• Install incinerators in Glasgow, Edinburgh and Aberdeen;
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• Install one new incinerator for the whole of Scotland in Glasgow.
)
(McCullough, undated).
Scottish O ffice Recom m endation
The Scottish Office made the recommendation that each Health Board 
should incinerate its own waste in its own incinerator. However, concerns 
over technology and cost led many Health Boards to delay the 
commissioning of new plant or the up-grading of existing plant. The gap 
between the required standard and the then current operating standard 
) was too great for many Health Boards; years of under-investment through
Crown Immunity meant that Health Boards could simply not afford to up­
grade or purchase new equipment. A Scottish Office study in 1992 
showed that less than half of all NHSScotland incinerators at the time had 
the potentia l to comply with interim regulatory standards (valid until 1995) 
and few of these would be able to comply with more stringent regulatory 
standards to be introduced in 1995 (McLaughlan, undated).
Move from  Health Boards to NHS Trusts
) Between 1993 and 1995 the structure of NHSScotland was reorganised,
from Health Boards to new ‘un its ’ called Trusts. Each Trust is its own 
legally entity and includes a number of hospitals. The Trusts were much 
smaller than the Health Boards and were unable to fo llow the original 
Scottish Office recommendation that each Health Board (now Trust) should 
operate its own incinerator.
It was considered uneconomical for Trusts to continue the operation of the 
on-site incinerators previously managed by the Health Boards. Instead, 
Trusts ‘bought-in ’ the services of contractors for the transport and disposal 
) of waste off-site. As the number of treatment and disposal sites in
Scotland was limited, many Trusts s igned contracts with contractors based 
in England and the waste was transported by road across the border for 
treatment and disposal. A limited number of NHSScotland incinerators
continued to operate post 1995, these were located in Melrose,
Kilmarknock and Hartwood Hill, with limited capacity available in the Local 
Authority owned and operated munic ipal incinerator in Dundee.
Frustrated with the lack of a national plan and the need to com ply with 
* legislation, a number of Trusts in the North of Scotland decided to
proactively move things forward and the Northern Consortium was formed.
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Form ation of the Northern Consortium
Although membership of the Northern Consortium has changed only 
slightly over the past decade, it is comprised of all of the Trusts north of 
the Forth Estuary. The Northern Consortium was orig inally formed as 
Trusts became disenchanted with the Scottish O ff ice ’s attempts to push 
forward the need for NHS incineration capacity. The Trusts considered 
that the need for several new incinerators was uneconomic and impractical 
as the facilit ies would require signif icant capital expenditure and would 
only operate for a couple of hours per day. There was also growing 
concern that the Scottish Office would not have the necessary budget 
available and that would lead to a signif icant delay in the commissioning of 
new plant.
The Northern Consortium reviewed the treatment and disposal options 
available to them and key members of the Consortiums Steering Group 
travelled to other countries to review best practice arrangements.
In 1993 the Northern Consortium advertised for a waste management, 
transport and disposal contractor in the Official Journal of the European 
Communities (OJEC). The Northern Consortium received 18 tenders from 
which it generated a short-l is t of 6 companies.
Scotsafe UK
In 1994 Scotsafe was awarded the Northern Consortium contract, requiring 
them to transport and treat all the Northern C onsort ium ’s clinical waste 
from 1995. Scotsafe was the first contractor to utilise a large-scale non­
incineration treatment technology in the UK. The Scotsafe technology was 
a heat disinfection system, orig inating from the U.S.A. The technology 
had a proven track record both in the food industry as well as the waste 
industry. Scotsafe purchased the disinfection equipment from Biomed 
based in Boston USA, and the UK rights from Biomed’s parent company, 
Biosafe.
During the commissioning of the Scotsafe plant in Arbroath, the U.S.A 
company Biomed fi led for Chapter Eleven of the U.S. bankruptcy 
regulations (equivalent to receivership proceedings in the UK), this 
hindered the commissioning of the Scotsafe Arbroath facil ity  and left 
Scotsafe in a vulnerable position as it limited the technological back-up 
available.
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Problems started to arise within a few months of the Scotsafe contract. 
) The actual amount of waste received by Scotsafe was approximate ly half
that stated in the tender documents. The Trus ts ’ estimates were 
inaccurate and the wording of the contracting was such that the Trusts 
only paid for the waste treated and not the contracted amount. This left 
Scotsafe is a vu lnerable f inancial position as alternative sources of clinical 
waste were limited; other Trusts (not part of the Northen Consortium) had 
already signed contracts for the disposal of clinical waste with companies 
based in England. The financia l strain on Scotsafe was compounded when 
Scotsafe won a contract to treat and dispose of clinical waste in the North 
of England. The tender process for the English treatment plant had 
started prior to the demise of Biomed. The design of the English plant, 
based in Newcastle, was slightly different from the Arbroath system and 
design problems emerged leading to the opening of the fac il i ty  six months 
later than expected. During the six month delay, Scotsafe were still 
obliged to collect and dispose of waste from the North of England Trusts. 
Following the loss of Crown Immunity throughout the UK, disposal capacity  
for clinical waste was limited and the cost of spare capacity  increased 
significantly. In order to meet the terms and conditions of their contract 
) with the North of England Trusts, Scotsafe had to pay other contractors to
dispose of the waste for them. In doing this, Scotsafe made a s ign if icant 
f inancial loss, the extent of which was thought be in the region of hundreds 
of pounds per tonne.
Eurocare Environm ental Services Ltd
In 1997 Scotsafe was in f inancia l trouble and was eventua lly  sold to 
Eurocare Environmental Services Ltd in 1998. Eurocare acquired the 
assets of the company but not the existing contracts and the NHSScotland 
) Northern Consortium was required to re-tender for d isposal services.
Contractual agreement could not be reached between the Northern 
Consortium and Eurocare and ‘emergency contingency proceed ings ’ were 
put in place with the Scottish Executive Central Legal Office (CLO) 
intervening, during which time waste from the Northern Consortium 
continued to be treated at the Eurocare facility.
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NHSScotland C lin ical W aste W orking Group
In the interest of co-operation and information gathering, Chief Executives 
from Trusts throughout Scotland held bi-monthly meetings to discuss NHS 
business and working groups focusing on specific topics were formed as a 
result of these meetings.
Michael Bewes, the then Chief Executive of Inverclyde NHS Trust, was 
asked to chair the Clinical Waste Working Group. The formation of this 
group was timely and coincided with the problems the Northern 
Consortium was having with the Scotsafe/Eurocare contract and the 
closure of the Hartwood Hill and Dundee (Local Authority operated) 
incineration facilit ies. The initial aims of the working group were to review 
current clinical waste disposal provisions and collect data on arisings.
In a similar way to the formation of the Northern Consortium, NHS Trusts 
in other geographic regions had jo ined forces as Consortia in order to 
‘purchase ’ waste transport and disposal services. Thus the membership of 
the Clinical Waste Working Group comprised of five ‘ regional g roups ’ : the 
North Group (formed from the previous Northern Consortium), the Central 
and West Group, the Lothian and Forth Valley Group, Greater Glasgow 
and the Borders. Figure 19 shows the location of the regional groups on a 
map of Scotland. The Orkney Isles are part of the Northern Consortium for 
administration purposes, however they have their own waste management 
arrangements and clinical waste generated on the islands is d isposed of in 
the gasification facil ity located in Kirkwall.
Although part of the steering group, the Borders Trusts and Greater 
Glasgow Group of Trusts did not require waste disposal services. Borders 
General Hospital continued to own and operate their own incineration 
facility, albeit of limited capacity. Greater Glasgow had recently s igned a 
contract with Shanks and McEwan that was valid until 2005, under which 
the waste is transported to Glasgow and Dundee for treatment and 
disposal.
The Clinical Waste Working Group therefore focused on the areas that 
would require a waste management service: the Northern Group, Central 
and West Group and the Lothian and Forth Valley Group.
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Figure 19. Location of Regional Clinical Waste Groups in Scotland.
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Clinical waste data was collected from the three regional groups requiring 
waste disposal services in 1998 and is shown in Table 25.
>
i
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) Table 25. Clinical waste data gathered by NHSScotland clinical waste w orking group,
1998.
Waste Type Northern Group Central & West Lothian & Forth Total
(Vpa) Group (t/pa) Valley Group
(t/pa)
Sanpro Waste 
(approximate)
2275.89 3344.53 1737.26 7 357.68
Clinical Waste 949.66 1430.90 957.22 3 337.78
Clinical & Sanpro 
Waste Combined (1)
3225.55 4775.43 2694.48 10 695.46
Sharps Waste (2) 270.03 526.95 224.03 1 021.01
Pharmaceutical Waste 
(3)
34.69 55.33 17.69 107.71
Radioactive Waste (4) 2.58 4.20 5.27 12.05
Pathological Waste (5) 40.11 45.80 28.88 114.79
Total (1+2+3+4+5) 3 572.96 5 407.71 2 970.35 11 951.02
Information was gathered about different types of clinical waste in order to 
establish which disposal option(s) would be the most suitable. 
Pharmaceutical, radioactive and pathological waste require high 
temperature treatment, such as incineration, whilst clinical, sanpro and 
sharps waste could be adequately treated using a non-burn technology.
The data in Table 25 was used as the basis for a European Tender for 
clinical waste management services for the three regional groups; 
Northern Group, Central & W est Group and Lothian & Forth Group. As 
these three regional Groups represented 39 Trusts from all over Scotland 
they were jo in t ly  called the ‘Pan Scotland Consort ia ’ .
Pan-Scotland Consortia
In 1999 Eurocare Environmental Services were awarded the Pan-Scotland 
contract. In addition to utilising their heat d isinfection fac il i ty  in Arbroath, 
Eurocare built an additional, and larger facility, in Cumbernauld.
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The E u roca re  P a n -S co tla nd  co n tra c t is s till in o p e ra tio n  to d a y  and 
E u roca re , now  ow ned by the  S te rile  T e ch n o lo g ie s  G roup , tre a ts  and 
d isp o se s  of a p p ro x im a te ly  80%  of a ll c lin ic a l w aste  p ro du ced  in S co tlan d . 
T he vas t m a jo rity  of w aste  co lle c te d  by E u roca re  is tre a te d  in the  A rb ro a th  
and C um be rna u ld  fa c ilit ie s . H ow eve r a p p ro x im a te ly  3% , th a t w h ich  
req u ires  in c in e ra tio n , is tra n s p o rte d  to an in c in e ra to r based  in E ng land .
Current C linical W aste M anagem ent in Scotland
T od ay  th e re  are c u rre n tly  s ix  c lin ic a l w aste  d isp o sa l fa c ilit ie s  in S co tlan d  
used by the  N HS; th ey  are show n be low  in F igu re  19.
Figure 19 Clinical waste disposal fac ilities  in Scotland 1999/2000.
M ATERIAL REDACTED AT REQUEST OF UNIVERSITY
The tw o la rge s t fa c ilit ie s  are  E u roca re  fa c ilit ie s  based  in A rb ro a th  and 
C um bernau ld . The NHS in c in e ra to r based  at B o rde rs  G e ne ra l H o sp ita l is 
the  on ly  NHS inc in e ra tio n  fa c ility  in o p e ra tio n , as fo llo w in g  g ro w in g  
p ressu re  by the S co ttish  E n v iro n m e n t P ro tec tio n  A g en cy , in 1998 the
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Crosshouse Hospital incinerator in K ilmarnock closed. The gasification 
) facil ity  in Kirkwall, O rkney Islands continues to operate although it only
treats waste from the Orkney Islands. Clinical waste generated by the 
Greater G lasgow Group of Trusts is treated in the municipal waste 
incinerator in Dundee and the Microwave facil ity  in Glasgow. A small 
amount of waste from Glasgow is transported to England for incineration.
The W ay Forward
In meeting the challenges presented by the loss of crown immunity 
) NHSScotland has had to review the amount and type of waste produced.
Joint working has been a key strength in NHSScotland’s approach at both 
a national and regional level. However the transition from the use of in- 
house treatment to the use of external contractors was not stra ightforward 
and has been subject to both f inancial and technological vulnerability.
With regard to c linical waste treatment and disposal, Scotland is not self- 
suffic ient and relies on high temperature incineration facil it ies in England 
to deal with the most hazardous fractions of clinical waste.
) Reliance on a s ingle or a small number of contractors has lead to a
situation where the clinical waste market in Scotland is controlled by a 
small number of companies, which are able to tightly control d isposal 
capacity and market price. There is little or no spare capacity, and 
contingency options in the event of closure of a clinical waste company are 
limited.
In order to learn from past experiences, NHSScotland is a lready reviewing 
options for the next series of contracts and is currently liasing with other 
industries in Scotland looking for waste disposal synergies. In order to 
)  utilise the available resources at national level, the NHSScotland waste
strategy is being written to dove-tail with the Scottish Environment 
Protection Agency ’s (SEPA’s) National Waste Strategy.
The NHSScotland waste strategy is due for publication in early 2005 and 
will be incorporated within the NHSScotland waste guidance document: 
Scottish Hospital Technical Note 3 (SHTN3).
)
197
))
198
APPENDICES
))
200
Appendix A Healthcare Waste Definitions.
In te rn atio n a l D e fin itio n s
A1 World Health Organisation.
The following text is taken from the World Health Organization (WHO) 
publication titled, Safe Managem ent of W astes from  Health-Care  
A ctivities, 1998. The publication provides a number of definitions and 
classifications for wastes arising from healthcare.
Definition of H ealthcare W aste
Health-care waste includes all the waste generated by health-care 
establishments, research facilities, and laboratories. In addition, it includes 
the waste originating from “minor” or “scattered” sources such as that 
produced in the course of health-care undertaken in the home (dialysis, 
insulin injections, etc.).
Categories of Healthcare Waste
Tables 26 and 27 summarise the main WHO healthcare waste 
classification groups for non-hazardous and hazardous healthcare waste.
Table 26. WHO Classification of non-hazardous healthcare waste
Waste Category Description and Example
Non-Hazardous
Non-risk or “General” Healthcare 
Waste
Waste that is comparable to domestic 
waste.
Table 27. WHO Classification of hazardous healthcare waste
Waste Category Description and Example
Hazardous
Infectious Waste
Waste suspected to contain pathogens 
e.g. laboratory cultures; waste from 
isolation wards; tissues, (swabs), materials, 
or equipment that have been in contact with 
infected patients; excreta.
Pathological Waste
Human tissues or fluids. E.g. body parts; 
blood and other body fluids; fetuses.
2 0 2
Table 27 continued.
Waste Category Description and Example
Sharps Waste
Sharp waste e.g. needles; infusion sets; 
scalpels; knives; blades; broken glass
Pharmaceutical Waste
Waste containing pharmaceuticals e.g. 
pharmaceuticals that are expired or no 
longer needed; items contaminated by or 
containing pharmaceuticals (bottles, boxes)
Genotoxic Waste
Waste containing substances with 
genotoxic properties e.g. waste containing 
cytostatic drugs (often used in cancer 
therapy); genotoxic chemicals
Chemical Waste
Waste containing chemical substances 
e.g. laboratory reagents; film developer; 
disinfectants that are expired or no longer 
needed; solvents
Wastes with high content of heavy metals
Batteries; broken thermometers; blood- 
pressure gauges; etc.
Pressurized containers
Gas cylinders; gas cartridges; aerosol cans
Radioactive waste
Waste containing radioactive substances 
e.g. unused liquids from radiotherapy or 
laboratory research; contaminated 
glassware, packages, or absorbent paper; 
urine and excreta from patients treated or 
tested with unsealed radionuclides; sealed 
sources
Source (WHO, 1998)
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A2 International Solid Waste Association
The International Solid Waste Association (ISWA) does not use a specific 
definition to define healthcare waste. Instead, the Association describes 
the types of waste that constitute healthcare waste as identified by their 
Healthcare Working Group.
ISWA defines healthcare as:
“...solid or liquid wastes produced during the diagnosis, monitoring, 
treatment, prevention of disease, or alleviation of handicap in humans and  
animals together with the research related to those activities. ”
The ISWA description also addresses “...the development and  
manufacture of healthcare products and the production, segregation, 
transport, treatment and disposal of healthcare waste. ”
ISWA also states that:
“Healthcare waste is the solid or liquid waste arising from healthcare and  
includes personal hygiene products”.
“Healthcare risk waste includes biological waste, infectious waste, sharps, 
chemical, toxic or pharmaceutical waste including cytotoxins and 
radioactive wastes.”
Source (ISWA, 2002)
)
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A3 United Nations
Current UN definitions linked to international transport regulation are 
derived from the UN 12th Model Regulations which have been incorporated 
into ADR 2003 and the GB’s Carriage of Dangerous Goods and 
Transportable Pressurised Equipment (CDGTPE) Regulations 2004.
The definition of an infectious substance for the purpose of transport 
regulation is shown below and is taken from ADR 2003, Class 6.2: 
“Infectious substances are those substances known or reasonably 
expected to contain pathogens. Pathogens are defined as micro­
organisms (including bacteria, viruses, rickettsia, parasites, fungi) or 
recombinant micro-organisms (hybrid or mutant), that are known or 
reasonably expected to cause infectious disease in animals or humans” 
(UN, 2002).
Infectious substances classified in Class 6.2 are assigned a four digit 
waste identification number, called the UN Number’. The UN Number 
provides a consistent way of identifying hazardous goods throughout the 
world and alerts those involved in their transportation to the most 
appropriate means of handling. The assignation of UN Numbers is based 
on primary hazard; an infectious hazard is considered to take precedence 
over all other hazards and therefore all waste with infectious 
characteristics are classified in Class 6.2.
Table 28 shows the UN Number applicable to clinical and healthcare 
waste.
Table 28. UN Number applicable to clinical and healthcare wastes.
UN Number Description of Dangerous Good.
2814 Infectious substance, affecting humans.
2900 Infectious substance, affecting animals.
3291
Clinical waste unspecified (N.O.S) Not Otherwise Specified. 
Regulated Medical Waste (N.O.S)
(Bio) Medical Waste (NO.S)
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Table 28 continued.
1851 Medicine, liquid toxic (N.O.S)
3249 Medicine, solid toxic, (N.O.S)
3248 Medicine, flammable, liquid, toxic, (N.O.S)
Source: (UN, 2002)
Infectious substances are assigned to UN2814 and UN2900 as 
appropriate, on the basis of their allocation to one of three risk groups 
based on criteria developed by the World Health Organisation (W HO) and 
published in the W HO “Laboratory B iosafety  Manual" published in 1993.
The risk groups are characterised by the pathogenicity of the organism, 
the mode and relative ease of transmission, the degree of risk to both an 
individual and a community, and the reversibility of the disease through 
the availability of known and effective preventative agents and treatment 
(ADR, 2002).
The criteria for each of the W HO risks groups is shown below:
Risk Group 4
A pathogen that usually causes serious human or animal disease and that 
can be readily transmitted from one individual to another, directly or 
indirectly, and for which effective treatment and preventative measures are 
not usually available (i.e. high individual and community risk).
Risk Group 3
A pathogen that usually causes serious human or animal disease but does 
not ordinarily spread from one infective individual to another, and for which 
effective treatment and preventative measures are available (i.e. high 
individual risk and low community risk).
Risk Group 2
A pathogen that can cause human or animal disease but is unlikely to be a 
serious hazard, and, while capable of causing serious infection on 
exposure, for which effective treatment and preventative measures are 
available and the risk of spread of infection is limited (i.e. moderate 
individual risk and low community risk).
206
Risk Group 1 includes micro-organisms that are unlikely to cause human 
or animal disease (i.e. .No, or very low, individual or community risk). 
Substances containing any such micro-organisms are not considered 
infectious substances.
Source: (ADR, 2002)
The relationship between the W HO Risk Groups and UN Numbers in 
relation to infectious healthcare waste is shown in Table 29.
Table 29. Relationship between the WHO Risk Groups and UN Numbers in relation to 
infectious healthcare waste.
UN
Number
Description of Dangerous Good. WHO Risk Group
2814 Infectious substance, affecting humans. Where pathogens are known and 
have been identified by 
laboratory analysis - WHO Risk 
Groups 2, 3 & 4
2900 Infectious substance, affecting animals. Where pathogens are known and 
have been identified by 
laboratory analysis - WHO Risk 
Groups 2,3 & 4
3291 Clinical waste unspecified (N.O.S) Not 
Otherwise Specified.
Regulated Medical Waste (N.O.S)
(Bio) Medical Waste (NO.S)
Where pathogens are known or 
suspected to be present but have 
not been identified
Not
Applicable
Not Applicable WHO Risk Group 1
In practice, cases where a W HO Risk Group 4 is known or suspected, 
public health bodies identify the pathogen involved. In such circumstances
th is waste is assigned UN 2814 / UN 2900. W ith the exception of waste 
laboratory cultures and specim ens it is not normal practice to identify 
pathogens in waste using labora tory analysis. Therefore the vast m ajority 
of c lin ica l waste is assigned as UN 3291.
R elationship between WHO Risk Groups and UK ACDP C lassification.
It should be noted that the W HO Risk Groups were used as the foundation 
of the UK categorisa tion  of b io log ica l agents by the A dvisory Com m ittee of 
Dangerous Pathogens (ACDP) which can be found in Appendix C. W hilst 
the WHO Risk Groups refer to both human and anim al pathogens, it should 
be noted that the ACDP groupings called ‘Hazard G roups’ refer to human 
pathogens only (see Appendix C)
2 0 8
A4 United States
Table 30 shows the US ERA categories of regulated medical waste.
Table 30 US EPA categories of regulated medical waste.
Classl Cultures and Stocks
Cultures and stocks of infectious agents and associated biologicals, including: 
cultures from medical pathological laboratories; cultures and stocks of infectious 
agents from research and industrial laboratories; discarded live and attenuated 
vaccines; and culture dishes and devices used to transfer, inoculate and mix 
cultures.
Class 2 Pathological Wastes
Human pathological wastes, including tissues, organs, body parts and body 
fluids that are removed during surgery or autopsy, or other medical procedure, 
and specimens of body fluids and their containers.
Class 3 Human Blood and Blood Products
(1) Liquid human blood; (2) products of blood; (3) items saturated and/or 
dripping with human blood; or (4) items saturated and/or dripping with human 
blood or that caked with dried human blood; including serum, plasma, and other 
blood components, and their containers, which were used or intended for use in 
patient care, testing or laboratory analysis, or development of pharmaceuticals. 
Intravenous bags are included.
Class 4 Used Sharps
Sharps that have been used in animal or human patient care or treatment or in 
medical, research or industrial laboratories, including hypodermic needles, 
syringes (with or without the attached needles), Pasteur pipettes, scalpel 
blades, blood vials, needles with attached tubing, and culture disuses 
(regardless of the presence of infectious agents). Also included are other types 
of broken and unbroken glassware that were in contact with infectious agents, 
such as used slides and cover slips.
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Table 30 continued.
Class 5 Animal Waste
Contaminated animal carcasses, body parts and bedding of animals that were 
known to have been exposed to infectious agents during research (including 
research in veterinary hospitals), production of biologicals, or testing of 
pharmaceuticals.
Class 6 Isolation Wastes
Biological waste and discarded materials contaminated with blood, excretion, 
exudates or secretions from humans who are isolated to protect others from 
highly communicable diseases, or isolated animals known to be infected with 
highly communicable diseases.
Class 7 Unused Sharps
Hypodermic needles, suture needles, syringes and scalpel blades.
Source: (EPA, 1989)
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Appendix B European Waste Catalog
The aim of this appendix is to provide guidance on the use of the 
European Waste Catalogue (EW C 2002). It reproduces the EWC 2002 in 
full, including amendments, with the “absolute entries” highlighted in red 
and the “mirror entries” highlighted in blue, to help determine if threshold 
limits need to be used in the assessment of a particular waste. There are 
a number of absolute entries which have corresponding non-hazardous 
entries, which should be used when the absolute entry is not appropriate.
“A bsolute Entries” Hazardous waste regardless of any A
threshold concentrations:
“M irro r Entries” Hazardous waste only if dangerous M
substances are present above threshold concentrations:
Under the Duty of Care, waste producers have a duty to classify and 
describe their waste correctly; this includes selecting the most appropriate 
code from the EWC 2002. Further guidance on the coding of waste for 
Duty of Care purposes can be found in an Environment Agency document 
entitled: “Coding Waste Using the EW C”
Using the EWC 2002
The EWC 2002 details a series of steps for identifying wastes in the 
catalogue and determining whether a waste is covered by a hazardous 
waste entry. Wastes in the catalogue are listed according to individual six­
digit codes. The full description of a waste includes the two-digit and four­
digit chapter headings, which identify generic sources and types of waste.
Set out below and overleaf are the steps to be followed when using the 
catalogue:
Step 1 Identification by Waste Source j
First consider the entries in Chapters 01 to 12 and 17 to 20 and select the j
appropriate six-digit code. However it should be noted that: j
•  six-digit codes ending “99” (which represents “wastes not otherwise specified” I
under a particular two-digit and four-digit code) should not be used at this |
stage and are only to be used if no other code applies to a waste (Step 3 
below) I
• certain producers may need to look in more than one of these Chapters if their
activity has a number of different process J
• separately collected packaging waste should be classified under 15 01 and I
not 20 01
Step 2 Identification by Waste Type
If a suitable waste code cannot be found in Chapters 01 to 12 and 17 to 20, an 
appropriate six-digit code from Chapters 13 to 15 should be used.
Step 3 Waste not otherwise specified
If a suitable waste code can not be found in Chapters 13 to 15, a six-digit code 
from Chapter 16 should be used to identify the waste.
Only if no suitable six-digit code can be found in Chapter 16 should a six-digit 
code ending “99” in Chapters 01 to 12 and 17 to 20 be used.
Step 4 Hazardous Waste Entries
Any waste whose six-digit code is marked with an asterisk (*) is a hazardous 
waste, however there are two types of hazardous waste entries in the catalogue:
“Absolute entries”:
Those entries with an asterisk (*) and without a specific or general reference to 
“dangerous substances". Wastes covered under these entries are hazardous 
waste regardless of the concentration of any “dangerous substance” within the 
waste. “Absolute entries" are highlighted in red and marked with an “A”.
“Mirror entries”:
Those entries with an asterisk (*) and with a specific or general reference to 
“dangerous substances”, which are generally identified by the word “containing in 
the description and have a corresponding entry without an asterisk (*). For 
example:
Example of a general reference to dangerous substances:
07 01 11* sludges from on-site effluent treatment containing dangerous 
substances
07 01 12 sludges from on-site effluent treatment other than those 
mentioned in 07 01 11
Example of a specific reference to dangerous substances:
06 06 02* wastes containing dangerous sulphides 
06 06 03 wastes containing sulphides other than those mentioned in 06 
06 02
These “mirror entries" cover wastes that have the potential to be either hazardous 
or non-hazardous depending on their actual composition and the concentrations of 
“dangerous substances” within the waste.
The “dangerous substances" within these wastes need to be assessed to 
determine if a particular waste is hazardous or non-hazardous. For “mirror 
entries” with specific references to “dangerous substances”, only the named 
“dangerous substance(s)” needs to be assessed.
Threshold concentrations for the hazardous properties H3 to H8, H10 and H11 are 
set out in Article 2 of the EWC 2002, with the threshold concentrations for the 
other hazardous properties set out in Chapter 3 and Appendix C of this document.
“Mirror entries” are highlighted in blue and marked with an “M”.
Note: Some entries in the EWC 2002 make reference to “dangerous substances” 
and the only alternative entries are “absolute entries”, for example entries under 
11 03. In such case the entry has been identified as an “absolute entrf.
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01 W ASTES RESULTING FROM EXPLORATION, M INING, 
QUARRYING, AND PHYSICAL AND CHEM ICAL TREATM ENT OF 
M INERALS
01 w astes from  m ineral excavation
0 1  0 1  0 1 wastes from mineral metalliferous excavation
0 1  0 1  0 2 wastes from mineral non-metalliferous excavation
1 03 wastes from  physical and chem ical processing of m etalliferous  
m inerals
01 03 04* acid-generating tailings from processing of sulphide ore A
01 03 05* other tailings containing dangerous substances M
01 03 06 tailings other than those mentioned in 01 03 04 and 01 03 05
01 03 07* other wastes containing dangerous substances from physical and chemical processing of 
metalliferous minerals
M
01 03 08 dusty and powdery wastes other than those mentioned in 01 03 07
01 03 09 red mud from alumina production other than the wastes mentioned in 01 03 07
01 03 99 wastes not otherwise specified
1 04 w astes from  physical and chem ical processing of non- 
m etalliferous m inerals
01 04 07* wastes containing dangerous substances from physical and chemical processing of non- 
metalliferous minerals
M
01 04 08 waste gravel and crushed rocks other than those mentioned in 01 04 07
01 04 09 waste sand and clays
01 04 10 dusty and powdery wastes other than those mentioned in 01 04 07
010411 wastes from potash and rock salt processing other than those mentioned in 01 04 07
01 04 12 tailings and other wastes from washing and cleaning of minerals other than those mentioned 
in 01 04 07 and 01 04 11
01 04 13 wastes from stone cutting and sawing other than those mentioned in 01 04 07
01 04 99 wastes not otherwise specified
1 05 drilling  muds and other d rilling  w astes
01 05 04 freshwater drilling muds and wastes
01 05 05* oil-containing drilling muds and wastes M
01 05 06* drilling muds and other drilling wastes containing dangerous substances M
01 05 07 barite-containing drilling muds and wastes other than those mentioned in 01 05 05 and 01 
05 06
01 05 08 chloride-containing drilling muds and wastes other than those mentioned in 01 05 05 and 01 
05 06
01 05 99 wastes not otherwise specified
02 W ASTES FROM AGRICULTURE, HO RTICULTURE,
AQUACULTURE, FORESTRY, HUNTING AND FISHING , FOOD
PREPARATION AND PROCESSING
2 01 w astes from  agricu lture, horticu lture , aquaculture, fo restry ,
hunting and fishing
0 2  0 1  0 1 sludges from washing and cleaning
) 0 2  0 1  0 2 animal-tissue waste
02 01 03 plant-tissue waste
02 01 04 waste plastics (except packaging)
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0 2  0 1  06 animal faeces, urine and manure (including spoiled straw), effluent, collected separately 
and treated off-site
02 01 07 wastes from forestry
0 2  0 1  08* agrochemical waste containing dangerous substances
02 0109 agrochemical waste other than those mentioned in 0 2  0 1  08
0 2  0 1  1 0 waste metal
02 01 99 wastes not otherwise specified
2 02 w astes from  the preparation and processing of meat, fish and  
other foods of anim al origin
0 2  0 2  0 1 sludges from washing and cleaning
0 2  0 2  0 2 animal-tissue waste
02 02 03 materials unsuitable for consumption or processing
02 02 04 sludges from on-site effluent treatment
02 02 99 wastes not otherwise specified
2 03 w astes from  fru it, vegetab les, cereals, ed ib le oils, cocoa, 
coffee, tea and tobacco preparation and processing; conserve  
production; yeast and yeast extract production, m olasses  
preparation and ferm entation
02 03 01 sludges from washing, cleaning, peeling, centrifuging and separation
02 03 02 wastes from preserving agents
02 03 03 wastes from solvent extraction
02 03 04 materials unsuitable for consumption or processing
02 03 05 sludges from on-site effluent treatment
02 03 99 wastes not otherwise specified
2 04 w astes from  sugar processing
02 04 01 soil from cleaning and washing beet
02 04 02 off-specification calcium carbonate
02 04 03 sludges from on-site effluent treatment
02 04 99 wastes not otherwise specified
2 05 w astes from  the dairy  products industry
02 05 01 materials unsuitable for consumption or processing
02 05 02 sludges from on-site effluent treatment
02 05 99 wastes not otherwise specified
2 06 w astes from  the baking and confectionery industry
0 2  06 0 1 materials unsuitable for consumption or processing
0 2  06 0 2 wastes from preserving agents
02 06 03 sludges from on-site effluent treatment
02 06 99 wastes not otherwise specified
2 07 w astes from  the production of a lcoholic  and non-alcoholic  
beverages (except coffee, tea and cocoa)
02 07 01 wastes from washing, cleaning and mechanical reduction of raw materials
02 07 02 wastes from spirits distillation
02 07 03 wastes from chemical treatment
02 07 04 materials unsuitable for consumption or processing
02 07 05 sludges from on-site effluent treatment
02 07 99 wastes not otherwise specified
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03 W ASTES FROM WOOD PROCESSING AND THE PRODUCTION  
OF PANELS AND FURNITURE, PULP, PAPER AND  
CARDBOARD
3 01 wastes from  wood processing and the production of panels  
and fu rn itu re
03 01 01 waste bark and cork
03 01 04* sawdust, shavings, cuttings, wood, particle board and veneer containing dangerous 
substances
M
03 01 05 sawdust, shavings, cuttings, wood, particle board and veneer other than those mentioned in 
03 0104
03 01 99 wastes not otherwise specified
3 02 w astes from  wood preservation
03 02 01* non-halogenated organic wood preservatives A
03 02 02* organochlorinated wood preservatives A
03 02 03* organometallic wood preservatives A
03 02 04* inorganic wood preservatives A
03 02 05* other wood preservatives containing dangerous substances M
03 02 99 wood preservatives not otherwise specified
03 03 w astes from  pulp, paper and cardboard production and 
processing
03 03 01 waste bark and wood
03 03 02 green liquor sludge (from recovery of cooking liquor)
03 03 05 de-inking sludges from paper recycling
03 03 07 mechanically separated rejects from pulping of waste paper and cardboard
03 03 08 wastes from sorting of paper and cardboard destined for recycling
03 03 09 lime mud waste
03 03 10 fibre rejects, fibre-, filler- and coating-sludges from mechanical separation
03 03 11 sludges from on-site effluent treatment other than those mentioned in 03 03 10
03 03 99 wastes not otherwise specified
04 WASTES FROM THE LEATHER, FUR AND TEXTILE INDUSTRIES
4 01 w astes from  the leather and fu r industry
04 01 01 fleshings and lime split wastes
04 01 02 liming waste
04 01 03* degreasing wastes containing solvents without a liquid phase
04 01 04 tanning liquor containing chromium
04 01 05 tanning liquor free of chromium
04 01 06 sludges, in particular from on-site effluent treatment containing chromium
04 01 07 sludges, in particular from on-site effluent treatment free of chromium
04 01 08 waste tanned leather (blue sheetings, shavings, cuttings, buffing dust) containing chromium
04 01 09 wastes from dressing and finishing
04 0199 wastes not otherwise specified
4 02 w astes from  the tex tile  industry
04 02 09 wastes from composite materials (impregnated textile, elastomer, plastomer)
04 0210 organic matter from natural products (for example grease, wax)
04 02 14* wastes from finishing containing organic solvents
216
04 02 15 wastes from finishing other than those mentioned in 04 02 14 
\  04 02 16;i: dyestuffs and pigments containing dangerous substances M
04 02 17 dyestuffs and pigments other than those mentioned in 04 02 16
04 02 IV" sludges from on-site effluent treatment containing dangerous substances iVl
04 02 20 sludges from on-site effluent treatment other than those mentioned in 04 02 19
04 02 21 wastes from unprocessed textile fibres
04 02 22 wastes from processed textile fibres
04 02 99 wastes not otherwise specified
05 W ASTES FROM PETROLEUM REFINING, NATURAL GAS
PURIFICATION AND PYROLYTIC TREATM ENT OF COAL 
wastes from  petroleum  refining
desalter sludges A
tank bottom sludges A
acid alkyl sludges A
oil spills A
oily sludges from maintenance operations o f the plant or equipment A
acid tars A
other tars A
sludges from on-site effluent treatment containing dangerous substances M
sludges from on-site effluent treatment other than those mentioned in 05 01 09 
wastes from cleaning o f fuels with bases A
oil containing acids M
boiler feedwater sludges 
wastes from cooling columns
spent filter clays A
sulphur-containing wastes from petroleum desulphurisation 
bitumen
wastes not otherwise specified
w astes from  the pyrolytic  treatm ent of coal
acid tars A
other tars A
waste from cooling columns 
wastes not otherwise specified
wastes from  natural gas purification  and transportation
wastes containing mercury M
wastes containing sulphur 
wastes not otherwise specified
5 01
05 01 02=>
05 01 03*
05 01 04*
05 01 05*
05 01 06*
05 01 07*
05 01 08*
05 01 09*
05 01 10
05 01 11*
05 01 12*
05 01 13
05 01 14
05 01 15*
05 01 16
05 01 17
05 01 99
5 06
05 06 01*
05 06 03*
05 06 04
05 06 99
5 07
05 07 01*
05 07 02
05 07 99
06 W ASTES FROM INORGANIC CHEM ICAL PROCESSES
6 01 w astes from the m anufacture, form ulation , supply
(MFSU) of acids
06 01 01* sulphuric acid and sulphurous acid
06 01 02* hydrochloric acid
06 01 03* hydrofluoric acid
06 01 04* phosphoric and phosphorous acid
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06 01 05* nitric acid and nitrous acid A
06 0 1  06* other acids A
06 01 99 wastes not otherwise specified
6 02 w astes from  the MFSU of bases
06 0 2  0 1 * calcium hydroxide A
06 02 03* ammonium hydroxide A
06 02 04* sodium and potassium hydroxide A
06 02 05* other bases A
06 02 99 wastes not otherwise specified
6 03 w astes from  the MFSU of salts and the ir solutions and m etallic  
oxides
06 03 11* solid salts and solutions containing cyanides M
06 03 13* solid salts and solutions containing heavy metals M
06 03 14 solid salts and solutions other than those mentioned in 06 03 11 and 06 03 13
06 03 15* metallic oxides containing heavy metals M
06 03 16 metallic oxides other than those mentioned in 06 03 15
06 03 99 wastes not otherwise specified
6 04 m etal-contain ing w astes other than those m entioned in 06 03
06 04 03* wastes containing arsenic M
06 04 04* wastes containing mercury M
06 04 05* wastes containing other heavy metals M
06 04 99 wastes not otherwise specified
6 05 sludges from  on-site e ffluent treatm ent
06 05 02* sludges from on-site effluent treatment containing dangerous substances M
06 05 03 sludges from on-site effluent treatment other than those mentioned in 06 05 02
6 06 w astes from  the MFSU of su lphur chem icals, su lphur chem ical 
processes and desulphurisation  processes
06 06 0 2 * wastes containing dangerous sulphides M
06 06 03 wastes containing sulphides other than those mentioned in 06 06 0 2
06 06 99 wastes not otherwise specified
6 07 w astes from  the MFSU of halogens and halogen chem ical 
processes
06 07 01* wastes containing asbestos from electrolysis M
06 07 02* activated carbon from chlorine production A
06 07 03* barium sulphate sludge containing mercury M
06 07 04* solutions and acids, for example contact acid A
06 07 99 wastes not otherwise specified
6 08 wastes from  the MFSU of silicon and silicon derivatives
06 08 0 2 * wastes containing dangerous silicones M
06 08 99 wastes not otherwise specified
6 09 wastes from  the MSFU of phosphorous chem icals and  
phosphorous chem ical processes
06 09 02 phosphorous slag
06 09 03* calcium-based reaction wastes containing or contaminated with dangerous substances M
06 09 04 calcium-based reaction wastes other than those mentioned in 06 09 03
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06 09 99 wastes not otherwise specified
6 10 wastes from  the MFSU of nitrogen chem icals, nitrogen  
chem ical processes and fertiliser m anufacture
06 10 02* wastes containing dangerous substances
06 10 99 wastes not otherwise specified
6 11 wastes from  the m anufacture of inorganic pigm ents and 
opacific iers
06 11 01 calcium-based reaction wastes from titanium dioxide production
06 11 99 wastes not otherwise specified
6 13 w astes from  inorganic chem ical processes not otherw ise  
specified
06 1301* inorganic plant protection products, wood-preserving agents and other biocides.
06 13 02* spent activated carbon (except 06 07 02)
06 13 03 carbon black
06 13 04* wastes from asbestos processing
06 13 05* soot
06 13 99 wastes not otherwise specified
07
7 01
07 01 01*
07 01 03*
07 01 04*
07 01 07*
07 01 08*
07 01 09*
07 01 10*
07 01 1 1
07 01 12
07 01 99
7 i02
07 02 01*
07 02 03*
07 02 04*
07 02 07*
07 02 08*
07 02 09*
07 02 10*
07 02 11*
07 02 12
07 02 13
07 02 14*
07 02 15
07 02 16*
07 02 17
07 02 99
W ASTES FROM ORGANIC CHEMICAL PROCESSES  
w astes from  the m anufacture, form ulation , supply and use 
(M FSU) of basic organic chem icals
aqueous washing liquids and mother liquors A
organic halogenated solvents, washing liquids and mother liquors A
other organic solvents, washing liquids and mother liquors A
halogenated still bottoms and reaction residues A
other still bottoms and reaction residues A
halogenated filter cakes and spent absorbents A
other filter cakes and spent absorbents A
sludges from on-site effluent treatment containing dangerous substances M
sludges from on-site effluent treatment other than those mentioned in 07 01 11 
wastes not otherwise specified
w astes from  the MFSU of p lastics, synthetic rubber and man- 
made fibres
aqueous washing liquids and mother liquors A
organic halogenated solvents, washing liquids and mother liquors A
other organic solvents, washing liquids and mother liquors A
halogenated still bottoms and reaction residues A
other still bottoms and reaction residues A
halogenated filter cakes and spent absorbents A
other filter cakes and spent absorbents A
sludges from on-site effluent treatment containing dangerous substances M
sludges from on-site effluent treatment other than those mentioned in 07 02 11 
waste plastic
wastes from additives containing dangerous substances M
wastes from additives other than those mentioned in 07 02 14
wastes containing dangerous silicones M
wastes containing silicones other than those mentioned in 07 02 16 
wastes not otherwise specified
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7 03
07 03 01*
07 03 03*
07 03 04*
07 03 07*
07 03 08*
07 03 09*
07 03 10*
07 03 11 *
07 03 12
07 03 99
7 04
07 04 01*
07 04 03*
07 04 04*
07 04 07*
07 04 08*
07 04 09*
07 04 1 0 *
07 04 11*
07 04 12
07 04 13*
07 04 99
7 05
07 05 0 1 *
07 05 03*
07 05 04*
07 05 07*
07 05 08*
07 05 09*
07 05 10*
07 05 11*
07 05 12
07 05 13*
07 05 14
07 05 99
7 i06
07 06 01*
07 06 03*
07 06 04*
07 06 07*
07 06 08*
07 06 09*
07 06 10*
07 06 11*
07 06 12
w astes from  the MFSU of organic dyes and pigm ents (except 
06 11)
aqueous washing liquids and mother liquors A
organic halogenated solvents, washing liquids and mother liquors A
other organic solvents, washing liquids and mother liquors A
halogenated still bottoms and reaction residues A
other still bottoms and reaction residues A
halogenated filter cakes and spent absorbents A
other filter cakes and spent absorbents A
sludges from on-site effluent treatment containing dangerous substances M
sludges from on-site effluent treatment other than those mentioned in 07 03 11 
wastes not otherwise specified
w astes from the MFSU of organic plant protection products  
(except 02 01 08 and 02 01 09), wood preserving agents (except 
03 02) and other b iocides
aqueous washing liquids and mother liquors A
organic halogenated solvents, washing liquids and mother liquors A
other organic solvents, washing liquids and mother liquors A
halogenated still bottoms and reaction residues A
other still bottoms and reaction residues A
halogenated filter cakes and spent absorbents A
other filter cakes and spent absorbents A
sludges from on-site effluent treatment containing dangerous substances M
sludges from on-site effluent treatment other than those mentioned in 07 04 11 
solid wastes containing dangerous substances M
wastes not otherwise specified
wastes from  the MFSU of pharm aceuticals
aqueous washing liquids and mother liquors A
organic halogenated solvents, washing liquids and mother liquors A
other organic solvents, washing liquids and mother liquors A
halogenated still bottoms and reaction residues A
other still bottoms and reaction residues A
halogenated filter cakes and spent absorbents A
other filter cakes and spent absorbents A
sludges from on-site effluent treatment containing dangerous substances M
sludges from on-site effluent treatment other than those mentioned in 07 05 11 
solid wastes containing dangerous substances M
solid wastes other than those mentioned in 07 05 13 
wastes not otherwise specified
wastes from  the MFSU of fats, grease, soaps, detergents, 
disinfectants and cosm etics
aqueous washing liquids and mother liquors A
organic halogenated solvents, washing liquids and mother liquors A
other organic solvents, washing liquids and mother liquors A
halogenated still bottoms and reaction residues A
other still bottoms and reaction residues A
halogenated filter cakes and spent absorbents A
other filter cakes and spent absorbents A
sludges from on-site effluent treatment containing dangerous substances M
sludges from on-site effluent treatment other than those mentioned in 07 06 11
2 2 0
07 06 99 wastes not otherwise specified
7 07 w astes from  the MFSU of fine chem icals and chem ical 
products not otherw ise specified
07 07 01* aqueous washing liquids and mother liquors A
07 07 03* organic halogenated solvents, washing liquids and mother liquors A
07 07 04* other organic solvents, washing liquids and mother liquors A
07 07 07* halogenated still bottoms and reaction residues A
07 07 08* other still bottoms and reaction residues A
07 07 09* halogenated filter cakes and spent absorbents A
07 07 10* other filter cakes and spent absorbents A
07 07 11 * sludges from on-site effluent treatment containing dangerous substances M
07 07 12 sludges from on-site effluent treatment other than those mentioned in 07 07 11
07 07 99 wastes not otherwise specified
08 W ASTES FROM THE M ANUFACTURE, FORM ULATION, SUPPLY
AND USE (M FSU) OF COATINGS (PAINTS, VARNISHES AND
VITREOUS ENAM ELS), ADHESIVES, SEALANTS AND PRINTING
INKS
8 01 w astes from  MFSU and rem oval of paint and varnish
08 0 1 I I * waste paint and varnish containing organic solvents or other dangerous substances M
08 01 12 waste paint and varnish other than those mentioned in 08 01 11
08 01 13* sludges from paint oi varnish containing organic solvents or other dangerous substances M
08 01 14 sludges from paint or varnish other than those mentioned in 08 01 13
08 01 15* aqueous sludges containing paint or varnish containing organic solvents or other dangerous M
y substances
08 01 16 aqueous sludges containing paint or varnish other than those mentioned in 08 01 15
08 01 17* wastes from paint oi varnish removal containing organic solvents or other dangerous M
substances
0801 18 wastes from paint or varnish removal other than those mentioned in 08 01 17
08 01 19* aqueous suspensions containing paint or varnish containing organic solvents or other M
dangerous substances
08 01 20 aqueous suspensions containing paint or varnish other than those mentioned in 08 01 19
08 01 21* waste paint or varnish remover A
08 01 99 wastes not otherwise specified
8 02 w astes from  MFSU of other coatings (including ceram ic
m aterials)
08 02 01 waste coating powders
) 08 02 02 aqueous sludges containing ceramic materials
08 02 03 aqueous suspensions containing ceramic materials
08 02 99 wastes not otherwise specified
8 03 wastes from MFSU of printing inks
08 03 07 aqueous sludges containing ink
08 03 08 aqueous liquid waste containing ink
08 03 12* waste ink containing dangerous substances M
08 03 13 waste ink other than those mentioned in 08 03 12
08 03 14* ink sludges containing dangerous substances M
08 03 15 ink sludges other than those mentioned in 08 03 14
08 03 16* waste etching solutions A
08 03 17* waste printing toner containing dangerous substances M
08 03 18 waste printing toner other than those mentioned in 08 03 17
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08 03 19* disperse oil A
08 03 99 wastes not otherwise specified
8 04 w astes from  MFSU of adhesives and sealants (including  
w aterproofing products)
08 04 09* waste adhesives and sealants containing organic solvents or other dangerous substances M
08 04 10 waste adhesives and sealants other than those mentioned in 08 04 09
08 04 1 1 * adhesive and sealant sludges containing organic solvents or other dangerous substances M
08 04 12 adhesive and sealant sludges other than those mentioned in 08 04 11
08 04 13* aqueous sludges containing adhesives or sealants containing organic solvents or other 
dangerous substances
M
08 04 14 aqueous sludges containing adhesives or sealants other than those mentioned in 08 04 13
08 04 15* aqueous liquid waste containing adhesives or sealants containing organic solvents or other 
dangerous substances
M
08 04 16 aqueous liquid waste containing adhesives or sealants other than those mentioned in 08 04 
15
08 04 17* rosin oil A
08 04 99 wastes not otherwise specified
8 05 w astes not otherw ise specified in 08
08 05 01* waste isocyanates A
09 W ASTES FROM THE PHOTOGRAPHIC INDUSTRY
9 01 w astes from  the photographic industry
09 01 01* water-based developer and activator solutions A
09 01 02* water-based offset plate developer solutions A
09 01 03* solvent-based developer solutions A
09 01 04* fixer solutions A
09 01 05* bleach solutions and bleach fixer solutions A
09 01 06* wastes containing silver from on-site treatment o f photographic wastes M
09 01 07 photographic film  and paper containing silver or silver compounds
09 01 08 photographic film  and paper free o f silver or silver compounds
09 01 10 single-use cameras without batteries
09 01 11* single-use cameras containing batteries included in 16 06 01, 16 06 02 or 16 06 03 A
09 01 12 single-use cameras containing batteries other than those mentioned in 09 01 11
09 01 13* aqueous liquid waste from on-site reclamation of silver other than those mentioned in 09 01 
06
A
09 01 99 wastes not otherwise specified
10 W ASTES FROM THERMAL PROCESSES
10 01 w astes from  power stations and other com bustion plants  
(except 19)
1001 01 bottom ash, slag and boiler dust (excluding boiler dust mentioned in 10 01 04)
1001 02 coal fly  ash
1001 03 fly  ash from peat and untreated wood
10 01 04* oil fly ash and boiler dust A
1001 05 calcium-based reaction wastes from flue-gas desulphurisation in solid form
1001 07 calcium-based reaction wastes from flue-gas desulphurisation in sludge form
10 01 09* sulphuric acid A
10 01 13* fly ash from emulsified hydrocarbons used as fuel A
2 2 2
10 01 14:
10 01 15
10 01 \(r
10 01 17
10 01 18=
10 01 19
10 01 20=
10 01 21
10 01 22=
10 01 23
10 01 24
10 01 25
10 01 26
10 01 99
10 02
10 02 01
10 02 02
10 02 07 =
10 02 08
10 02 10
10 02 11 =
10 02 12
10 02 13
10 02 14
10 02 15
10 02 99
10I 03
10 03 02
10 03 04=
10 03 05
10 03 08=
10 03 09=
10 03 15=
10 03 16
10 03 17=
10 03 18
10 03 19=
10 03 20
10 03 21 =
10 03 22
10 03 23 =
10 03 24
10 03 25=
10 03 26
10 03 27=
10 03 28
10 03 29=
10 03 30
bottom ash, slag and boiler dust from co-incineration containing dangerous substances M
bottom ash, slag and boiler dust from co-incineration other than those mentioned in 10 01
14
fly  ash from co-incineration containing dangerous substances M
fly  ash from co-incineration other than those mentioned in 10 01 16
wastes from gas cleaning containing dangerous substances M
wastes from gas cleaning other than those mentioned in 10 01 05, 10 01 07 and 10 01 18
sludges from on-site effluent treatment containing dangerous substances M
sludges from on-site effluent treatment other than those mentioned in 10 01 20
aqueous sludges from boiler cleansing containing dangerous substances M
aqueous sludges from boiler cleansing other than those mentioned in 10 01 22
sands from fluidised beds
wastes from fuel storage and preparation o f coal-fired power plants 
wastes from cooling-water treatment 
wastes not otherwise specified
wastes from  the iron and steel industry
wastes from the processing o f slag 
unprocessed slag
solid wastes from gas treatment containing dangerous substances M
solid wastes from gas treatment other than those mentioned in 10 02 07 
m ill scales
wastes from cooling-water treatment containing oil M
wastes from cooling-water treatment other than those mentioned in 10 02 11
sludges and filter cakes from gas treatment containing dangerous substances M
sludges and filte r cakes from gas treatment other than those mentioned in 10 02 13
other sludges and filte r cakes
wastes not otherwise specified
wastes from  alum inium  therm al m etallurgy
anode scraps
primary production slags A
waste alumina
salt slags from secondary production A
black drosses from secondary production A
skimmings that are flammable or emit, upon contact with water, flammable gases in M
dangerous quantities
skimmings other than those mentioned in 10 03 15
tar-containing wastes from anode manufacture M
carbon-containing wastes from anode manufacture other than those mentioned in 10 03 17 
flue-gas dust containing dangerous substances M
flue-gas dust other than those mentioned in 10 03 19
other particulates and dust (including ball-m iII dust) containing dangerous substances M
other particulates and dust (including ba ll-m ill dust) other than those mentioned in 10 03 21
solid wastes from gas treatment containing dangerous substances M
solid wastes from gas treatment other than those mentioned in 10 03 23
sludges and filter cakes from gas treatment containing dangerous substances M
sludges and filter cakes from gas treatment other than those mentioned in 10 03 25
wastes from cooling-water treatment containing oil M
wastes from cooling-water treatment other than those mentioned in 10 03 27
wastes from treatment o f salt slags and black drosses containing dangerous substances M
wastes from treatment o f salt slags and black drosses other than those mentioned in 10 03
29
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10 03 99 wastes not otherwise specified
10 04 wastes from  lead therm al m etallurgy
10 04 0 1 * slags from primary and secondary production A
10 04 02* dross and skimmings from primary and secondary production A
10 04 03* calcium arsenate A
10 04 04* flue-gas dust A
10 04 05* other particulates and dust A
10 04 06* solid wastes from gas treatment A
10 04 07* sludges and filter cakes from gas treatment A
10 04 09* wastes from cooling-water treatment containing oil M
10 04 10 wastes from cooling-water treatment other than those mentioned in 10 04 09
1004 99 wastes not otherwise specified
10 05 wastes from  zinc therm al m etallurgy
10 05 01 slags from primary and secondary production
10 05 03* flue-gas dust A
1005 04 other particulates and dust
10 05 05* solid waste from gas treatment A
10 05 06* sludges and filter cakes from gas treatment A
10 05 08* wastes from cooling-water treatment containing oil M
10 05 09 wastes from cooling-water treatment other than those mentioned in 10 05 08
10 05 10* dross and skimmings that are flammable or emit, upon contact with water, flammable gases M
in dangerous quantities 
10 05 11 dross and skimmings other than those mentioned in 10 05 10
10 05 99 wastes not otherwise specified
10 06 wastes from  copper therm al m etallurgy
10 06 01 slags from primary and secondary production
10 06 02 dross and skimmings from primary and secondary production
10 06 03* flue-gas dust A
10 06 04 other particulates and dust
10 06 06* solid wastes from gas treatment A
10 06 07* sludges and filter cakes from gas treatment A
10 06 09* wastes from cooling-water treatment containing oil M
10 06 10 wastes from cooling-water treatment other than those mentioned in 10 06 09
10 06 99 wastes not otherwise specified
10 07 wastes from  silver, gold and platinum  therm al m etallurgy
10 07 01 slags from primary and secondary production
10 07 02 dross and skimmings from primary and secondary production
10 07 03 solid wastes from gas treatment
1007 04 other particulates and dust
10 07 05 sludges and filter cakes from gas treatment
10 07 07* wastes from cooling-water treatment containing oil M
10 07 08 wastes from cooling-water treatment other than those mentioned in 10 07 07
10 07 99 wastes not otherwise specified
10 08 wastes from other non-ferrous therm al m etallurgy
10 08 04 particulates and dust
10 08 08* salt slag from primary and secondary production A
10 08 09 other slags
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1 0  08 1 0 * dross and skimmings that are flammable or emit, upon contact with water, flammable gases 
in dangerous quantities
M
1008 1 1 dross and skimmings other than those mentioned in 1 0  08 1 0
1 0  08 1 2 * tar-containing wastes from anode manufacture M
10 08 13 carbon-containing wastes from anode manufacture other than those mentioned in 1 0  08 1 2
10 08 14 anode scrap
10 08 15* flue-gas dust containing dangerous substances M
1 0  08 16 flue-gas dust other than those mentioned in 10 08 15
10 08 17* sludges and filter cakes from flue-gas treatment containing dangerous substances M
1 0  08 18 sludges and filter cakes from flue-gas treatment other than those mentioned in 10 08 17
10 08 19* wastes from cooling-water treatment containing oil M
1 0  08 2 0 wastes from cooling-water treatment other than those mentioned in 10 08 19
10 08 99 wastes not otherwise specified
10 09 w astes from  casting of ferrous pieces
10 09 03 furnace slag
10 09 05* casting cores and moulds which have not undergone pouring containing dangerous 
substances
M
10 09 06 casting cores and moulds which have not undergone pouring other than those mentioned in 
10 09 05
10 09 07* casting cores and moulds which have undergone pouring containing dangerous substances M
10 09 08 casting cores and moulds which have undergone pouring other than those mentioned in 1 0  
09 07
10 09 09* flue-gas dust containing dangerous substances M
10 09 10 flue-gas dust other than those mentioned in 10 09 09
10 09 11* other particulates containing dangerous substances M
10 09 12 other particulates other than those mentioned in 10 09 11
10 09 13* waste binders containing dangerous substances M
10 09 14 waste binders other than those mentioned in 10 09 13
10 09 15* waste crack-indicating agent containing dangerous substances M
10 09 16 waste crack-indicating agent other than those mentioned in 10 09 15
10 09 99 wastes not otherwise specified
10 10 w astes from  casting of non-ferrous pieces
10 10 03 furnace slag
1010 05* casting cores and moulds which have not undergone pouring, containing dangerous 
substances
M
1 0 1 0  06 casting cores and moulds which have not undergone pouring, other than those mentioned in 
1 0 1 0  05
10 10 07* casting cores and moulds which have undergone pouring, containing dangerous substances M
1 0 1 0  08 casting cores and moulds which have undergone pouring, other than those mentioned in 1 0  
10 07
1010 09* flue-gas dust containing dangerous substances M
1 0 1 0 1 0 flue-gas dust other than those mentioned in 10 10 09
1 0 1 0 1 1 * other particulates containing dangerous substances M
1 0 1 0 1 2 other particulates other than those mentioned in 1 0  1 0  1 1
101013* waste binders containing dangerous substances M
101014 waste binders other than those mentioned in 10 10 13
10 10 15* waste crack-indicating agent containing dangerous substances M
1 0  1016 waste crack-indicating agent other than those mentioned in 10 10 15
1010 99 wastes not otherwise specified
)
10 11 w astes from  m anufacture of g lass and glass products
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101103 waste glass-based fibrous materials
1011 05 particulates and dust
1011 09* waste preparation mixture before thermal processing, containing dangerous substances M
1 0 1 1  1 0 waste preparation mixture before thermal processing, other than those mentioned in 1 0  1 1  
09
1 0  1 1  1 1 * waste glass in small particles and glass powder containing heavy metals (for example from 
cathode ray tubes)
M
1 0 1 1  1 2 waste glass other than those mentioned in 1 0  1 1  1 1
10 1113* glass-polishing and -grinding sludge containing dangerous substances M
1011 14 glass-polishing and -grinding sludge other than those mentioned in 1 0  1 1  13
1011 15* solid wastes from flue-gas treatment containing dangerous substances M
1 0  1 1  16 solid wastes from flue-gas treatment other than those mentioned in 10 11 15
10 11 17* sludges and filter cakes from flue-gas treatment containing dangerous substances M
1 0 1 1  18 sludges and filter cakes from flue-gas treatment other than those mentioned in 10 11 17
1011 19* solid wastes from on-site effluent treatment containing dangerous substances M
1 0 1 1 2 0 solid wastes from on-site effluent treatment other than those mentioned in 1 0  1 1  19
101199 wastes not otherwise specified
10 12 w astes from  m anufacture of ceram ic goods, bricks, tiles  and 
construction products
1 0 1 2  0 1 waste preparation mixture before thermal processing
1012 03 particulates and dust
1012 05 sludges and filter cakes from gas treatment
101206 discarded moulds
1 0 1 2  08 waste ceramics, bricks, tiles and construction products (after thermal processing)
1012 09* solid wastes from gas treatment containing dangerous substances M
1 0 1 2 1 0 solid wastes from gas treatment other than those mentioned in 1 0  1 2  09
1 0 1 2  1 1 * wastes from glazing containing heavy metals M
1 0 1 2 1 2 wastes from glazing other than those mentioned in 1 0  1 2  1 1
101213 sludge from on-site effluent treatment
1012 99 wastes not otherwise specified
10 13 w astes from  m anufacture of cem ent, lime and p laster and 
artic les and products made from  them
1013 01 waste preparation mixture before thermal processing
10 13 04 wastes from calcination and hydration of lime
10 13 06 particulates and dust (except 10 13 12 and 10 13 13)
10 13 07 sludges and filter cakes from gas treatment
1013 09* wastes from asbestos-cement manufacture containing asbestos M
1013 10 wastes from asbestos-cement manufacture other than those mentioned in 10 13 09
1013 11 wastes from cement-based composite materials other than those mentioned in 10 13 09 and 
1013 10
1013 12* solid wastes from gas treatment containing dangerous substances M
10 13 13 solid wastes from gas treatment other than those mentioned in 10 13 12
1013 14 waste concrete and concrete sludge
1013 99 wastes not otherwise specified
10 14 w aste from  crem atoria
101401* waste from gas cleaning containing mercury M
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11 W ASTES FROM CHEM ICAL SURFACE TREATM ENT AND 
COATING OF METALS AND OTHER MATERIALS; NON- 
FERROUS HYDRO-M ETALLURGY
11 01 w astes from  chem ical surface treatm ent and coating of metals  
and other m aterials (for exam ple galvanic processes, zinc  
coating processes, pickling processes, etching, 
phosphatising, a lkaline degreasing, anodising)
110105* pickling acids A
11 01 06* acids not otherwise specified A
l l  01 07* pickling bases A
11 01 08* phosphatising sludges A
1101 09* sludges and fille r cakes containing dangerous substances M
1101 10 sludges and filte r cakes other than those mentioned in 11 01 09
1101 11* aqueous rinsing liquids containing dangerous substances IY1
11 01 12 aqueous rinsing liquids other than those mentioned in 11 01 11
1101 13* degreasing wastes containing dangerous substances M
11 01 14 degreasing wastes other than those mentioned in 11 01 13
I I 01 15* eluate and sludges from membrane systems or ion exchange systems containing dangerous M
substances
110116*  saturated or spent ion exchange resins A
I I  01 98* other wastes containing dangerous substances M
11 01 99 wastes not otherwise specified
11 02 w astes from  non-ferrous hydrom etallurg ical processes
11 02 02* sludges from zinc hydrometallurgy (including jarosite, goethite) A
11 02 03 wastes from the production o f anodes for aqueous electrolytical processes
I I 02 05* wastes from copper hydrometallurgical processes containing dangerous substances M
I I  02 06 wastes from copper hydrometallurgical processes other than those mentioned in 11 02 05
I I 02 07* other wastes containing dangerous substances M
I I  02 99 wastes not otherwise specified
11 03 sludges and solids from tem pering processes
11 03 01 * wastes containing cyanide A
11 03 02* other wastes A
11 05 wastes from  hot galvanising processes
11 05 01 hard zinc
11 05 02 zinc ash
11 05 03* solid wastes from gas treatment A
11 05 04* spent flux A
11 05 99 wastes not otherwise specified
12 W ASTES FROM SHAPING AND PHYSICAL AND M ECHANICAL
SURFACE TREATM ENT OF METALS AND PLASTICS
12 01 w astes from  shaping and physical and m echanical surface
treatm ent of m etals and plastics
12 01 01 ferrous metal filings and turnings
12 01 02 ferrous metal dust and particles
2 2 7
12 01 03
12 01 04
12 01 05
12 01 06*
12 01 07*
12 01 08*
12 01 09*
12 01 10*
12 01 12*
12 01 13
12 01 14*
12 01 15
12 01 16*
12 01 17
12 01 18*
12 01 19*
12 01 20*
12 01 21
12 01 99
12 03
12 03 01*
12 03 02*
non-ferrous metal filings and turnings 
non-ferrous metal dust and particles 
plastics shavings and turnings
mineral-based machining oils containing halogens (except emulsions and solutions) A
mineral-based machining oils free o f halogens (except emulsions and solutions) A
machining emulsions and solutions containing halogens A
machining emulsions and solutions free o f halogens A
synthetic machining oils A
spent waxes and fats A
welding wastes
machining sludges containing dangerous substances M
machining sludges other than those mentioned in 12 01 14
waste blasting material containing dangerous substances M
waste blasting material other than those mentioned in 12 01 16
metal sludge (grinding, honing and lapping sludge) containing oil M
readily biodegradable machining oil A
spent grinding bodies and grinding materials containing dangerous substances M
spent grinding bodies and grinding materials other than those mentioned in 12 01 20 
wastes not otherwise specified
w astes from  w ater and steam degreasing processes (except 
11)
aqueous washing liquids A
steam degreasing wastes A
13 OIL W ASTES AND W ASTES OF LIQUID FUELS (except edib le
oils, and those in chapters 05, 12 and 19)
13 01 w aste hydraulic oils
13 01 01 * hydraulic oils, containing PCBS25 A
13 01 04* chlorinated emulsions A
13 01 05* non-chlorinated emulsions A
13 01 09* mineral-based chlorinated hydraulic oils A
13 01 10* mineral based non-chlorinated hydraulic oils A
13 01 11* synthetic hydraulic oils A
13 01 12* readily biodegradable hydraulic oils A
13 01 13* other hydraulic oils A
13 02 w aste engine, gear and lubricating oils
13 02 04* mineral-based chlorinated engine, gear and lubricating oils A
13 02 05* mineral-based non-chlorinated engine, gear and lubricating oils A
13 02 06* synthetic engine, gear and lubricating oils A
13 02 07* readily biodegradable engine, gear and lubricating oils A
13 02 08* other engine, gear and lubricating oils A
13 03 w aste insulating and heat transm ission oils
13 03 01* insulating or heat transmission oils containing PCBs A
13 03 06* mineral-based chlorinated insulating and heat transmission oils other than those mentioned A
in 13 03 01
13 03 07* mineral-based non-chlorinated insulating and heat transmission oils A
25 For the purpose o f this list o f wastes, PCBs w ill be defined as in Directive 96/59/EC .
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13 03 08* synthetic insulating and heat transmission oils A
 ^ 13 03 09* readily biodegradable insulating and heat transmission oils A
13 0310* other insulating and heat transmission oils A
13 04 bilge oils
13 04 01* bilge oils from inland navigation A
13 04 02* bilge oils from je tty sewers A
13 04 03* bilge oils from other navigation A
13 05 o il/w ater separator contents
13 05 01 * solids from grit chambers and oil/water separators A
13 05 02* sludges from oil/water separators A
) 13 05 03* interceptor sludges A
13 05 06* oil from oil/water separators A
13 05 07* o ily water from oil/water separators A
13 05 08* mixtures of wastes from grit chambers and oil/water separators A
13 07 w astes of liquid fuels
13 07 01 * fuel oil and diesel A
13 07 02* petrol A
13 07 03* other fuels (including mixtures) A
13 08 oil w astes not otherw ise specified
13 08 01* desalter sludges or emulsions A
13 08 02* other emulsions A
13 08 99* wastes not otherwise specified A
14 W ASTE ORGANIC SOLVENTS, REFRIGERANTS AND
PROPELLANTS (except 07 and 08)
14 06 waste organic solvents, refrigerants
propellants
14 06 01* chlorofluorocarbons, HCFC, HFC
14 06 02* other halogenated solvents and solvent mixtures
14 06 03* other solvents and solvent mixtures
14 06 04* sludges or solid wastes containing halogenated solvents
14 06 05* sludges or solid wastes containing other solvents
15 W ASTE PACKAGING; ABSORBENTS, W IPING CLOTHS, FILTER  
MATERIALS AND PROTECTIVE CLOTHING NOT OTHERW ISE  
SPECIFIED
15 01 packaging (including separately collected m unicipal
packaging waste)
15 01 01 paper and cardboard packaging
15 01 02 plastic packaging
15 01 03 wooden packaging
15 01 04 metallic packaging
15 01 05 composite packaging
15 01 06 mixed packaging
and foam /aerosol
A
A
A
A
A
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15 01 07 glass packaging
15 01 09 textile packaging
15 01 10* packaging containing residues of or contaminated by dangerous substances M
15 01 11* metallic packaging containing a dangerous solid porous matrix (for example asbestos), 
including empty pressure containers
M
15 02 absorbents, filter materials, wiping cloths and protective 
clothing
15 02 02* absorbents, filter materials (including oil filters not otherwise specified), wiping cloths, 
protective clothing contaminated by dangerous substances
M
15 02 03 absorbents, filter materials, wiping cloths and protective clothing other than those 
mentioned in 15 02 02
) 16 W ASTES NOT OTHERW ISE SPECIFIED IN THE LIST
16 01 end-o f-life  vehicles from  d ifferen t means of transport
(including off-road m achinery) and wastes from  dism antling  of
end-o f-life  vehicles and veh icle m aintenance (except 13, 14, 16
06 and 16 08)
16 0103 end-of-life tyres
16 01 04* end-of-life vehicles M
16 01 06 end-of-life vehicles, containing neither liquids nor other hazardous components
16 01 07* oil filters A
16 0108* components containing mercury M
16 01 09* components containing PCBs M
160110* explosive components (for example air bags) A
1 160111* brake pads containing asbestos M
16 01 12 brake pads other than those mentioned in 16 01 11
1601 13* brake fluids A
16 0114* antifreeze fluids containing dangerous substances M
16 01 15 antifreeze fluids other than those mentioned in 16 01 14
16 0116 tanks for liquefied gas
16 01 17 ferrous metal
160118 non-ferrous metal
16 0119 Plastic
16 0120 Glass
160121* hazardous components other than those mentioned in 16 01 07 to 16 01 11 and 16 01 13 M
and 16 01 14
16 0122 components not otherwise specified
16 0199
)
wastes not otherwise specified
16 02 w astes from  electrical and electron ic  equipm ent
16 02 09* transformers and capacitors containing PCBs M
16 02 10* discarded equipment containing or contaminated by PCBs other than those mentioned in 16 M
02 09
160211* discarded equipment containing chlorofluorocarbons, HCFC, HFC M
16 0212* discarded equipment containing free asbestos M
16 02 13* discarded equipment containing hazardous components 2 6  other than those mentioned in 16 M
02 09 to 16 02 12
26 Hazardous components from electrical and electronic equipment may include 
accumulators and batteries mentioned in 16 06 and marked as hazardous; mercury 
switches, glass from cathode ray tubes and other activated glass, etc.
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16 02 14 discarded equipment other than those mentioned in 16 02 09 to 16 02 13
1602 15':= hazardous components removed from discarded equipment A
16 02 16 components removed from discarded equipment other than those mentioned in 16 02 15
16 03 off-specification  batches and unused products
16 03 03':= inorganic wastes containing dangerous substances M
16 03 04 inorganic wastes other than those mentioned in 16 03 03
16 03 05=: organic wastes containing dangerous substances M
16 03 06 organic wastes other than those mentioned in 16 03 05
16 04 waste explosives
160401* waste ammunition A
16 04 02* fireworks wastes A
16 04 03* other waste explosives A
16 05 gases in pressure containers and discarded chem icals
16 05 04* gases in pressure containers (including halons) containing dangerous substances M
16 05 05 gases in pressure containers other than those mentioned in 16 05 04
16 05 06* laboratory chemicals, consisting of or containing dangerous substances, including mixtures 
o f laboratory chemicals
M
16 05 07* discarded inorganic chemicals consisting o f or containing dangerous substances M
16 05 08* discarded organic chemicals consisting o f or containing dangerous substances M
16 05 09 discarded chemicals other than those mentioned in 16 05 06, 16 05 07 or 16 05 08
16 06 batteries and accum ulators
16 06 0 1 lead batteries A
16 06 02* Ni-Cd batteries A
16 06 03* mercury-containing batteries A
16 06 04 alkaline batteries (except 16 06 03)
16 06 05 other batteries and accumulators
16 06 06* separately collected electrolyte from batteries and accumulators A
16 07 wastes from  transport tank, storage tank and barrel c leaning  
(except 05 and 13)
16 07 08* wastes containing oil M
16 07 09* wastes containing other dangerous substances M
16 07 99 wastes not otherwise specified
16 08 spent catalysts
16 08 01 spent catalysts containing gold, silver, rhenium, rhodium, palladium, irid ium  or platinum 
(except 16 08 07)
16 08 02* spent catalysts containing dangerous transition metalsgyor dangerous transition metal 
compounds
M
16 08 03 spent catalysts containing transition metals or transition metal compounds not otherwise 
specified
16 08 04 spent flu id catalytic cracking catalysts (except 16 08 07)
16 08 05* spent catalysts containing phosphoric acid M
27 For the purpose o f this entry, transition metals are: scandium, vanadium, manganese, cobalt, 
copper, yttrium, niobium, hafnium, tungsten, titanium, chromium, iron, nickel, zinc, zirconium, 
molybdenum and tantalum. These metals or their compounds are dangerous i f  they are classified 
as dangerous substances. The classification o f dangerous substances shall determine which among 
those transition metals and which transition metal compounds are hazardous.
16 08 06* spent liquids used as catalysts A
16 08 07* spent catalysts contaminated with dangerous substances M
16 09 oxidising substances
16 09 0 1 * permanganates, for example potassium permanganate A
16 09 02* chromâtes, for example potassium chromate, potassium or sodium dichromate A
16 09 03* peroxides, for example hydrogen peroxide A
16 09 04* oxidising substances, not otherwise specified A
16 10 aqueous liquid wastes destined for off-s ite  treatm ent
16 10 01 * aqueous liquid wastes containing dangerous substances M
16 10 02 aqueous liquid wastes other than those mentioned in 16 10 01
16 10 03* aqueous concentrates containing dangerous substances M
16 10 04 aqueous concentrates other than those mentioned in 16 10 03
16 11 w aste lin ings and refractories
16 11 01 * carbon-based linings and refractories from metallurgical processes containing dangerous M
substances
16 11 02 carbon-based linings and refractories from metallurgical processes others than those
mentioned in 16 11 01
16 11 03* other linings and refractories from metallurgical processes containing dangerous substances M
16 11 04 other linings and refractories from metallurgical processes other than those mentioned in 16
11 03
16 11 05* linings and refractories from non-metallurgical processes containing dangerous substances M
16 11 06 linings and refractories from non-metallurgical processes others than those mentioned in 16
11 05
17 CONSTRUCTION AND DEM OLITION W ASTES (INCLUDING
EXCAVATED SOIL FROM CONTAM INATED SITES)
17 01 concrete, bricks, tiles and ceram ics
17 01 01 concrete
17 01 02 bricks
17 01 03 tiles and ceramics
17 01 06* mixtures of, or separate fractions of concrete, bricks, tiles and ceramics containing M
dangerous substances
17 01 07 mixtures o f concrete, bricks, tiles and ceramics other than those mentioned in 17 01 06
17 02 wood, glass and plastic
17 02 01 wood
17 02 02 glass
17 02 03 plastic
17 02 04* glass, plastic and wood containing or contaminated with dangerous substances M
17 03 bitum inous m ixtures, coal tar and tarred products
17 03 01 * bituminous mixtures containing coal tar M
17 03 02 bituminous mixtures other than those mentioned in 17 03 01
17 03 03* coal tar and tarred products A
17 04 m etals (including their alloys)
17 04 01 copper, bronze, brass
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17 04 02 aluminium
17 04 03 lead
17 04 04 zinc
17 04 05 iron and steel
17 04 06 tin
17 04 07 mixed metals
17 04 09* metal waste contaminated with dangerous substances M
17 04 10* cables containing oil, coal tar and other dangerous substances M
17 0411 cables other than those mentioned in 17 04 10
17 05 soil (including excavated soil from  contam inated s ites), stones  
and dredging spoil
17 05 03* soil and stones containing dangerous substances M
17 05 04 soil and stones other than those mentioned in 17 05 03
17 05 05* dredging spoil containing dangerous substances M
17 05 06 dredging spoil other than those mentioned in 17 05 05
17 05 07* track ballast containing dangerous substances M
17 05 08 track ballast other than those mentioned in 17 05 07
17 06 insulation m aterials and asbestos-contain ing  construction  
m aterials
17 06 01* insulation materials containing asbestos M
17 06 03* other insulation materials consisting of or containing dangerous substances M
17 06 04 insulation materials other than those mentioned in 17 06 01 and 17 06 03
17 06 05* construction materials containing asbestos^ M
17 08 gypsum -based construction m aterial
17 08 01* gypsum-based construction materials contaminated with dangerous substances M
17 08 02 gypsum-based construction materials other than those mentioned in 17 08 01
17 09 other construction and dem olition wastes
17 09 01* construction and demolition wastes containing mercury
17 09 02* construction and demolition wastes containing PCB (for example PCB-containing sealants,
PCB-containing resin-based floorings, PCB-containing sealed glazing units, PCB- 
containing capacitors)
17 09 03* other construction and demolition wastes (including mixed wastes) containing dangerous
substances
17 09 04 mixed construction and demolition wastes other than those mentioned in 17 09 01,17 09 02
and 17 09 03
)
18 W ASTES FROM HUMAN OR ANIM AL HEALTH CARE AND/OR  
RELATED RESEARCH (except kitchen and restaurant w astes  
not arising from  im m ediate health care)
18 01 wastes from  natal care, d iagnosis, treatm ent or prevention of
disease in humans
18 0101 sharps (except 18 01 03)
28 As far as the landfilling o f waste is concerned, M em ber States may decide to postpone the entry 
into force o f this entry until the establishment o f appropriate measures for the treatment and 
disposal o f waste from  construction material containing asbestos. These measures are to be 
) established according to the procedure referred to in Article
17 o f Council Directive 1999/31/EC on the landfill o f waste (OJ L  182,16.7.1999,p. 1) and shall be 
adopted by 16 July 2002 at the latest.’
M
M
M
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18 01 02
18 01 03*
18 01 04
18 01 06*
18 01 07
18 01 08*
18 01 09
18 01 10*
18 02
18 02 01
18 02 02*
18 02 03
18 02 05*
18 02 06
18 02 07*
18 02 08
Body parts and organs including blood bags and blood preserves (except 18 01 03)
wastes whose collection and disposal is subject to special requirements in order to prevent A
infection
wastes whose collection and disposal is not subject to special requirements in order to 
prevent infection(for example dressings, plaster casts, linen, disposable clothing, diapers) 
chemicals consisting o f or containing dangerous substances M
chemicals other than those mentioned in 18 01 06
cytotoxic and cytostatic medicines A
medicines other than those mentioned in 18 01 08
amalgam waste from dental care A
w astes from  research, d iagnosis, treatm ent or prevention of 
disease involving anim als
sharps (except 18 02 02)
wastes whose collection and disposal is subject to special requirements in order to prevent A 
infection
wastes whose collection and disposal is not subject to special requirements in order to 
prevent infection
chemicals consisting o f or containing dangerous substances M
chemicals other than those mentioned in 18 02 05
cytotoxic and cytostatic medicines A
medicines other than those mentioned in 18 02 07
19 W ASTES FROM W ASTE MANAGEM ENT FACILITIES, O FF-SITE
WASTE W ATER TREATM ENT PLANTS AND THE PREPARATION  
OF WATER INTENDED FOR HUMAN CONSUM PTION AND  
WATER FOR INDUSTRIAL USE
19 01 w astes from  incineration or pyrolysis of waste
1901 02 ferrous materials removed from bottom ash
19 01 05* filter cake from gas treatment
19 01 06* aqueous liquid wastes from gas treatment and other aqueous liquid wastes
19 01 07* solid wastes from gas treatment
1901 10* spent activated carbon from flue-gas treatment
19 01 11* bottom ash and slag containing dangerous substances
1901 12 bottom ash and slag other than those mentioned in 19 01 11
1901 13* fly  ash containing dangerous substances
1901 14 fly  ash other than those mentioned in 19 01 13
19 01 15* boiler dust containing dangerous substances
19 01 16 boiler dust other than those mentioned in 19 01 15
1901 17* pyrolysis wastes containing dangerous substances
1901 18 pyrolysis wastes other than those mentioned in 19 01 17
1901 19 sands from fluidised beds
1901 99 wastes not otherwise specified
19 02 wastes from  physico/chem ical treatm ents of w aste (includ ing
dechrom atation, decyanidation , neutra lisation)
19 02 03 premixed wastes composed only o f non-hazardous wastes
19 02 04* premixed wastes composed o f at least one hazardous waste A
19 02 05* sludges from physico/chemical treatment containing dangerous substances M
19 02 06 sludges from physico/chemical treatment other than those mentioned in 19 02 05
19 02 07* oil and concentrates from separation A
19 02 08* liquid combustible wastes containing dangerous substances M
19 02 09* solid combustible wastes containing dangerous substances M
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19 0210 combustible wastes other than those mentioned in 19 02 08 and 19 02 09
19 02 11* other wastes containing dangerous substances M
19 02 99 wastes not otherwise specified
19 03 stab ilised /so lid ified  w astes 29
19 03 04* wastes marked as hazardous, partly 3 0  stabilised A
19 03 05 stabilised wastes other than those mentioned in 19 03 04
19 03 06* wastes marked as hazardous, solidified A
19 03 07 solidified wastes other than those mentioned in 19 03 06
19 04 vitrified  w aste and w astes from  v itrification
19 04 01 vitrified waste
19 04 02* fly ash and other flue-gas treatment wastes A
19 04 03* non-vitrified solid phase A
19 04 04 aqueous liquid wastes from vitrified waste tempering
19 05 w astes from  aerobic treatm ent of solid w astes
19 05 01 non-composted fraction of municipal and similar wastes
19 05 02 non-composted fraction of animal and vegetable waste
19 05 03 off-specification compost
19 05 99 wastes not otherwise specified
19 06 w astes from  anaerobic treatm ent of w aste
19 06 03 liquor from anaerobic treatment of municipal waste
19 06 04 digestate from anaerobic treatment of municipal waste
19 06 05 liquor from anaerobic treatment of animal and vegetable waste
19 06 06 digestate from anaerobic treatment of animal and vegetable waste
19 06 99 wastes not otherwise specified
19 07 landfill leachate
19 07 02* landfill leachate containing dangerous substances M
19 07 03 landfill leachate other than those mentioned in 19 07 02
19 08 w astes from  w aste w ater treatm ent p lants not otherw ise  
specified
19 08 01 screenings
19 08 02 waste from desanding
19 08 05 sludges from treatment of urban waste water
19 08 06* saturated or spent ion exchange resins A
19 08 07* solutions and sludges from regeneration of ion exchangers A
19 08 08* membrane system waste containing heavy metals M
19 08 09 grease and oil mixture from oil/water separation containing only edible oil and fats
19 08 10* grease and oil mixture from oil/water separation other than those mentioned in 19 08 09 A
29 Stabilisation processes change the dangerousness o f the constituents in the waste and thus 
transform hazardous waste into non-hazardous waste. Solidification processes only change the 
physical state o f the waste (e.g. liquid into solid) by using additives without changing the chemical 
properties o f the waste.
) so A  waste is considered as partly stabilised if, after the stabilisation process, dangerous
constituents which have not been changed completely into non-dangerous constituents could be 
released into the environment in the short, middle or long term.
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19 08 11* sludges containing dangerous substances from biological treatment of industrial waste 
water
M
19 08 12 sludges from biological treatment of industrial waste water other than those mentioned in 
19 08 11
19 08 13* sludges containing dangerous substances from other treatment of industrial waste water M
19 08 14 sludges from other treatment of industrial waste water other than those mentioned in 19 08 
13
19 08 99 wastes not otherwise specified
19 09 w astes from  the preparation of w ater intended fo r human  
consum ption or w ater for industria l use
19 09 01 solid waste from primary filtration and screenings
19 09 02 sludges from water clarification
19 09 03 sludges from decarbonation
19 09 04 spent activated carbon
19 09 05 saturated or spent ion exchange resins
19 09 06 solutions and sludges from regeneration of ion exchangers
19 09 99 wastes not otherwise specified
19 10 w astes from  shredding of m etal-contain ing w astes
19 1001 iron and steel waste
19 10 02 non-ferrous waste
19 10 03* fluff-light fraction and dust containing dangerous substances M
1910 04 fluff-light fraction and dust other than those mentioned in 19 10 03
19 10 05* other fractions containing dangerous substances M
19 10 06 other fractions other than those mentioned in 19 10 05
19 11 w astes from  oil regeneration
19 11 01* spent filter clays A
19 11 02* acid tars A
19 11 03* aqueous liquid wastes A
19 11 04* wastes from cleaning of fuel with bases A
19 11 05* sludges from on-site effluent treatment containing dangerous substances M
19 1106 sludges from on-site effluent treatment other than those mentioned in 19 11 05
19 11 07* wastes from flue-gas cleaning A
191199 wastes not otherwise specified
19 12 w astes from  the m echanical treatm ent of w aste (for exam ple
sorting, crushing, com pacting, pelletis ing) not o therw ise  
specified
19 12 01 paper and cardboard
1912 02 ferrous metal
19 12 03 non-ferrous metal
19 12 04 plastic and rubber
19 12 05 glass
19 12 06* wood containing dangerous substances M
19 12 07 wood other than that mentioned in 19 12 06
19 12 08 textiles
19 12 09 minerals (for example sand, stones)
19 12 10 combustible waste (refuse derived fuel)
19 12 11* other wastes (including mixtures of materials) from mechanical treatment of waste M
containing dangerous substances 
1912 12 other wastes (including mixtures of materials) from mechanical treatment of wastes other
than those mentioned in 19 12 11
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19 13 wastes from  soil and groundw ater rem ediation
19 13 01* solid wastes from soil remediation containing dangerous substances M
19 13 02 solid wastes from soil remediation other than those mentioned in 19 13 01
19 13 03* sludges from soil remediation containing dangerous substances M
19 13 04 sludges from soil remediation other than those mentioned in 19 13 03
19 13 05* sludges from groundwater remediation containing dangerous substances M
19 13 06 sludges from groundwater remediation other than those mentioned in 19 13 05
19 13 07* aqueous liquid wastes and aqueous concentrates from groundwater remediation containing 
dangerous substances
M
19 13 08 aqueous liquid wastes and aqueous concentrates from groundwater remediation other than 
those mentioned in 19 13 07
)
20 MUNICIPAL W ASTES (HOUSEHOLD W ASTE AND SIM ILAR
COM M ERCIAL, INDUSTRIAL AND INSTITUTIO NAL W ASTES) 
INCLUDING SEPARATELY COLLECTED FRACTIONS
20 01 separately collected fractions (except 15 01)
20 01 01 paper and cardboard
20 01 02 glass
20 01 08 biodegradable kitchen and canteen waste
20 01 10 clothes
20 01 11 textiles
2001 13* solvents A
20 01 14* acids A
2001 15* alkalines A
20 01 17* photochemicals A
2001 19* pesticides A
2001 21* fluorescent tubes and other mercury-containing waste A
20 01 23* discarded equipment containing chlorofluorocarbons M
20 01 25 edible oil and fat
20 01 26* oil and fat other than those mentioned in 20 01 25 A
20 01 27* paint, inks, adhesives and resins containing dangerous substances M
20 01 28 paint, inks, adhesives and resins other than those mentioned in 20 01 27
20 01 29* detergents containing dangerous substances M
20 01 30 detergents other than those mentioned in 20 01 29
2001 31* cytotoxic and cytostatic medicines A
20 01 32 medicines other than those mentioned in 20 01 31
20 01 33* batteries and accumulators included in 16 06 01, 16 06 02 or 16 06 03 and unsorted 
batteries and accumulators containing these batteries
A
20 01 34 batteries and accumulators other than those mentioned in 20 01 33
20 01 35* discarded electrical and electronic equipment other than those mentioned in 20 0121 and 
20 01 23 containing hazardous components^
M
20 01 36 discarded electrical and electronic equipment other than those mentioned in 20 01 21, 20 01 
23 and 20 01 35
20 01 37* wood containing dangerous substances M
20 01 38 wood other than that mentioned in 20 01 37
20 01 39 plastics
20 01 40 metals
20 01 41 wastes from chimney sweeping
20 01 99 other fractions not otherwise specified
2 3 7
20 02 garden and park w astes (including cem etery w aste)
20 02 01 
20 02 02 
20 02 03
20 03
20 03 01 
20 03 02 
20 03 03 
20 03 04 
20 03 06 
20 03 07 
20 03 99
biodegradable waste 
soil and stones
other non-biodegradable wastes
other m unicipal w astes
mixed municipal waste 
waste from markets 
street-cleaning residues 
septic tank sludge 
waste from sewage cleaning 
bulky waste
municipal wastes not otherwise specified
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Appendix C Categorisation of Biological Agents
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Advisory Committee on Dangerous Pathogens
The Advisory Committee on Dangerous Pathogens was appointed by the 
Health and Safety Commission as part of its formal advisory structure. 
The guidance presented by the ACDP is considered to be good practice 
and to represent minimum compliance with the law (ACDP, 1995*).
The categorisation of biological agents by the ACDP incorporates the 
requirements of the European Directives 90/679/EEC and 89/391/EEC 
relating to the protection of workers from risks related to exposure to 
biological agents at work. The UK Advisory Committee on Dangerous 
Pathogens categorises biological agents (pathogens) into 4 groups, based 
on their availabil ity  to cause disease by infection, the severity of the 
disease caused and the availabil ity  of prophylactic (preventative) 
treatment. The four groups, known as Hazard Groups, are shown below:
ACDP Hazard Group criteria: 
Hazard Group 1
A biological agent unlikely to cause human disease.
Hazard Group 2
A biological agent that can cause human disease and presents a hazard to 
employees; it is unlikely to spread to the community and there is usually 
prophylaxis or effective treatment available.
Hazard Group 3
A biological agent that can cause severe human disease and presents a 
serious hazard to employees; it is likely to spread to the community, but 
there is usually prophylaxis or treatment available.
Hazard Group 4
A biological agent that causes serve human disease and is a serious 
hazard to employees; it is likely to spread to the community and there is 
usually no effective prophylaxis available.
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The ACDP publish an ‘Approved List’ in which biological agents are listed 
according to their ability to cause disease by infection. Only agents in 
Groups 2, 3 and 4 are listed. Those not listed in these groups are not 
implic itly c lassified as Group 1.
In allocating agents to a Hazard Group in the Approved List, no account is 
taken of particular effects on those whose susceptib il ity  to infection may 
be affected for one or other reasons such as pre-existing disease, 
medication and compromised immunity.
Exam ples of B iological Agents in Hazard Groups 2, 3 and 4 :
Hazard Group 2
C am pylobacte r spp 
Escherich ia  co li 
Legionella  spp 
Salm onella enteritid is  
Streptococcus  spp 
Influenza types A, B and C 
Herpes Simplex types 1 and 2
Measles 
Mumps 
Hepatitis A 
Rubella
C ryptosporid ium  spp
Hazard Group 3
Escherich ia  co li 0157
M ycobacterium  tubercu losis  Rabies
W *  Bovine eoongiiorm
S Œ 'S S  tS
Creutzfe ldt-Jakob disease
Hazard Group 4
Lassa fever Ebola
Congo Haemorrhagic fever Equine morbilliv irus
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Appendix D ST A ATT Microbial Inactivation 
Standards.
In the absence of International standards for the treatment of infectious 
waste, reference is made to the treatment levels identif ied in the USA, by 
the State and Territoria l Association on Alternative Treatment 
Technologies (STAATT).
The STAATT guidance was orig inally published in April 1994 and was 
written with the intention of standardising the assessment criteria for 
infectious waste treatment technologies throughout all US States. The 
STAATT guidance took 18 months to write and involved 27 agencies from 
21 USA States, five federal agencies, two Canadian Ministries and a 
consultant (Turnberg, 1996).
Table 31 shows the four levels of microbial inactivation for infectious 
waste published by STAATT. The minimum required microbial inactivation 
for clinical waste treatment plants in the UK must be equivalent to STAATT 
III or greater.
Table 31 STAATT microbial inactivation levels.
Level I
Inactivation of vegetat ive  bacteria, fungi and l ipophi l l ic  v iruses at a 6 log-m 
reduction or greater.
Level II
Inactivat ion of vegetat ive  bacteria, fungi, l ipoph i l ic /hydroph i l ic  viruses, parasites 
and m ycobacteria  at a 6 logio Reduction or greater.
Level III
Inact ivat ion of vegetat ive  bacteria, fungi, l ipoph i l ic /hydroph i l ic  v iruses, parasites 
and mycobacterium at a 6 logio reduction or greater; and inactivation of B. 
s tearo therm oph ilus  or B. Subti l is  spores at a 4 logio reduction or greater.
Level IV
Inactivation of vegetat ive bacter ia, fungi, l ipoph i l ic /hydroph i l ic  v iruses parasites 
and m ycobacteria  and B. s trearo therm oph ilus  spores at a 6 logio reduction or 
greater.
Source: (Turnberg, 1996)
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Appendix E Healthcare Waste Guidance
E1 British Standards Institu tion , 1973/87
Table 32 BSI (1973/87) classification of hospital waste
Class A: Ward Waste
(1) Ward and sanitary dressings, general ward waste such as f lowers.
(2) D isposable  paper art ic les and floor sweepings, excluding uncontam inated tins, 
bott les, food wastes, p lastics and d isposab le  bedpans.
Class B Plastic Materials and Dirty Paper
(1) D isposable syringes, petri d ishes and s im ilar art ic les.
(2) P last ic ised paper, food w rapp ings and plastic cups.
Class C Theatre and Laboratory Waste
(1) operating theatre waste and human tissue.
(2) D isposable  theatre garm ents and p laster casts.
(3) Pathological wastes, specimens and animals.
Class D Maternity Waste
(1) P lacentae and matern ity dressings.
(2) D isposable  napkins and general m atern ity  waste excluding uncontam inated  tins, 
bott les, food wastes, plastics and d isposab les bedpans.
Source: (BSI, 1987)
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E2 Health Service Advisory Committee 1982
Table 33 HSAC (1982) categorisation of clinical waste
Group A
Soiled surgical dressings, swabs and all other contaminated waste from 
treatment areas;
Material other than linen from cases of infectious disease and;
All human tissue (whether infected or not), animal carcasses and tissues from 
laboratories and all related swabs and dressings._______________________________
Group B
Discarded syringes, needles, cartridges, broken glass and other sharp 
instruments.___________________________________________________________________
Group C
Laboratory and post mortem waste other than waste included in Group A._______
Group D
Certain pharmaceutical and chemical wastes (those falling within the definition 
of clinical waste).______________________________________________________________
Group E
Used disposable bedpans liners, urine containers, incontinence pads and stoma 
bags.__________________________________________________________________________
Source: (HSAC, 1982)
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E3 London Waste Regulation Authority, 1989
Table 34 London W aste Regulation Authority (1989) classification of healthcare w aste.
1. Soiled surgical dressings, swabs and instruments.
2. Materials other than linen from infectious disease cases.
3. All human and animal tissue and excretions, including blood, whether infected or 
not.
4. Discarded syringes, needles, cartridges, broken glass and other sharp surgical 
instruments, which have been in contacted with the materials listed in 1, 2 and 3.
5. Pharmaceutical and chemical products utilised for treatment purposes.
6. Used disposable bedpans liners, urine containers, incontinence pads, sanitary 
towels, and any other items contaminated as in 3.
Source: (LWRA, 1989)
2 4 8
E4 Health Services Advisory Committee 1992.
Table 35 HSAC (1992) categorisation of clinical waste
Group A
All human tissue, including blood (whether infected or not), animal carcasses and tissue 
from veterinary centres, hospitals or laboratories, and all related swabs and dressings.
Waste materials, where the assessment indicates a risk to staff handling them, for 
example, from infectious disease cases.
Soiled surgical dressings, swabs and other soiled waste from treatment areas.
Group B
Discarded syringe needles, cartridges, broken glass and any other contaminated 
disposable sharp instruments or items.
Group C
Microbiological cultures and potentially infected waste from pathology departments 
(laboratory and post mortem rooms) and other clinical or research laboratories.
Group D
Certain pharmaceutical products and chemical wastes.
Group E
Items used to dispose of urine, faeces and other bodily secretions or excretions 
assessed as not falling within Group A. This includes used disposable bed pans or bed 
pans liners, incontinence pads, stoma bags, and urine containers.
It will be apparent that Group E contains items which usually present a low level of risk. 
However, as the actual risk cannot be readily demonstrated, items within this group 
should be treated as clinical waste taking into account local circumstances.
Source: (HSAC, 1992)
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E5 Health Services Advisory Committee 1999.
Table 36 HSAC (1999) categorisation of clinical waste
Group A
Includes the following items: identifiable human tissue, blood, animal carcasses and 
tissue from veterinary centres, hospitals or laboratories.
Soiled surgical dressings, hospitals or laboratories.
Other waste materials, for example from infectious disease cases, excluding any in 
Groups B-E.
Group B
Discarded syringes needles, cartridges, broken glass and any other contaminated 
disposable sharp instruments or items.
Group C
Microbiological cultures and potentially infected waste from pathology departments and 
other clinical or research laboratories.
Group D
Drugs or other pharmaceutical products.
Group E
Items used to dispose of urine, faeces and other bodily secretions or excretions 
assessed as not falling within Group A. This includes used disposable bed pans or bed 
pan liners, incontinence pads, stoma bags, and urine containers.*
* Where the risk assessment shows there is no infection risk, Group E wastes are not clinical 
waste as defined.
Source: (HSAC, 1999)
E6 NHSScotland Property and Environm ent Forum. 2002
Figure 20 on the following page shows the NHSScotland classif ication flow 
diagram.
Source: (NHSScotland, 2002)
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Appendix F Analysis of Municipal Solid Waste 
(MSW)
)
)
)
253
Table 37 summarises the results of a Municipal Solid Waste (MSW) analysis as 
part of the National Household Waste Analysis Programme Pilot Study in Wales. 
The study was conducted for the National Assembly for Wales by ABA 
Technology.
Table 37 Municipal solid waste (MSW) analysis, composition by weight
Material Percentage (%) by Weight
Newspapers & magazines 8.7%
Other recyclable paper 4.0%
Card packaging 7.8%
Other paper 5.1%
Plastic film 3.2%
Dense plastic packaging 3.3%
Other dense plastic 0.8%
Textiles 2.2%
Other combustibles 12.1%
Glass 6.2%
Compostable kitchen waste 7.9%
Garden waste 10.3%
Soil & other putrescibles 10.6%
Ferrous cans 1.7%
Other ferrous metals 2.8%
Non-ferrous metals 1.0%
WEEE 2.9%
Potentially hazardous 0.4%
Fines 3.7%
DIY & other combustibles 5.1%
Source: (ABA Technology, 2002)
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Appendix G Introduction To Common 
Pathogens
This basic introduction to common pathogen groups is adapted from the 
Domain Knowledge Guide for the NEBOSH (Health and Safety) Diploma 
Part 2 (Act, 2002).
Most biological agents are micro-organisms, of which there are three basic 
groups:
1. Bacteria;
2. Viruses;
3. Fungi.
Fungus -  any of a group of unicellular, multi-cellular or multinucleate non­
photosynthetic organisms which feed on organic matter, which include 
yeast, moulds, mushrooms and toadstools. They are simple, parasitic life 
forms with more than 100,000 different species. Most are harmless; 
however, a number of fungi can cause fatal disease and illness in humans. 
Many fungi form minute bodies called spores, which are like seeds. The 
spores can be carried in air and, if they settle in a suitable location with 
nutrients available, will grow.
Fungi can cause disease in a variety of ways. The fruiting bodies may 
contain toxins which may be poisonous. Inhaled spores of some fungi can 
cause an allergic reaction. Some fungi are able to invade and form 
colonies in the lungs, in the skin, beneath the skin, or in various tissues 
throughout the body. This can lead to conditions ranging from mild skin 
irritation to severe, sometime fatal, w idespread infection and illness.
Bacteria -  a group of s ingle-celled micro-organisms, some of which cause 
disease. They are commonly known as ‘germ s’ and have been recognised 
as a cause of disease for over a century. Most bacteria are harmless to 
humans and some are beneficia l. Bacteria that cause disease in humans 
are known as pathogens.
Bacteria can enter the body through the lungs if droplets that are breathed, 
coughed or sneezed out by an infected person are inhaled. They can 
infect the digestive tract if contaminated food is eaten. Bacteria can enter 
the genito-urinary system. They can also penetrate the skin through 
various ways: through hair fo llicles, cuts and abrasions, and through deep 
wounds.
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Bacteria cause disease because they produce toxins that are harmful to 
human cells. If they are present in suffic ient quantit ies and the affected 
person is not immune, they will cause disease.
Some bacteria release endotoxins, which cause fever, haemorrhage and 
shock. Others produce exotoxins, which account for the damage done in 
d iseases such as d iphtheria, tetanus and tox ic-shock syndrome.
Viruses -  are the smallest known types of infectious agent. They are 
about one half to one hundredth the size of the smallest bacteria. Their 
sole activ ity is to invade the cells of other living organisms, which they 
take over to make copies of themselves. Outside living cells, they are 
tota lly  inert. There are probably more types of virus than the number of 
types of all other organisms. They parasitise all recognised life forms, and 
while not all cause disease, many of them do. Infections caused by 
viruses range from the common cold to serious d iseases such as rabies, 
and can lead to the development of AIDS and various cancers.
Viruses gain entry to the body through all possible routes. They are 
inhaled in droplets; swallowed in food and liquids; passed through 
punctured skin on infected needles, in the salvia of feeding insects or 
rabid dogs. V iruses are accepted directly by the mucous membranes of 
the genital tract and by the conjunctiva of the eye.
Many viruses invade cells and multip ly near their site of entry. Some enter 
the lymphatic vessels and spread to the lymph nodes. Some, such as the 
HIV virus, invade the lymphocytes (a type of white cell). Many pass from 
the lymphatic system to the blood and are quickly carried to every part of 
the body. They may invade specific target organs, such as the liver, 
lungs, brain, and start to multiply. Some viruses travel a long the nerve 
fibres to their target organs.
Viruses can cause disease in a variety of waste:
♦ They can destroy or d isrupt the cells they invade, causing serious 
illness if it is a vital organ;
♦ The response of the body ’s immune system may lead to fever and 
fatigue;
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♦ Anti-bodies produced by the immune system may attach to viral 
particles and be circulated in the blood. The antibodies may then 
be deposited in various parts of the body causing inflammation and 
tissue damage;
♦ They may interact with the chromosomes of the host cells causing 
cancer;
♦ They may weaken the activity of the T-lymphocytes and so 
interfere with the immune system, the body ’s normal defences 
against a whole range of infections.
Source: (ACT, 2002).
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Appendix H Examples Of Infections Caused By 
Exposure to Healthcare Waste.
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Table 38 shows examples of infections caused by exposure to healthcare 
waste.
Table 38 Examples of infections caused by exposure to healthcare waste.____________
Type of Infection Examples of Causative 
Organisms
Transmission Vehicle
Gastroenteric infections Enterobacteria, e.g 
Salmonella, Sheigella  spp.; 
vibrio cholerae, helminths
Faeces and/or vomit
Respiratory infections Mycobacterium  
tuberculosis; measles virus; 
Streptococcus pneumoniae
Inhaled secretions; saliva
Ocular infection Herpesvirus Eye secretions
Genital infections Neisseria gonorrhoeae; 
herpesvirus
Genital secretions
Skin infections Streptococcus spp. Pus
Anthrax Bacillus anthracis Skin secretions
Meningitis Neisseria m eningitidis Cerebrospinal fluid
Acquired Immunodeficiency 
Syndrome (AIDS)
Human immunodeficiency 
virus (HIV)
Blood, sexual secretions
Haemorrhagic fevers Junin, Lassa, Ebola and 
Marbug viruses
All blood products and 
secretions
Septicaemia Staphylococcus spp. Blood
Bacteraemia Coagulase-negative 
Staphylococcus spp. 
Staphylococcus aureus; 
Enterbacter, Enterococcus, 
Klebsiella  and 
Streptococcus spp
Blood
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Table 38 continued
Candidaem ia Candida albicans Blood
Viral hepatit is  A Hepatit is  A virus Faeces
Viral hepatit is  B and C Hepatit is  B and C viruses Blood and bodi ly  flu ids
Source: (Prüss et al, 1999)
)
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Appendix I Prevalence of Selected Blood Borne 
Infections
263
Table 39 Hepatitis B (HBV) notifications (England and Wales)
Year Total (Notifications) Year Total (Notifications)
1990 435 1997 730
1991 488 1998 886
1992 489 1999 864
1993 581 2000 1035
1994 528 2001 1028
1995 623 2002 1073
1996 613
Source: (HPA, 2003a)
Table 40 Hepatitis C (HCV) notifications (England and Wales)
Year Total (Notifications) Year Total(Notifications)
1992 241 1998 4483
1993 435 1999 5745
1994 829 2000 5236
1995 1167 2001 4885
1996 2544 2002* 5917
1997 3058
*
Provisional data 
Source: (HPA, 2003a)
).
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Table 41 Human Immunodeficiency Virus (HIV) notifications (United Kingdom)
Year Total (Notifications) Year Total(Notifications)
1992 or earlier* 22 236 1998 28 14
1993 2620 1999 30 67
1994 2 5 74 2000 38 20
1995 2651 2001 4 9 7 4
1996 2691 2002* 55 42
1997 2 7 35 Total Number of 
notified cases in 
UK.
55, 724
s u rv e i l la n c e  b e g a n  in 1982  
S o u rc e :  (H P A , 2 0 0 3 b)
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Appendix J Infection Pathways for Selected 
Hospital Acquired Infections.
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The fo llow ing tab les are based on em pirica l data from a num ber of 
sources, w ith a number of assum ptions about the v iab ility  of the pathogen 
in the environm ent and suscep tib ility  of the host.
Table 42 Respiratory infections
Pathogen Summary Infection
Pathway
Total viable 
count of 
Organisms per 
gram to initiate  
infection.
Significant risk 
in infectious  
waste ?
Asperillus
spp
Ubiquitous
fungus,
sporeform in
9-
Airborne 
( inhalat ion); 
also contact 
t ransm iss ion.
2 x 103 NO
(Common 
contam inant -  
reservoirs  
aspergiiius  
fumigates 
natura lly 
occurr ing in the 
env ironment)
Mycobacterium
tuberculosis
Infectious 
d isease that 
attacks the 
lungs.
Aero l isa t ion of 
bacter ia ( inha la t 
ion)
accurate 
methods of 
measuring the 
concentra tion of 
infectious 
droplet nuclei in 
a room have not 
been deve loped
NO
Majority  of 
popula t ion 
vacc ina ted  with 
BCG. However, 
there are 
publ ished 
reports of a 
waste opera tor 
being in fected in 
USA.
Source: (Johnson, 2000); (Horton etal, 2002), (Albright, 2001), (Center for Disease 
Control, 1999), (Sprenger, 1997)
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Table 43 G astroenteric  infections
Pathogen Summary Infection
Pathway
Total viable  
count of 
Organisms per 
gram to initiate  
infection.
Significant risk 
in infectious  
waste ?
Clostridium
diffic ile
Spore 
forming 
bacil lus 
responsib le 
for the 
deve lopm ent 
of antib iot ic- 
associated 
d iarrhoea 
and colit is.
C. d iffic ile  
forms heat- 
resistant 
spores that 
can persist in 
the
env ironment 
for several 
months to 
years.
Ingestion
(Faecal -O ra l  
route)
NO
Availab le  in 
natural 
environment. 
Infection 
requires 
d isruption of 
the normal 
bacter ia  flora of 
the colon.
Escherichia
coli
Gram- 
negative 
bacill i  
occuring ly  
s ingly or in 
pairs. 
Facultative 
anaerob ic 
metabolism. 
E co li is a 
major 
facultat ive 
inhabitant of 
the large 
intestine.
Contact
and
Ingestion
(Faecal -O ra l  
route and may 
be food 
associa ted).
Greater than 
100
?
Variab le  in ‘fresh 
w a s te ’ however 
str ic t a ttention to 
personal and 
env ironmenta l 
hygiene wil l 
prevent 
infection.
Source: (Horton etal, 2002), (Albright, 2001), (Centerfor Disease Control, 1999), 
(Sprenger, 1997)
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Table 44 Skin infections
Pathogen Summary Infection Pathway Total viable 
count of 
Organisms 
per gram to 
initiate  
infection.
Significant risk 
in infectious  
waste ?
Klebsiella  spp. Gram-
negative
bacillus.
Ubiquitous 
colonise 
skin, 
pharynx, or 
gastro in tes 
tinal tract.
Klebsiella  
may be 
regarded 
as normal 
flora in 
many parts 
of the 
colon and 
intestinal 
tract.
Contact and 
contam inated 
invasive devices 
and resp ira tory 
support equ ipment.
Greater than 
100
NO
A vailab le  in 
natural 
env ironm ent 
and are 
cons idered 
normal flora of 
the body.
Strict a ttention 
to personal and 
environm enta l 
hygiene will 
p revent 
in fection.
Staphylococcus
spp.
Gram-
positive
bacterium.
Can 
w ithstand 
desiccation 
and is thus 
a frequent 
component 
of hospital 
dust.
Contact ?
str ict a ttent ion to 
personal and 
environm enta l 
hygiene will 
p revent 
infection.
Multip le 
res is tance to 
antib iot ics is of 
concern (MRSA)
Source: (Horton etal, 2002), (Albright, 2001); (Center for Disease Control, 1999), 
(Sprenger, 1997), (Perry, 2001), (Williams, 2003)
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Table 45 Blood Borne infections
Pathogen Summary Infection
Pathway
Total viable 
count of 
Organisms per 
gram to 
initiate  
infection.
Significant 
risk in 
infectious  
waste ?
Hepatitis B 
Virus
(HBV)
HBV is a 
Hepadna 
virus. HBV 
is resistant 
to extreme 
tem pera ture  
s and 
humidity. It 
can survive 
for 6 months 
at room 
tem pera ture  
and 7 days 
at 44QC.
Blood, infectious 
bodily fluids.
Data per gram 
not available.
Less than 0.04 
pL (10'8) of 
infected blood 
required to 
init ia te infection 
fol lowing 
needle-stick 
injury.
YES
Risk posed by 
l iquid blood 
and in fectious 
bodily  fluids.
Most 
s ign if icant risk 
presented by 
sharps.
Human 
Immunodefic ie  
ncy Virus 
(HIV)
HIV is an 
unstable 
v irus and 
ceases to be 
v iable within 
hours of 
leaving host.
Blood, infectious 
bodily fluids.
Data per gram 
not available.
Less than 100 
pL (10'4) of 
infected blood 
required to 
in it ia te infection 
fo l lowing 
needle-stick 
injury.
YES
Risk posed by 
l iquid blood 
and infectious 
bodi ly  f luids.
Most 
s ign if ican t risk 
presented by 
sharps.
Source: (Horton etal, 2002), (Albright, 2001), (CDC, 1999), (Sprenger, 1997), (Perry, 
2001), (Napoli etal, 1987), (PHLS, 1999), (Slade etal, 1989).
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Appendix K Microbial Characteristics of Human 
Hygiene Waste.
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The data in th is section orig inated from the m icrob io log ica l exam ination of 
bagged human hygiene waste co llected by Personal Hygiene Services 
(PHS) Ltd from ladies lavatories in public, industria l, retail and leisure 
prem ises, representing a broad com m unity spectrum .
Samples of waste were removed and the waste was d ilu ted and pulverised 
and spread over the surface of agar p lates. The plates were incubated for 
48 hours and co lony-form ing units were counted and recorded. The 
results are shown in Table 46.
Table 46 Total viable count (cfuVgram) of bagged human hygiene
Sample Material Total Viable Count (cfu*/gram)
Sanitary Towel 5.0 x 107
Sanitary Towel 5.7 x 105
Sanitary Towel 4.9 x 107
Sanitary Towel 9.1 x 109
Sanitary Towel 5.0 x 107
Sanitary Towel 5.0 x 107
Tampon 1.4 x 109
Tampon 2.8 x 108
Tampon 7.3 x 106
Nappy 3.9 x 108
Nappy 3.7 x 105
Nappy 2.8 x 107
*cfu= co lony form ing units.
Source: (W impey, 1995)
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Table 47 Bacterial isolates from bagged human hygiene
Bacteria l isolates included the fo llow ing: 
Staphylococcus  spp.
Escherichia coli 
Proteus mirabilis  
Morganella morganii 
Proteus vulgaris 
Pseudomonas aeruginosa  
Bacillus  spp.
Citrobacter freundii 
Acinetobacter  spp
Source: (W impey, 1995)
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Appendix L NHSScotland Clinical Waste Data
277
The following data was provided by NHSScotland Property and Environment 
Forum. The data was collated for inclusion in the 2000-2001 NHSScotland 
Environment Report. The data shows the amount of clinical waste produced by 
hospital site and by care group.
Table 48 NHSScotland Trusts
Key of Trust Name Abbreviations
Trust Abbrevia tion
Used
Argyll & Clyde Acute Hospitals NHS Trust ACAHT
Ayrshire and Arran Primary Care Trust AAPCT
Ays hi re & Arran Acute Hopitals NHS Trust AAAHT
Borders General Hospital NHS Trust BGHT
Borders Primary Care NHS Trust BPCT
Dumfries & Galloway Acute & Maternity DGAM
Dumfries & Galloway Primary Care NHS Trust DGPCT
Fife Acute Hospitals NHS Trust FAHT
Fife Primary Care NHS Trust FPCT
Forth Valley Acute FVAHT
Forth Valley Primary Care NHS Trust FVPCT
Grampian Primary Care NHS Trust GPCT
Grampian University Hospitals NHS Trust GUHT
Greater Glasgow Primary Care NHS Trust GGPCT
Highland Acute Hospitals NHS Trust HAHT
Highland Primary Care NHS Trust HPCT
Lanarkshire Acute Hospitals NHS Trust LANAHT
Lanarkshire Primary Care NHS Trust LANPCT
Lomond & Argyll Primary Care NHS Trust LAPCT
Lothian Primary Care NHS Trust LPCT
Lothian University Hospitals NHS Trust LUHT
North Glasgow University Hospitals NHS Trust NGUHT
Orkney Health Board OHB
Renfrew & Inverclyde Primary Care NHS Trust RIPCT
Shetland Health Board SHB
South Glasgow University Hospitals NHS Trust SGUHT
Tayside Primary Care NHS Trust TPCT
Tayside University Hospitals NHS Trust TUHT
The State Hospital THS
West Lothian Healthcare NHS Trust WLHT
Western Isles Health Unit WIHU
Yorkhill NHS Trust YT
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Table 49 NHSScotland clinical waste data for major acute hospitals 2000-2001.
Major Acute Hospitals (carecroup d
Trust Hospital Hospital Name Clinical Number of tonnes/ Heated tonnes /
Code Waste
Tonnage
Beds bed Volume
(100m3)
100m3
Argyll & Clyde Acute Hospitals NHS Trust C313H Inverclyde Royal Hospital 198.00 489 0.40 1077 0.18
Argyll & Clyde Acute Hospitals NHS Trust C418H Royal Alexandra Hospital 307.00 600 0.51 1709 0.18
Argyll & Clyde Acute Hospitals NHS Trust C206H Vale Of Leven Hospital 166.00 350 0.47 756 0.22
Ayshire & Arran Acute Hopitals NHS Trust A210H Ayr Hospital 162.00 350 0.46 1030 0.16
Ayshire & Arran Acute Hopitals NHS Trust A103H Ayrshire Central Hospital 138.00 312 0.44 1122 0.12
Ayshire & Arran Acute Hopitals NHS Trust A111H Crosshouse Hospital 315.00 622 0.51 1587 0.20
Borders General Hospital NHS Trust B026H Borders General Hospital 95.00 354 0.27 970 0.10
Dumfries & Galloway Acute & Maternity Y104H Dumfries & Galloway Royal Infirmary 102.10 386 0.26 1394 0.07
Fife Acute Hospitals NHS Trust F805H Queen Margaret Hospital 250.96 400 0.63 1078 0.23
Fife Acute Hospitals NHS Trust F704H Victoria Hospital 168.63 304 0.55 976 0.17
Forth Valley Acute V102H Falkirk & District Royal Infirmary 263.79 557 0.47 1297 0.20
Forth Valley Acute V201H Stirling Royal Infirmary 238.32 497 0.48 1109 0.21
Grampian Primary Care NHS Trust N103H City Hospital (Grampian) 22.71 45 0.50 159 0.14
Grampian University Hospitals NHS Trust N411H Dr. Grays Hospital 72.00 242 0.30 590 0.12
Grampian University Hospitals NHS Trust N121H Royal Aberdeen Children's Hospital 50.43 108 0.47 421 0.12
Grampian University Hospitals NHS Trust N102H Woodend Hospital 144.37 451 0.32 1182 0.12
Highland Acute Hospitals NHS Trust H202H Raigmore Hospital 233.71 600 0.39 1566 0.15
Lanarkshire Acute Hospitals NHS Trust L302H Hairmyres Hospital 246.00 488 0.50 1100 0.22
Lanarkshire Acute Hospitals NHS Trust L106H Monklands Hospital 260.66 560 0.47 1318 0.20
Lanarkshire Acute Hospitals NHS Trust L304H Stonehouse Hospital 350.00 560 0.63 1318 0.27
Lanarkshire Acute Hospitals NHS Trust L500H Wishaw General 20.05 99 0.20 477 0.04
Lothian Primary Care NHS Trust S201H Astley Ainslie Hospital 114.09 278 0.41 535 0.21
Lothian Primary Care NHS Trust S105H Eastern General Hospital 15.81 69 0.23 502 0.03
Lothian University Hospitals NHS Trust S204H City Hospital (Edinburgh) 54.36 26 2.09 338 0.16
Lothian University Hospitals NHS Trust S212H Princess Margaret Rose Hospital 40.63 78 0.52 546 0.07
Lothian University Hospitals NHS Trust S225H Royal Hospital For Sick Children 90.50 173 0.52 663 0.14
North Glasgow University Hospitals NHS Trust G102H Canniesburn Hospital 97.38 132 0.74 640 0.15
North Glasgow University Hospitals NHS Trust G504H Gartnavel General Hospital 517.35 628 0.82 1256 0.41
North Glasgow University Hospitals NHS Trust G207H Stobhill Hospital 429.55 629 0.68 2566 0.17
South Glasgow University Hospitals NHS Trust G405H Southern General Hospital 540.00 954 0.57 2699 0.20
South Glasgow University Hospitals NHS Trust G306H Victoria Infirmary 300.38 475 0.63 1457 0.21
Tayside University Hospitals NHS Trust T104H Kings Cross Hospital 167.94 46 3.65 388 0.43
Tayside University Hospitals NHS Trust T202H Perth Royal Infirmary 164.25 281 0.58 1230 0.13
Tayside University Hospitals NHS Trust T312H Stracathro Hospital 167.94 53 3.17 797 0.21
West Lothian Healthcare NHS Trust S308H St. John's Hospital 237.02 530 0.45 1598 0.15
Western Isles Health Unit W107H Western Isles Hospital 89.55 212 0.42 392 0.23
Yorkhill NHS Trust G513H Royal Hospital For Sick Children Yorkhill 246.00 259 0.95 1224 0.20
AVERAGE 191.28 356.68 0.69 1055.86 0.18
TOTAL 7077.46 13197 39067
279
Figure 21 NHSScotland clinical waste data for major acute hospitals 2000-2001.
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Table 50 NHSScotland clinical waste data for elderly hospitals 2000-2001.
Elderly Hospitals (care croup 2)
Trust Hospital Hospital Name Clinical Waste Number of tonnes / bed Heated Volume tonnes
Code Tonnage Beds (100m3) /100m3
Ayrshire And Arran Primary Care Trust A206H Holmhead Hospital 7.25 56 0.13 63 0.12
Ayrshire And Arran Primary Care Trust A105H Kirklandside Hospital 68.50 95 0.72 107 0.64
Ayshire & Arran Acute Hopitals NHS Trust A208H Biggart Hospital 41.00 167 0.25 215 0.19
Borders Primary Care NHS Trust B007H Crumhaugh House 12.85 36 0.36 51 0.25
Borders Primary Care NHS Trust B012H Hay Lodge Hospital 12.07 46 0.26 107 0.11
Dumfries & Galloway Primary Care NHS Trust Y120H Annan Hospital 13.47 30 0.45 47 0.29
Dumfries & Galloway Primary Care NHS Trust Y108H Lochmaben Hospital 7.63 17 0.45 32 0.24
Dumfries & Galloway Primary Care NHS Trust Y105H Nithbank Hospital 10.78 24 0.45 97 0.11
Fife Primary Care NHS Trust F716H Glenrothes Hospital 4.03 62 0.07 87 0.05
Forth Valley Primary Care NHS Trust V202H Bannockburn Hospital 26.77 94 0.28 114 0.23
Forth Valley Primary Care NHS Trust V107H Bonnybridge Hospital 28.64 87 0.33 121 0.24
Forth Valley Primary Care NHS Trust V203H Kildean Hospital 14.30 30 0.48 66 0.22
Forth Valley Primary Care NHS Trust V205H Sauchie Hospital 37.23 70 0.53 157 0.24
Grampian Primary Care NHS Trust N353H Campbell - Portsoy Hospital 7.23 26 0.28 51 0.14
Grampian Primary Care NHS Trust N453H Spynie Hospital 19.44 60 0.32 91 0.21
Grampian Primary Care NHS Trust N352H Ugie Peterhead Hospital 10.50 44 0.24 55 0.19
Grampian University Hospitals NHS Trust N161H Aberdeen Maternity Hospital 81.94 144 0.57 344 0.24
Highland Primary Care NHS Trust H219H County Hospital 0.00 44 - 149 -
Highland Primary Care NHS Trust H701P New Craigs 0.00 214 - 374.22 -
Highland Primary Care NHS Trust H201H Royal Northern Infirmary 0.00 30 - 329
Lanarkshire Primary Care NHS Trust L203H Cleland Hospital 56.16 124 0.45 231 0.24
Lanarkshire Primary Care NHS Trust L103H Coathill Hospital 18.72 96 0.20 264 0.07
Lanarkshire Primary Care NHS Trust L213H Strathclyde Hospital 18.72 68 0.28 295 0.06
Lanarkshire Primary Care NHS Trust L105H Wester Moffat Hospital 24.96 60 0.42 91 0.27
Lomond & Argyll Primary Care NHS Trust C204H Dumbarton Joint Hospital 15.00 60 0.25 107 0.14
Lothian Primary Care NHS Trust S102H Belhaven Hospital 12.14 53 0.23 78 0.16
Lothian Primary Care NHS Trust S103H Corstorphine Hospital 37.35 91 0.41 122 0.31
Lothian Primary Care NHS Trust S209H Liberton Hospital 41.92 183 0.23 259 0.16
Lothian Primary Care NHS Trust 8327V Murraypark Nursing Home 7.39 18 0.41 19 0.39
Lothian University Hospitals NHS Trust S114H Royal Victoria Hospital 87.43 250 0.35 641 0.14
North Glasgow University Hospitals NHS Trust G501H Blawarthill Hospital 33.02 90 0.37 138 0.24
North Glasgow University Hospitals NHS Trust G503H Drumchapel Hospital 33.02 120 0.28 150 0.22
North Glasgow University Hospitals NHS Trust G204H Lenzie Hospital 0.00 60 0.00 124 0.00
North Glasgow University Hospitals NHS Trust G109H Lightburn Hospital 26.56 120 0.22 139 0.19
Renfrew & Inverclyde Primary Care NHS Trust C406H Johnstone Hospital 35.00 92 0.38 110 0.32
Shetland Health Board Z103H Montfield Hospital 5.00 48 0.10 65 0.08
South Glasgow University Hospitals NHS Trust G307H Victoria Geriatric Hospital 121.62 256 0.48 348 0.35
Tayside Primary Care NHS Trust T105H Ashludie Hospital 55.16 165 0.33 343 0.16
Tayside Primary Care NHS Trust T309H Little Cairnie Hospital 15.16 38 0.40 65 0.23
Tayside Primary Care NHS Trust T107H Royal Victoria Hospital 51.71 147 0.35 432 0.12
Tayside Primary Care NHS Trust T313H Whitehills Hospital 11.37 20 0.57 89 0.13
AVERAGE 27.10 86.22 0.34 165.05 0.20
TOTAL 1111.04 3535 6767.22
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Figure 22 NHSScotland clinical waste data for elderly hospitals 2000-2001.
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Table 51 NHSScotland clinical waste data for maternity hospitals 2000-2001.
Maternity Hospitals (careGroups)
Trust Hospital Hospital Name Clinical Number of tonnes/ Heated tonnes /
Code Waste Beds bed Volume 100m3
Tonnage (100m3)
Dumfries & Galloway Acute & Maternity Y102H Cresswell Maternity Hospital 16.50 28 0.59 184 0.09
Fife Acute Hospitals NHS Trust F705H Forth Park Hospital 45.89 130 0.35 294 0.16
North Glasgow University Hospitals NHS Trust G108H Glasgow Royal Maternity Hospital 97.38 80 1.22 568 0.17
Yorkhill NHS Trust G515H Queen Mother's Hospital 65.00 97 0.67 323 0.20
AVERAGE 56.19 83.75 0.71 342.25 0.15
TOTAL 224.77 335 1369
) Figure 23 NHSScotland clinical waste data for maternity hospitals 2000-2001.
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Table 52 NHSScotland clinical waste data for psychiatrie hospitals 2000-2001.
Psychiatric Hospitals < c a r e G r o u p s
Trust Hospital Code Hospital Name Clinical Waste Number of Beds tonnes / bed Heated Volume tonnes 1
Ayrshire And Arran Primary Care Trust A201H Ailsa Hospital
Tonnage
113.34 514 0.22
(100m3)
823
100m3
0.14
Borders Primary Care NHS Trust B021H Dingleton Hospital 0.42 22 0.02 63 0.01
Borders Primary Care NHS Trust B024H East /  West Brig 2.36 17 0.14 28 0.08
Borders Primary Care NHS Trust B028H Gala Vale Hospital 5.44 17 0.32 34 0.16
Borders Primary Care NHS Trust B008H Huntlyburn House 1.97 30 0.07 40 0.05
Borders Primary Care NHS Trust B022H Melburn Lodge 9.91 20 0.50 29 0.34
Dumfries & Galloway Primary Care NHS Trust Y103H Crichton Royal Hospital 33.67 75 0.45 501 0.07
Fife Primary Care NHS Trust F701H Cameron Hospital 31.55 133 0.24 367 0.09
Fife Primary Care NHS Trust F810H Lynebank Hospital 62.80 100 0.63 493 0.13
Fife Primary Care NHS Trust F712H Stratheden Hospital 159.66 307 0.52 858 0.19
Forth Valley Primary Care NHS Trust V 1 0 1 H Royal Scottish National Hospital 148.92 175 0.85 632 0.24
Grampian Primary Care NHS Trust N391H Ladysbridge Hospital 11.36 104 0.11 438 0.03
Grampian Primary Care NHS Trust N198H Royal Cornhill 84.32 416 0.20 1515 0.06
Grampian Primary Care NHS Trust N197H Woodlands & Wellwood Hospital 12.76 5 4 0.24 181 0.07
Greater Glasgow Primary Care NHS Trust G505H Gartnavel Royal Hospital 119.10 322 0.37 773 0.15
Greater Glasgow Primary Care NHS Trust G203H Lennox Castle 88.33 252 0.35 732 0.12
Greater Glasgow Primary Care NHS Trust G302H Leverndale Hospital 38.20 262 0.15 448 0.09
Greater Glasgow Primary Care NHS Trust G600H / G111H /  G201H Overtoun Court /  Parkhead / Woodilee 81.40 156 0.52 190 0.43
Highland Primary Care NHS Trust H104H Town & County, Wick 0.00 20 17
Lanarkshire Primary Care NHS Trust L202H Birkwood Hospital 21.84 81 0.27 238 0.09
Lanarkshire Primary Care NHS Trust L204H Hartwood Hospital 24.96 223 0.11 520 0.05
Lanarkshire Primary Care NHS Trust L216H Kirklands Hospital 74.88 179 0.42 392 0.19
Lomond & Argyll Primary Care NHS Trust C101H Argyll & Bute Hospital 0.00 205 549
Lothian Primary Care NHS Trust S235H Greenbank Centre 2.76 12 0.23 25 0.11
Lothian Primary Care NHS Trust S109H Herdmanflat and Hopetoun Hospital 19.01 83 0.23 276 0.07
Lothian Primary Care NHS Trust S312H Lothian Health Care Houses 8.28 36 0.23 44 0.19
Lothian Primary Care NHS Trust S214H Rosslynlee Hospital 24.24 115 0.21 328 0.07
Lothian Primary Care NHS Trust S217H Royal Edinburgh Hospital 97.07 571 0.17 1039 0.09
Lothian Primary Care NHS Trust S234H 2.76 12 0.23 21 0.13
Renfrew & Inverclyde Primary Care NHS Trust C403H Dykebar Hospital 102.00 326 0.31 655 0.16
Renfrew & Inverclyde Primary Care NHS Trust C405H Hawkhead Hospital 22.00 85 0.26 389 0.06
Renfrew & Inverclyde Primary Care NHS Trust C407H Merchiston Hospital 72.00 173 0.42 338 0.21
Renfrew & Inverclyde Primary Care NHS Trust C310H Ravenscraig Hospital 128.00 237 0.54 511 0.25
Tayside Primary Care NHS Trust T215H Murray Royal Hospital 38.68 156 0.25 743 0.05
Tayside Primary Care NHS Trust T701P Carseview centre 3.45 84 0.04 160 0.02
Tayside Primary Care NHS Trust T114H Royal Dundee Lift Hospital 17.24 153 0.11 804 0.02
Tayside Primary Care NHS Trust T115H Strathmartine Hospital 6.90 101 0.07 400 0.02
Tayside Primary Care NHS Trust T311H Sunnyside Royal 22.74 136 0.17 691 0.03
West Lothian Healthcare NHS Trust S302H Bangour Village Hospital 28.00 56 0.50 656.77 0.04
AVERAGE
TOTAL
44.16
1722.30
154.36
6020
0.29 434.40
16941.77
0.12
284
Figure 24 NHSScotland clinical waste data for psychiatrie hospitals 2000-2001.
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) Table 53 NHSScotland clinical waste data for small acute hospitals 2000-2001.
Small Acute Hospitals (careGroups)
Hospital Hospital Name Clinical Waste Number of tonnes/ bed Heated Volume tonnes/
Tonnage Beds (100m3) 100m3
Argyll & Clyde Acute Hospitals NHS Trust C121H Lorn & Islands District General Hospital (Oban) 48.00 138 0.35 281 0.17
Borders Primary Care NHS Trust B017H Kelso Hospital 19.79 55 0.36 91 0.22
Dumfries & Galloway Primary Care NHS Trust Y1t3H Dalrymple Hospital 21.55 48 0.45 128 0.17
Dumfries & Galloway Primary Care NHS Trust Y t t t H Garrick Hospital 18.86 42 0.45 77 0.24
Fife Primary Care NHS Trust F708H Adamson Hospital 4.12 39 0.11 110 0.04
Fife Primary Care NHS Trust F710H Randolph Wemyss Memorial Hospital 2.96 54 0.05 97 0.03
Fife Primary Care NHS Trust F715H Whytemans Brae Hospital 37.50 108 0.35 294 0.13
Forth Valley Primary Care NHS Trust V204H Clackmannan County Hospital 17.18 32 0.54 74 0.23
Grampian Primary Care NHS Trust N337H Chalmers Hospital 9.88 58 0.17 152 0.07
Grampian Primary Care NHS Trust N334H Fraserburgh Hospital 17.29 61 0.28 114 0.15
Grampian Primary Care NHS Trust N181H Glen O'dee Hospital 12.67 48 0.26 63 0.20
Grampian Primary Care NHS Trust N331H Inverurie Hospital 15.07 73 0.21 116 0.13
Grampian Primary Care NHS Trust N335H Jubilee Huntly Hospital 8.23 51 0.16 123 0.07
Grampian Primary Care NHS Trust N434H Leanchoil Hospital 4.09 35 0.12 82 0.05
Grampian Primary Care NHS Trust N333H Peterhead Community Hospital 7.12 35 0.20 153 0.05
Grampian Primary Care NHS Trust N431H Seafield Hospital 16.93 66 0.26 89 0.19
Highland Primary Care NHS Trust H212H Belford Hospital 0.00 72 153
Highland Primary Care NHS Trust H103H Caithness General Hospital 0.00 93 222
Highland Primary Care NHS Trust H108H Migdale Hospital 0.00 35 59
Lanarkshire Primary Care NHS Trust L211H Roadmeetings Hospital 37.44 58 0.65 81 0.46
Lomond & Argyll Primary Care NHS Trust C122H Campeltown Hospital 13.00 62 0.21 85 0.15
Lomond & Argyll Primary Care NHS Trust C106H Dunoon & District Hospital 18.00 85 0.21 236 0.08
Lomond & Argyll Primary Care NHS Trust C110H Mid Argyll Hospital 45.00 47 0.96 182 0.25
Lothian Primary Care NHS Trust S107H Edenhall Hospital 13.80 46 0.30 302 005
Lothian Primary Care NHS Trust S702P Elian's Glen House 10.54 60 0.18 63 0.17
Lothian Primary Care NHS Trust S210H Loanhead Hospital 9.16 40 0.23 39 0.23
Lothian Primary Care NHS Trust S1I3H Roodlands Hospital 14.89 65 0.23 240 0.06
Orkney Health Board R101H Balfour Hospital 18.68 98 0.19 250 0.07
Shetland Health Board Z102H Gilbert Bain Hospital 15.00 68 0.22 199 0.08
Tayside Primary Care NHS Trust T304H Arbroath Infirmary 22.74 56 0.41 163 0.14
Tayside Primary Care NHS Trust T209H Blairgowrie Cottage Hospital 11.40 46 0.25 69 0.17
Tayside Primary Care NHS Trust T305H Brechin Infirmary 11.37 54 0.21 85 0.13
Tayside Primary Care NHS Trust T307H Forfar Infirmary 15.16 43 0.35 83 0.18
Tayside Primary Care NHS Trust T310H Montrose Royal Infirmary 11.37 31 0.37 69 0.16
Western Isles Health Unit W200H Uist & Barra Hospital 8.50 29 0.29 85 0.10
AVERAGE 15.35 58.03 0.30 134.54 0.14
TOTAL 537.29 2031 4709
2 8 6
Figure 25 NHSScotland clinical waste data for small acute hospitals 2000-2001.
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Table 54 NHSScotland clinical waste data for cottage hospitals 2000-2001.
Cottage Hospitals (carecroupe)
Trust Hospital Hospital Name Clinical Number of tonnes / Heated tonnes
Code Waste
Tonnage
Beds bed Volume
(100m3)
/100m3
Ayrshire And Arran Primary Care Trust A101H Arran War Memorial 64.86 22 2.95 38 1.71
Ayrshire And Arran Primary Care Trust A112H Brooksby Hospital 13.75 20 0.69 36 0.38
Ayrshire And Arran Primary Care Trust A207H Davidson Hospital 9.02 30 0.30 39 0.23
Ayrshire And Arran Primary Care Trust A110H Lady Margaret Hospital 7.00 14 0.50 21 0.33
Ayrshire And Arran Primary Care Trust A107H Strathlea Resource Centre 34.89 65 0.54 93 0.38
Borders Primary Care NHS Trust B001H Coldstream Hospital 6.67 14 0.48 37 0.18
Borders Primary Care NHS Trust B010H Hawick Cottage Hospital 5.54 23 0.24 57 0.10
Borders Primary Care NHS Trust B006H Knoll Hospital Duns 4.81 29 0.17 59 0.08
Borders Primary Care NHS Trust B004H Sister Margaret Jedburgh Hospital 1.88 9 0.21 9 0.21
Dumfries & Galloway Primary Care NHS Trust Y101H Castle Douglas Hospital 10.78 24 0.45 56 0.19
Dumfries & Galloway Primary Care NHS Trust Y106H Kirkcudbright Hospital 6.29 14 0.45 24 0.26
Dumfries & Galloway Primary Care NHS Trust Y109H Moffat Hospital 6.74 15 0.45 29 0.23
Dumfries & Galloway Primary Care NHS Trust Y110H Newton Stewart Hospital 11.22 25 0.45 29 0.39
Dumfries & Galloway Primary Care NHS Trust Y107H Thomas Hope Hospital 6.29 14 0.45 43 0.15
Dumfries & Galloway Primary Care NHS Trust Y114H Thornhill Hospital 6.74 15 0.45 49 0.14
Fife Primary Care NHS Trust F703H Netherlea Hospital 0.36 10 0.04 26 0.01
Fife Primary Care NHS Trust F709H St Andrews Memorial Hospital 2.02 34 0.06 88 0.02
Forth Valley Primary Care NHS Trust V105H Bo'ness Hospital 13.34 40 0.33 58 0.23
Grampian Primary Care NHS Trust N151H Aboyne Hospital 2.06 25 0.08 46 0.04
Grampian Primary Care NHS Trust N451H Fleming Hospital 2.25 15 0.15 36 0.06
Grampian Primary Care NHS Trust N332H Insch & Dist War Memorial 1.99 13 0.15 14 0.14
Grampian Primary Care NHS Trust N171H Kincardine O'neil Hospital 1.03 11 0.09 13 0.08
Grampian Primary Care NHS Trust N351H Maud Hospital 12.36 50 0.25 65 0.19
Grampian Primary Care NHS Trust N432H Stephen Hospital 2.01 21 0.10 40 0.05
Grampian Primary Care NHS Trust N433H Turner Hospital 2.79 22 0.13 66 0.04
Grampian Primary Care NHS Trust N336H Turriff Hospital 1.66 19 0.09 53 0.03
Grampian University Hospitals NHS Trust N182H Tor-Na-Dee Hospital 40.97 92 0.45 207 0.20
Highland Primary Care NHS Trust H101H Dunbar Hospital 0.00 16 - 54
Highland Primary Care NHS Trust H216H Gesto Hospital 0.00 16 - 17
Highland Primary Care NHS Trust H213H Glencoe Hospital 0.00 25 42
Highland Primary Care NHS Trust H210H Ian Charles Hospital 0.00 18 - 34
Highland Primary Care NHS Trust H106H Lawson Memorial Hospital 0.00 45 - 72 -
Highland Primary Care NHS Trust H214H Mackinnon Memorial Hospital 0.00 25 44 -
Highland Primary Care NHS Trust H215H Portree Hospital 0.00 13 - 31 -
Highland Primary Care NHS Trust H217H Ross Memorial Hospital 0.00 31 62 -
Highland Primary Care NHS Trust H211H St Vincents Hospital 0.00 39 44
Highland Primary Care NHS Trust H208H Town & County Hospital (Nairn) 0.00 20 - 44
Lanarkshire Primary Care NHS Trust L210H Airbles Centre 7.80 33 0.24 55 0.14
Lanarkshire Primary Care NHS Trust L101H Alexander Hospital 3.12 20 0.16 32 0.10
Lanarkshire Primary Care NHS Trust L206H Kello Hospital 3.12 22 0.14 27 0.12
Lanarkshire Primary Care NHS Trust L207H Ladyhome Hospital 3.12 22 0.14 25 0.12
Lanarkshire Primary Care NHS Trust L209H Lockhart Hospital 3.90 30 0.13 30 0.13
Lanarkshire Primary Care NHS Trust L305H Udston Hospital 17.72 134 0.13 186 0.10
Lanarkshire Primary Care NHS Trust L104H Victoria Hospital 3.12 17 0.18 20 0.16
Lomond & Argyll Primary Care NHS Trust C108H Islay Hospital 0.50 23 0.02 63 0.01
Lomond & Argyll Primary Care NHS Trust C113H Victoria Hospital (Rothesay) / Annex 16.00 53 0.30 86 0.19
Lomond & Argyll Primary Care NHS Trust C207H Victoria Infirmary (Helensburgh) 10.00 36 0.28 82 0.12
Lothian Primary Care NHS Trust S703P Ferryfield House 2.06 60 0.03 56 0.04
Lothian Primary Care NHS Trust S108H Edington Hospital 13.80 9 1.53 21 0.66
Tayside Primary Care NHS Trust T207H Aberfeldy Cottage Hospital 5.21 21 0.25 37 0.14
Tayside Primary Care NHS Trust T216H Crieff Hospital 10.41 42 0.25 82 0.13
Tayside Primary Care NHS Trust T208H Irvine Memorial Hospital 5.70 23 0.25 33 0.17
Tayside Primary Care NHS Trust T205H St Margarets Hospital 4.00 16 0.25 19 0.21
West Lothian Healthcare NHS Trust S305H St. Michael's Hospital 14.81 30 0.49 51 0.29
Western Isles Health Unit W106H St Brendans Hospital 2.00 17 0.12 27 0.07
AVERAGE 7.38 28.02 0.35 49.22 0.20
TOTALS 405.68 1541 2707
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Figure 26 NHSScotland clinical waste data for cottage hospitals 2000-2001.
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Table 55 NHSScotland clinical waste data for teaching hospitals 2000-2001.
Teaching Hospitals (careGroup?)
Trust Hospital Hospital Name Clinical Number of tonnes / bed Heated tonnes/
Code Waste Beds Volume 100m3
Tonnage (100m3)
Grampian University Hospitals NHS Trust N101H Aberdeen Royal Infirmary 456.99 982 0.47 3238 0.14
Lothian University Hospitals NHS Trust S226H Royal Infirmary Of Edinburgh 801.32 769 1.04 4106 0.20
Lothian University Hospitals NHS Trust S118H Western General Hospital 450.54 540 0.83 4285 0.11
North Glasgow University Hospitals NHS Trust G107H Glasgow Royal Infirmary 663.93 721 0.92 3473 0.19
North Glasgow University Hospitals NHS Trust G516H Western Infirmary 517.35 599 0.86 2592 0.20
Tayside University Hospitals NHS Trust T101H Ninewells Hospital 579.93 876 0.66 4960 0.12
AVERAGE 578.34 747.83 0.80 3775.667 0.16
TOTAL 3470.07 4487.00 22654
)
Figure 27 NHSScotland clinical waste data for teaching hospitals 2000-2001.
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Table 56 NHSScotland clinical waste data for other hospitals 2000-2001.
O t h e r  H O S p i t a l S  (Care Group 8)
Trust Hospital Hospital Name Clinical Waste Number tonnes/ Heated tonnes
Code Tonnage of Beds bed Volume /100m3
(100m3)
Ayrshire And Arran Primary Care Trust A204H Arrol Park Resource Centre 25.65 86 0.30 117 0.22
Grampian Primary Care NHS Trust N701P Kincardine Community Hospital, Stonehaven 2.95 214 0.01 99.35 0.03
North Glasgow University Hospitals NHS Trust G106H Glasgow Dental Hospital & School 0.00 0 410
Tayside University Hospitals NHS Trust T113H Dundee Dental Hospital & School 0.00 0 90
The State Hospital D001H State Hospital, Carstairs 0.70 256 0.00 595 0.00
West Lothian Healthcare NHS Trust S306H Tippethill Hospital 24.25 60 0.40 39 0.62
AVERAGE 8.93 102.6667 0.18 225.06 0.22
TOTAL 53.55 616 1350.35
)
Figure 28 NHSScotland clinical waste data for other hospitals 2000-2001.
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Appendix M. Sample Questionnaires Used 
producer survey of Greater Edinburgh Area.
)
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Covering Letter Sent with Questionnaires.
tor Roland C lift ODE FEng FlOiemE FRSA 
tor of Environmental Technology 
)r of Centre for Emironmenta! Strategy 
of Chemical, Civil and Environmental Engineering 
for Environmental Strategy 
sity of Surrey
3rd Surrey GU2 5XH UK 
Direct Line:
University: 0148S. 300800 Ext.......
Fax Direct: 01483. 259521/259394
January 1999.
This questionnaire is designed to find out information relating to the types, 
volumes, transportation and disposal arrangements of Clinical Waste in 
Scotland. The information gathered will form an important part o f a Ph.D. 
thesis. The thesis focuses on the management of Clinical Wastes from all 
sources. The information gathered from this questionnaire will form part of 
an Edinburgh case study. Similar questionnaires have been sent to Vets, 
Residential Homes, Independent Hospitals as well as a number o f smaller 
sources of Clinical Waste such as Beauticians, Tatooists, etc. The results of 
all of the questionnaires in conjunction with the results of a NHS survey 
carried out by the University of Strathclyde will provide a comprehensive 
picture of Clinical Waste management in Edinburgh.
All information provided will remain confidential and anonymous, it will 
ONLY be used by W. Rayner for Ph.D. research. The environmental impacts 
associated with the transport of waste are considerable, it is therefore 
important that I am able to calculate transport distances. To enable me to do 
this I ask you to provide me with the first section of your postcode. The first 
section of the postcode enables me to place you in a particular area of the 
city. I understand that this means that the questionnaire is no longer truly 
anonymous. I would like to reassure you that I will be the only person to 
view the results and once the approximate transport distances have been 
calculated the postcodes will be discarded.
If you would like to verify that this questionnaire forms part of a Ph.D. 
thesis please do not hesitate to contact the Lothian Registration and 
Inspection Authority, my supervisor, Dr Cowell at the University of Surrey 
(01483 300 800 ex. 2283),
Thank you very much for your co-operation,
Wendy Rayner
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Sam ple Q uestionnaire Sent to Veterinary Surgeons
Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
( W)
To enable me to calculate approximate transport distances. Please state the first 
section of your postcode. Once transport distances have been calculated this section 
o f the questionnaire will be discarded, and all answers w ill be treated anonymously.
e.g. EH17, EH3, etc.
The questionnaire is divided into four sections, each section asks about a specific type o f  
Clinical Waste. I f  your establishment disposes o f  each waste type separately, please f i l l  
in each section. I f  a number o f  waste types are collected together, please state which 
types are collected w ith  all relevant details in one section.
Once completed, please return this questionnaire to:
Clinical Waste Questionnaire,
Wendy Rayner
Thank you very much for your co-operation,
Wendy Rayner
Confidential Page I
Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
Waste Type 1 
Examples:
Blood, Soiled Dressings, Swabs and Other S im ilar Soiled Waste.
(Not including Tissue Waste, see waste type 4)
{  __
I. Please state type of container used for storing this waste :
| e.g. Black Bag, Yellow  Bag, Red Bag, Orange Bag, Yellow  Box, Other.
2. Please state size of container: _________ .
j e.g. Standard Yellow  Bags, 5 Litre Solid Yellow Container etc.
3. Please state number of containers produced per month:
4. Please state approximate weight of each container:
? e.g. 10kg.
5. Please state final disposal destination:
î e.g. Incineration , Landfill, Heat Treatment
Please state location i f  known:
e.g. Incineration at Crosshouse Hospital, Heat Treatment at Arbroath, etc.
Please state type o f collection vehicle ( i f  known): 
e.g. Van, Lorry, Articulated Lorry
6. Please state length and value of current clinical waste disposal contract:
e.g. 2 years
e.g. £ xxx per year or £ xxx per tonne
Confidential Page 2
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Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
Waste Type 2 
\ Examples:
i Microbiological Cultures & Other Pathological Waste
L  Please state type of container used for storing this waste :
| e.g. Black Bag, Yellow Bag, Red Bag, Orange Bag, Yellow Box, Other.
2. Please state size of container: ________________
\ e.g. Standard Yellow Bags, 5 Litre Solid Yellow Container etc.
3. Please state number of containers produced per month:
4. Please state approximate weight of each container:
e.g. 10kg.
5. Please state final disposal destination:
e.g. Incineration, Landfill, Heat Treatment
Please state location if  known:
e.2. Incineration at Crosshouse Hospital, Heat Treatment at Arbroath, etc.
Please state tvne of collection vehicle (if  known): 
e.g. Van, Lorry, Articulated Lorry
7. Please state length and value of current clinical waste disposal contract:
e.g. 2 years
e.g. £ xxx per year or £ xxx per tonne
Confidential Page 3
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IClinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
Waste Type 3 
Examples:
Highly Infectious Wastes (Special Wastes).
1. Please state type of container used for storing this waste :
e.g. Black Bag, Yellow Bag, Red Bag, Orange Bag, Other.
2. Please state size of container: ________________
e.g. Standard Yellow Bags, 5 Litre Solid Yellow Container etc.
3. Please state number of containers produced per month:
4. Please state approximate weight of each container: 
e.g. 10kg.
5. Please state final disposal destination:
e.g. Incineration, Landfill, Heat Treatment
Please state location i f  kno wn:
e.g. Incineration at Crosshouse Hospital, Heat Treatment at Arbroath, etc.
Please state tvne of collection vehicle (if known):
eg. Van, Lorry, Articulated Lorry
8. Please state length and value of current clinical waste disposal contract:
e.g. 2 years
e.g. £ xxx per year or £ xxx per tonne
Confidential Page 4
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Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
Waste Type 4______ ■_______ '_______ ._____  ■ ______
Examples:
Tissue Waste
(N ot including Cadavers)
1. Please state type of container used for storing this waste :
e.g. Black Bag, Yellow  Bag, Red Bag, Orange Bag, Other.
2. Please state size of container:____________________ _
I e.g. Standard Yellow  Bags, 5 Litre Solid Yellow  Container etc.
3. Please state number of containers produced per month:
4. Please state approximate weight of each container:________ __________
j e.g. 10kg.
|       : -
5. Please state final disposal destination:__________________ ___________
e.g. Incineration , Landfill, Heat Treatment
Please state location if  kno wn:
e.g. Incineration at Crosshouse Hospital, Heat Treatment at Arbroath, etc.
Please state tvne of collection vehicle (if known): 
e.g. Van, Lorry, Articulated Lorry
9. Please state length and value of current clinical waste disposal contract:
e.g. 2 years
e.g. £ xxx per year or £ xxx per tonne
Confidential Page 5
Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
Waste Type 5 
Examples:
Cytotoxic Drugs and Other Pharmaceutical Products.
1. Please state type of container used for storing this waste :
e.g. Black Bag, Yellow Bag, Red Bag, Orange Bag, Other.
2. Please state size of container:   .
e.g. Standard Yellow Bags, 5 Litre Solid Yellow Container etc.
3. Please state number of containers produced per month:
4. Please state approximate weight of each container:
e.g. 10kg.
5. Please state final disposal destination:_______ _____ __________
I e.g. Incineration, Landfill, Heat Treatment
|
| Please state location if  known:
| e.g. Incineration at Crosshouse Hospital, Heat Treatment at Arbroath, etc.
Î . . . ■
I Please state type of collection vehicle (if known):
| e.g. Van, Lorry, Articulated Lorry
10. Please state length and value of current clinical waste disposal contract:
; e.g. 2 years
| e.g. £ xxx per year or £ xxx per tonne
Confidential Page 6
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Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
Waste Type 6 
Examples:
Sharps (Used and Unused Needles, etc.)
1. Please state type of container used for storing this waste :
e.g. Black Bag, Yellow Bag, Red Bag, Orange Bag, Solid Yellow Container, Sharps Box
Other. :
2. Please state size of container: ______________ _______________ ___
e-g. Standard Yellow Bags, 5 Litre Solid Yellow Container, 2 Litre Sharps Box etc.
3. Please state number of containers produced per month:
4. Please state approximate weight of each container: 
le.g. 10kg.
5. Please state final disposal destination:   _ _
! e.g. Incineration, Landfill, Heat Treatment
| Please state location if  known:
; e.g. Incineration at Crosshouse Hospital, Heat Treatment at Arbroath, etc.
Please state type of collection vehicle (if known): 
e.g. Van, Lorry, Articulated Lorry
11. Please state length and value of current clinical waste disposal contract:
e.g. 2 years
e.g. £ xxx per year or £ xxx per tonne
Confidential Page 7
Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
Waste Type 7 
Examples:
Radioactive Wastes
1. Please state type of container used for storing this waste :
e.g. Black Bag, Yellow Bag, Red Bag, Orange Bag, Other.
2. Please state size of container:
e.g. Standard Yellow Bags, 5 Litre Solid Yellow Container etc.
3. Please state number of containers nroduced ner m onth:
4. Please state approximate weight of each container:
e.g. 10kg.
5. Please state final disposal destination:
eg. Incineration , Landfill, Heat Treatment
Please state location i f  known:
eg Incineration at Crosshouse Hospital, Heat Treatment at Arbroath, etc.
Please state tvne of collection vehicle (if known):
eg. Van, Lorry, Articulated Lorry
12. Please state length and value of current clinical waste disposal contract:
e.g. 2 years
e.g. £ xxx per year or £ xxx per tonne
Confidential Page 8
Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
Waste Type 8 
Examples:
Animal Cadavers
1. Please state type of container used for storing this waste : 
e.g. Black Bag, Yellow Bag, Red Bag, Orange Bag, Other.
2. Please state size of container:______________ ______
e.g. Standard Yellow Bags, 5 Litre Solid Yellow Container etc.
3. Please state number of containers produced per month:
4. Please state approximate weight pf each container: 
e.g. 10kg.
5. Please state final disposal destination:
e.g. Incineration , Landfill, Heat Treatment
Please state location if  known:
e.g. Incineration at Crosshouse Hospital, Heat Treatment at Arbroath, etc.
Please state tvne of collection vehicle (if known): 
e.g. Van, Lorry, Articulated Lorry
13. Please state length and value of current clinical waste disposal contract:
e.g. 2 years
e.g. £ xxx per year or £ xxx per tonne
Confidential Page 9
Sample Questionnaire Sent to Nursing Homes
Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
>
V
To enable me to calculate approximate transport distances. Please state the first 
section of your postcode. Once transport distances have been calculated this section 
of the questionnaire will be discarded, and all answers will be treated anonymously, 
e.g. EH17, EH3, etc.
The questionnaire is divided into four sections, each section asks about a specific type of 
Clinical Waste. If  your establishment disposes of each waste type separately, please fill 
in each section. I f  a number of waste types are collected together, please state which 
types are collected with all relevant details in one section.
Once completed, please return this questionnaire to:
Clinical Waste Questionnaire,
c/o Lothian Registration & Inspection Authority,
Deaconess House, The Pleasance, Edinburgh.
Please note that Lothian Registration &  Inspection have kindly allowed me to use their 
postal address. I intend to collect the unopened questionnaires from their office at regular 
intervals.
Thank you very much for your co-operation,
Confidential Page 1
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Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
Waste Type 1 
{Examples:
| Human tissue, blood, soiled dressings, swabs and other similar soiled waste.
1. Please state type of container used for storing this waste : 
black bag, yellow bag, red bag, orange bag, other.
2. Please state size of container:
j e.g. standard yellow bags, etc.
Please state number of containers produced per month:
4. Please state approximate weight of each container:_____________
j e.g. 10kg.
5. Please state final disposal destination:_________ _____ _
i e.g. Incineration, Landfill, Heat Treatment
I Please state location if  known:
| e.g. Incineration at Crosshouse Hospital, Heat Treatment at Arbroath, etc.
6. Please state length and value of current clinical waste disposal contract:
e.g. 2 years
* e.g. £ xxx per year or £ xxx per tonne
Confidential Page 2
Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
Waste Type 2 
Examples:
Items used for the collection o f human excreta/secreta e.g. incontinence pads, 
sanitary towels, etc.
1. Please state type of container used for storing this waste : 
e.g. black bag, yellow bag, red bag, orange bag, other.
2. Please state size of container:
j e.g. standard yellow bags, etc.
j
3. Please state number of containers produced per month:
4. Please state approximate weight of each container: 
e.g. 10kg.
5. Please state final disposal destination:  _ _
e.g. Incineration, Landfill, Heat Treatment
Please state location if  known:
e.g. Incineration at Crosshouse Hospital, Heat Treatment at Arbroath, etc.
7. Please state length and value of current clinical waste disposal contract: 
e g. 2 years
e.g. £ xxx per year or £ xxx per tonne
Confidential Page 3
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Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
Waste Type 3 
Examples:
Pharmaceutical products, e.g. unused medicines.
1. Please state type of container used for storing this waste :
e.g. black bag, yellow bag, red bag, orange bag, disposal to sewer, drugs storage 
cupboard, other:
2, Please state size of container: _____
e.g. standard yellow bags, 2 litre yellow box etc,
3. Please state number of containers produced per month:
4. Please state approximate weight of each container:
e.g. 10kg.
5. Please state final disposal destination: __________________
e.g. Incineration, Landfill, Heat Treatment, Returned to Pharmacy
Please state location if  known:
e.g. Incineration at Crosshouse Hospital, Heat Treatment at Arbroath, etc.
8. Please state length and value of current clinical w aste disposal contract: 
e.g. 2 years
e.g. £ xxx per year or £ xxx per tonne
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Clinical Waste Questionnaire
Centre for Environmental Strategy -  University of Surrey
Waste Type 4 
Examples:
Sharps, e.g. used and unused needles.
1. Please state type of container used for storing this waste :
e.g. black bag, yellow bag, red bag, orange bag, 1 litre sharps box, 2 litre sharps box.
other.
2. Please state size of container: 
e.g. standard yellow bags, etc.
3. Please state number of containers produced per month:
4, Please state approximate weight of each container: 
e.g. 10kg.
5. Please state final disposal destination:________________________
e.g. Incineration, Landfill, Heat Treatment
Please state location if  known:
e.g. Incineration at Crosshouse Hospital, Heat Treatment at Arbroath, etc.
9. Please state length and value of current clinical w aste disposal contract: 
e.g. 2 years
e.g. £ xxx per year or £ xxx per tonne
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Table 57 Hospital episode statistics (England) 2000-2001
Department of Health (England), Hospital Episode Statistics - 2000/01.
Table 2. Primary Diagnosis - Summary Finished Consultant Episodes Admissions
Total 12 ,2 64 ,67 7  11,116 ,161
A 0 0 -A 0 9  In te s tina l in fec tio us  d ise a se s  3 8 ,9 9 7  35 ,7 22
A 1 5 -A 1 9 T u b e rc u lo s is  4 ,8 6 7  3 ,523
A 20 -A 4 9  C e rta in  b a c te ria l d is e a s e s  23,121  17,200
A 5 0 -A 6 4  In fe c tio n s  w ith  p re d o m in a n tly  se xua l m o d e  o f tra n s m is s io n  3 ,2 8 8  3 ,193
A 65 -A 7 9  O th e r in fe c tio u s  and  p a ra s it ic  d is o rd e rs  3 35  305
A 80 -A 8 9  V ira l in fe c tio n s  o f the  ce n tra l n e rvo u s  s ys te m  4 ,7 8 2  4 ,024
A 90 -A 9 9  A rth ro p o d -b o rn e  v ira l fe v e rs  & v ira l h a e m o rrh a g ic  fe v e rs  2 8  2 6
B 00 -B 0 9  V ira l in fec tio ns  c h a ra c te rize d  by sk in  & m u c o u s  m e m . lesns. 12 ,778  11,851
B 15 -B 1 9 V ira l h ep a titis  5 ,1 9 3  4 ,614
B 20 -B 2 4  H u m a n  im m u n o d e fic ie n c y  v irus  [H IV ] d ise a se  4 ,2 5 3  3 ,229
B 2 5 -B 3 4  O th e r v ira l d is e a s e s  4 7 ,2 0 8  4 5 ,2 92
B 3 5 -B 4 9  M yco se s  3 ,6 4 3  3 ,0 4 8
B 5 0 -B 6 4  P ro tozoa l d is e a s e s  2,971 2 ,5 5 8
B 65 -B 8 3  H e lm in th ia s e s  431 395
B 8 5 -B 9 9  O th e r in fe c tio u s  a nd  p a ra s itic  d ise a se s  1 ,378  1 ,190
C 0 0-C 1 4  M a lig n an t n eo p lasm  of lipo ra l c a v ity  and  p ha ryn x  13 ,062  11,841
C 1 5-C 2 6  M a lig n an t n eo p lasm  of d ige s tive  o rg an s  2 5 6 ,1 7 6  2 31 ,10 8
C 3 0-C 3 9  M a lig n an t n e o p la sm s  of re s p ira to ry  &  in tra th o ra c ic  o rg a n s  8 6 ,6 32  7 4 ,0 98
C 40-C 41 M a lig n an t n eo p lasm  of bone  and  a rtic u la r ca rtila g e  5 ,0 6 4  4 ,853
C 4 3-C 4 4  M a lig n an t n e o p la sm s  of sk in  6 0 ,3 9 9  59 ,764
C 4 5-C 4 9  M a lig n an t n e o p la sm s  of m é so th é lia l and  s o ft tis s u e  11 ,546  10 ,607
C 50  M a lig n an t n eo p lasm  o f b re as t 126 ,734  124 ,637
C 5 1-C 5 8  M a lig n an t n e o p la sm s  o f fe m a le  g en ita l o rg an s  54,331 51 ,5 82
C 6 0-C 6 3  M a lig n an t n e o p la s m s  o f m a le  g en ita l o rg an s  4 2 ,6 6 8  3 9 ,4 04
C 6 4-C 6 8  M a lig n an t n e o p la s m s  o f u rin a ry  tra c t 9 1 ,6 3 8  86 ,8 80
C 6 9-C 7 2  M a lig n an t n e o p la sm s  o f eye, bra in  & o th e r p a rts  o f C N S  18 ,187  16,244
C 8 1-C 9 6  M a lig n an t n e o p la s m s  o f lym ph o id , h a e m a to p o ie tic  & rel. tiss . 2 1 1 ,9 8 4  2 02 ,81 4
C 7 3-C 8 0, C 97  M a lig n an t neo p lsm . o f thy ro id  and  o th . endo. G la nd s  e tc . 8 9 ,3 44  7 8 ,7 39
DOO-D48 In s itu  & ben ign  n e o p la s m s  and  o th e rs  of u n c e rta in ty  2 86 ,13 2  276 ,731
D 5 0-D 64  A n a e m ia s  118 ,900  100 ,766
0 6 5 -0 8 9  D ise a ses  o f th e  b loo d  a nd  b lo o d -fo rm in g  o rg a n s  4 9 ,1 9 3  4 6 ,4 80
E 00 -E 0 7  D iso rd e rs  o f thy ro id  g lan d  11 ,075  10,183
E 10 -E 1 4  D ia b e te s  M e llitu s  7 2 ,3 5 2  60 ,2 53
E 15 -E 9 0  E nd o crin e  n u trition a l and  m e ta b o lic  d ise a se s  6 5 ,3 5 8  57 ,7 13
F 0 0-F 03  D e m e n tia  2 7 ,7 5 9  2 3 ,3 77
F 0 4-F 09  O th e r o rg a n ic  in c lu d in g  s y m p to m a tic  m en ta l d is o rd e rs  4 ,7 8 9  3 ,8 1 7
F 1 0 -F 19  M e n ta l and  b eh av iou ra l d is o rd e rs  d ue  to  p sycho ac tive  su bs t. 4 0 ,6 0 7  36,391
F 2 0-F 29  S ch izop h ren ia , sch izo typ a l and  d e lu s io n a l d is o rd e rs  3 6 ,1 0 9  31 ,8 93
F 30-F 39  M ood  [a ffe c tive ] d is o rd e rs  5 2 ,1 92  4 7 ,6 0 5
F 4 0-F 69  N e u ro tic , b ah av iou ra l & p e rson a lity  d is o rd e rs  2 8 ,9 2 6  26,581
F 7 0-F 79  M en ta l re ta rda tion  18,781 17,709
F 8 0-F 99  O th e r m e n ta l and  b eh av iou ra l d is o rd e rs  11 ,580  10 ,915
G 00 -G 0 9  In fla m m a to ry  d is e a s e s  o f th e  ce n tra l ne rvou s  s ys te m  4 ,9 9 3  4 ,0 0 5
G 2 0 -G 2 6  E x trap y ra m id a l & m o v e m e n t d is o rd e rs  (incl. P a rk inso n ism ). 13 ,855  11,224
G 10 -G 1 3 , G 3 0 -G 3 2  O th e r d e g e n e ra tive  d ise a se s  (incl. A lzh e im er). 14,401 11,682
G 3 5 -G 3 7  D e m ye lin a tin g  d is e a s e s  (inc l M u ltip le  S c le ros is ) o f th e  C N S . 17,794  16 ,126
G 4 0 -G 4 7  E p ilep sym ig ra in e  & o th e r e p iso d ic  d is o rd e rs  8 7 ,6 5 7  7 4 ,5 88
G 50 -G 7 3 , G 9 0 -G 9 9  O th e r d is e a s e s  & d is o rd e rs  o f th e  n e rvo u s  syst. 7 7 ,8 8 7  7 3 ,5 73
G 80 -G 8 3  C e re b ra l pa lsy  & o th e r p a ra ly tic  syn d ro m e s  18,869  13,264
H 1 0-H 1 3  D iso rd e rs  o f c o n ju n c tiv a  ( inc lud ing  c o n ju n c tiv itis ) 4 ,2 2 4  4 ,1 4 6
H 2 5-H 2 8  D iso rd e rs  o f lens  (inc lu d ing  ca ta ra c ts ) 2 5 6 ,9 9 7  2 55 ,96 5
H 4 0-H 4 2  G la u c o m a  14,590  14 ,476
H 00-H 06, H 15-H 22, H 3 0 -H 3 6 , H 4 3 -H 5  O th e r d iso rde rs  o f th e  eye e tc . 113 ,590  112 ,052
H 6 0-H 9 5  D ise a ses  o f th e  e a r a nd  m a s to id  p ro cess  9 0 ,2 24  8 8 ,9 00
I00 -I09  R h eu m a tic  hea rt d is e a s e  5 ,3 3 8  4,291
110-115 H yp e rten s ive  d is e a s e s  17,953  14 ,699
I20 -I25  Isch a e m ic  hea rt d is e a s e s  3 7 8 ,5 3 2  293 ,911
I26 -I28  P u lm on a ry  hea rt d is e a s e  & d ise a se s  o f p u lm o n a ry  c ircu la tio n  2 4 ,1 1 7  17 ,477
I30 -I52  O th e r fo rm s  o f hea rt d is e a s e  263 ,551  198 ,36 6
I60 -I69  C e re b ro v a s c u la r d is e a s e s  144,661 9 7 ,6 92
170-179 D ise a ses  o f a rte ries , a rte r io le s  & ca p illa r ie s  7 5 ,9 6 6  6 4 ,1 90
I80 -I89  D ise a ses  o f ve in s  & lym ph a tic  sys tem  nec. 150 ,332  138 ,45 7
I95 -I99  O the r & u n sp e c ifie d  d is o rd e rs  o f th e  c ircu la to ry  s ys tem  11 ,545  8,511
J0 0 -J0 6  A cu te  u p p e r re s p ira to ry  in fec tio ns  8 1 ,5 42  7 9 ,2 39
J 1 0 -J 1 8 In flu e nza  & p n e u m o n ia  101 ,922  7 3 ,8 27
J2 0 -J2 2  O th e r a cu te  lo w e r re s p ira to ry  in fec tio ns  115 ,973  9 3 ,7 67
J3 0 -J3 9  O th e r d ise a se s  o f u p p e r re sp ira to ry  tra c t 130 ,660  129 ,587
J 4 0 -J 4 7  C h ro n ic  lo w e r re s p ira to ry  d is e a s e s  213 ,881  162 ,495
J6 0 -J7 0  Lung  d is e a s e s  due  to  e x te rn a l a ge n ts  6,011 3 ,8 5 0
J8 0 -J9 9  O th e r d ise a se s  o f th e  re sp ira to ry  sys tem  5 5 ,9 10  4 2 ,4 34
K 00-K 14  D ise a ses  o f ora l ca v ity , sa liva ry  g la n d s  & ja w s  170 ,19 6  168 ,682
K20-K31 D ise a ses  o f o e s o p h a g u s s to m a c h  & d u o de n um  3 3 3 ,1 5 4  2 80 ,92 4
K 35 -K 3 8  D ise a ses  o f a p p en d ix  3 8 ,9 5 7  3 6 ,0 84
K 40 -K 4 6  H e rn ia  159 ,666  153 ,507
K 50-K 52  N o n in fe c tive  e n te ritis  & co litis  118 ,302  101 ,776
K 55 -K 6 3  O th e r d ise a se s  o f in tes tin es  2 4 8 ,4 4 2  2 21 ,64 3
K 65 -K 6 7  D ise a ses  o f pe r iton eu m  8 ,1 3 3  6 ,3 2 5
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K70-K77 Diseases of liver
K80-K87 Disorders of gall bladder, biliary tract & pancreas 
K90-K93 Other diseases of the digestive system 
L20-L30 Dermatitis and eczema 
L40-L45 Papulosquamous disorders (including Psoriasis)
L50-L54 Urticaria and erythems
L00-L14, L55-L99 Other infections and disorders of the skin 
M 00-M25 Arthropathies
M 30-M36 Systemic connective tissue disorders
M 40-M54 Dorsopathies
M 60-M79 Soft tissue disorders
M 80-M 94 Osteopathies and chondropathies
M 95-M99 Other disorders of the musculoskeletal system & conn. tiss.
N00-N08, N10-N16 Diseases of the kidney
N17-N19 Renal failure
N20-N23 Urolithiasis
N25-N29 Other disorders of kidney & ureter 
N30-N39 Other diseases of the urinary system 
N40-N51 Diseases of male genital organs 
N60-N64 Disorders of breast
N70-N77 Inflammatory diseases of female pelvic organs
N80-N98 Noninflammatory disorders of female genital tract
N99 Other disorders of the genitourinary system
0 0 0 -0 0 8  Pregnancy with abortive outcome
0 1 0 -0 7 5 ,0 8 5 -0 9 2 ,0 9 5 -0 9 9  Complications of labour and delivery
0 8 0 -0 8 4  Delivery
P00-P04 Complications of fetus/neonate affected by maternal 
P05- P96 Other conditions originating in the perinatal period 
0 0 0 -0 8 9  Congenital malformations 
0 9 0 -0 9 9  Chromosomal abnormalities nec.
R00-R09 Symptoms & signs inv. the circulatory/respiratory system 
R10-R19 Symptoms & signs inv. the digestive system & abdomen 
R20-R23 Symptoms & signs inv. the skin & subcutaneous tissue 
R25-R29 Symptoms & signs inv. the nervous & musculoskeletal sys. 
R30-R39 Symptoms & signs involving the urinary system 
R40-R46 Symptoms & signs inv. Cognition, perception etc.
R47-R49 Symptoms & signs inv. speech & voice
R50-R68 General symptoms & signs
R69 Unknown & unspecified causes of morbidity
R70-R89 Abnormal findings of bodily fluids or samples without diag.
R90-R94 Abnormal findings on diagnostic imaging/function studies
R95-R99 Ill-defined & unknown causes of mortality
500 -50 9  Injuries to the head
S10-S19 Injuries to the neck
520 -52 9  Injuries to the thorax
830 -83 9  Injuries to abdomen, lower back, lumbar spine & pelvis
540 -54 9  Injuries to the shoulder & upper arm
550 -55 9  Injuries to the elbow & forearm
560 -56 9  Injuries to the wrist & hand
570 -57 9  Injuries to the hip & thigh
580 -58 9  Injuries to the knee & lower leg
590 -59 9  Injuries to the ankle & foot
T00-T07 Injuries involving multiple body regions
T08-T14 Injuries to unspecified part of trunk limb or body
T15-T19 Effects of foreign body entering through natural orifice
T20-T32 Burns and corrosions
T33-T35 Frostbite
T36-T50 Poisonings by drugs medicaments & biological substances 
T51-T65 Tox. effets, of substnces. chiefly non-medicinal as to source 
T66-T78 Other and unspecified effects of external causes 
T79 Certain early complications of trauma 
T80-T88 Complications of surgical & medical care nec.
T90-T98 Sequelae of injuriesof poisoning & other consequences 
Z00-Z13 Examination and investigation
Z20-Z29 Potential health hazards related to communicable diseases 
Z30-Z39 Health services in circumstances related to reproduction 
Z40-Z54 Persons encountering health services for specific care 
Z55-Z65 Potential health hazards reltd. to socioeconomic & psychosoc.l 
Z70-Z76 Persons encountering health services in other circs.
Z80-Z99 Persons with potential health hazards related to family
27,827
128,517
69,188
11,645
14,718
4,763
240,400
314,108
14,797
149,808
131,040
44,200
4,009
31,009
68,568
55,492
4,031
175,152
118,196
29,182
28,512
280,463
3,135
167.894 
881,836  
103,764
12,087
166.894 
95,833
1,561
315,888
355,333
28,292
26,159
128,198
38,061
7,811
235,157
337,613
30,666
22,248
125
120,387
6,222
14,660
25,625
26,951
59,148
61,526
82,607
64,658
11,555
1,687
5,175
11,842
9,151
42
91,264
8,064
8,619
3,180
119,382
1,608
213,641
6,827
540,648
158,963
1,445
73,825
17,167
19,660
106,230
49,580
10,691
13,950
4,350
221.708  
303,324
13,120
142,523
124.708 
40,853
3,878
26,718
55,695
50,483
3,562
156,440
113,854
28,831
27,398
277.078  
2,820
165,219
866,294
102,940
11,391
145,093
88,809
1,405
274,416
323,089
26,798
19,521
119,560
30,407
7,106
201,655
296,268
30,096
20,308
109
112,978
5,652
12,594
21,935
24,094
56,289
59,381
69,769
59,739
10,703
1,493
4,613
11,351
8,636
36
81,635
7,400
7,967
2,772
105,535
1,458
210,321
6,783
528,582
142.078  
1,223
66,190
16,115
Total 12,264,665 11,116,150
Total Infectious / Parastitic 153,273 136,170
Percentage of Infectious / Parastic of Total 1.2 1.2
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Table 58 ADR 2005 Category A pathogen list.
INDICATIVE EXAMPLES OF INFECTIOUS SUBSTANCES INCLUDED IN CATEGORY A 
IN ANY FORM UNLESS OTHERWISE INDICATED 
(2.6.3.2.2.1 (a))
UN Number and 
Proper Shipping 
Name
Micro-organism
UN 2814
Infectious 
substances 
affecting humans
Bacillus anthracis (cultures only)
Brucella abortus (cultures only)
Brucella melitensis (cultures only)
Brucella suis (cultures only)
Burkholderia mallei - Pseudomonas mallei -  Glanders 
(cultures only)
Burkholderia pseudomallei -  Pseudomonas 
pseudomallei (cultures only)
Chlamydia psittaci- avian strains (cultures only) 
Clostridium botulinum (cultures only)
Coccidioides immitis (cultures only)
Coxiella burnetii (cultures only)
Crimean-Congo hemorrhagic fever virus 
Dengue virus (cultures only)
Eastern equine encephalitis virus (cultures only) 
Escherichia co/i, verotoxigenic (cultures only)
Ebola virus 
Flexal virus
Francisella tularensis (cultures only)
Guanarito virus 
Hantaan virus
Hantaviruses causing hantavirus pulmonary
syndrome
Hendra virus
Hepatitis B virus (cultures only)
Herpes B virus (cultures only)
Human immunodeficiency virus (cultures only)
Highly pathogenic avian influenza virus (cultures only) 
Japanese Encephalitis virus (cultures only)
Junin virus
Kyasanur Forest disease virus 
Lassa virus 
Machupo virus 
Marburg virus 
Monkeypox virus
Mycobacterium tuberculosis (cultures only)
Nipah virus
Omsk hemorrhagic fever virus 
Poliovirus (cultures only)
Rabies virus
Rickettsia prowazekii (cultures only)
Rickettsia rickettsii (cultures only)
Rift Valley fever virus
Russian spring-summer encephalitis virus (cultures 
only)
Sabia virus
Shigella dysenteriae type 1 (cultures only)
Tick-borne encephalitis virus (cultures only)
Variola virus
Venezuelan equine encephalitis virus 
West Nile virus (cultures only)
Yellow fever virus (cultures only)
Yersinia pestis (cultures only)
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Table 58 continued
UN 2900
Infectious 
substances 
affecting animals 
only
African horse sickness virus 
African swine fever virus
Avian paramyxovirus Type 1 - Newcastle disease 
virus
Bluetongue virus
Classical swine fever virus
Foot and mouth disease virus
Lumpy skin disease virus
Mycoplasma mycoides - Contagious bovine
pleuropneumonia
Peste des petits ruminants virus
Rinderpest virus
Sheep-pox virus
Goatpox virus
Swine vesicular disease virus 
Vesicular stomatitis virus
315
I316
